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Novel compounds related to kynurenic acid were synthesised in-house and were 
pharmacologically characterised with the aim of developing novel GluK2 subunit-selective 
antagonists. Compounds with relative selectivity on GluN2A, GluN2B and GluN2D 
subunits of NMDA receptors and GluN2D genetic knockout mice were used to characterise 
the physiological roles of GluN2D-containing NMDA receptors. 
Derivatives of kynurenic acid were tested on GluK1, GluK2 and GluA1 homomeric 
receptors expressed on HEK293 cells using a calcium fluorescence assay, and on f-EPSP 
recordings from the CA1 subregion of the hippocampus with the aim to develop novel 
GluK2 antagonists with GluK2 over AMPAR and GluK2 over GluK1 selectivity. 
Substitutions were made on the 6-position to develop 6-ethylkynurenic acid (UBP2054), 
which has a GluK2 Ki of 54.0 ± 10.9 µM and estimated IC50 values of > 1 mM and > 2 mM 
on GluK1 and GluA1, respectively. 
UBP2054 has an IC50 of > 300 µM for inhibiting AMPAR-mediated f-EPSPs from the CA1 
subregion of the hippocampus. Molecular modelling was used to rationalise the 
pharmacological profile observed in the functional assays. 
Physiological investigations of GluN2D receptors revealed that the GluN2D NMDAR 
subunit mediates the induction of LTP in hippocampal Schaffer collateral to CA1 
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Chapter 1  
Introduction 
  
Chapter 1 – Introduction 
2 
A central question in neuroscience is: what are the cellular processes that lead to the storage 
and processing of information in the human brain? Cells of the nervous system (neurons) 
communicate with each other at specialised junctions known as synapses. While different 
types of synapses have been discovered, majority of the communication between neurons 
is believed to occur at chemical synapses, which use molecules known as neurotransmitters 
to transmit signals from one neuron to another (see Glickstein, 2006 for a review). Early 
studies that investigated the neuronal responses of exogenously applied molecules provided 
evidence for the role of L-glutamate (or (S)-glutamate), a naturally occurring metabolite of 
cellular respiration, as a neurotransmitter in the mammalian brain (Hayashi, 1954).  
The abundance of amino acids in the brain and their requirement in metabolic pathways, 
including for protein synthesis, raised doubts regarding their identity as neurotransmitters 
(see Watkins and Jane, 2006 for a review). These suspicions were supported by early 
reports suggesting that negatively charged amino acids such as L-glutamate and L-aspartate 
activated, whereas neutral amino acids such as γ-aminobutyric acid (GABA), β-alanine and 
taurine inhibited neurons in a non-specific manner (Curtis and Watkins, 1960, 1963; 
Takeuchi and Takeuchi, 1963). However, further pharmacological investigations revealed 
that the inhibitory effects of GABA and glycine were selectively blocked by bicuculline 
and strychnine, respectively (Curtis and Johnston, 1974). These results suggested that 
excitatory signalling may also be mediated by amino acids. Furthermore, the differential 
distribution of L-glutamate and L-aspartate in the central nervous system (CNS) also 
suggested that these excitatory amino acids mediated different roles in neurotransmission 
(Graham et al., 1967; Johnston, 1968; Duggan and Johnston, 1970). While L-glutamate and 
L-aspartate activated excitatory synapses in neuronal populations across the CNS, studies 
on thalamic and spinal neurons revealed that excitatory neurons have different sensitivities 
to L-glutamate and L-aspartate which suggested that they may have acted on different 
targets to produce the excitatory responses (Mclennan et al., 1968; Duggan, 1974).  
Pharmacological studies of the neurotransmission mediated by L-glutamate (and L-
aspartate) have spanned over six decades and have led to the discovery of glutamate 
receptors, which are responsible for binding L-glutamate (and L-aspartate) and eliciting 
excitatory responses in neurons (Nakanishi, 1992; Hollmann and Heinemann, 1994). These 
glutamate receptors are classified according to their mechanism of signal transduction, their 
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pharmacology and amino acid sequence homology (reviewed in Niswender and Conn, 2010 
and Traynelis et al., 2010).  
1.1. Glutamate receptors and neurotransmission 
1.1.1. Classification of glutamate receptors 
Glutamate receptors are broadly classed according to their mechanism of signal 
transduction once L-glutamate (herein referred to as glutamate unless specified) binds to 
and activates the receptor (Figure 1.1). Ionotropic glutamate receptors (iGluRs) have an 
integral ion channel, which opens upon receptor activation to allow conductance of cations 
such as sodium (Na+), potassium (K+) and calcium (Ca2+) between the extracellular space 
and the neuron (MacDermott et al., 1986; Mayer and Westbrook, 1987). Another class of 
glutamate receptors, namely metabotropic glutamate receptors (mGluRs), mediates 
neurotransmission by binding to intracellular guanine nucleotide-binding proteins (or G 
proteins) once activated by glutamate or other agonists (Monaghan et al., 1989; Niswender 
and Conn, 2010).  
Diversity in the types of depolarising responses mediated by iGluRs led to the classification 
of iGluRs based on selective agonists (Figure 1.2), which elicited distinct responses, and 
selective antagonists, which inhibited the distinct responses mediated by those selective 
agonists (Davies and Watkins, 1979; Honoré et al., 1988). Hence, these iGluRs were named 
according to the agonists that most potently and selectively activated them, i.e. (S)-α-
amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) activated receptors 
(AMPARs), N-methyl-D-aspartate activated receptors (NMDARs), and kainic acid 
activated receptors (KARs) (Davies and Watkins, 1981, 1985; Lodge, 2009). Analysis of 
the gene sequences that code for glutamate receptors initially suggested, and X-ray crystal 
structures of glutamate receptors later confirmed that functional glutamate receptors are 
assembled from modular proteins known as subunits (Hollmann et al., 1989; Armstrong et 
al., 1998; Sobolevsky et al., 2009). While there are amino acid sequence similarities 
between subunits that compose each family of iGluRs (AMPAR, NMDAR, and KAR), the 
differences between subunits are responsible for the variability in their regional- and 
developmental-specific functions (e.g. Lerma and Marques, 2013 and Paoletti et al., 2013). 
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Advances in molecular biology techniques led to the cloning of functional iGluRs based on 
DNA sequence homology to each other and led to the identification of genes that encode 
the four AMPAR subunits (GluA1-4), five KAR subunits (GluK1-5) and the seven genes 
that encode the NMDAR subunits (GluN1, GluN2A-D, GluN3A-B) (Hollmann et al., 1989; 
Bettler et al., 1990; Boulter et al., 1990; Nakanishi et al., 1990; Egebjerg et al., 1991; 
Moriyoshi et al., 1991; Hollmann and Heinemann, 1994). Subunits for another class of 
iGluR – known as delta (δ) receptors – were also cloned based on DNA sequence 
homology: GluD1 and GluD2 (Lomeli et al., 1993) (Figure 1.1). Over the years, different 
names have been used to refer to iGluR subunits, which was a cause for confusion when 
comparing studies of iGluRs from different research groups; therefore, the naming of the 
iGluR subunits was unified in 2010 to match the names of the subunit with the genes that 
encode them (Collingridge et al., 2009). Similarly, eight genes which code for mGluR 
subunits (mGluR1-8) were also discovered and classified into three groups (I, II and III) 
based on amino acid sequence homology, agonist pharmacology and second messenger 
systems that are activated following glutamate binding to mGluRs (reviewed in Niswender 
and Conn, 2010).  
 
Figure 1.1. Classification of glutamate receptor subunits. Subunits for ionotropic glutamate 
receptors are divided into groups based on agonist pharmacology (AMPA, NMDA and kainate) and 
sequence homology (delta). Metabotropic glutamate receptor subunits are grouped (Group I-III) 
according to agonist pharmacology, second messenger systems and amino acid sequence homology. 
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Figure 1.2. Agonists of ionotropic glutamate receptors. L-glutamate and L-aspartate were 
prototypic agonists of glutamate receptors before subtype selective agonists (AMPA, NMDA and 
kainic acid) were identified. 
1.1.2. Structure of ionotropic glutamate receptors 
The iGluR protein complex is formed by four subunits assembled in a dimer of dimer 
arrangement (e.g. Sobolevsky et al., 2009) (Figure 1.3). Each subunit in the protein contains 
an extracellular amino-terminal domain (ATD), an extracellular ligand binding domain 
(LBD), a transmembrane domain (TMD) which contains 3 membrane-spanning helices 
(M1, M3, M4) and a re-entrant loop (M2), and an intracellular carboxyl-terminal domain 
(CTD) (Sobolevsky et al., 2009). The semi-autonomous nature of the subunit domains was 
demonstrated by the fact that the LBD can be isolated and still formed dimers that are 
structurally similar to the LBD found in functional iGluRs (Kuusinen et al., 1995; Deming 
et al., 2003). 
X-ray crystallography studies have revealed the structure of the full length iGluR complex 
at high resolutions (e.g. 3.6 Å, Sobolevsky et al., 2009) (Figure 1.4). The ATD of iGluR 
subunits contains a signal peptide (14–33 residues) that is responsible for trafficking the 
receptor to the plasma membrane but is cleaved upon successful assembly of the receptor 
(von Heijne, 1986; Hollmann et al., 1989; Traynelis et al., 2010). The numbering of amino 
acid sequences of AMPARs and KARs has traditionally omitted the signalling peptide 
whereas NMDAR amino acid numbering begins at the initiating methionine (Armstrong et 
al., 1998; Furukawa and Gouaux, 2003). This convention of amino acid numbering is 
followed in this thesis to aid comparisons with previous studies.  
The subunit arrangement in the ATD layer of the GluA2 homomeric receptor structure is 
such that there are two local dimers – one dimer formed by subunits A and B, and the other 
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dimer formed by subunits C and D (Sobolevsky et al., 2009). From the ATD to the LBD, 
there is a crossover of the subunits that make up the two dimers – subunits A and D form 
one dimer, and subunits B and C form the other dimer in the LBD (Sobolevsky et al., 2009). 
In both the ATD and LBD, there is a two-fold axis of rotational symmetry whereas in the 
TMD, a four-fold rotational symmetry is observed (Sobolevsky et al., 2009; Karakas and 
Furukawa, 2014; Meyerson et al., 2014). 
The X-ray crystal structure of the GluA2 homomeric tetramer revealed that the ATD of 
each iGluR subunit assumes a clamshell-like shape (Figure 1.3), which contains two lobes 
(R1 and R2) (Sobolevsky et al., 2009). In the dimer of dimer arrangement of the ATD layer 
of the GluA2 homomeric receptor, an inter-dimer interface is created by subunits B and D 
(Sobolevsky et al., 2009). In the case of the GluN1- and GluN2A-containing diheteromeric 
receptor, the subunit arrangement in the ATD is: GluN1-GluN2-GluN1-GluN2, with inter-
dimer interactions occurring between the upper (R1) lobes of GluN1 and GluN2 whereas 
there is a weak interface between the R2 lobes (Karakas and Furukawa, 2014). The ATD 
contains binding sites for extracellular ligands such as Zn2+ (in the case of NMDARs) and 
allosteric modulators (Karakas et al., 2009; Perin-Dureau et al., 2002). The ATD also 
controls the kinetics of the ion channel, desensitisation of the receptor, trafficking of the 
receptor to the plasma membrane, assembly of the tetrameric receptor complex, and affects 
agonist and antagonist pharmacology (Kuusinen et al., 1999; Leuschner and Hoch, 1999; 
Ayalon et al., 2005; Yuan et al., 2009a). A significant difference between AMPAR and 
NMDAR structures is the greater interactions between the ATD and the upper lobe of the 
LBD in NMDARs, which gives NMDARs a more compact structure compared to AMPARs 
(Karakas and Furukawa, 2014). The ATD-LBD interface in NMDARs contains the binding 
site for allosteric modulators (Khatri et al., 2014). 
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Figure 1.3. The topology of an ionotropic glutamate receptor subunit showing the X-ray 
crystal structure of the amino terminal domain and ligand binding domain. Topology of a 
KAR subunit depicting the amino terminal domain (ATD), ligand binding domain (LBD) and 
transmembrane domain (TMD). D1 and D2 are the lobes of the LBD whereas R1 and R2 
corresponds to the lobes of the ATD. The TMD is composed of helices M1, M3 and M4 and the re-
entrant loop (M2). Adapted from Contractor et al., (2011). Images of ATD and LBD structures in 
inset are from Kumar et al., (2009) and Mayer, (2005), respectively.  
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Figure 1.4. X-ray structure of NMDAR and AMPAR. Full length X-ray structure of the 
GluN1/GluN2 diheteromeric NMDAR (left) and the GluA2 homomeric AMPAR (right). The 
amino terminal (ATD) and carboxy terminal (CTD) domains of some subunits are labelled for 
clarity. L-glutamate (L-Glu) and glycine (Gly) bound to the NMDAR GluN2B and GluN1 subunits, 
respectively are shown as spheres. The NMDAR structure was taken from Karakas and Furukawa 
(2014) and the AMPAR structure was taken from Sobolevsky et al. (2009). 
The LBD contains the glutamate binding site and has high sequence homology between 
subunits of the same iGluR family (Traynelis et al., 2010). The LBD of each subunit is 
formed from two peptide sequences, one of the sequences (S1) is formed by the polypeptide 
chain linking the ATD to the M1 helix of TMD whereas the other peptide sequence (S2) is 
formed from the polypeptide chain between M3 and M4 (Hollmann and Heinemann, 1994). 
The S1 and S2 polypeptide chains have been isolated and when artificially linked, form a 
water-soluble LBD (Hollmann and Heinemann, 1994; Armstrong et al., 1998). The LBD 
assumes a clamshell-like conformation which contains two lobes, D1 and D2, separated by 
a cleft in which glutamate and other orthosteric ligands bind (Figure 1.3 and Figure 1.4). 
The AMPAR crystal structure has revealed that the LBD layer of the iGluR has a dimer of 
dimer arrangement similar to the ATD (see above), but there is a crossover of subunits 
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compared to the ATD such that one LBD dimer is composed of subunits A and D, and the 
other dimer is composed of subunits B and C (Sobolevsky et al., 2009). This arrangement 
results in an inter-dimer interface between subunits A and C (Sobolevsky et al., 2009). The 
inter-dimer interface of AMPAR (GluA2 homomer) LBDs contains the binding sites for 
positive allosteric modulators (such as cyclothiazide and aniracetam), which block 
desensitisation of the receptor and causes slowing of deactivation (Sun et al., 2002; Jin et 
al., 2005). Studies in GluK2 homomeric receptors have also shown that stability of the LBD 
dimer interface affects the rate of desensitisation (Nayeem et al., 2011, 2013). In NMDARs 
(specifically the GluN1/GluN2A heterotetramer), the LBD dimer interface has an aromatic 
ring of a tyrosine residue (Tyr-535) from GluN1, which overlaps with the positive allosteric 
modulator aniracetam in AMPAR, acts as a naturally tethered ligand in the primary 
sequence (Furukawa et al., 2005). In summary, the inter-dimer interactions in the LBD 
layer determines the desensitisation and deactivation rates in iGluRs and the presence of 
Tyr-535 in NMDARs may explain the slower currents (less desensitisation and 
deactivation) produced by NMDARs compared to AMPARs.  
Upon agonist binding to the LBD cleft, the LBD undergoes conformational changes leading 
to the closing of the D1–D2 cleft which pulls the S2 polypeptide chain linking the LBD to 
the TMD and leads to opening of the ion channel (Armstrong et al., 1998; Armstrong and 
Gouaux, 2000; Mayer, 2005). The movements of the receptor TMD caused by the LBD 
domain closure induces strain on the receptor complex, which is relieved by the opening of 
the LBD clamshell and the subsequent closing of the ion channel (Armstrong and Gouaux, 
2000; Hansen et al., 2007). A significant feature of the AMPAR LBD is that alternative 
splicing creates two isoforms of the LBD termed flip and flop (Sommer et al., 1990) which 
affects receptor desensitisation and sensitivity to positive allosteric modulators (Mosbacher 
et al., 1994; Partin et al., 1994, 1995). For example, the AMPAR positive allosteric 
modulator cyclothiazide significantly inhibits the desensitisation of flip splice variants but 
only slows the rate of onset of desensitisation for the flop variant (Johansen et al., 1995; 
Partin et al., 1996).  
The TMD contributes to the ion channel of the iGluR and contains amino acid sequences 
responsible for channel properties such as ion selectivity and gating (Hume et al., 1991; 
Watanabe et al., 2002). The core of an iGluR ion channel is composed of the 
Chapter 1 – Introduction 
10 
transmembrane helices M1, M3 and M4 from each of the four subunits in the tetrameric 
receptor complex (Wo and Oswald, 1995; Kuner et al., 2003). The inner cavity of the ion 
channel pore is formed by the M2 re-entrant loop from each subunit in the tetramer 
(Sobolevsky et al., 2009). At the apex of the re-entrant M2 loop of GluA2-containing 
AMPARs and GluK1 and GluK2 KARs is a glutamine/arginine RNA editing site (also 
known as Q/R site) which is subject to post-transcriptional modification by the enzyme 
adenosine deaminase (Sommer et al., 1991). Upon editing of the AMPAR or KAR Q/R site 
from glutamine (Q) to arginine (R), the Ca2+ permeability of the ion channel is significantly 
lowered (Burnashev et al., 1996). Editing at the Q/R site also renders AMPARs and KARs 
insensitive to block by intracellular and extracellular polyamines such as spermine and 
spermidine, which block the unedited (Q) receptor’s ion channel (Bowie and Mayer, 1995; 
Donevan and Rogawski, 1995; Kamboj et al., 1995). In the brain, the Q/R site of the GluA2 
subunit RNA is found almost exclusively in the edited form (containing arginine) (Seeburg 
et al., 1998). In GluN1 and GluN2 NMDAR subunits, the Q/R site equivalent always 
contains an asparagine (N) residue, which confers NMDARs with Ca2+ permeability and 
Mg2+ block of the ion channel pore (Burnashev et al., 1992a; Mori et al., 1992).  
Amongst all domains of iGluRs, the CTD has the least amino acid sequence homology 
between each iGluR family and encodes docking motifs for intracellular binding proteins 
(Traynelis et al., 2010). The deletion of the CTD does not abolish the receptor’s function 
but alters its regulation in some subunits (e.g. GluN1, GluN2A) (Köhr and Seeburg, 1996; 
Ehlers et al., 1998). Indeed, the regulation of iGluR activity by intracellular kinases depends 
on phosphorylation sites in the CTD (Tingley et al., 1997; Barria et al., 1997; Rivera et al., 
2007). In addition, many iGluR subunits directly associate with signalling proteins; e.g. 
NMDAR subunits and type II Ca2+/calmodulin-dependent protein kinase (CamKII) 
(Gardoni et al., 1998; Strack and Colbran, 1998). In summary, the CTD interacts with 
intracellular proteins that are involved in second messenger signalling, localisation of the 
receptor to specific cellular regions, stabilisation of the receptor within synapses, 
posttranslational modifications and targeting for degradation (Derkach et al., 1999; Boehm 
et al., 2006). 
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1.1.3. Accessory proteins of ionotropic glutamate receptors 
In addition to the four subunits that form an iGluR complex, many accessory proteins that 
interact with iGluRs in the CNS have been described (Tomita, 2010; Lerma and Marques, 
2013). Accessory proteins (also known as auxiliary subunits) have been shown to control 
the pharmacology and channel current kinetics of the receptor (Menuz et al., 2007; Kato et 
al., 2008) and affect trafficking and localisation of the receptor to the plasma membrane 
(Hashimoto et al., 1999; Tomita et al., 2003).  
The importance of accessory proteins to iGluR function became apparent with the lack of 
agreement between studies using recombinant AMPARs expressed in heterologous 
systems and those using native AMPARs. Particularly, efficacy of agonists (measured as 
the currents mediated by AMPARs upon activation by glutamate) in recombinant AMPARs 
without accessory proteins is lower compared to the presence of accessory proteins (Tomita 
et al., 2003; Cho et al., 2007; Kott et al., 2007). These discrepancies were partly attributed 
to transmembrane AMPAR regulatory proteins (TARPs), which are accessory proteins of 
AMPAR found in native tissue (Chen et al., 2000; Tomita et al., 2003). TARPs are integral 
membrane proteins, which include four members; γ-2, γ-3, γ-4 and γ-8 (Chen et al., 2000; 
Tomita et al., 2003). TARPs can associate with AMPARs early during protein translation 
and trafficking (Vandenberghe et al., 2005). Additionally, TARPs may interact with 
AMPARs at the plasma membrane to increase single channel conductance, increase the 
channel open probability, increase the activation rate, slow the deactivation rate, and reduce 
desensitisation (Chen et al., 2003; Tomita et al., 2004, 2005; Carbone and Plested, 2016).  
The majority of AMPARs in the brain are associated with TARPs (Fukata et al., 2005; 
Nakagawa et al., 2005). Association of TARPs with AMPAR subunits also seems to be 
subunit dependent (Soto et al., 2007, 2009; Kato et al., 2008). Indeed, the γ-2 TARP 
reduced AMPAR affinity for polyamine block but only in GluA2-lacking receptors (Soto 
et al., 2007). The γ-8 TARP is preferentially expressed in the hippocampus (Tomita et al., 
2003) whereas in the cerebellum, most AMPARs are associated with the γ-2 TARP (Letts 
et al., 1998; Chen et al., 2000). Knockout mice lacking the γ-8 TARP produced AMPARs 
with reduced current amplitudes and impaired AMPAR neurotransmission in the 
hippocampus (Rouach et al., 2005). Therefore, the expression of γ-8 TARP is not necessary 
for AMPAR expression but does alter AMPAR function in the hippocampus.  
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In the case of KARs, the accessory proteins Neuropilin and tolloid-like protein-1 and -2 
(Neto1 and Neto2), have been demonstrated to alter the onset and recovery from 
desensitisation of the ion channel (Zhang et al., 2009; Wyeth et al., 2014). Other accessory 
proteins including postsynaptic density protein 95 (PSD95) (Garcia et al., 1998), protein 
interacting with C kinase 1 (PICK1) and glutamate receptor interacting protein (GRIP) 
(Hirbec et al., 2003) have been shown to interact with KARs (see Lerma and Marques, 
2013). The heterogeneity of the accessory proteins is believed to confer the KAR complex 
with the ability to mediate its multiphasic regulatory functions in the CNS (as discussed 
later). 
In similarity with AMPARs, accessory proteins modulate KAR ion channel function and 
affects expression of KARs (Laezza et al., 2007; Copits et al., 2011; Tomita and Castillo, 
2012). Native KARs have higher current amplitudes compared to recombinant KARs 
(Zhang et al., 2009). Subsequently, co-expression of KARs with Neto2 in cultured 
cerebellar granule cells resulted in currents with larger amplitudes in response to glutamate 
compared to KARs expressed without Neto2 (Zhang et al., 2009). Neto also slows the decay 
of the current following removal of glutamate (Zhang et al., 2009). This slowing of the 
KAR deactivation current by Neto suggests that steady state glutamate affinity of KARs 
may be higher in the presence of Neto and reconcile the difference in affinities between 
native and recombinant KARs.  
Another critical effect of Neto on KAR-mediated EPSCs is the slowing of the KAR EPSC 
decay (Zhang et al., 2009; Straub et al., 2011). EPSCs mediated by KARs without Neto 
and EPSCs mediated by AMPARs have similar decay kinetics (Straub et al., 2011). 
However, in native conditions, KARs mediate slower decaying EPSCs compared to 
AMPARs (Castillo et al., 1997). The slower current of KARs may allow them to act as 
synaptic integrators of activity (Straub et al., 2011), whereby the slower decay of KAR 
EPSCs allows persistent AMPAR activity (which has faster decay) to depolarise the 
membrane potential and subsequently activate NMDARs and other intracellular 
mechanisms (discussed later).  
Neto may not be necessary for trafficking of KARs to the plasma membrane because Neto 
knockout mice have KAR expression at synapses (Straub et al., 2011; Tang et al., 2011) 
Chapter 1 – Introduction 
13 
and expression of Neto in Xenopus laevis (X. laevis) oocytes increases glutamate-evoked 
KAR currents without increasing surface expression (Zhang et al., 2009). Moreover, Neto 
can also associate with other receptors (Ng et al., 2009; Ivakine et al., 2013) and may 
therefore act as general modulatory proteins at the plasma membrane. This has led to the 
theory that there may be two populations of KARs – those with and without Neto 
association (Lerma and Marques, 2013).  
Neto1 was first suggested to act as an NMDAR-interacting protein as mice lacking Neto 
had impaired NMDAR-mediated synaptic plasticity and reduced GluN2A expression in the 
hippocampus (Ng et al., 2009). However, a subsequent study showed that Neto1 knockout 
did not affect expression of GluN1, GluN2A or GluN2B, and Neto1 knockout did not affect 
NMDAR current kinetics (Straub et al., 2011). Another study suggested that Neto1 may 
interact with the CTD of GluN2A subunits but not with the extracellular ATD or the TMD 
and therefore, may not be auxiliary subunits (Cousins et al., 2013). Another study has 
suggested that Neto protein may also regulate the expression of GluN2B-containing 
NMDARs in the cornu ammonis 3 (CA3) subregion of the hippocampus (Wyeth et al., 
2014). More recently, genetic screening in C. elegans discovered a presynaptically released 
accessory protein known as NMDAR auxiliary protein 1 (NRAP-1) that may be critical for 
activation of NMDARs (Lei et al., 2017).  
In summary, any investigation of iGluRs requires the consideration of the contribution of 
its accessory proteins. The effects of accessory proteins are particularly important in studies 
that employ glutamate (and possibly other orthosteric ligands) binding to the iGluR because 
accessory proteins affect the kinetics of glutamate induced currents. The possible influence 
of accessory proteins on the current study will be discussed in later chapters.  
1.1.4. The roles of ionotropic glutamate receptors in neuronal signalling  
What are the processes by which billions of neurons in the brain coordinate their activity? 
An important step in answering that question is to understand neurotransmission, the 
process by which activity in one neuron (presynaptic neuron) is transmitted to another 
(postsynaptic neuron). A brief introduction to neurotransmission, and the roles that iGluRs 
play in neurotransmission and activity dependent modulation in efficacy of 
neurotransmission is presented in this section. The specific roles of iGluRs studied in this 
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thesis, namely KARs and NMDARs, are discussed in subsequent sections. In this thesis, 
the study of glutamatergic neurotransmission was conducted in the hippocampus; therefore, 
the discussion of neurotransmission will be based on findings from the hippocampus but 
results from other brain regions will be discussed when relevant. 
Prior to beginning the discussion on neurotransmission mediated by glutamate, it is 
necessary to briefly describe the molecular events underlying electrical activity in neurons. 
The membrane potential, or potential difference across the plasma membrane of a cell, is 
dependent on the concentrations of physiologically permeable ions (mainly Na+, K+ and 
Cl–) across the membrane and the permeability of the membrane to those ions (Hodgkin 
and Huxley, 1952). Each ion separated by the plasma membrane is acted on by an 
electromotive force, which depends on the charge of the ion, and the ion’s concentration 
gradient across the membrane; the force acting on the ion can be determined from the ion’s 
equilibrium potential (the membrane potential at equilibrium, i.e. when there is no net flow 
of the ion across the membrane) and the membrane potential (which depends on the 
concentration gradients and membrane permeabilities of all permeable ions) (Hodgkin and 
Huxley, 1952). At rest, the ionic concentration gradients across the neuronal plasma 
membrane for the most permeable ions, namely Na+, K+, Cl–, and Ca2+, are maintained by 
(1) pumps that require the hydrolysis of adenosine triphosphate (ATP) to adenosine 
diphosphate (ADP) for energy, collectively known as ATPase pumps (e.g. Na+/K+-
ATPase), and (2) ion exchangers, which use the concentration gradient of one ion species 
to transport another ion species across the membrane (e.g. Na+/Ca2+ exchanger) (e.g. Rang 
and Ritchie, 1968; Philipson et al., 2002). The typical resting membrane potential in 
neurons (in the range of –85 mV to –60 mV in hippocampal pyramidal neurons) is due to 
(1) the Na+/K+-ATPase pump, which carries three Na+ ions out of the cell for every two K+ 
ions that are carried into the cell (Rang and Ritchie, 1968), and (2) the higher permeability 
of the plasma membrane to K+ ions than Cl– and Na+ ions at rest (Hodgkin and Huxley, 
1952). The membrane permeabilities of Ca2+ and Cl– may also change during 
neurotransmission, leading to the disruption of resting concentration gradients for both Ca2+ 
and Cl–; the resting concentration gradients for these ions are then restored (discussed later).  
An action potential is a regenerative, all-or-none, electrical event caused by a voltage-
dependent change in the plasma membrane’s permeabilities to Na+ and K+ ions; and is 
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responsible for neurotransmission (discussed in 1.1.4.1). The neuron’s membrane potential 
waveform during an action potential is determined mainly by the movement of Na+ and K+ 
ions across the plasma membrane (Hodgkin and Huxley, 1952). The initial rising phase of 
the action potential (depolarisation) is mediated by the influx of Na+ into the neuron through 
voltage-gated sodium channels (VGSCs) due to the higher concentration of Na+ outside the 
neuron compared to inside (Hodgkin et al., 1952; see Hille, 1992 for VGSCs). The influx 
of Na+ ions drives the membrane potential towards the equilibrium potential of Na+ (~60 
mV); however, the VGSCs inactivate (see Hille, 1992). Inactivation of VGSCs coincides 
with the opening of voltage-gated potassium channels (VGKCs), which causes the efflux 
of K+ down its concentration gradient (higher inside the cell than outside). The efflux of K+ 
repolarises the membrane potential towards the K+ equilibrium potential (approximately –
100 mV), which causes the membrane potential to become hyperpolarised (Hodgkin et al., 
1952; see Hille, 1992). During hyperpolarisation, VGKCs inactivate and the membrane 
potential is restored to the resting membrane potential by the combined actions of (1) the 
Na+/K+-ATPase pump, and (2) potassium leak channels, which render the plasma 
membrane more permeable to K+ than other ions at resting membrane potentials (Rang and 
Ritchie, 1968; Gustafsson et al., 1982; Storm, 1990).  
1.1.4.1. Synthesis and release of the neurotransmitter glutamate 
Neurotransmission takes place at the synapse, a specialised junction between the pre- and 
postsynaptic neurons (the term synapse was coined by Charles Sherrington; see Foster and 
Sherrington, 1897, p. 60, for an early description). Two types of synapses, which differ in 
their mechanism of transmission are known – electrical and chemical synapses. At 
electrical synapses, signalling occurs by passive flow of electrical current between neurons 
via specialisations known as gap junctions (reviewed in Bennett and Zukin, 2004, and 
Connors and Long, 2004). The more common type of synapses in the mammalian brain is 
the chemical synapse, which involves the release of a neurotransmitter from the presynaptic 
neuron (reviewed in Zucker et al., 2014). Glutamatergic synapses are chemical synapses 
that use glutamate as the neurotransmitter. The presynaptic portion of chemical synapses 
contains the active zone, which is an electron-dense entity containing the molecular 
machinery that participate in the release of the neurotransmitter (reviewed in Südhof, 
2012). The postsynaptic side of excitatory synapses such as glutamatergic synapses 
contains a pronounced post-synaptic density (PSD) that contains receptor and effector 
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proteins, which sense the neurotransmitter and transduce the signal in the postsynaptic 
neuron (see Boeckers, 2006 for a review). At glutamatergic synapses, glutamate is 
packaged into synaptic vesicles in the terminals of the presynaptic neuron (Palay and 
Palade, 1955). Cytoplasmic glutamate in the presynaptic neuron is synthesised from α-
ketoglutarate, which is an intermediate in the Kreb’s cycle, by transaminases (e.g. Cho et 
al., 2001). Glutamate can also be synthesised from glutamine by the enzyme glutaminase 
(Hu et al., 2010). Glutamate in the presynaptic neuron is loaded into presynaptic vesicles 
via vesicular glutamate transporters (VGLUTs; VGLUT1-3) of which VGLUT1 is the 
predominantly expressed form in the hippocampus (van der Hel et al., 2009). VGLUTs use 
the H+ ion concentration gradient (higher H+ concentration inside the vesicle compared to 
the cytoplasm) created by the H+-ATPase pump, to transport glutamate into the vesicle and 
counter-transport H+ (reviewed in Ozkan and Ueda, 1998). The H+-ATPase pump requires 
hydrolysis of cytosolic adenosine triphosphate (ATP) to adenosine diphosphate (ADP) to 
direct H+ flow into the synaptic vesicle (Naito and Ueda, 1983). Vesicles in the presynaptic 
bouton are reversibly tethered by synapsin molecules to the presynaptic actin scaffold 
(Huttner et al., 1983). A subset of presynaptic vesicles is in close proximity to the 
presynaptic active zone (known as “docked”), possibly in readiness for exocytosis (Harris 
and Sultan, 1995). This set of vesicles may form a physiologically defined readily 
releasable pool of vesicles, which are available for release at a rapid time scale (Stevens 
and Tsujimoto, 1995).  
An action potential reaching the presynaptic terminal results in the opening of P/Q- and N-
type voltage-gated calcium channels (VGCCs), which are located near the docked vesicles 
in the presynaptic terminal, leading to a transient increase of Ca2+ ions in the presynaptic 
active zone (Koester and Sakmann, 2000). The transient Ca2+ increase is sensed by 
synaptotagmin I, which leads to the fusion of vesicular membrane with the presynaptic 
neuron plasma membrane and release of glutamate into the synaptic cleft (Fernández-
Chacón et al., 2001). The fusion of vesicles with the presynaptic membrane is mediated by 
(1) SNAREs (for soluble NSF attachment receptor proteins; NSF: N-ethylmaleimide-
sensitive factor) on the vesicular and target (the presynaptic neuron) membranes, and (2) 
SM proteins (for Sec1/Munc18-like proteins) (see Südhof, 2013 for a review). Vesicular 
SNAREs (v-SNAREs) include vesicle-associated membrane protein (VAMP), also known 
as synaptobrevin; and target SNAREs (t-SNAREs) include SNAP-25 and syntaxin 
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(Südhof, 2013). A complex between synaptobrevin, and SNAP-25 and syntaxin mediated 
by the SM proteins forces the vesicular and presynaptic membrane together in preparation 
for the fusion of two membranes (Söllner et al., 1993a). Fusion of the membranes causes 
release of the intravesicular glutamate into the synaptic cleft so that glutamate can passively 
diffuse to its targets. 
The Ca2+ increase caused by the opening of VGCCs disrupts the resting electrochemical 
gradient for Ca2+. The electrochemical gradient for Ca2+ is re-established by (1) buffering 
of intracellular Ca2+ by calcium binding proteins such as parvalbumin and calbindin, (2) 
uptake of Ca2+ into mitochondria and smooth endoplasmic reticulum, and (3) removal of 
Ca2+ ions from the neuron by ATP-dependent Ca2+ pumps and by Ca2+ exchangers (see 
Blaustein, 1988 for a review). Under prolonged influx of Ca2+, the restoration of Ca2+ 
concentration gradient could take several minutes (e.g. Müller and Connor, 1991) and this 
clearance of Ca2+ could lead to successive action potentials to become increasingly 
effective in triggering neurotransmitter release (further discussed in 1.1.4.3). The SNARE 
proteins are made available for another round of exocytosis by the soluble ATPase NSF 
and α-SNAP (soluble NSF attachment protein) (Söllner et al., 1993b; Mayer et al., 1996). 
The process of recovering fused synaptic vesicles proceeds by the formation of a coat of 
clathrin molecules on the cytoplasmic face of the plasma membrane (Wickelgren et al., 
1985). The clathrin coating increases the membrane curvature and initiates budding of the 
vesicular membrane (Heuser and Reese, 1973). The coated vesicles are “pinched off” the 
plasma membrane partly by the enzyme dynamin, following which the recycled vesicle 
enters the presynaptic pool (Heuser and Reese, 1973). 
Glutamate in the synaptic cleft binds to glutamate receptors (both iGluRs and mGluRs) 
expressed on either the presynaptic (e.g. Berretta and Jones, 1996; Rodríguez-Moreno et 
al., 2000; Rusakov et al., 2005; McGuinness et al., 2010) or postsynaptic terminal (e.g. 
Collingridge et al., 1983; Malinow and Malenka, 2002). The glutamate concentration in the 
synaptic cleft is controlled by passive diffusion of glutamate (down its electrochemical 
gradient) away from the synaptic cleft and reuptake of glutamate via excitatory amino acid 
transporters (EAATs) located on astrocytes or neurons (Clark and Barbour, 1997; Bergles 
and Jahr, 1997). In hippocampal astrocytes, EAAT2 has the highest expression whereas 
EAAT3 is expressed in neurons at low levels (see Danbolt, 2001). Glutamate concentration 
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in astrocytes is kept low by the action of glutamine synthetase, which converts glutamate 
to glutamine (Martinez-Hernandez et al., 1977; Ottersen et al., 1992; Laake et al., 1995). 
The lower intracellular glutamate in astrocytes creates the concentration gradient by which 
EAATs can transport glutamate into astrocytes (reviewed in Marcaggi and Attwell, 2004). 
In addition to the glutamate concentration gradient, EAATs also use the electrochemical 
gradient of Na+ and K+ such that three Na+ ions are co-transported with each glutamate 
(into the cell) and one K+ ion is counter-transported (out of the cell) (Zerangue and 
Kavanaugh, 1996). Astrocytic glutamine, which is formed from glutamate, diffuses down 
its concentration gradient into the extracellular space and into the presynaptic neuron where 
it can be recycled to glutamate and packaged into vesicles for further release (reviewed in 
Danbolt, 2001). High levels of extracellular glutamate leads to the death of neurons due to 
activation of glutamate receptors, a phenomenon known as excitotoxicity (Lucas and 
Newhouse, 1957; Olney, 1969). Glutamate clearance from the extracellular space depends 
on the concentration gradients of Na+ and K+, which is maintained by the Na+/K+-ATPase 
pump (Rang and Ritchie, 1968). Neuronal death in animal models of ischaemia has been 
attributed to excitotoxicity caused by increased extracellular glutamate (Hirose and Chan, 
1993; Fujisawa et al., 1993). The energy-dependent removal of glutamate from the synaptic 
cleft may be disrupted due to low ATP levels in ischaemia (e.g. Olney, 1971; Rothman, 
1983) and exacerbate neuronal cell death.  
1.1.4.2. Ionotropic glutamate receptors mediate neurotransmission 
Ionotropic glutamate receptors contain an ion channel that opens when the receptor is 
activated following agonist binding (Sobolevsky et al., 2009). Through the open iGluR ion 
channel, cations such as Na+, K+ and Ca2+ may flow according to their electrochemical 
gradients across the plasma membrane. The permeabilities of AMPARs, KARs and 
NMDARs to Na+ and K+ ions (PNa and PK, respectively) are roughly equal – PK/PNa ~1.25 
for AMPARs and KARs and PK/PNa ~1.14 for NMDARs (Jatzke et al., 2002). As described 
earlier, RNA editing of the Q/R site glutamine residue to arginine in AMPARs and KARs 
renders them Ca2+ impermeable (see section 1.1.2). However, NMDARs (GluN2A- or 
GluN2B-containing) have ~3-fold greater Ca2+ permeability compared to Q/R un-edited 
AMPARs and KARs (e.g. Burnashev et al., 1995).  
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The flow of ions through iGluRs produce synaptic currents, which can be recorded from 
groups of synapses using field potential recordings or from individual cells using 
intracellular recordings or whole-cell patch-clamp recordings (Figure 1.5) (Neher and 
Sakmann, 1976; MacDermott et al., 1986; Mayer and Westbrook, 1987). The iGluR 
channel gating properties (such as rates of activation, desensitisation and deactivation) 
define the time course of synaptic currents at glutamate synapses (Lester et al., 1990). The 
AMPA-preferring iGluRs (AMPARs) have fast activation and deactivation rates and show 
strong desensitisation, which limits AMPAR-mediated neuronal transmission to the 
millisecond time scale (Mosbacher et al., 1994; Edmonds et al., 1995; Erreger et al., 2004). 
However, currents mediated by KARs and NMDARs have slower activation and decay 
time courses compared to AMPAR currents (Figure 1.5B) (Monyer et al., 1992; Castillo et 
al., 1997; Kidd and Isaac, 1999, 2001). NMDAR activation has two important differences 
when compared to AMPARs. Firstly, NMDAR activation also requires binding of the co-
agonist glycine in addition to glutamate (Johnson and Ascher, 1987; Kleckner and 
Dingledine, 1988). The second important difference is that at resting membrane potential 
(approximately –70 mV for hippocampal neurons), NMDARs are blocked by magnesium 
ions (Mg2+) (Mayer et al., 1984; Nowak et al., 1984). The sensitivity of Mg2+ block of 
NMDARs is dependent on the subunit composition of NMDARs such that GluN2A- or 
GluN2B-containing NMDARs have higher sensitivity to Mg2+ block compared to GluN2C- 
or GluN2D-containing NMDARs (Mayer et al., 1984; Nowak et al., 1984; Monyer et al., 
1992). NMDARs also have higher Ca2+ permeability but slower activating and 
desensitising currents than AMPARs and KARs; therefore, NMDAR currents activate in 
milliseconds and deactivate between tens and thousands of milliseconds with minimal 
desensitisation (Monyer et al., 1992; Vicini et al., 1998; Wyllie et al., 1998).  
Movement of cations across AMPARs and KARs has multiple effects on the cell: firstly, 
the influx of Na+ along its concentration gradient leads to depolarisation of the membrane 
potential from the resting potential towards the threshold voltage required for generation of 
an action potential (Geiger et al., 1997). When the sum of membrane voltage caused by 
synaptic currents exceeds the threshold required for an action potential, voltage-dependent 
sodium channels in the axon initial segment are activated, which leads to the formation of 
an action potential within the postsynaptic neuron (e.g. Colbert and Johnston, 1996). The 
second consequence of activation of AMPARs and KARs is that the resultant 
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depolarisation also facilitates the removal of Mg2+ from the NMDAR channel pore, 
allowing Ca2+ ions to enter the cell through the open NMDARs (Mayer et al., 1984; Ascher 
and Nowak, 1988; Monyer et al., 1992). The increased intracellular Ca2+ acts as a second 
messenger and leads to (1) modulation of AMPAR trafficking to the plasma membrane, (2) 
modulation of AMPAR channel conductance due to phosphorylation (or 
dephosphorylation) by intracellular kinases (or phosphatases), and (3) synthesis of AMPAR 
proteins (Kang and Schuman, 1996; Huber et al., 2000; Scheetz et al., 2000; Lee et al., 
2000; Huang et al., 2002). In summary, glutamate mediates fast excitatory synaptic 
transmission in synapses of the CNS by activating iGluRs, which have varied channel 
properties owing to its subunit heterogeneity.  
 
Figure 1.5. Ionotropic glutamate receptors mediate neurotransmission. A, Glutamate (L-Glu) 
release by a presynaptic action potential leads to activation and ion flux into the cell through 
AMPARs, KARs and NMDARs. The Mg2+ block of NMDARs at resting membrane potential is 
relieved by depolarisation of the postsynaptic neuron caused by activation of AMPARs and KARs 
and the subsequent influx of ions Na+. B, Schematic showing scaled responses (excitatory 
postsynaptic current or EPSC) from postsynaptic neurons highlight the slower rate of decay of 
KAR- and NMDAR-mediated EPSCs compared to the AMPAR mediated EPSC (based on (Lerma 
and Marques, 2013)). 
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1.1.4.3. Ionotropic glutamate receptors mediate induction of synaptic plasticity 
Even before the discovery of the mechanisms underlying neurotransmission at the 
neuromuscular junction, the possibility of neuronal changes that might explain the basis of 
learning and memory were suggested. The Polish psychologist Jerzy Konorski coined the 
term “plasticity” in reference to the nervous system to describe the ability of neurons in the 
cortex to undergo “certain permanent functional transformations” that might explain the 
mechanisms underlying learning in the brain (Konorski, 1948). The Canadian psychologist 
Donald Hebb formulated a theory of how learning might occur in the brain (Hebb, 1949). 
Hebb’s postulate was that “when an axon of cell A is near enough to excite a cell B and 
repeatedly or persistently takes part in firing it, some growth process or metabolic change 
takes place in one or both cells such that A's efficiency, as one of the cells firing B, is 
increased” (Hebb, 1949). Given that synapses are the regions that allow transmission of 
activity between neurons, synapses which encode information must be those that support 
the activity-dependent change in efficacy of synaptic transmission (synaptic plasticity) and 
if the plasticity at the synapse follows Hebb’s rules, it is often referred to as a Hebbian 
synapse. Hebb also theorised that in the brain, memories are represented by an ensemble of 
neurons connected together in order to build a memory structure (he referred to this 
ensemble as a cell assembly), and that a series of cell assemblies fire consecutively to form 
a phase sequence, which represents a more complete mental model or a “train of thought” 
(Hebb, 1949).  
In the 1970s, the first detailed description of long-lasting potentiation in the CNS was 
published (Bliss and Lømo, 1973; Bliss and Gardner-Medwin, 1973). Bliss and colleagues 
demonstrated that tetanisation (trains of high frequency stimulation) of perforant path fibres 
(presynaptic axons) from the entorhinal cortex, which projects to granule cells 
(postsynaptic cell) in the hippocampus, produced a long-term potentiation (LTP) of 
extracellularly recorded postsynaptic responses (Bliss and Lømo, 1973). The study of this 
phenomenon was greatly aided by the development of the in vitro hippocampal slice 
preparation, which allows (1) stable extracellular and intracellular recordings, (2) 
application of pharmacological agents to the extracellular environment and (3) access to 
dentate gyrus and all cornu ammonis (CA) regions of the hippocampus and the pathways 
between the cells of these regions (Andersen et al., 1971; Skrede and Westgaard, 1971). 
Hippocampus-targeted lesion studies in animals, and results from surgical excision of parts 
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of temporal cortex, including the hippocampus in humans, have suggested that the 
hippocampus is responsible for processing of at least some forms of memory; including 
processes involved in spatial and declarative memory (e.g. O’Keefe and Dostrovsky, 1971; 
O’Keefe and Nadel, 1978; Morris et al., 1990; Squire, 1992; VanElzakker et al., 2008). 
Therefore, the study of hippocampal LTP has become an established model for the study 
of synaptic plasticity in the mammalian brain and the quest to understand the physiological 
basis of learning and memory. In this section, the features of LTP and the early links 
between LTP and iGluRs (AMPARs, KARs and NMDARs) in the hippocampus will be 
described. In the subsequent sections (1.2.5 and 1.3.7), more specific roles that KARs and 
NMDARs fulfil in synaptic plasticity will be discussed.  
While LTP was first observed using in vivo extracellular recordings from a population of 
neurons (Bliss and Lømo, 1970, 1973), the potentiation of synaptic signalling during LTP 
can also be recorded from individual postsynaptic neurons using intracellular recording 
techniques such as the whole-cell configuration of the patch clamp technique (e.g. Cormier 
and Kelly, 1996; Stricker et al., 1999). LTP can be induced by delivering a train of pulses 
(typically between 50-100) at a frequency of 100 Hz or more to the afferent pathway of 
interest (a protocol known as high frequency stimulation or HFS) (Dunwiddie and Lynch, 
1978). LTP can also be induced by the theta burst stimulation (TBS) protocol which 
involves 10 bursts of 4 shocks at 100 Hz delivered at an interval of 200 ms (Larson et al., 
1986). The interval of 200 ms between the bursts represents frequency in the theta range 
(4-5 Hz), which is a neuronal firing rate observed for the hippocampus cornu ammonis 
(CA) 1 pyramidal cells and dentate granule cells from in vivo electroencephalograph (EEG) 
recordings (Bland et al., 1980; Larson et al., 1986). When recording from individual 
neurons, two additional protocols can be used for induction of LTP, namely pairing and 
spike timing. In the pairing protocol, single afferent stimuli repeated at low frequency (e.g. 
0.1 Hz) are paired with depolarising pulses (lasting 200 – 400 ms) that induce firing of the 
postsynaptic neuron (Abraham et al., 1986). In the case of spike timing, potentiation (spike 
timing-dependent potentiation, or STDP) is induced when a single afferent stimulus is 
paired with a brief depolarisation of the postsynaptic neuron that fires the postsynaptic 
neuron only once (Kelso et al., 1986; Bi and Poo, 1998). The timing between pre- and 
postsynaptic firing in STDP is critical – presynaptic stimulus must precede the firing of the 
postsynaptic neuron for induction of LTP (Bi and Poo, 1998). 
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Not all changes in synaptic efficacy represent long-term potentiation. Two transient forms 
of synaptic plasticity are observed when a pair of stimuli is delivered to the target pathway 
of interest – facilitation and depression. Initially discovered in the neuromuscular junction, 
transient facilitation and depression during paired-pulse stimulation, was also observed at 
hippocampal synapses (McNaughton, 1980). When the interstimulus interval between the 
paired pulses is less than ~100-150 ms, the response to the second pulse is larger in its 
magnitude when compared to the first, i.e. paired-pulse facilitation (PPF) (Eccles et al., 
1941; McNaughton, 1980). PPF is caused by an increase in Ca2+ levels in the presynaptic 
terminal following the first stimulus, which causes an increase in the probability of 
neurotransmitter release for a subsequent stimulus (Wu and Saggau, 1994). In contrast to 
PPF, depression of the second response compared to the first during paired pulse 
stimulation at short interstimulus intervals can be observed in synapses with high 
probability of neurotransmitter release (Zucker and Regehr, 2002). The primary reason for 
transient depression is believed to be a decrease in presynaptic probability of 
neurotransmitter release following the first stimulus through depletion of readily releasable 
vesicles; this was suggested by experiments in which extracellular Ca2+ was artificially 
reduced thus leading to decrease in probability of neurotransmitter release, which led to 
attenuation of depression compared to normal extracellular Ca2+ (e.g. Betz, 1970 and 
Dittman and Regehr, 1998). However, release from presynaptic terminals can also be 
affected by autoreceptors on the presynaptic terminal’s plasma membrane, which are 
activated by neurotransmitter released by the first stimulus and lead to a negative feedback 
loop in order to reduce neurotransmitter release from subsequent stimuli (Davies et al., 
1991). Therefore, paired-pulse facilitation and depression are generally considered as 
presynaptic phenomena and paired-pulse stimulation has been used to investigate the locus 
of expression of synaptic potentiation (McNaughton, 1980, 1982). However, some 
postsynaptic forms of PPF and PPD have also been discussed in the literature (e.g. Rozov 
and Burnashev, 1999; Brenowitz and Trussell, 2001).  
LTP is defined by three hallmark features that highlight its suitability as a physiological 
model for information storage: input specificity, cooperativity and associativity. Input 
specificity is a feature of Hebb’s postulate such that firing in the postsynaptic neuron (“cell 
B”) is mediated by persistent activity in the presynaptic neuron (“cell A”) (Hebb, 1949). 
The input specificity of LTP was first described by studies using the transverse 
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hippocampal slice preparation in which two sets of fibres converging onto the CA1 
pyramidal cell dendrites were activated independently of each other (Andersen et al., 1977; 
Lynch et al., 1977). Tetanisation of either pathway caused selective potentiation in that 
pathway and not the other pathway (Andersen et al., 1977). However, input specificity 
recorded by two-pathway experiments does not necessarily guarantee that there is 
specificity of potentiation at the synapse level. Synapse specificity was investigated 
intracellularly using spatially restricted induction of LTP at specific synapses (using the 
pairing protocol), which suggested that synapse specificity breaks down at distances < 70 
µm but specificity is maintained at distances > 100 µm (Engert and Bonhoeffer, 1997).  
The cooperativity feature of LTP induction means that a threshold number of inputs needs 
to be co-activated for LTP to be induced, meaning that “weak” tetani activating relatively 
few afferent fibres do not trigger LTP (McNaughton et al., 1978). An extension of the 
cooperativity idea is that LTP is associative, meaning that a weak tetanus otherwise 
insufficient to induce LTP would induce LTP if paired with a strong tetanus in an 
independent input onto the same postsynaptic neuron (McNaughton et al., 1978; Levy and 
Steward, 1979). The threshold requirement for induction of LTP was highlighted by studies 
in which a “sub-threshold” tetanus led to a transient form of potentiation of synaptic 
responses, post-tetanic potentiation (PTP), which decayed to baseline levels within minutes 
but did not produce a long-term increase in synaptic efficacy (McNaughton, 1982). PTP is 
caused by an increase in Ca2+ in the presynaptic terminal which gradually decayed to pre-
tetanic levels as the increased Ca2+ was cleared (Wu and Saggau, 1994).  
In addition to the perforant path to granule cell synapses, LTP was also demonstrated at 
many other synapses in the CNS; including the neurons of layers II-IV of visual cortex 
(Artola and Singer, 1987), and in the motor cortex after stimulation of sensory cortex fibres 
(Sakamoto et al., 1987), and neurons in the lateral and basolateral nuclei of the amygdala 
after stimulation of the external capsule (Chapman et al., 1990), to mention a few. Perhaps 
the most extensively characterised synapse in relation to synaptic plasticity is the Schaffer 
collateral to CA1 pyramidal cell (SC-CA1) synapse of the hippocampus (Figure 1.6) 
(Andersen et al., 1977; Collingridge et al., 1983; Bortolotto et al., 1999; Volianskis and 
Jensen, 2003; Christie and Jahr, 2006).  
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Figure 1.6. Potentiation of synaptic responses in the hippocampus. A, the hippocampal slice 
preparation has been used extensively to study synaptic plasticity (Skrede and Westgaard, 1971). 
The perforant path (pp) fibres originate from the entorhinal cortex and form synapses with dentate 
gyrus principle cells. The mossy fibre (mf) axons originate from the dentate gyrus (DG) principle 
cells and synapse with CA3 principle cells. The Schaffer collateral (SC) axons and commissural 
(comm) axons originate from the principle cells of the cornu ammonis (CA) 3 region of the 
hippocampus of the same and opposite brain hemispheres, respectively. Sch and comm fibres form 
synapses with pyramidal cells of the CA1 region (SC-CA1). Pulses are delivered to the Sch and 
comm axons using a stimulation electrode (Stim) and extracellular field excitatory postsynaptic 
potential (f-EPSP) responses are recorded from the SC-CA1 synapses (red box). Responses are 
acquired at a frequency of 
1
15
 Hz whereas potentiation can be induced using a theta burst stimulation 
(TBS) protocol. B, tetanisation of SC-CA1 axons using TBS (arrowhead) leads to a sudden increase 
in synaptic responses short-term potentiation (STP), which decays to a stable long-term potentiation 
of synaptic responses (LTP). Recording of post-tetanic potentiation (PTP) was avoided by pausing 
stimulation for 3 min after tetanus. C, potentiation in the SC-CA1 synapses is induced by Ca2+ entry 
through NMDARs and activation of Ca2+-dependent kinases; in the postsynaptic neuron, this leads 
to an increase in AMPAR conductance and increased AMPAR trafficking to the membrane.  
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The identity of the neurotransmitter that mediated signalling at the excitatory synapses that 
displayed LTP in hippocampus was resolved about a decade after the discovery of LTP 
(Dolphin et al., 1982). Dolphin and colleagues used the push-pull cannula technique to 
demonstrate that glutamate concentration is increased during LTP at the perforant path to 
dentate gyrus granule cell synapse, suggesting that glutamate was the neurotransmitter that 
was responsible for LTP (Dolphin et al., 1982). This finding complemented previous 
investigations (Biscoe and Straughan, 1966; Storm-Mathisen and Iversen, 1979) and was 
corroborated by later studies using the dialysis electrode technique (Walker et al., 1995) 
and antibody staining of glutamate (Ottersen et al., 1990), together showing that glutamate 
is indeed the excitatory neurotransmitter at hippocampal synapses. Investigations of the 
molecular mechanisms underlying LTP were aided by the development of subtype-
selective glutamate receptor antagonists (Davies et al., 1981a; Watkins and Jane, 2006).  
Collingridge and colleagues demonstrated first that the NMDAR-selective antagonist D-2-
amino-5-phosphonopentanoic acid (D-AP5) blocked the induction of LTP at the SC-CA1 
synapse, suggesting that NMDAR activation was critical for the induction of LTP 
(Collingridge et al., 1983). Application of D-AP5 during baseline neurotransmission or 
after induction of LTP did not affect the synaptic responses (specifically, the f-EPSPs); 
therefore, D-AP5 blocked the induction of LTP and not baseline transmission nor the 
maintenance of LTP (Collingridge et al., 1983). In another study, Lynch and colleagues 
demonstrated that injection of the calcium chelator ethyleneglycol-bis-(β-
aminoethylether)-N,N,N′,N′,-tetraacetic acid (EGTA) into the postsynaptic CA1 neuron 
blocked the induction of LTP at SC-CA1 synapses, suggesting that a rise in postsynaptic 
Ca2+ was also critical for induction of LTP (Lynch et al., 1983). Following the two 
observations described above, it was found that NMDAR activation is voltage-dependent 
and that at the resting membrane potential, NMDARs are blocked by extracellular Mg2+; 
the Mg2+ block was relieved by depolarisation of the plasma membrane during 
depolarisation (Mayer et al., 1984; Nowak et al., 1984). At synapses, dependence of the 
induction of LTP on postsynaptic depolarisation was observed in intracellular studies in 
which the postsynaptic depolarisation could be paired to presynaptic stimuli (Kelso et al., 
1986; Malinow and Miller, 1986; Gustafsson et al., 1987). Further investigations examining 
the equilibrium potential created by NDMAR opening, and the use of Ca2+ sensitive dyes 
revealed that NMDARs were permeable to Ca2+ (Ascher and Nowak, 1988; MacDermott 
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et al., 1986). Taken together, these findings provided an explanation for the synaptic 
changes that underlie induction of synaptic plasticity at the SC-CA1 synapse; i.e. glutamate 
release from presynaptic cell and subsequent binding to NMDARs leads to Ca2+ influx 
provided that the postsynaptic neuron is sufficiently depolarised to remove the Mg2+ block 
(Figure 1.6B and C) (Collingridge, 1985). Indeed, these observations explain the Hebbian 
features of LTP, the requirement of concurrent activity in pre- and postsynaptic neurons, 
synapse specificity, cooperativity and associativity. 
As mentioned earlier, D-AP5 application does not affect the baseline neurotransmission in 
LTP experiments (Collingridge et al., 1983). Pharmacological studies using AMPAR-




 Hz) of afferent fibres at the SC-CA1 synapse are mediated by AMPARs on the 
postsynaptic neuron (Davies and Collingridge, 1989). While the role of NMDARs in 
inducing LTP was established, it was becoming clear that NMDAR activation is not the 
only mechanism by which LTP can be induced at synapses, including the SC-CA1 synapse. 
The rise in intracellular Ca2+ during LTP can come from a variety of sources, such as 
opening of calcium channels or through release of Ca2+ from intracellular sources (e.g. 
smooth endoplasmic reticulum); LTP can even be induced by activation of Ca2+-permeable 
AMPARs, and L-type voltage-gated calcium channels using different protocols from that 
required for the NMDAR-dependent form of LTP (Jia et al., 1996; Plant et al., 2006; Grover 
and Teyler, 1990). Furthermore, blockade of KARs inhibits induction of LTP at the mossy-
fibre to CA3 pyramidal cell (MF-CA3) synapse (Bortolotto et al., 1999). Therefore, 
AMPARs, KARs and NMDARs all can play a role in inducing long-term synaptic plasticity 
in the hippocampus and a role for mGluRs in the induction of LTP has also been described 
(Bashir et al., 1993; Bortolotto and Collingridge, 1993). 
Long-term depression (LTD) of synaptic responses has also been observed (Lynch et al., 
1977). Induction of LTD requires a different set of protocols compared to LTP and, at some 
synapses, requires NMDARs and/or mGluRs for its induction (e.g. NMDAR-dependent 
LTD at the SC-CA1 synapse can be induced in slices from juvenile rats by delivering 900 
pulses at 1 Hz pulse) (e.g. Kemp et al., 2000). LTP has been further characterised based on 
its temporal features and sensitivity to kinase inhibitors (McNaughton, 1982; Kauer et al., 
1988). Particularly, the initial decaying phase of potentiation following PTP, which lasts 
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for 30-60 min and precedes the long-lasting non-decremental component of stable LTP, is 
referred to as short-term potentiation (STP) (Figure 1.6B). STP, like the stable phase of 
LTP, is absent when NMDARs are pharmacologically blocked during induction 
(Collingridge et al., 1983; Malenka, 1991). Induction of STP depends also on the transient 
rise in postsynaptic Ca2+ (Malenka et al., 1988; Anwyl et al., 1988; Malenka et al., 1992).  
Although the discussion above has focused on the induction mechanisms that trigger 
potentiation, the expression mechanisms that underlie STP and LTP have also been studied. 
An early indication that STP and LTP may be expressed by different mechanisms was that 
STP cannot but LTP can be blocked when protein kinase C (PKC) is pharmacologically 
inhibited (Kauer et al., 1988). The non-decremental phase of potentiation (LTP) is further 
classified as early-LTP (E-LTP) and late-LTP (L-LTP) based on its onset of expression and 
sensitivity to protein synthesis inhibitors (Krug et al., 1984; Frey et al., 1988). Application 
of protein synthesis inhibitors, inhibitors of mRNA transcription, or inhibitors of PKMζ, 
which is the autonomously active catalytic domain of the PKC isoform PKCζ, during the 
induction of potentiation prevents the expression of L-LTP, which begins ~2 hours after 
LTP induction, but does not prevent expression of E-LTP (Krug et al., 1984; Frey et al., 
1988; Ling et al., 2002; Serrano et al., 2005). Moreover, many kinases (including PKA and 
CaMKII) are believed to play a role in the expression of E-LTP (Malenka et al., 1986; 
Malinow et al., 1989; Ito et al., 1991; Silva et al., 1992; Huang and Kandel, 1994). In 
addition to kinases, many secondary messengers and retrograde messengers (such as nitric 
oxide and arachidonic acid), which communicate between the pre- and postsynaptic 
compartments have been demonstrated to be involved in the induction and expression of 
LTP (Dumuis et al., 1988; Williams and Bliss, 1988; Böhme et al., 1991; Son et al., 1996). 
Pre- and postsynaptic forms of LTP have been described, whereas the precise 
understanding of the mechanisms that regulate their induction and expression are still under 
discussion (reviewed in MacDougall and Fine, 2013, and Padamsey and Emptage, 2013).  
1.2. Kainate receptors 
Much of the knowledge regarding the physiological significance of iGluRs comes from 
studies employing subtype-selective pharmacological tools. However, the identity of the 
subunit within the iGluR complex affects the pharmacological and physiological features 
of the receptor (Chittajallu et al., 1999). The KAR subtype family of iGluRs contains five 
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subunits, GluK1-5, which have structural and amino acid sequence similarities to AMPAR 
and NMDAR subunits (Bettler and Mulle, 1995; Traynelis et al., 2010). The principle 
subunits GluK1, GluK2 and GluK3 can form homomeric glutamate-gated ion channels in 
heterologous expression systems (Herb et al., 1992). However, native KARs exist in the 
heteromeric form containing GluK4 and/or GluK5 subunits in addition to the principle 
subunits (Werner et al., 1991; Herb et al., 1992). The structural diversity of KARs is 
increased by the presence of splice variants of GluK1-3 with a different cytoplasmic 
carboxy-terminal domain (CTD) amino-acid sequence, which may affect the modes of 
cellular trafficking and associations with intracellular proteins of the KAR (Contractor et 
al., 2011; Lerma and Marques, 2013). 
Development of subunit-selective antagonists is a significant avenue to aid future studies 
of KARs. An aim of this thesis is to develop novel GluK2-selective competitive 
antagonists. In this section, the rationale for development of novel subunit-selective 
antagonists is made by firstly discussing currently available pharmacological tools such as 
agonists, antagonists and allosteric modulators of KARs. Secondly, studies investigating 
the roles of KARs in synaptic signalling are discussed, which highlight the need for better 
competitive antagonists with selectivity for GluK2 over other iGluR subunits. Thirdly, 
studies investigating the therapeutic potential of KAR antagonists are described to show 
that GluK2-selective antagonists may help to better understand the roles of KAR subunits 
in pathophysiology and may lead to the development of more selective therapeutic agents. 
1.2.1. Agonists of kainate receptors 
Kainic acid (Figure 1.7), a glutamate analogue isolated from the seaweed Diegenea simplex 
(Nitta et al., 1958; Shinozaki and Konishi, 1970) is a potent agonist for KARs. The 
structurally related domoic acid is a higher potency KAR agonist than kainate on GluK1 
and GluK2 but not GluK3 (Biscoe et al., 1975; Schiffer et al., 1997). Domoic acid acts as 
a selective agonist of KARs over AMPARs at low concentrations (Bureau et al., 1999) and 
produces non-desensitising currents from KARs (Christensen et al., 2004a). Other agonists 
of KARs include (2S,4R)-4-methylglutamate (SYM2081, Figure 1.7), quisqualate and the 
synthetic glutamate derivative, AMPA which activates recombinant GluK2/GluK5 
heteromeric KARs (Alt et al., 2004; Mayer, 2005).  
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While the KAR agonists described above also activate AMPARs, SYM2081 was reported 
to have weaker effects on AMPARs compared to KARs (Jones et al., 1997; Zhou et al., 
1997; Donevan et al., 1998; Alt et al., 2004). An analogue of SYM2081, (2S,4R)-4-[3-(2-
naphthyl)-2-(E)-propenyl]glutamic acid (LY339434, Figure 1.7), was reported to have high 
affinity on GluK1 with much lower affinity on GluK2, GluA1, GluA2 and GluA4 (Small 
et al., 1998; Baker et al., 2000). Another class of agonists showing KAR over AMPAR 
selectivity was based on neodysiherbaine (neoDH, Figure 1.7), a naturally occurring 
analogue of the 4-substituted glutamate analogue, dysiherbaine, isolated from the marine 
sponge Dysidea herbacea (Sakai et al., 1997). Particularly, analogues such as 8-deoxy-
neoDH, 9-F-8-epi-neoDH and 9-deoxy-neoDH had high affinity on GluK1 compared to 
GluK2, GluK3, GluK5, GluA1 and GluA2 (Lash et al., 2008). Selectivity for KAR over 
AMPAR was also reported with derivatives of the natural product willardiine, which can 
be isolated from the seeds of Acacia willardiiana. Notably, (S)-5-iodowillardiine (Figure 
1.7) has high affinity for GluK1 and selectivity for KAR vs. AMPARs and NMDARs (Jane 
et al., 1997). Another KAR selective agonist is the AMPA analogue, (S)-2-amino-3-(5-tert-
butyl-3-hydroxy-4-isoxazolyl)propionic acid (ATPA, Figure 1.7), which activated 
recombinant GluK1 receptors with > 1000-fold greater affinity compared to AMPARs (Alt 
et al., 2004). 
Despite the development of GluK1 over AMPAR selective agonists such as ATPA and 5-
iodowillardiine, GluK2-selective agonists are still unavailable. An important consideration 
when comparing activity of most KAR agonists mentioned above (with the notable 
exception of domoic acid) is that they produce fast desensitisation of KARs which must be 
overcome using a desensitisation blocker such as the plant lectin, concanavalin A (con A) 
(Wong et al., 1994).  
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Figure 1.7. Structures of kainate receptor agonists.  
1.2.2. Antagonists of kainate receptors  
Development of KAR-selective antagonists has lagged behind that of AMPAR- and 
NMDAR-selective antagonists partly due to a lack of KAR-selective agonists for use in 
functional assays that investigated native KARs (Jane et al., 2009). Native tissue 
preparations in which GluK1-containing KARs were expressed without the presence of 
AMPARs, e.g. the dorsal root ganglion (DRG) cells and the isolated dorsal root preparation 
(Bettler et al., 1990; Partin et al., 1993) aided the development of GluK1-selective 
antagonists.  
Early studies used quisqualate and kainate as agonists to evoke KAR responses from native 
tissue, but these agonists are not specific to KARs. Particularly, quisqualate also activates 
AMPARs and group I metabotropic glutamate receptors (mGluRs), which made it difficult 
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to determine the antagonist activity of compounds on KARs (Abe et al., 1992; Aramori and 
Nakanishi, 1992; Mayer, 2005). Moreover, preparations such as cortical slices were shown 
to express both AMPARs and KARs (Wisden and Seeburg, 1993). Kainate produced non-
desensitising currents at AMPARs which further complicated the interpretation of results 
from early studies (Kiskin et al., 1986). More recently, cloning of KAR subunits and their 
expression in heterologous systems such as human embryonic kidney 293 (HEK293) cells 
have helped to characterise the activity of compounds selectively on KARs (Hollmann and 
Heinemann, 1994; Alt et al., 2004).  
Early studies of iGluR antagonists in dorsal horn neurons led to the AMPAR and KAR 
antagonist γ-D-glutamylaminomethylsulfonate (GAMS, Figure 1.9) (Davies and Watkins, 
1985). While these studies used quisqualate as the agonist to evoke KAR responses, later 
studies using the more selective agonists kainate and AMPA reported that GAMS may be 
a KAR antagonist (Zhou et al., 1993). Studies using recombinant KARs reported that 
GAMS was a weak KAR antagonist with no effect on GluK2 homomeric receptors up to 
30 mM (Alt et al., 2004). Other early AMPAR/KAR antagonists include 1-(4-bromo-
benzoyl)piperazine-2,3-dicarboxylic acid (p-BB-PzDA) and 1-(4-
chlorobenzoyl)piperazine-2,3-dicarboxylic acid (p-CB-PzDA) (Figure 1.8) (Davies et al., 
1984). However, both p-BB-PzDA and p-CB-PzDA were reported to inhibit NMDA-
evoked receptors with greater potency than kainate-induced responses (Ganong et al., 
1986). Despite the weak antagonist effect of p-BB-PzDA and p-CB-PzDA on KARs 
expressed in the dorsal root preparation (Evans et al., 1987), their effects on recombinant 
KARs and AMPARs remain undetermined. Another early KAR antagonist with greater 
selectivity for KARs over AMPARs was the oxime derivative, 5-nitro-6,7,8,9-
tetrahydrobenzo[g]indole-2,3-dione-3-oxime (NS-102, Figure 1.9) which had GluK2 and 
GluK1 antagonist activity with weaker effects on recombinant GluA2/GluA4-containing 
AMPARs and native AMPARs in cortical slices (Verdoorn et al., 1994; Wilding and 
Huettner, 1996). However, NS-102 has limited use as a pharmacological tool due to its 
poor water solubility (see Verdoorn et al., 1994). 
Work at Eli Lilly led to the development of KAR selective antagonists based on the 
decahydroisoquinoline structure, which led to the development of (3S,4aR,6S,8aR)-6-((4-
carboxyphenyl)methyl)-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline-3-carboxylic acid 
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(LY382884, Figure 1.9), which had an IC50 value of 2 μM on GluK1 with no activity on 
GluK2 at concentrations up to 100 μM (Bleisch et al., 1997). Subsequently, the more potent 
antagonist (3S,4aR,6S,8aR)-6-[[(2S)-2-carboxy-4,4-difluoro-1-pyrro-
lidinyl]methyl]decahydro-3-isoquinolinecarboxylicacid (LY466195, Figure 1.9) was 
developed, and was demonstrated to have a GluK1 Kb value of 13 nM with little or no 
activity on AMPARs and NMDARs (Jones et al., 2006; Weiss et al., 2006). 
Another class of KAR-selective antagonists with greater activity on GluK1 compared to 
AMPAR subunits is derived from willardiine with substitutions on the N3 position of the 
uracil ring (More et al., 2004; Dolman et al., 2005, 2006, 2007; Mayer et al., 2006). These 
include (S)-1-(2-amino-2-carboxyethyl)-3-(2-carboxybenzyl)pyrimidine-2,4-dione 
(UBP302, Figure 1.9) (More et al., 2004). A thiophene ring at the N3 position and a methyl 
group on the 5-position of the uracil ring of willardiine resulted in (S)-1-(2-amino-2-
carboxyethyl)-3-(2-carboxythiophene-3-yl-methyl)-5-methylpyrimidine-2,4-dione 
(UBP310, Figure 1.9), with nanomolar potency for GluK1 homomers and GluK1/GluK5 
heteromers, and > 100 μM potency at GluK2 homomers and GluA2-containing AMPARs 
(Dolman et al., 2007). X-ray crystal structures of UBP310 in complex with the GluK1 
ligand binding domain (LBD) revealed that UBP310 stabilises an even greater degree of 
clamshell opening of the LBD than observed in structures of antagonists in complex with 
the GluA2 and GluN1 LBD (Mayer et al., 2006; Alushin et al., 2011).  
Based on the X-ray structure and modelling studies of the GluK1, GluK2, GluK3 and 
AMPARs, a compound with greater GluK1 affinity and improved GluK1 over native 
AMPAR selectivity was developed, namely ((S)-2-amino-2-carboxyethyl)-3-(2-carboxy-5-
phenylthiophene-3-yl-methyl)-5-methylpyrimidine-2,4-dione (UBP316, also known as 
ACET, Figure 1.9) (Dolman et al., 2007; Dargan et al., 2009). ACET was shown to have 
greater GluK1 affinity and selectivity for GluK1 over AMPAR in functional assays using 
recombinant GluK1 receptors and native KARs expressed on dorsal root ganglion (DRG) 
C-fibres (Dolman et al., 2007). Further characterisation of ACET has revealed that 
recombinant GluK3 homomeric receptors are blocked by ACET with an IC50 value for 
inhibition of GluK3-mediated currents of approximately 92 nM (Perrais et al., 2009). The 
GluK3 activity of ACET is surprising because earlier derivatives of willardiine structurally 
similar to ACET has Ki > 100 µM on recombinant human GluK3 homomeric receptors 
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(Dolman et al., 2005, 2006). Moreover, UBP310 has 30-fold lower GluK3 affinity 
compared to GluK1 in a radioligand saturation binding assay (Atlason et al., 2010). The 
lack of NMDAR activity and high KAR over AMPAR selectivity of ACET and similar 
willardiine derivatives have made these compounds useful tools to elucidate the roles of 
the GluK1 subunit for induction of LTP in the CNS (Barker et al., 2006; Huxter et al., 
2007).  
An endogenous metabolite of tryptophan, 4-oxo-1,4-dihydro-quinoline-2-carboxylic acid 
(kynurenic acid, Figure 1.8), is an antagonist of AMPAR, KAR and NMDARs (Ganong et 
al., 1983; Leeson et al., 1991). Derivatives of kynurenic acid have been developed to 
produce potent NMDAR antagonists that bind to the glycine site of the NMDAR (discussed 
in more detail in Chapter 2). An example of a widely used NMDAR antagonist based on 
kynurenic acid is 5-,7-dichlorokynurenic acid (DCKA) which binds to NMDARs with a Kb 
value of 3.0 μM (Leeson et al., 1991). DCKA was used to obtain an X-ray crystal structure 
of the GluN1 LBD in complex with the NMDAR co-agonist glycine (further discussed in 
Chapter 3) (Furukawa and Gouaux, 2003).  
In assays that use native tissue containing a mixture of AMPARs and KARs, an important 
strategy to better understand KARs is to isolate the KAR-mediated responses by inhibiting 
AMPAR responses selectively. In such cases, AMPAR-selective antagonists are required 
for the study of KARs. Attempts to improve AMPAR over KAR selectivity of iGluR 
antagonists resulted in quinoxalinedione derivates such as 6-cyano-7-nitroquinoxaline-2,3-
dione (CNQX) and 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo[f]quinoxaline (NBQX) 
(Figure 1.8) (Fletcher et al., 1988; Sheardown et al., 1990). AMPAR over KAR selectivity 
of CNQX is poor (approximately similar affinity on AMPARs and KARs) but NBQX has 
approximately 3-fold selectivity for AMPARs over KARs (Wilding and Huettner, 1996); 
however, NBQX alone cannot be used to completely isolate KAR-mediated responses from 
native tissue due to its overlapping activity on AMPARs and KARs.  
An important advancement in the quest to isolate KAR-mediated responses was the 
development of 1-(4-aminophenyl)-3-methylcarbamyl-4-methyl-3,4-dihydro-7,8-
methylenedioxy-5H-2,3-benzodiazepine hydrochloride (GYKI53655), a 2,3-
benzodiazepine derivative (Paternain et al., 1995). GYKI53655 is a negative allosteric 
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modulator (NAM) at AMPARs and has been used to selectively inhibit AMPARs to study 
KAR function (Chittajallu et al., 1996; Frerking et al., 2001). However, there has been a 
report of GYKI53655 inhibiting GluK3 homomeric and GluK2/GluK3 heteromeric KARs 
at concentrations used to block AMPARs (50 μM) (Perrais et al., 2009). 
 
Figure 1.8. Structures of antagonists that block AMPARs and KARs. 
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Figure 1.9. Structures of KAR-selective orthosteric antagonists. 
1.2.3. Allosteric modulators of kainate receptors 
Allosteric modulators are molecules that bind to a site remote to the glutamate binding site 
(see Yelshanskaya et al., 2016 and Yi et al., 2016). Development of allosteric modulators 
may provide an avenue to obtain greater selectivity between AMPARs and KARs 
compared to orthosteric agonists and antagonists because allosteric binding sites usually 
have lower amino acid sequence homology between iGluR subtypes than the glutamate 
binding site, which is highly conserved between all iGluRs (Traynelis et al., 2010). Because 
negative allosteric modulators (NAMs) do not compete with glutamate to bind to the 
receptor, they are also non-competitive antagonists. 
NAMs of KARs based on 2-arylureidobenzoic acids (AUBAs) were assayed on 
recombinant homomeric and heteromeric KARs (Valgeirsson et al., 2003). These 
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compounds did not displace binding of [3H]ATPA to GluK1 and therefore are believed to 
be non-competitive antagonists (Valgeirsson et al., 2003). Of these compounds, compound 
I (Figure 1.10), displayed 50-fold selectivity for GluK1 over GluK2 while compound II 
(Figure 1.10) antagonised GluK1 and GluK2 with similar potency (Valgeirsson et al., 2003, 
2004). Neither of these compounds displayed activity on GluA1-4 AMPAR subunits at 100 
μM (Valgeirsson et al., 2003, 2004).  
Another NAM of KAR subunits is the GluK1-selective 5-carboxy-2,4-dibenzamido-
benzoic acid (NS3763, Figure 1.10), which has no activity on heteromeric GluK1/GluK5 
or GluK1/GluK2 receptors, AMPARs and NMDARs (Christensen et al., 2004a, 2004b). 
NS3763 and LY382884 (an antagonist of GluK1-containing KARs) has been used to 
determine that GluK1 heteromeric KARs are expressed presynaptically in the hippocampal 
CA1 inhibitory interneurons (Christensen et al., 2004b). The GluK1 NAM NS3763 has also 
been used to inhibit the ATPA-induced activation of KARs to suggest that GluK1 activation 
may lead to neuroprotection against ischaemic neuronal injury (Lv et al., 2012). The 
activity of NS3763 on GluK3-containing KARs remains to be determined.  
Another class of allosteric modulators that have been useful in studies of KARs are positive 
allosteric modulators (PAMs), which bind to an allosteric site on the receptor and 
subsequently potentiate KAR currents in the presence of orthosteric agonists such as 
glutamate and kainate. In native and recombinant KARs, glutamate induces a rapid 
desensitisation and the recovery from the desensitisation is slow (Wong et al., 1994; 
Wilding and Huettner, 1997). The plant lectin concanavalin A (con A) blocks the 
desensitisation of KAR-mediated currents in DRG neurons and in recombinant GluK1- and 
GluK2-containing KARs (Huettner, 1990; Partin et al., 1993; Paternain et al., 1998). 
Therefore, con A has been used to characterise novel antagonists in assays, which use 
recombinant GluK1- and GluK2-containing KARs (Bleakman et al., 1996; Alt et al., 2004). 
Desensitisation of recombinant GluK3-containing KARs is less susceptible to inhibition by 
con A; therefore, recombinant GluK3-containing KARs have been more difficult to use in 
pharmacological characterisation assays (Schiffer et al., 1997).  
More recently, a class of KAR PAMs based on benzothiadiazine was characterised (Larsen 
et al., 2017). Of these benzothiadiazine-based PAMs, 4-cyclopropyl-7-fluoro-3,4-dihydro-
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2H-1,2,4-benzothiadiazine-1,1-dioxide (BPAM344) potentiated glutamate-evoked 
currents in GluK1-3 and GluA1 subunits (Larsen et al., 2017). Other PAMs of KARs 
include volatile anaesthetics such as halothane and isofluorane, which potentiate GluK2 
channel currents (Dildy-Mayfield et al., 1996) and the triarylmethane dye, brilliant green 
(Bufler et al., 2001). The activity of brilliant green on different KAR subunits remains to 
be determined. Due to the fast desensitisation of KARs caused by agonists, development 
of novel subunit-selective KAR PAMs can be of great utility in studies investigating the 
functional roles of specific KAR subunits.  
 
Figure 1.10. Structures of KAR-selective negative allosteric modulators (NAMs). 
1.2.4. Kainate receptor expression in the hippocampus 
Early studies employed radioligand binding using [3H]kainate to find kainate binding sites 
in the brain (Monaghan and Cotman, 1982). Using in situ hybridisation (ISH), KAR subunit 
mRNA was detected in many regions of the brain including the hippocampus, amygdala, 
dorsal root ganglia (DRG), cerebellum and cerebral cortex (Wisden and Seeburg, 1993). A 
lack of specific antibodies for KAR subunits has made detection of KAR protein levels 
using immunohistochemistry (IHC) difficult, however, genetic knockout mice lacking 
specific KAR subunits have been used to assess the degree of antibody specificity in the 
case of antibodies targeting GluK2, GluK4 or GluK5 (Darstein et al., 2003; Ruiz et al., 
2005). While the neuronal localisation of the KAR subunit proteins in many regions of the 
CNS is yet to be determined, a large body of work describes the distribution and functional 
Chapter 1 – Introduction 
39 
roles of KARs in the hippocampus (Wisden and Seeburg, 1993; Bureau et al., 1999; 
Paternain et al., 2000; Breustedt and Schmitz, 2004; Wondolowski and Frerking, 2009). 
Radioligand binding studies, ISH and IHC have helped to detect the presence of KARs in 
the hippocampus, however investigations of the neuronal localisation (presynaptic or 
postsynaptic) and the functional roles of each subunit requires selective pharmacological 
tools (agonists, antagonists and allosteric modulators). In fact, studies that have used one 
or more of the techniques mentioned above have revealed that KAR subunit expression in 
the hippocampus depends on the cell type, developmental stage and sub-cellular 
localisation (Bahn et al., 1994; Castillo et al., 1997; Pinheiro and Mulle, 2006). 
Radioligand binding studies revealed that the hippocampus contains a high density of 
kainate binding sites, particularly in the cornu ammonis 3 (CA3) subregion of hippocampus 
(Monaghan and Cotman, 1982). Studies probing mRNA levels using ISH revealed that 
GluK1 mRNA is expressed in interneurons in all subregions of rat and mouse hippocampus 
(Bureau et al., 1999; Paternain et al., 2000). The GluK2 subunit mRNA is expressed in the 
principle cells and interneurons of CA1-CA3 subregions in the hippocampus (Paternain et 
al., 2000; Fisahn et al., 2004). GluK3 is expressed in granule cells of the dentate gyrus 
subregion of the hippocampus and in interneurons of stratum oriens and stratum radiatum 
layers of the hippocampus (Wisden and Seeburg, 1993; Contractor et al., 2001). GluK4 is 
expressed in CA3 pyramidal cells and in the CA1 and dentate gyrus subregions (Wisden 
and Seeburg, 1993; Fernandes et al., 2009; Lowry et al., 2013). GluK5 mRNA shows the 
highest expression levels amongst KAR subunits in the hippocampus, with presence in all 
subregions and mainly in the principle cell layer of the hippocampus (Wisden and Seeburg, 
1993). The expression patterns suggested by ISH and knockout mice were later confirmed 
using pharmacological tools (as discussed below). 
1.2.5. Kainate receptors in synaptic signalling 
Determining the functional roles that KARs play in neuronal signalling was initially 
difficult due to lack of KAR-selective agonists and antagonists. The functions of natively 
expressed KARs remained a mystery until the AMPAR-selective non-competitive 
antagonist based on 2,3-benzodiazepines, GYKI53655, was used to block AMPARs 
selectively (although GYKI53655 was later found to have antagonist activity on GluK3 and 
GluK2/GluK3-containng KARs at high concentrations) (Paternain et al., 1995; Perrais et 
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al., 2009). In the presence of AMPAR blockage using GYKI53655, kainate can be used as 
KAR agonists without activating AMPARs (e.g. Wilding and Huettner, 1997). Chittajallu 
and colleagues used whole-cell patch-clamp recordings to show that application of low 
concentration (300 nM) of kainate after AMPAR blockage using GYKI52466 (an earlier 
analogue of GYKI53655) causes facilitation of synaptic responses (NMDAR-mediated 
EPSCs) in CA1 pyramidal cells, whereas a high concentration (1 μM) of kainate causes 
depression of synaptic responses (Chittajallu et al., 1996). In the same study, both the 
facilitation and depression of synaptic responses mediated by kainate (and domoate) were 
partially blocked by the KAR antagonists NS-102 and CNQX (Chittajallu et al., 1996). 
These findings were taken as evidence for the presence of KARs on presynaptic terminals 
in the Schaffer-collateral to CA1 pyramidal cell (SC-CA1) synapse and further studies have 
corroborated this hypothesis (Figure 1.11) (Kamiya and Ozawa, 1998; Frerking et al., 
2001).  
In addition to modulating glutamate release from presynaptic terminals (i.e. as 
autoreceptors), presynaptic KARs in the CA1 function as autoreceptors that can modulate 
the release of γ-aminobutyric acid (GABA) from presynaptic terminals of GABAergic 
interneurons (Figure 1.11) (Clarke et al., 1997; Rodríguez-Moreno et al., 1997). Clarke and 
colleagues used GYKI53655 to block AMPARs and D-2-amino-5-phosphonopentanoate 
(D-AP5) to block NMDARs while performing intracellular recordings from the 
hippocampal CA1 cell body layer to record inhibitory postsynaptic currents (IPSCs), which 
are mediated by GABA receptors (Clarke et al., 1997). Application of kainate and the 
GluK1-selective agonist ATPA after blocking AMPARs and NMDARs revealed that 
activation of KARs depresses monosynaptic inhibition mediated by GABA (Clarke et al., 
1997). Moreover, the inhibition of IPSCs by kainate and ATPA can be blocked by the 
GluK1 antagonist (3SR,4aRS,6SR,8aRS)-6-((((1H-tetrazol-5-yl)methyl)oxy)methyl)-
1,2,3,4, 4a,5,6,7,8,8a-decahydroisoquinoline-3-carboxylic acid (LY294486 – an analogue 
of LY382884, which was discussed earlier). The use of the GluK1-selective agonist 
(ATPA) and antagonist (LY294486) in the study by Clarke and colleagues further 
suggested that the KARs that mediate the presynaptic modulation may contain GluK1 
subunits (Clarke et al., 1997). The presynaptic locus of the KARs that inhibit GABA release 
by the CA1 interneurons were also reported by Rodríguez-Moreno and colleagues who 
showed that in the CA1 pyramidal cells, the frequency of miniature IPSCs (mIPSCs) is 
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decreased by kainate (Rodríguez-Moreno et al., 1997). This result suggests that activation 
of KAR autoreceptors at the GABAergic interneurons depresses GABA release onto CA1 
pyramidal cells. In similarity with SC-CA1 pyramidal cell synapses, application of low 
concentrations of kainate facilitates, whereas high concentrations of kainate depresses, 
GABA release at the interneuron-pyramidal cell synapses in the CA1 (Jiang et al., 2001). 
An intriguing facet of KAR function is that KARs exert their effects partly through a 
metabotropic mechanism (by association with G-proteins) and subsequent activation of 
protein kinase C (PKC) (Rodríguez-Moreno and Lerma, 1998; Rodríguez-Moreno et al., 
2000). The metabotropic signalling was observed in the case of presynaptic KARs that 
inhibit GABA release (Rodríguez-Moreno et al., 2000). The metabotropic mode of KAR 
signalling has also been established in dorsal root ganglion neurons and occurrs 
independent of the KAR ion channel function (Rozas et al., 2003). A significant effect of 
the metabotropic signalling of KARs in the CA1 pyramidal cells of the hippocampus is its 
inhibition of the slow afterhyperpolarisation current (IAHP) mediated by Ca
2+-dependent K+ 
channels, which is observed during trains of action potentials (the activation of the IAHP 
being dependent on the number and frequency of action potentials in the train) (Melyan et 
al., 2002). Importantly, the slow IAHP regulates spike frequency adaptation in neurons 
(reviewed in Ha and Cheong, 2017). Spike frequency adaptation ensures that following an 
extended period of excitation, the frequency of discharge of action potentials (or spikes) 
from a neuron progressively slows after an initial high frequency of firing. Spike frequency 
adaptation therefore controls the ability of neurons to generate action potentials in response 
to sustained stimulus and disruption of spike frequency adaptation due to the inhibition of 
IAHP highlights a regulatory role for KARs in generation of action potentials in the CA1 
pyramidal cells (Melyan et al., 2002). Inhibition of IAHP mediated by KARs has also been 
found in mossy fibre to CA3 pyramidal cell synapses and studies at these synapses 
demonstrated that KARs containing the GluK2 and GluK5 subunits are necessary for the 
metabotropic signalling (Ruiz et al., 2005). However, another study has shown that double 
knockout of GluK4 and GluK5 did not affect inhibition of IAHP (Fernandes et al., 2009). 
More recently, GluK2-containing KARs employing metabotropic signalling were shown 
to contribute to an NMDAR-independent form of LTP in the SC-CA1 synapse (Petrovic et 
al., 2017). Therefore, the studies investigating metabotropic mode of signalling by KARs 
could also be aided by the development of GluK2 selective antagonists. 
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In addition to the presynaptic KARs in the SC-CA1 synapse, postsynaptic currents in many 
CA1 GABAergic interneurons (including the stratum oriens–lacunosum moleculare cells) 
are believed to contain a KAR-mediated component (Figure 1.11) (Cossart et al., 1998; 
Frerking et al., 1998). While GluK1-containing KARs have been suggested to mediate 
EPSCs in CA1 interneurons (using GluK1-selective antagonists, e.g. Cossart et al., 1998), 
it is known that GluK2 subunits are also present in interneurons, therefore whether the 
GluK2 subunit is part of the KAR complex, which contributes to synaptic currents in 
interneurons, remains to be determined (Bureau et al., 1999; Mulle et al., 2000). 
Hippocampal interneuron activity is involved in the generation and maintenance of 
behaviourally relevant neural oscillations (Klausberger and Somogyi, 2008). Moreover, the 
GluK1 antagonist UBP304 (willardiine derivative analogue of UBP302, which was 
discussed earlier) reduces the frequency of neural oscillations in the theta frequency range 
in all layers of the hippocampus (Huxter et al., 2007). However, analogues of UBP304 such 
as UBP310 and UBP316 also inhibit native (Pinheiro et al., 2013) but not recombinant 
(Dolman et al., 2007) GluK2/GluK5 heteromers at high concentrations. Therefore, UBP304 
may also inhibit KARs in the hippocampus where GluK2 and GluK5 are abundantly 
expressed (Wisden and Seeburg, 1993). In addition to the postsynaptic KARs on many 
GABAergic interneurons, presynaptic KARs were found to be autoreceptors on Schaffer 
collaterals making synaptic contacts onto a subset of stratum radiatum interneurons (Sun 
and Dobrunz, 2006). These autoreceptors are believed to control short-term facilitation of 
glutamate release onto interneurons which was attenuated by the KAR antagonist NS-102 
(Sylwestrak and Ghosh, 2012). In summary, the resolution of uncertainties regarding the 
identity of KAR subunits that contribute to the synaptic signalling in interneurons will be 
aided by GluK2-selective antagonists. 
Other studies also pointed to a role for KARs (containing the GluK1 subunit) in 
postsynaptic neurotransmission in the hippocampal mossy fibre-CA3 pyramidal cell (MF-
CA3) synapses (Figure 1.11) (Castillo et al., 1997; Vignes et al., 1997). Vignes and 
colleagues blocked AMPARs and NMDARs and recorded from CA3 pyramidal cells to 
show that KARs mediate currents in the CA3 which were inhibited by the KAR antagonist 
CNQX and the GluK1-selective antagonist LY294486 (Vignes and Collingridge, 1997; 
Vignes et al., 1997). Therefore, KARs (containing the GluK1 subunit) mediate postsynaptic 
currents in response to activation by glutamate. The currents mediated by KARs had slower 
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activation and decay than AMPAR-mediated currents (Castillo et al., 1997; Kidd and Isaac, 
2001). The slower current kinetics of KARs compared to AMPARs means that instead of 
mediating fast neuronal signalling, KARs could function as integrators of persistent 
presynaptic activity by summation of subsequent EPSCs – thereby increasing the 
probability for formation of action potentials in the postsynaptic neuron especially during 
prolonged stimulation or trains of stimuli (e.g. Frerking and Ohliger-Frerking, 2002; 
Sachidhanandam et al., 2009). In contrast with the suggestions that GluK1-containing 
KARs mediate EPSCs in MF-CA3 synapse, reports have suggested that GluK2 but not 
GluK1 or GluK3 knockout mice lack KAR-mediated EPSCs (Mulle et al., 1998; 
Sachidhanandam et al., 2009).  
Further studies using either the GluK1-selective antagonist LY382884 or genetic GluK1 or 
GluK2 knockout mice have revealed that KARs mediate synaptic plasticity at the MF-CA3 
synapse in a subunit-specific manner (Bortolotto et al., 1999; Paternain et al., 2000; 
Contractor et al., 2001; Breustedt and Schmitz, 2004). The MF-CA3 synapse exhibits long-
term potentiation (LTP) that is not dependent on NMDARs (Harris and Cotman, 1986). 
Bortolotto and colleagues showed that LY382884 inhibited LTP of field excitatory 
postsynaptic potentials (f-EPSPs) at the MF-CA3 synapse whereas LTP mediated by 
NMDARs as a result of tetanisation of associational/commissural fibres was resistant to 
LY382884 (Bortolotto et al., 1999). Therefore, MF-CA3 synaptic plasticity was suggested 
to be mediated by GluK1-containing KARs. A later study by Breustedt and Schmitz using 
both LY382884 and GluK1 or GluK2 knockout mice showed that MF-CA3 LTP was 
present in GluK1 knockout mice but absent in GluK2 knockout mice (Breustedt and 
Schmitz, 2004). Moreover, the same study found that MF-CA3 LTP was not blocked by 
LY382884 (10 μM, same concentration as in the study by Bortolotto and colleagues). The 
contradicting results from these studies have been attributed to the differences in slice 
preparations (parasagittal slices by Bortolotto et al. compared to transverse by Breustedt et 
al.) used in these two studies, which ultimately changes the neuronal population which 
contributes to the synaptic potentials recorded (Sherwood et al., 2012). Another explanation 
for the discrepancies is that knockout of the GluK1 subunit may lead to compensatory 
mechanisms such as increased contribution from another KAR subunit type (e.g. 
Christensen et al., 2004). A comprehensive investigation of the involvement of KAR 
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subunits in synaptic plasticity will therefore be facilitated by development of selective 
GluK2 antagonists. 
Another set of studies has shown that KARs act as presynaptic facilitatory receptors at the 
MF-CA3 synapse (Figure 1.11) (Contractor et al., 2001; Lauri et al., 2001). Lauri and 
colleagues showed that the GluK1 antagonist LY382884 blocked facilitation of mossy fibre 
EPSCs evoked at a frequency of 50 Hz (Lauri et al., 2001). Lauri and colleagues suggested 
that the KAR-mediated facilitation of EPSCs was due to presynaptic KARs and blockage 
of the KAR-mediated facilitation with LY382884 prevents MF-CA3 LTP (Lauri et al., 
2001). Interestingly, during MF-CA3 LTP, the frequency facilitation was occluded, 
suggesting that both MF-CA3 LTP and frequency facilitation may involve the presynaptic 
GluK1-containing KARs (Lauri et al., 2001). However, studies by Contractor and 
colleagues using GluK1 and GluK2 knockout mice have suggested that GluK2 but not 
GluK1 is the subunit in the KAR presynaptic autoreceptors at MF-CA3 synapses 
(Contractor et al., 2000, 2001). These discrepancies have further highlighted the need for 
better genetic and pharmacological tools. Particularly, a long-term knockout of GluK1 can 
lead to compensatory mechanisms from other KAR subunits as mentioned earlier. 
Moreover, while LY382884 is thought to be inactive at GluK2 and GluK3 homomers and 
the GluK2/GluK5 heteromers (Bortolotto et al., 1999), the activity of LY382884 on other 
GluK1-lacking heteromeric KARs remains to be determined.  
In the MF-CA3 synapse, measuring Ca2+ movement into the presynaptic bouton revealed 
that activation of presynaptic KARs could induce Ca2+ transients (a transient increase in 
intracellular Ca2+ levels) following a single action potential (Lauri et al., 2003; Nisticò et 
al., 2011). But not all synapses show the Ca2+ signal – only giant boutons of mossy fibre 
axons (from the dentate gyrus) which form synapses with pyramidal cells have the Ca2+ 
movement (Scott and Rusakov, 2006). The GluK1 antagonist ACET blocks the Ca2+ influx 
at MF-CA3 synapses (Dargan et al., 2009) whereas studies using GluK2 and GluK3 
knockout mice suggests a role for these subunits in presynaptic KARs in MF-CA3 synapses 
(Contractor et al., 2001; Pinheiro et al., 2007). These discrepancies further highlight the 
need for better pharmacological agents with selectivity for specific KAR subunits 
(including the GluK2 subunit) to determine the identity of the subunits that are responsible 
for presynaptic facilitation at the MF-CA3 synapse.   
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Figure 1.11. Neuronal signalling mediated by kainate receptors in the hippocampus. 
Schematic showing the localisation of KARs within hippocampal synapses (arrowheads for 
glutamatergic synapses and arrows terminating with black circles for GABAergic synapses) based 
on the current evidence (discussed in text). KARs on pre- and postsynaptic terminals can signal 
using ionotropic and metabotropic mechanisms. Recurrent excitatory synapses (dashed line) at 
dentate gyrus granule cells (DG cells) are observed in preclinical models of temporal lobe epilepsy 
(more details in section 1.2.6.1). Physiological studies have demonstrated KAR-mediated synaptic 
processes in the pyramidal cells of CA1 and CA3 subregions, and in CA1 interneurons (CA1 IN). 
The subunit identity in KARs at pre- and postsynaptic sites is not fully understood due to a lack of 
subunit-selective pharmacological tools and limitations of long-term genetic knockout mice. 
1.2.6. Clinical relevance of kainate receptors 
There is overwhelming evidence that KARs are regulatory receptors in addition to 
postsynaptic targets for glutamate during neurotransmission (see above). Moreover, the 
direction of modulation by KARs may depend on the type of subunit that make up the 
receptor (Chittajallu et al., 1996; Bortolotto et al., 1999). Therefore, KAR subunits may be 
suitable therapeutic targets for pathophysiological conditions in which the balance of 
excitatory-inhibitory neurotransmission is impaired. Early observations that systemic 
injection of kainic acid led to convulsions and neurotoxicity pointed to a role for KARs in 
these pathological conditions (e.g. Ben-Ari, 1985). Moreover, kainic acid causes 
depolarisation of sensory neurons in the dorsal root, which are responsible for conveying 
pain information to the spinal cord (Davies and Watkins, 1979; Agrawal and Evans, 1986). 
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Subsequent studies found KAR-mediated currents in the dorsal root ganglia (DRG) cells 
(Huettner, 1990). The rationale for targeting of KARs in epilepsy and pain are described 
below to highlight the need for more GluK2-selective pharmacological agents, which may 
be therapeutically beneficial and help to understand the role of KARs in these 
pathophysiological states.  
1.2.6.1. Epilepsy 
Epilepsy is a neurological disorder characterised by the occurrence of prolonged and 
synchronised neuronal discharges (also known as spontaneous neuronal seizures) 
(reviewed in Stafstrom and Carmant, 2015). The recurrent seizures arise from multiple 
brain structures – including the hippocampus and may propagate to the amygdala and the 
entorhinal cortex (Lothman et al., 1991). Many current antiepileptic drugs work by 
inhibiting voltage-gated sodium (Na+) and calcium (Ca2+) channels, which results in the 
reduction of neuronal excitability, or by an enhancement in GABAergic inhibition (see 
Stafstrom and Carmant, 2015). Given the pervasive nature of the voltage-gated Na+ and 
Ca2+ channels, current anticonvulsant drugs have many unwanted side effects including 
cognitive impairments, tremor and depression (Perucca and Meador, 2005; Goldenberg, 
2010). Moreover, the treatment window for severe cases of epilepsy is narrow and in a 
significant proportion of cases, drug treatments are ineffective (Goldenberg, 2010). Given 
the modulatory roles that KARs play in maintaining the excitatory-inhibitory balance in the 
hippocampus and other structures in the CNS, using subunit-selective antagonists to target 
KARs for therapy of epilepsy is an exciting prospect (Rogawski et al., 2003).  
Intraventricular injections and intra-amygdaloid application of kainate in rats induced cell 
degeneration in the hippocampus and seizures originating in the CA3 region of the 
hippocampus (Nadler et al., 1978; Ben-Ari et al., 1979; Nadler, 1981), and variants of this 
protocol has been used as animal models of acute and chronic seizures and it resembles 
aspects of temporal lobe epilepsy (a common form of epilepsy in humans) (Rodríguez-
Moreno et al., 1997; Mulle et al., 1998; Fritsch et al., 2014). However, whether the kainate-
induced forms of epilepsy is caused by direct activation of KARs or through indirect 
mechanisms involving other receptors (such as AMPARs at which kainate is a non-
desensitising agonist (Swanson et al., 1997)) is unknown. Chronic epilepsy develops in a 
large proportion of animals that receive systemic administration of kainate or pilocarpine 
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(an agonist of muscarinic cholinergic receptors) for 1-3 days (Ben-Ari, 1985; Leite et al., 
1990). A long-lasting phase of spontaneous recurrent limbic seizures with increasing 
frequency develops after a period of days or weeks (Hellier et al., 1998; Williams et al., 
2009). Kainate-induced seizures in animals leads to activity-dependent neuronal and cell 
loss, and cell death of astrocytes and hippocampal CA1 and CA3 pyramidal cells, 
characteristics which resemble human temporal lobe epilepsy (TLE) (Nadler et al., 1978; 
Ben-Ari, 1985).  
The acute seizures induced by kainate have been the subject of many studies and the 
epileptogenesis is believed to be caused by KAR-mediated inhibition of GABA release and 
activation of postsynaptic KARs on glutamatergic neurons (Rodríguez-Moreno et al., 1997; 
Mulle et al., 1998). GluK1-containing KARs are present in the axons and dendrites of 
hippocampal interneurons in the CA1 region (Paternain et al., 2000; Rodríguez-Moreno et 
al., 2000). As described earlier for the hippocampus, kainate facilitates GABA release and 
therefore is responsible for controlling the inhibitory drive of the neuronal network (Cossart 
et al., 1998). KARs expressed at the interneuron-pyramidal cell synapses display 
concentration-dependent effects wherein GABA release is suppressed at high 
concentrations of kainate (Clarke et al., 1997; Rodríguez-Moreno et al., 1997) but GABA 
release is facilitated at low kainate concentrations (300 nM) (Jiang et al., 2001; Khalilov et 
al., 2002). Contrary to the conclusions from the physiological studies, which predicted that 
application of low doses of a KAR agonist would increase inhibition through GABA, 
systemic application of the GluK1 agonist ATPA in vivo led to hippocampal and amygdala 
seizures, an effect that was missing from GluK1 knockout mice (Fritsch et al., 2014). 
Consistently, antagonism of GluK1-containing KARs in vivo blocked seizures induced by 
pilocarpine (Smolders et al., 2002). Additionally, the excitatory glutamatergic neurons also 
contain KARs on presynaptic and postsynaptic terminals (see section 1.2.5). At presynaptic 
terminals, low concentrations of kainate facilitate whereas high concentrations of kainate 
depress synaptic responses of CA1 pyramidal cells (Chittajallu et al., 1996). The 
postsynaptic KARs are thought to contain at least one GluK2 subunit and their activation 
leads to modulation of neuronal excitability through ionotropic and metabotropic KAR 
signalling (see section 1.2.5) (Melyan et al., 2002, 2004). In summary, KAR activation 
decreases GABA release and increases excitability in the postsynaptic glutamatergic 
neurons, which promotes epileptic activity by creating an imbalance between excitation 
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and inhibition in the neuronal networks involved. In agreement with the studies in animals, 
a clinical study of members of a family affected by idiopathic juvenile absence epilepsy 
reported increased levels of polymorphisms of the Grik1 gene which codes for the GluK1 
subunit (Sander et al., 1997). Moreover, reorganisation of KAR subunits may occur in 
patients of TLE who have upregulation of GluK1 (Li et al., 2010). The AMPAR and KAR 
antagonist NS1209 alleviated refractory status epilepticus (prolonged or sequential seizures 
lasting for more than 30 minutes with resistance to current antiepileptic drugs) in phase II 
clinical trials and may have partly mediated its effects by blocking KARs (Swanson, 2009).  
In contrast to the evidence in preclinical and clinical studies of acute seizures described 
above, the roles that KARs play in producing chronic seizures that last for many months 
after repetitive treatment with kainate (e.g. Hellier et al., 1998) or pilocarpine (an agonist 
of muscarinic acetylcholine receptor) (e.g. Leite et al., 1990) remain a mystery. However, 
based on similarities in recordable symptoms and changes in neuronal morphology between 
clinical and animal studies of chronic epilepsy, a role for KARs has been proposed. The 
CA3 region of the hippocampus has been long-proposed to be a key area for origin of 
seizures (reviewed in Ben-Ari and Cossart, 2000). In the CA3 region, KARs that contain 
GluK2 are abundantly expressed and modulate synaptic signalling (see sections 1.2.4 and 
1.2.5); therefore, GluK2 has been proposed to be important in limbic epilepsies (Werner et 
al., 1991). In agreement with this theory, deletion of GluK2 in mice led to lower 
sensitivities to seizures after kainate injection (Mulle et al., 1998). A major characteristic 
of TLE patients and animal models of kainate-induced epilepsy is mossy fibre sprouting in 
the dentate gyrus of the hippocampus (Epsztein et al., 2005; Artinian et al., 2011, 2015). 
Mossy fibre sprouting occurs as a result of the neuronal reorganisation in the dentate gyrus 
during chronic epilepsy (Ben-Ari et al., 2008). The mossy fibre axons of the dentate gyrus 
granule cells undergo sprouting and form novel synapses with the dentate granule cells to 
create a recurrent mossy fibre network (Tauck and Nadler, 1985; Represa et al., 1987; 
Sutula and Dudek, 2007). The formation of these new aberrant synapses results in an 
upregulation of KARs, which are expressed abundantly in the dentate gyrus (Represa et al., 
1987, 1989). In the dentate gyrus, postsynaptic KARs mediates glutamatergic transmission 
at the mossy fibre to granule cell (MF-GC) synapses (Epsztein et al., 2005). Therefore, the 
novel synapses and the upregulation of postsynaptic KARs affects the synaptic signalling 
at MF-GC synapses by causing overexcitability in granule cells (Epsztein et al., 2005; Peret 
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et al., 2014). This overexcitability is believed to result in epileptiform activity in the dentate 
gyrus, a pathophysiological trait that may be aggravated by the suppression of GABAergic 
inhibitory transmission in the network (Epsztein et al., 2005).  
In a study by Pinheiro and colleagues, UBP310 (a compound developed as GluK1-selective 
antagonist, see section on KAR agonists) was shown to be an antagonist of recombinant 
GluK2/GluK5-containing heteromeric KARs with fast glutamate application mimicking 
synaptic conditions (IC50 ~1 µM) (Pinheiro et al., 2013). Pinheiro and colleagues reported 
that the postsynaptic KARs inserted in the novel aberrant MF-GC synapses in pilocarpine-
induced TLE animal model are likely heteromeric KARs containing GluK2/GluK5 
subunits (Pinheiro et al., 2013). Indeed, studies using genetic knockout mice have 
suggested that KARs containing one of more of GluK2, GluK4 and GluK5 subunits may 
mediate postsynaptic neurotransmission and may be involved in generation of recurrent 
seizures during chronic epilepsy (Mulle et al., 1998; Contractor et al., 2003; Fernandes et 
al., 2009). At the dentate granule cells, addition of novel KARs has been proposed to induce 
seizures by altering the firing rate of dentate granule cells which have basally sparse firing 
rates (Artinian et al., 2011, 2015). In addition to KARs in the dentate gyrus, mossy fibre 
presynaptic KARs containing GluK2, GluK5 and possibly GluK1 have also been reported 
to mediate synaptic plasticity (see section 1.2.5). Further evidence for the involvement of 
KARs in epilepsy comes from Yu and colleagues who used genetically modified mice (see 
Nakashiba et al., 2008), which had inducible CA3 synaptic silencing wherein the protein 
tetanus toxin (inhibitor of neurotransmitter release) was inducible in CA3 pyramidal cells, 
to show that kainate-induced seizures and network oscillations were reduced during CA3 
synaptic silencing (Yu et al., 2016). 
Explorations of the therapeutic potential of KAR targeting in chronic seizures have been 
rare. In a study using a TLE animal model (where TLE was induced by pilocarpine), 
interictal (between seizures) and ictal (during seizure) discharges were reduced in mice 
lacking the GluK2 subunit but not in mice lacking GluK1 or when postsynaptic 
GluK2/GluK5-containing heteromeric KARs were blocked with UBP310 (Peret et al., 
2014). However, the ATD of GluK2 is critical in forming the GluK2/GluK5 heteromer and 
subsequently affects surface expression of GluK5-containing KARs (Gallyas et al., 2003; 
Kumar et al., 2011), whether GluK1 subunit also forms part of this receptor complex is 
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unknown. Therefore, investigations into the role of specific subunits in chronic epilepsy 
(and subsequently more specific therapeutic targeting) warrants the development of subunit 
selective KAR antagonists.  
1.2.6.2. Pain 
While sensation of acute pain is a beneficial process involving multiple levels of peripheral 
and central nervous systems (Basbaum et al., 2009), which prevents tissue damage, chronic 
pain has unknown causes and arises from overactivation (or sensitisation) of (one or more 
of) the peripheral or central components of pain transduction pathways (Costigan et al., 
2009; Woolf, 2011). Overactivation of the peripheral nociceptors is initially due to 
overexposure to neurogenic inflammatory factors such as substance P, adenosine 
triphosphate (ATP), serotonin, or noxious chemicals (Basbaum et al., 2009). Overactivation 
(or sensitisation) of central pain transduction pathways may be a result of the nociceptive 
sensory neurons of the spinal cord dorsal horn becoming hyperexcitable, which is 
manifested as an increase in responses from the dorsal horn neurons caused by repetitive 
activation (a phenomenon known as wind-up), or LTP of excitatory synapses of these 
neurons (Seal et al., 2009; Pfau et al., 2011). The overexcitability in pain sensing neurons 
may be expressed as loss of presynaptic inhibition in transmitter release or increase in 
postsynaptic membrane excitability (Fang et al., 2002; Lee et al., 2002; Witschi et al., 
2011). KARs are present on both presynaptic and postsynaptic terminals of synapses 
involved in processing pain information, including neurons in the dorsal horn of spinal cord 
(Lu et al., 2005) and dorsal root ganglion (DRG) neurons (Huettner, 1990; Partin et al., 
1993; Lucifora et al., 2006).  
The DRG KAR currents had similar activation and decay kinetics as those gated by 
recombinant GluK1-containing receptors expressed in HEK293 cells (Huettner, 1990; Herb 
et al., 1992; Swanson and Heinemann, 1998). Consistently, GluK1 mRNA is prominently 
expressed by DRG neurons however smaller amounts of mRNAs of other KAR subunits 
have also been reported (Partin et al., 1993). Moreover, mice lacking the GluK1 subunit 
lack KAR currents in DRG neurons (Mulle et al., 2000) and genetic deletion of GluK2 
subunit increased the rate and extent of desensitisation of the current from DRG neurons 
but in dorsal horn neurons, GluK2 deletion abolished KAR currents (Kerchner et al., 2002). 
The use of the GluK1-selective antagonist LY382884 and genetic knockout of GluK1 or 
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GluK2 revealed that GluK1-containing KARs are required for expression of KAR currents 
in the DRG neurons (Kerchner et al., 2002). GluK1-selective agonists such as ATPA and 
5-iodowillardiine (see section 1.2.1) activate GluK1-containing KARs in DRG neurons 
with similar potencies and gating properties compared to recombinant GluK1-containing 
receptors (Wong et al., 1994; Clarke et al., 1997; Kerchner et al., 2001; Wilding and 
Huettner, 2001). Moreover, GluK1-selective antagonists with a wide range of GluK1-
selectivity, including LY382884 (and analogues) and the antagonists based on willardiine 
(see section 1.2.2), inhibited KAR currents in DRG neurons (Bleakman et al., 1996; 
Dolman et al., 2005; Weiss et al., 2006). Therefore, there is strong evidence for KAR 
expression in nociceptive neurons of DRG and dorsal horn. 
Peripheral application of KAR agonists leads to nociceptive signalling and pain behaviours 
(Ault and Hildebrand, 1993; Du et al., 2006). Experimental induction of inflammation in 
rodent paw increased KAR immunoreactivity (Carlton and Coggeshall, 1999; Du et al., 
2006). An upregulation of KAR expression in some sensory neurons was proposed to also 
occur when inflammation was induced experimentally (using complete Freund’s adjuvant 
injection) (Du et al., 2006). In DRG neurons, a major function of KARs appears to be as 
presynaptic autoreceptors that inhibit glutamate release at the synapses of DRG neurons at 
the dorsal horn (Kerchner et al., 2001). However, the modulation of neurotransmission by 
KARs at the dorsal horn seems to be biphasic (both inhibitory and facilitatory) because low 
concentrations (30 nM) of kainate facilitated but higher concentrations (3 µM) depressed 
glutamate release (Youn and Randic, 2004). Presynaptically mediated inhibition of dorsal 
horn EPSCs by KARs is absent in GluK1 knockout mice (Kerchner et al., 2002) however 
the involvement of GluK2 in presynaptic KARs remains to determined and will require 
GluK2-selective pharmacological agents.  
Early studies demonstrated that non-selectively blocking AMPARs and KARs reduces 
inflammatory signalling and behaviours linked to pain in rats (Hunter and Singh, 1994; 
Jackson et al., 1995; Simmons et al., 1998; Stanfa and Dickenson, 1999). Subsequently, 
targeting GluK1 with selective antagonists or genetic deletion produced analgesic effects 
following induction of chronic pain (Wu et al., 2007). While these results agreed with the 
inhibitory roles of presynaptic KARs that contain the GluK1 subunit (Kerchner et al., 2002; 
Youn and Randic, 2004), investigations of the roles of other KAR subunits requires 
Chapter 1 – Introduction 
52 
subunit-selective pharmacological agents that target specific subunits. A preclinical model 
of pain, namely assessment of pain behaviour after formalin injection into rat paw, also 
demonstrated the analgesic effects of the GluK1 antagonist LY382884, without the side-
effect of ataxia that followed inhibition of AMPARs (Simmons et al., 1998). Esterified 
prodrugs of LY382884 (see section 1.2.2) and the less GluK1-selective analogue, 
LY293558, also produced analgesic effects when delivered orally in the formalin model 
and in inflammation models of carrageenan-induced thermal hyperalgesia and capsaicin-
induced mechanical hyperalgesia (Dominguez et al., 2005; Jones et al., 2006). LY293558 
also produced analgesia in rats in the paw incision model of postoperative pain (which 
resulted in mechanical hyperalgesia) (Lee et al., 2006). Central infusion of 
decahydroisoquinoline class of compounds (such as LY382884) into the cisterna magna 
produced antinociceptive effects which correlated well with their activity on GluK1-
containing receptors (Jones et al., 2006), suggesting that supraspinal KARs may be a target 
for analgesic KAR antagonists.  
As discussed earlier, KAR agonists such as glutamate (and kainate) produces fast and 
persistent desensitisation in KARs following the initial activation (Wilding and Huettner, 
1997); this might allow KAR agonists to act as functional antagonists and analgesics. The 
high affinity agonist (2S,4R)-4-methylglutamate (SYM2081) produces fast desensitisation 
of both GluK1- and GluK2-containing KARs (Alt et al., 2004). SYM2081 has produced 
analgesic effects when administered intrathecally and intraperitoneally in thermal and 
mechanical hyperalgesia in preclinical models of pain, including chronic nerve 
constriction, capsaicin and carrageenan injections (Sutton et al., 1999; Ta et al., 2000; 
Turner et al., 2003). Another agonist of KARs MSVIII-19 also acts as a functional high-
affinity inhibitor of GluK1-containing KARs and produced analgesia for thermal and 
mechanical hyperalgesia in inflammatory and chronic constriction models (Qiu et al., 
2011).  
Genetic ablation of the GluK1 subunit reduced pain behaviours such as paw licking caused 
by capsaicin or formalin injections in mice, which was not seen in genetic knockout of the 
GluK2 subunit (Ko et al., 2005). However, knockout mice did not show a change in 
mechanical allodynia (in which an otherwise innocuous stimuli such as light touch causes 
pain) induced by injection of complete Freund’s adjuvant or in acute thermal and 
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mechanical sensitivity (Ko et al., 2005). The effects of long-term genetic deletion of KAR 
subunits on contribution from other KAR subunits or neurotransmitter systems, remains to 
be determined. Therefore, using developmental stage-specific or inducible knockout mice 
may help to better understand the role that KAR subunits play in neuronal signalling 
pathways of pain.  
In addition to preclinical validation, KAR antagonists have entered clinical trials for the 
treatment of pain with varied success. The decahydroisoquinoline LY293558 was effective 
in alleviation of migraine pain and pain induced by capsaicin injections (Sang et al., 1998). 
LY293558 was also efficacious in alleviating postoperative pain with minimal side-effects 
and acceptable tolerance (Gilron et al., 2000). LY293558 was tested in phase II clinical 
trials for treatment of migraine pain and the study reported alleviation of pain (Murphy et 
al., 2008). A prodrug of LY293558, known as NGX426, has been reported to significantly 
reduce pain and hyperalgesia induced by capsaicin injection (Wallace et al., 2012). A phase 
I clinical trial for use of NGX426 in hyperalgesia was conducted in 2008 but the results 
have not been published to-date (ClinicalTrials.gov reference: NCT00832546). 
In summary, a combination of pharmacological and genetic studies suggests that KARs are 
a viable target for treatment of pain. Both preclinical and clinical studies have also 
confirmed results from physiological investigations that compounds targeting KARs hold 
potential as therapeutic agents for treatment of pain. While the availability of GluK1-
selective pharmacological agents has helped to formalise the targeting of GluK1 in 
hyperalgesia, investigations of other KAR subunits require more subunit-selective agonists, 
antagonists and allosteric modulators. Therefore, development of novel KAR subunit-
selective compounds is an important step in establishing novel therapies for pain.  
1.3. NMDA receptors 
So far, the discussion about iGluRs has highlighted that postsynaptic neurotransmission in 
the CNS is mediated mainly by AMPARs and NMDARs whereas KARs act primarily as 
regulators of synaptic transmission. The multiplicity of KAR subunits and the lack of 
knowledge regarding the contribution of different KAR subunits to the KAR-mediated 
plasticity were previously highlighted. In contrast to KARs, the study of NMDARs has 
been more successful partly due to the availability of NMDAR-selective pharmacological 
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agents owing to lower amino acid sequence similarity between NMDARs and other iGluR 
subtypes (Traynelis et al., 2010). 
There is significant diversity in the composition of the tetrameric NMDAR due to the 
existence of seven NMDAR subunits, namely GluN1, GluN2A-D, GluN3A-B. Functional 
NMDARs require assembly of two GluN1 subunits along with either two GluN2 or GluN3 
subunits, or a combination of GluN2 and GluN3 subunits (Monyer et al., 1992; Chatterton 
et al., 2002; Schorge and Colquhoun, 2003; Ulbrich and Isacoff, 2007, 2008). The different 
NMDAR subtypes that result through the combination of these subunits have unique 
structural features, which accounts for their distinct pharmacological (Erreger et al., 2007) 
and functional (Monyer et al., 1992; Volianskis et al., 2013a) properties, which allows 
tuning of the receptor complex for a particular function (Cull-Candy et al., 2001).  
The involvement of NMDARs in LTP was briefly discussed previously (see section 
1.1.4.3). While NMDARs are expressed at synapses throughout the CNS, the wealth of 
information regarding NMDAR components in the cells of the hippocampus (discussed in 
sections 1.1.4.2, 1.1.4.3 and 1.3.7) has made it an ideal brain region to study novel functions 
of NMDARs. Therefore, the following review and our investigations will focus on the 
expression and synaptic functions of NMDAR subunits in the hippocampus.  
1.3.1. Glycine and its analogues are co-agonists of NMDA receptors 
An interesting characteristic of NMDAR activation is that a co-agonist, typically glycine 
(or D-serine), in addition to glutamate, is required for the activation of the receptor 
(Kleckner and Dingledine, 1988). X-ray crystal structures have revealed that glycine binds 
to the ligand binding domain (LBD) of GluN1 and GluN3 subunits (Furukawa and Gouaux, 
2003; Yao and Mayer, 2006; Yao et al., 2008). Glycine binding to the GluN1- and GluN3-
LBD involves some residues that are conserved between the two subunits although the 
amino acid sequence homology of GluN1 and GluN3 subunits is only ~30% (Traynelis et 
al., 2010). This difference in residues lining the LBD cleft contributes to larger number of 
possible interdomain interactions in GluN3 which could explain the 600-fold greater 
affinity of glycine for the GluN3 subunit compared to GluN1 (Yao and Mayer, 2006; Yao 
et al., 2008).  
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In diheteromeric GluN1/GluN2 NMDARs, the identity of the GluN2 subunit affects the 
potency of glycine through intra-receptor interactions (Sheinin et al., 2001; Chen et al., 
2008; Dravid et al., 2010; Jessen et al., 2017). Indeed, the potency of glycine at 
GluN1/GluN2A is ~10-fold lower than at GluN1/GluN2D (Chen et al., 2008). D-
cycloserine is a cyclic analogue of glycine that acts as a partial agonist at the GluN1 subunit 
(Hood et al., 1989; Dravid et al., 2010). While D-cyloserine (Figure 1.12) acts as a partial 
agonist at GluN2A-, GluN2B- and GluN2D-containing NMDARs, it produces much higher 
responses from GluN2C-containing NMDARs compared to glycine (Sheinin et al., 2001; 
Dravid et al., 2010). Therefore, the identity of the GluN2 subunit within the NMDAR also 
determines the potencies of D-cycloserine.  
In addition to glycine, D- and L-isomers of serine and alanine are also agonists at the GluN1 
subunit (Figure 1.12) (Pullan et al., 1987; McBain et al., 1989). D-Serine is more potent 
than L-serine and whether D-serine or glycine is the co-agonist may depend on the brain 
region and subcellular localisation of the NMDAR (Panatier et al., 2006; Papouin et al., 
2012; Mothet et al., 2015). For example, D-serine may be the primary co-agonist for 
NMDARs in the supraoptic nucleus (Panatier et al., 2006). Indeed, a study has suggested 
that at the hippocampal SC-CA1 pyramidal cell synapses, D-serine is the primary co-
agonist whereas glycine is more important at extrasynaptic sites (Papouin et al., 2012). 
While extracellular glycine (or D-serine) concentrations are fairly constant, it is unlikely to 
be at a saturating concentration for NMDAR co-agonist binding (Berger et al., 1998; 
Bergeron et al., 1998; Billups and Attwell, 2003). Therefore, the requirement of a co-
agonist provides an additional mechanism by which synaptic activation can be modulated 
by targeting the co-agonist binding site of NDMARs (Ahmadi et al., 2003; Meunier et al., 
2017).  
While GluN1/GluN2 diheteromeric NMDARs binds glycine as a co-agonist, GluN1 and 
GluN3 subunits are capable of forming diheteromeric GluN1/GluN3 receptors that produce 
excitatory currents after binding glycine in X. laevis oocytes and cerebrocortical neurons 
(Chatterton et al., 2002). It is also possible to have a GluN1/GluN2/GluN3 triheteromeric 
receptor in the X. laevis oocyte expression system (Das et al., 1998; Perez-Otano et al., 
2001). Diheteromeric (GluN1/GluN3A) and triheteromeric (GluN1/GluN3A/GluN3B) 
NMDARs have lower Ca2+ permeability and lower sensitivity to blockage by Mg2+ 
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compared to NMDARs containing only GluN1 and GluN2 (Das et al., 1998; Perez-Otano 
et al., 2001; Sasaki et al., 2002).  
1.3.2. Glutamate site agonists of NMDA receptors 
GluN2 subunits can be activated by glutamate, D- and L-aspartate (Benveniste, 1989; 
Nicholls, 1989; Fleck et al., 1993), homocysteate, and cysteinesulfinate (Do et al., 1986, 
1988; Olney et al., 1987). Cyclic analogues of glutamate such as (R,S)-(tetrazol-5-
yl)glycine (compound III) and (2S,3R,4S)-2-(carboxycyclopropyl) glycine (L-CCG-IV) are 
potent agonists of GluN2 subunits with EC50 values up to 10 times lower than glutamate 
(Figure 1.12) (Shinozaki et al., 1989; Schoepp et al., 1991; Erreger et al., 2007). Amongst 
most orthosteric agonists, there is a gradation of potency from GluN2A to GluN2D such 
that the agonist is least potent at GluN2A (highest EC50 value) and most potent at GluN2D 
(lowest EC50 value) (Kutsuwada et al., 1992; Monyer et al., 1992; Erreger et al., 2007). 
Subunit-selective agonists are unavailable but some agonists such as N-hydroxypyrazol-5-
ylglycine derivatives and SYM2081 (also a KAR agonist, see section 1.2.1) have promising 
subunit selectivity (Erreger et al., 2007; Clausen et al., 2008). For example, SYM2081 has 
46-fold greater potency on GluN2D over GluN2A containing NMDARs as represented by 
the EC50 for activation of diheteromers expressed on X. laevis oocytes (Erreger et al., 2007). 
A significant physiological feature of the GluN2 subunits in the function of NMDAR 
complex is the decay of the currents mediated by diheteromeric NMDARs containing the 
four GluN2 subunits (Figure 1.13). GluN2A shows the fastest current decay (decay time 
constant, τdecay ~22-230 ms) whereas GluN2D shows significantly slower decay (τdecay > 2 
s) following receptor activation by glutamate (and the co-agonist glycine) (Figure 1.13) 
(Monyer et al., 1992; Vicini et al., 1998). Given that NMDARs have a significant Ca2+ 
permeability (Mayer et al., 1984; Nowak et al., 1984), the nature of the intracellular signal 
transduction mechanism, which is dependent on Ca2+ influx through NMDARs, may be 
affected by the identity of subunits in the NMDAR complex (e.g. Erreger et al., 2005; 
Sobczyk et al., 2005; also reviewed in Shipton and Paulsen, 2014). 
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Figure 1.12. Structures of NMDA receptor agonists.  
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Figure 1.13. Current kinetics of GluN2-containing diheteromeric N-methyl-D-aspartate 
receptors. Schematic showing the decay (decay time constant, τdecay) of whole-cell patch-clamp 
currents (voltage clamped at –50 mV) mediated by diheteromeric glutamate-gated NMDARs 
expressed on HEK293 cells. The extracellular media was free of Mg2+ and contained 10 µM glycine. 
The receptors were activated by a 1 ms pulse of 1 mM glutamate indicated by open tip current 
(vertical deflection) above each current trace (decay traces based on Vicini et al., 1998). 
1.3.3. Competitive antagonists of NMDA receptors 
Competitive antagonists that act on the GluN1 subunit include the kynurenic acid derivative 
7-chlorokynurenic acid and its analogue 5,7-dichlorokynurenic acid (DCKA) (Figure 1.14) 
(Birch et al., 1988; Kemp et al., 1988; Mayer et al., 1988). In similarity with GluN1 
agonists, the identity of the GluN2 subunit in the NMDAR complex affects the potency of 
DCKA (Hess et al., 1998). Other antagonists that bind to the LBD of the GluN1 subunit 
include 4-trans-2-carboxy-5,7-dichloro-4-phenylaminocarbonylamino-1,2,3,4-
tetrahydroquinoline (L689,560) (Figure 1.14), which inhibits currents from 
GluN1/GluN2A and GluN1/GluN2B recombinant diheteromers expressed on X. laevis 
oocytes with Ki values of 4 nM and 20 nM, respectively (Hess et al., 1996).  
The competitive antagonist of GluN2 subunits, (R)-2-amino-5-phosphonopentanoate (D-
AP5) (Figure 1.14), and its analogues have been used to selectively block NMDAR 
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mediated responses without antagonist activity on AMPARs and KARs (Davies et al., 
1981a, 1986; Evans et al., 1982; Lester et al., 1990). The antagonist D-AP5 inhibited 
NMDARs expressed in X. laevis oocytes with Ki values between 0.28 and 3.7 µM such 
that the potency was highest at GluN2A- and lowest at GluN2D-containing diheteromers 
(Feng et al., 2005). Subunit-selective competitive antagonists of GluN2 have been difficult 
to develop due to the high sequence similarity between the binding clefts of GluN2A 
through to GluN2D (Traynelis et al., 2010). One example of a modestly GluN2A-selective 
competitive antagonist is (R)-[(S)-1-(4-bromo-phenyl)-ethylamino]-(2,3-dioxo-1,2,3,4-
tetrahydroquinoxalin-5-yl)-methyl-phosphonic acid (NVP-AAM077) which has 5- to 10-
fold selectivity for GluN2A over GluN2B containing receptors (GluN2A Ki = 5.4 nM) 
(Frizelle et al., 2006; Neyton and Paoletti, 2006; Volianskis et al., 2013a). Another example 
is the antagonist 3-((R)-2-carboxypiperazin-4-yl)-propyl-1-phosphonic acid (CPP) (Figure 
1.14) which has ~50-fold preference for GluN2A over GluN2D (GluN2A Ki = 41 nM) but 
intermediate affinities for GluN2B (Ki = 270 nM) and GluN2C (Ki = 630 nM) (Kutsuwada 
et al., 1992; Feng et al., 2005).   
Some competitive antagonists such as (2S,3R)-1-(phenanthren-2-carbonyl)piperazine-2,3-
dicarboxylic acid (PPDA) (Figure 1.14) and some of its derivatives have increased potency 
for GluN2C and GluN2D subunits compared to GluN2A and GluN2B subunits (Feng et al., 
2005). Attachment of the carbonyl linker in PPDA to the 3-position rather than the 2-
postion of the phenanthrene ring led to the development of a series of competitive 
antagonists with greater selectivity for GluN2D over GluN2A and GluN2B (Feng et al., 
2004, 2005; Morley et al., 2005; Costa et al., 2009; Irvine et al., 2012). The most selective 
in this class were (2R*,3S*)-1-(phenanthrene-3-carbonyl)piperazine-2,3-dicarboxylic acid 
(UBP141) and (2R*,3S*)-1-(9-bromophenanthrene-3-carbonyl)piperazine-2,3-
dicarboxylic acid (UBP145) both of which had ~10-fold selectivity for GluN2D (Ki ~1 µM, 
on recombinant diheteromers on X. laevis oocytes) over GluN2A or GluN2B (Costa et al., 
2009). Recent attempts to improve the GluN2D selectivity of PPDA analogues led to the 
development of (2R*,3S*)-1-(7-(2-carboxyethyl)phenanthrene-2-carbonyl)piperazine-2,3-
dicarboxylic acid (UBP791) in which a 2-carboxyethyl substituent was added to the 7-
position of the phenanthrene moiety of PPDA (Sapkota, 2016). UBP791 was shown to have 
much greater selectivity for GluN2D over GluN2A (> 130-fold; GluN2D Ki = 140 nM) and 
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GluN2B (~20-fold) subunits but similar potency on GluN2C and GluN2D subunits 
(Sapkota, 2016). 
 
Figure 1.14. Structures of antagonists of GluN1 glycine binding site and GluN2 glutamate 
binding site. 
1.3.4. Negative allosteric modulators of NMDA receptors 
Developing subunit-selective competitive antagonists are difficult due to the high sequence 
similarity in the LBD of subunit families (see section 1.3.3). However, negative allosteric 
modulators (NAMs), which bind to a site remote from the ligand binding site where the 
sequence similarity between subunits is lower compared to LBD, may be better candidates 
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for obtaining greater subunit selectivity. Indeed, the first subunit-selective inhibitor of 
NMDARs was the phenylethanolamine ifenprodil, a voltage-independent negative 
allosteric modulator of GluN2B-containing NMDARs (Williams, 1993; Hess et al., 1998). 
Ifenprodil (Figure 1.15) inhibits GluN2B-containing NMDARs with high affinity and is 
200-400-fold potent for GluN2B (IC50 ~150 nM) over GluN2A-, GluN2C- and GluN2D- 
containing NMDARs (Williams, 1993; Hess et al., 1998). More potent analogues of 
ifenprodil include α-(4-hydroxyphenyl)-β-methyl-4-(phenylmethyl)-1-piperidine propanol 
(Ro 25-6981) and traxoprodil mesylate (CP-101,606) (Figure 1.15) (Chenard et al., 1995; 
Fischer et al., 1997; Mott et al., 1998). Ro 25-6981 inhibits GluN2B diheteromeric 
receptors in X. laevis oocytes with IC50 value of 9 nM and is > 5000-fold selective for 
GluN2B over other GluN2 subunits (Fischer et al., 1997). Crystal structures of ifenprodil 
and Ro 25-6981 suggests that they bind to a known modulatory domain in the GluN2B 
amino terminal domain (ATD) and may stabilise an agonist-bound state of the receptor 
which has low open probability (Karakas et al., 2009). While ifenprodil has high affinity 
for diheteromeric GluN1/GluN2B NMDARs, its affinity for triheteromeric 
GluN1/GluN2A/GluN2B receptors is intermediate between its affinity for GluN1/GluN2A 
and GluN1/GluN2B diheteromers (Hatton and Paoletti, 2005; Hansen et al., 2014). 
Moreover, the effects of ifenprodil on current kinetics is different in 
GluN1/GluN2A/GluN2B triheteromeric receptors compared to GluN1/GluN2B 
diheteromers such that in the presence of ifenprodil, the rate of onset of the current was 
slower and the rate of decay of the current was faster in GluN1/GluN2A/GluN2B 
triheteromers compared to diheteromeric GluN1/GluN2B receptors (Hatton and Paoletti, 
2005).  
Another class of non-competitive NMDAR antagonists is based on the non-competitive 
antagonist of AMPARs, (S)-3-(2-chlorophenyl)-2-[2-(6-diethylaminomethyl-pyridin-2-
yl)-vinyl]-6-fluoro-3H-quinazolin-4-one (CP-465,022) (Mosley et al., 2010). Modification 
of the CP-465,022 ring structure led to quinazolin-4-ones with > 100-fold NMDAR 
selectivity over AMPAR and KAR (Mosley et al., 2010). Furthermore, some analogues 
were 50-fold more selective for GluN2C and GluN2D than for GluN2A and GluN2B 
(Mosley et al., 2010). These compounds do not interfere with glutamate binding and their 
action is voltage-independent, suggesting that they are not ion channel blockers (Mosley et 
al., 2010; Hansen and Traynelis, 2011).  
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More recently, a NAM of the glycine site of NMDARs, 3-chloro-4-fluoro-N-[(4-[(2-
(phenylcarbonyl)hydrazino)carbonyl]phenyl)methyl]-benzenesulfonamide (TCN-201), 
has been developed as a GluN2A-selective antagonist (Edman et al., 2012; Hansen et al., 
2012). TCN-201 (Figure 1.15) inhibits the binding of glycine (and D-serine) by binding to 
the GluN1/GluN2A LBD dimer interface (Hansen et al., 2012). TCN-201 inhibited 
GluN1/GluN2A diheteromers expressed in X. laevis oocytes with an IC50 of 320 nM and 
had no effect on GluN2B-D subunits at concentrations < 10 µM (Hansen et al., 2012).  
 
Figure 1.15. Structures of negative allosteric modulators of NMDA receptors 
1.3.5. Channel blockers of NMDA receptors 
As discussed earlier, NMDAR ion channel is blocked at resting membrane potential by 
Mg2+ (see section 1.1.4.3). Other molecules that block the ion channel include open channel 
blockers, which require the channels to be open for the blockers to bind to the ion channel 
pore in the transmembrane domain (TMD) (thus they are also known as uncompetitive 
antagonists) (Neely and Lingle, 1986; Huettner and Bean, 1988). Due to the requirement 
of the channel opening, the effect of channel blockers is use-dependent and increases with 
increase in channel open probability. Some channel blockers can become trapped in the ion 
channel after channel closure and their dissociation from the channel requires reopening of 
the channel and the dissociation is slow to reverse (Brackley et al., 1993; Parsons et al., 
1995; Blanpied et al., 1997). These blockers (known as trapping blockers) include the 
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dissociative anaesthetics dizocilpine maleate (MK-801), ketamine and phencyclidine 
(PCP) (Figure 1.16) (Anis et al., 1983; Martin and Lodge, 1985; Wong et al., 1986; 
Huettner and Bean, 1988). Some trapping blockers such as amantadine and memantine 
(Figure 1.16) have faster reversal of channel block (due to faster unbinding) and are known 
as partially trapping blockers (Blanpied et al., 1997). The faster unbinding of partial 
trapping blockers may be therapeutically beneficial because they block the overactivation 
of NMDARs while leaving the normal synaptic transmission unaffected (Chen and Lipton, 
2005).  
Most NMDAR channel blockers display some selectivity between GluN2 subunits, which 
contain the obligatory glutamate binding site in an NMDAR (Yamakura et al., 1993). For 
example, MK-801 is ~10-fold more selective for GluN2A- and GluN2B-containing 
receptors than GluN2C- and GluN2D-containing receptors (Bresink et al., 1996; Dravid et 
al., 2007). The amino acid sequence homology in the pore-forming regions of GluN2 
subunits means that targeting the pore region (i.e. using channel blockers) for subunit 
selectivity with small molecules may be difficult. An important consideration when 
determining the activity of channel blockers is to consider the pH and Mg2+ concentration 
in the pharmacological characterisation assay. For example, the association rate of the 
trapping blocker MK-801 is increased at lower pH (Dravid et al., 2007). Moreover, 
ketamine and memantine have 5- to 10-fold selectivity for GluN2C- and GluN2D-
containing receptors over GluN2A- and GluN2B-containing receptors in the presence of 1 
mM extracellular Mg2+, which is a physiological concentration of Mg2+ in rats; whereas no 
such selectivity is observed in the absence of extracellular Mg2+ (Jeong et al., 2006; 
Kotermanski and Johnson, 2009). In summary, channel blockers of NMDARs may be used 
to target specific NMDAR subunits and may help to elucidate the role of specific NMDAR 
subunits in both physiological and pathophysiological conditions. 
 
Figure 1.16. Structures of NMDA receptor channel blockers. 
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1.3.6. Zinc ions and protons inhibit NMDA receptors 
The zinc ion (Zn2+) is a potent inhibitor of native and recombinant NMDARs (Peters et al., 
1987; Westbrook and Mayer, 1987; Williams, 1996). At mammalian presynaptic neurons 
Zn2+ is co-packaged into vesicles with glutamate in the terminals of many synapses 
including synapses in the hippocampus where Zn2+ may be co-released with glutamate 
during neuronal activity (Pérez-Clausell and Danscher, 1985; Frederickson, 1989; Paoletti 
et al., 2009). GluN1/GluN2A diheteromeric receptors are inhibited by Zn2+ in a biphasic 
manner; the inhibition of GluN2A by Zn2+ involves a voltage-independent high-affinity (Ki 
= 80 nM) phase and a voltage-dependent low-affinity component (Ki = 45 µM) (Christine 
and Choi, 1990; Chen et al., 1997). GluN1/GluN2B diheteromeric receptors are inhibited 
by Zn2+ in a voltage-dependent and voltage-independent manner (Ki = 1.6 µM) (Williams, 
1996; Traynelis et al., 1998; Rachline et al., 2005). The high-affinity inhibition of GluN2A 
by Zn2+ is mediated through Zn2+ binding to the amino terminal domain (ATD) of the 
GluN2A (Gielen et al., 2009; Yuan et al., 2009a, 2009b). The low-affinity Zn2+ inhibition 
of GluN2A depends on residues inside the M2 re-entrant loop, which contributes to the 
channel pore (Legendre and Westbrook, 1990; Paoletti et al., 2000). Crystallographic 
studies suggest that Zn2+ inhibits GluN2B by binding to the cleft in the ATD bi-lobed 
domain and stabilises a closed cleft conformation within the ATD (Karakas et al., 2009). 
The structural changes that translate Zn2+ binding to ion channel closing is not fully 
understood; however, studies from ifenprodil binding to ATD demonstrated that the 
conformational changes in the ATD is translated to the LBD such that LBD dimer 
interaction is disrupted in a manner analogous to receptor desensitisation (Tajima et al., 
2016; see section 1.1.2), which is believed to lead to ion channel closure (reviewed in 
Hansen et al., 2018). 
In addition to the inhibition by Zn2+, NMDARs are also inhibited by protons in a voltage- 
and agonist-independent manner (Christensen and Hida, 1990; Giffard et al., 1990; 
Traynelis and Cull-Candy, 1990). Alternative RNA splicing of the GluN1 subunit in the 
ATD affects the potency of proton inhibition (Traynelis et al., 1995). Additionally, 
mutagenesis studies suggest that residues near the ion channel pore, which contribute to the 
channel gate and residues in the ligand binding domain (LBD) dimer interface mediate pH 
sensitivity (Low et al., 2003; Sobolevsky et al., 2009). Therefore, pH may have tight 
Chapter 1 – Introduction 
65 
coupling to the gating properties of the channel as suggested by the sensitivity of MK-801 
to pH (see section 1.3.5).  
1.3.7. NMDA receptors and induction of potentiation of synaptic responses 
Previously, the role that NMDAR plays in induction of LTP at the SC-CA1 synapses was 
briefly discussed (see section 1.1.4.3). The first evidence for the involvement of NMDAR 
in synaptic plasticity came from a study by Collingridge and colleagues, which 
demonstrated that inhibition of NMDARs using the NMDAR-specific antagonist D-AP5 
blocked the induction of long-term potentiation (LTP) at the SC-CA1 synapses in the 
hippocampus (Collingridge et al., 1983). In this study, LTP was induced by high frequency 
stimulation (HFS, pulses at 100 Hz given for 1 sec) of the afferent Schaffer collateral fibres 
to CA1 (Collingridge et al., 1983). In live animals, bursts of discharges at an interval that 
is aligned with the theta rhythm (neural oscillations with frequencies in the range 4-7 Hz) 
is observed (Bland et al., 1980). In line with this observation, a physiologically relevant 
stimulation paradigm, the theta burst stimulation (TBS, 10 bursts of 4 pulses at 100 Hz 
given at an interval of 200 ms) (Larson et al., 1986), has also been employed to induce 
NMDAR-mediated LTP blocked by the NMDAR antagonist D-AP5 (e.g. Volianskis and 
Jensen, 2003). The finding that NMDARs mediate induction of LTP has been confirmed 
by studies that used competitive NMDAR antagonists related to D-AP5 (Harris et al., 
1984), the use-dependent antagonist MK-801 (Coan et al., 1987) and the glycine site 
antagonist 7-chlorokynurenic acid (Bashir et al., 1990). Further evidence came from studies 
using genetically engineered mice, the obligatory GluN1 subunit was selectively knocked 
out in the CA1 region but not the dentate gyrus. In such studies, LTP could not be induced 
in the CA1 region but was induced in the dentate gyrus (Tsien et al., 1996).   
How does the NMDAR contribute to the induction of LTP? Hebbian plasticity requires that 
the presynaptic neuron engages in firing postsynaptic neuron for the synaptic weight to 
change (see section 1.1.4.3). However, there is evidence to suggest that firing of the 
postsynaptic cell is not necessary in all cases for the induction of LTP; this is the case in 
some investigations of pairing-induced LTP where a compound that inhibits postsynaptic 
cell firing (by blocking voltage-gated sodium channels) still produced LTP (Kelso et al., 
1986; Gustafsson et al., 1987). Whether depolarisation of the postsynaptic neuron occurs 
independently of the neuron firing in vivo is unresolved whereas experimentally, it is 
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possible to depolarise the postsynaptic membrane sufficiently without causing firing of the 
postsynaptic neuron (e.g. using caged glutamate that can be activated, or uncaged, 
specifically at dendritic spines by two-photon excitation; see Matsuzaki et al., 2004). The 
Hebbian rule described in section 1.1.4.3 can therefore be modified such that the coupling 
of presynaptic activity with the postsynaptic depolarisation can induce LTP.  
1.3.7.1. NMDA receptors mediate induction of long-term potentiation  
As discussed earlier, three important features of LTP are (1) cooperativity, (2) input-
specificity and (3) associativity (see section 1.1.4.3). NMDARs have been shown to be 
central in all three of these features.  
Input specificity is a property of LTP, which states that only the tetanised inputs are 
potentiated (see section 1.1.4.3); the voltage dependence and the high calcium (Ca2+) 
permeability of NMDAR ion channel confers NMDAR-dependent LTP with input 
specificity (MacDermott et al., 1986; Burnashev et al., 1995; Schneggenburger, 1996). The 
voltage-dependence of NMDARs means that the membrane potential must be sufficiently 
depolarised to allow opening of the NMDAR ion channel and induce LTP caused by 
increased influx of Ca2+ ions (Mayer et al., 1984; Nowak et al., 1984). During HFS or TBS, 
such a depolarisation is possible due to the prolonged activation of AMPAR (by glutamate) 
which depolarises the membrane and leads to removal of the NMDARs block Mg2+ (Dale 
and Roberts, 1985). Therefore, the voltage-dependent activation of NMDARs allows Ca2+ 
entry through the NMDAR ion channel, and lead to induction of LTP at inputs that have 
been tetanised but not at untetanised inputs (e.g. Müller and Connor, 1991).  
The rise in intracellular Ca2+ during LTP is important as LTP induction is prevented by 
chelation of Ca2+ in the postsynaptic neuron (Lynch et al., 1983). A combination of 
confocal calcium imaging (using Ca2+ sensitive dye) and whole-cell patch-clamping of 
CA1 pyramidal neurons have shown that HFS leads to an increase in Ca2+ signal (observed 
as transient Ca2+ signal) mediated by NMDARs in the dendritic spine of postsynaptic 
neurons (in these experiments, voltage-gated Ca2+ channels were eliminated by clamping 
membrane at ˗35mV and intracellular Ca2+ stores were depleted using thapsigargin) 
(Regehr and Tank, 1990; Müller and Connor, 1991). In dendritic spines activated by the 
HFS, the transient Ca2+ signal peaks at 200 ms and decays to pre-tetanic levels with a half-
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time of approximately 5 s (Alford et al., 1993). The Ca2+ transients were abolished by the 
NMDAR-selective antagonist D-AP5 but not CNQX (an AMPAR/KAR antagonist) (Alford 
et al., 1993). Moreover, the Ca2+ transients in spines that are potentiated lasts for > 7 min, 
whereas the Ca2+ signal in the dendritic tree decayed to pre-tetanic levels before 7 min 
(Müller and Connor, 1991). Therefore, the spine-specific long-lasting Ca2+ transients 
mediated by NMDARs provide further evidence for the input-specific nature of NMDAR-
mediated LTP. 
Cooperativity and associativity are features of LTP that assumes the requirement for a 
threshold for the induction of LTP (see section 1.1.4.3). A consequence of the voltage 
dependent Mg2+ block of NMDARs is that it allows NMDARs to act as co-incidence 
detectors of neuronal activity, which means that during persistent firing of the presynaptic 
neuron and the release of glutamate that follows, the depolarisation of postsynaptic neuron 
(caused by activation of AMPARs) is detected by NMDARs (Wigström and Gustafsson, 
1985). The co-incidence detection by NMDARs also explains the cooperative and 
associative nature of NMDAR-mediated LTP, such that a weak input stimulus onto a 
dendrite could lower the threshold for subsequent input stimuli (McNaughton et al., 1978; 
Levy and Steward, 1979; Wigström and Gustafsson, 1985). The intracellular increase in 
calcium caused by NDMAR activation is augmented by Ca2+ release from the endoplasmic 
reticulum (ER) (Alford et al., 1993). The NMDAR-mediated Ca2+ transients are 
significantly reduced by compounds that inhibit Ca2+-induced Ca2+ release from the ER and 
those that deplete intracellular Ca2+ stores – ryanodine and thapsigargin, respectively 
(Harvey and Collingridge, 1992; Alford et al., 1993). Blocking intracellular Ca2+ release 
from the ER using dantrolene (which inhibits ryanodine receptors to block intracellular 
Ca2+ release from the ER) and thapsigargin (which prevents refilling of intracellular Ca2+ 
stores by inhibiting Ca2+-ATPase pumps on the ER), result in inhibition of LTP (Obenaus 
et al., 1989; Harvey and Collingridge, 1992; Bortolotto and Collingridge, 1993). Studies 
have shown that activation of metabotropic glutamate receptors (mGluRs) is also involved 
in release of Ca2+ from the ER and can induce LTP by a thapsigargin-sensitive mechanism, 
even if NMDARs are blocked (Bortolotto and Collingridge, 1993). Indeed, NMDAR-
independent forms of LTP induction at the SC-CA1 synapse have been reported – such as 
LTP induced by L-type voltage-gated calcium channels (Grover and Teyler, 1990; 
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reviewed in Blundon and Zakharenko, 2008) and calcium permeable AMPARs (Jia et al., 
1996; Park et al., 2016).  
The EPSP in the CA1 pyramidal cell, which is evoked by the stimulation of Schaffer 
collateral axons using low-frequency stimulation (e.g. 
1
15
 Hz) is mediated by AMPARs as 
revealed by application of AMPAR-selective antagonist GYKI53655 (Seifert et al., 2000). 
Stimulation of Schaffer collateral also activates feedforward GABAergic interneurons 
through glutamatergic synapses (Davies and Collingridge, 1989). Activation of 
GABAergic interneurons by Schaffer collateral causes GABA release at GABAergic 
synapses from the interneurons onto CA1 pyramidal cells and leads to an inhibitory 
postsynaptic potential (IPSP) in the CA1 pyramidal cell (Andersen et al., 1964a, 1964b). 
The IPSP comprises a rapid GABAA receptor-mediated component and a slower GABAB 
receptor-mediated component (Alger and Nicoll, 1982). The IPSP is created by (1) the 
influx of Cl– ions via the integral ion channel of activated GABAA receptors (Biscoe and 
Duchen, 1985), and (2) the opening of K+ channels and modulation of voltage-gated Ca2+ 
channels caused by the activation of metabotropic GABAB receptors (Newberry and Nicoll, 
1985; Kavalali et al., 1997). The IPSPs act to hyperpolarise the cell, which intensifies the 
Mg2+ block of NMDAR and prevents NMDAR activation during low-frequency 
stimulation (Alger and Nicoll, 1982; Nowak et al., 1984). Application of GABAA receptor 
inhibitors during low-frequency stimulation revealed an NMDAR-mediated synaptic 
response (Herron et al., 1985; Dingledine et al., 1986). Moreover, blockade of GABA 
receptors (and therefore the GABA receptor mediated hyperpolarisation) can greatly 
facilitate the induction of NMDAR-dependent LTP (Wigström and Gustafsson, 1983).  
During high-frequency stimulation, the CA1 pyramidal cell is maintained in a depolarised 
state, which may be due to the temporal summation of AMPAR-mediated currents (e.g. 
Stuart and Sakmann, 1995) and shifting of the Cl– and K+ reversal potentials to more 
depolarised potentials due to the build-up of intracellular Cl– and extracellular K+ (Biscoe 
and Duchen, 1985; K+ currents are reviewed in Storm, 1990). In addition to postsynaptic 
GABA receptors, which mediate the biphasic IPSP, presynaptic GABAB autoreceptors on 
GABAergic interneurons also play a significant role in the induction of TBS-induced LTP 
such that activation of presynaptic GABAB autoreceptors leads to suppression of 
subsequent GABA release from the interneuron (Davies et al., 1991). The GABAB 
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autoreceptor mechanism takes ~20 ms to develop, peaks around 200 ms and has a duration 
of ~1 s (Davies et al., 1990). Therefore, theta patterns of activity (such as TBS, which has 
an interval of 200 ms between each train in the stimulus) are likely to most effectively 
suppress GABA release through the GABAB autoreceptor mechanism.  
1.3.7.2. NMDA receptors mediate short term potentiation  
Potentiation of excitatory field potentials, which is induced by HFS and TBS at the SC-
CA1 synapse has several components with distinct underlying mechanisms (see Bliss and 
Collingridge, 2013 for a review). The initial decaying phase of potentiation following 
tetanus, called post-tetanic potentiation (PTP), is followed by a decaying phase known as 
short-term potentiation (STP), and a stable phase of potentiation generally referred to as 
LTP (see section 1.1.4.3). Induction of STP is blocked by application of D-AP5 during 
tetanus whereas the presynaptically expressed Ca2+-dependent PTP was induced even in 
the presence of D-AP5 (e.g. Malenka, 1991). In vivo studies in which extracellular field 
potentials were recorded before, during and after exploratory learning in rats have reported 
a process resembling STP (potentiation that decayed to pre-learning levels in ~30 min) at 
perforant path to dentate gyrus granule cell synapses in the hippocampus (Moser et al., 
1993, 1994).   
Early evidence that STP could be induced and expressed independently of LTP was 
provided by experiments where a lower intensity tetanus than that required for induction of 
LTP could lead to STP (McNaughton, 1982). Experiments where potentiation was induced 
by application of NMDA instead of HFS (where NMDA was applied iontophoretically) 
also suggested that STP could be induced independently of LTP (Kauer et al., 1988). In the 
same study by Kauer and colleagues, induction of STP by NMDA application was not 
affected by the PKC inhibitor sphingosine, which blocked the induction of LTP (Kauer et 
al., 1988). The postsynaptic intracellular rise in Ca2+ following tetanus, which is required 
for LTP, is also necessary for STP induction (Anwyl et al., 1988; Malenka et al., 1988). 
Studies from single cells also suggest that induction of STP differs from that of LTP in that 
lower levels of postsynaptic depolarisation than that required for the induction of LTP can 
induce STP (through activation of the voltage-dependent NMDARs) (Malenka, 1991). 
Another difference in induction of STP and LTP is that the amplitude of STP depends on 
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the frequency of stimuli in the tetanus whereas amplitude of LTP depends on the number 
stimuli in the tetanus (Volianskis and Jensen, 2003).  
In addition to the differences in induction protocols that augment or decrease STP 
independently from LTP, there is substantial evidence that expression of STP may be 
separate from that of LTP (e.g. Schulz and Fitzgibbons, 1997; Volianskis and Jensen, 
2003). The first experiment to use paired-pulse stimulation during LTP expression also 
found that in the perforant path-dentate granule cell synapse, the early phase of LTP is 
associated with a decrease in paired-pulse facilitation (PPF) (McNaughton, 1982). 
Volianskis and Jensen conducted a detailed paired-pulse study to demonstrate that PPF was 
decreased during the STP phase of potentiation but PPF increased towards pre-tetanic 
levels as STP decayed (Volianskis and Jensen, 2003). As noted earlier, PPF is believed to 
be due to an increase in neurotransmitter release (i.e. it is a presynaptic phenomenon) (Wu 
and Saggau, 1994). However, changes in PPF during LTP may not be observed when 
recruitment of silent synapses are involved (Isaac et al., 1995; Liao et al., 1995). 
Postsynaptically silent synapses that lack AMPARs but contain only NMDARs are 
recruited during induction of LTP with the pairing protocol (Isaac et al., 1995; Liao et al., 
1995). Another postsynaptic explanation for a change in PPF after tetanus is that GluA2-
containing AMPARs may be inserted into the synapse after tetanus (Bagal et al., 2005). 
The increase in GluA2 subunit means that AMPARs have lower sensitivity to polyamine 
block since the GluA2 subunit is predominantly found in the Q/R edited form, which 
reduces the receptor’s sensitivity to block by polyamines (see section 1.1.2) (Bagal et al., 
2005). The lower sensitivity to blockage by polyamines of GluA2-containing AMPARs 
may explain the decrease in PPF after the tetanus due to the first pulse producing a larger 
response (than the second pulse) when compared to the pretetanic response to the first pulse 
(Bagal et al., 2005). In summary, while a change in PPF could arise due to postsynaptic 
mechanisms, the simplest explanation for these results is that STP involves a presynaptic 
component whereas LTP involves postsynaptic changes, at least in the SC-CA1 synapse.  
In addition to possible differences in expression mechanisms underlying STP and LTP, 
STP was found to have some remarkable properties. Firstly, decay of the STP depends on 
the number on the number of stimuli in the low-frequency stimulation following induction 
of potentiation (the lower the frequency the slower the decay) (Volianskis and Jensen, 
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2003). Taken to an extreme, if stimulation is stopped for a duration following the induction 
of potentiation, STP does not decay until the stimulation recommences. Indeed, STP can 
be stored for at least 6 hours during discontinued stimulation (Volianskis and Jensen, 2003). 
Moreover, the duration of STP (i.e. its decay time constant) depends on the number of 
stimuli in the HFS used for inducing potentiation (larger number of stimuli leads to slower 
decay of STP) whereas higher frequency stimuli in the HFS train increases the amplitude 
of STP (Volianskis and Jensen, 2003).  
An intriguing question concerning the different phases of potentiation is: do STP and LTP 
have different functional properties? Recordings from a population of neurons suggests that 
repetitive induction of STP using weak stimuli (30 Hz for 0.1 to 0.2s) and NMDA 
application transiently (lasting 50 to 80 min) increases the threshold for induction of LTP 
using a strong tetanus (100 Hz, 0.5 s) (Huang et al., 1992). A similar phenomenon is also 
observed in single CA1 pyramidal cells using the pairing protocol, where repetitive pairing 
of pre- and postsynaptic activity that produces STP led to smaller amplitude LTP after 10 
min (Huang et al., 1992). However, another study found that the induction of STP using a 
single HFS tetanus 20 min before the tetanisation with two HFS tetani leads to induction 
of LTP (Schulz and Fitzgibbons, 1997). The reason(s) for the difference between the 
induction of LTP after induction of STP in these studies may be due to the differences in 
tetanus protocols (five repetitive HFS in the study by Huang and colleagues whereas a 
single HFS tetanus by Schulz and Fitzgibbons) (Huang et al., 1992; Schulz and Fitzgibbons, 
1997). Nevertheless, these studies suggest that prior activity that leads to STP induction 
affects the induction of LTP. Another study investigating the effects of STP and LTP on 
neurotransmission found that during STP, synaptic responses to short bursts of pulses are 
potentiated in a non-linear manner (Volianskis et al., 2013b). However, the same burst of 
pulses during LTP results in linear amplification of synaptic responses (Volianskis et al., 
2013b; also see Pananceau et al., 1998; Selig et al., 1999). This suggests that STP confers 
on synapses the ability to dynamically control short-term facilitation (and potentiation) of 
synaptic responses compared to during control (pre-tetanic) periods and during LTP 
(Pananceau et al., 1998; Volianskis et al., 2013b).  
Pharmacological studies have shown that STP is less sensitive than LTP to the NMDAR 
antagonist D-AP5 (Malenka, 1991; Volianskis et al., 2013a). A study by Volianskis and 
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colleagues showed that induction of STP is inhibited by D-AP5 in a biphasic manner, 
comprising two distinct phases of roughly equal contribution to total STP (Volianskis et 
al., 2013a); however, sensitivity of LTP to D-AP5 contains a single component (Volianskis 
et al., 2013a). The components of STP were termed STP1 and STP2, where the sensitivity 
of D-AP5 is as follows: STP1 > LTP > STP2 (Volianskis et al., 2013a). STP1 and STP2 
appears to be distinct in that STP1 contributes to the peak of the total STP response, 
whereas STP2 contributes by slowing the decay of STP (Volianskis et al., 2013a). 
However, decay of both STP1 and STP2 is activity-dependent and both types of STP can 
be stored if stimulation is stopped following induction of potentiation (as described earlier).  
1.3.7.3. Different NMDA receptor subtypes mediate induction of short- and long-term 
potentiation 
Much of the information regarding the roles that distinct NMDAR subunits play in 
induction of STP and LTP has come from pharmacological studies that used NMDAR 
antagonists with relative selectivity for one subunit over another. The NMDAR antagonists 
that are typically used are: D-AP5 (GluN2A- and GluN2B-selective at ≤1 µM) (Davies et 
al., 1981b), NVP-AAM007 (NVP: GluN2A-preferring) (Auberson et al., 2002; Neyton and 
Paoletti, 2006), Ro 25–6981 (Ro: GluN2B-selective) (Fischer et al., 1997) and UBP145 
(GluN2D-preferring) (Costa et al., 2009); see sections 1.3.3 (D-AP5, NVP, UBP145) and 
1.3.4 (Ro) for more details about activities of the compounds. A pharmacological study 
using the GluN2A- and GluN2B-selective antagonist D-CPPene (~13-fold selectivity for 
GluN2A and GluN2B over GluN2C and GluN2D) suggested that GluN2A and/or GluN2B 
may be responsible for LTP whereas GluN2C and/or GluN2D may contribute to induction 
of LTD (Hrabetova et al., 2000). In the study by Hrabetova and colleagues, 1 µM D-CPPene 
(a concentration expected to block GluN2A and GluN2B but not GluN2C and GluN2D) 
blocked the induction of LTP with HFS (100 Hz train for 1 sec) but did not block the 
induction of LTD (Hrabetova et al., 2000). Another study, which used the NMDAR 
antagonists NVP, Ro, ifenprodil and GluN2A- and GluN2B-selective concentrations of D-
AP5, demonstrated that LTP induction (using HFS) is blocked by GluN2A-blocking 
concentration of NVP (0.4 µM) and D-AP5 (0.5 µM) but not the GluN2B diheteromer-
selective concentrations of ifenprodil (3 µM) and Ro (0.5 µM) (Liu et al., 2004). Other 
studies at the SC-CA1 synapse have corroborated the finding that blockage of GluN2A 
(using NVP at 0.1–0.4 µM) inhibits the induction of LTP, and concentrations of Ro capable 
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of blocking GluN2A/GluN2B triheteromeric receptors (using Ro at 5 and 10 µM) blocks 
induction of LTP at the SC-CA1 synapse especially of juvenile mice (postnatal day 14 or 
P14) (e.g. Bartlett et al., 2007; France et al., 2017).  
The discovery of dual components of STP (see section 1.3.7.2) was accompanied by a 
characterisation of the sensitivity of STP and LTP to various NMDAR antagonists with 
varying selectivity for the GluN2A, GluN2B or GluN2D NMDAR subunits, namely D-
AP5, Ro, NVP and UBP145 (Volianskis et al., 2013a). Concentration-response 
relationships describing the ability of these antagonists to inhibit STP and LTP revealed 
that inhibition of STP1 and LTP had the same rank order of potency amongst the 
antagonists – NVP > AP5 > Ro > UBP145 (Volianskis et al., 2013a). However, STP2, 
which contributes to the slow decay of STP, had a different rank order of potency, namely: 
Ro > NVP > UBP145 > AP5. Therefore, STP2 was suggested to represent a 




 Hz, STP1 decayed at a faster rate with a single exponential decay time 
constant (τ) of around 7 min when compared to STP2, which decayed with a τ value of 
around 16 min (Figure 1.17). In conclusion, it was found that STP2 contributes more to the 
decay of global STP whereas STP1 contributes more to the peak of potentiation (Figure 
1.17) (Volianskis et al., 2013a).  
The compounds mentioned above (D-AP5, NVP, Ro, UBP145) were also tested on 
pharmacologically isolated NMDAR-mediated postsynaptic currents (NMDAR-EPSCs) 
from CA1 pyramidal cells using the same slice preparations as was used for the LTP 
experiments (Volianskis et al., 2013a). The rank order of potency for inhibition of 
NMDAR-EPSCs, STP1 and LTP were highly correlated – i.e. the rank order was NVP > 
AP5 > Ro > UBP145 (Volianskis et al., 2013a). In contrast, STP2 did not correlate well to 
the rank order for inhibition of NMDAR-EPSCs, STP1 or LTP (Volianskis et al., 2013a). 
These results agree with the view that NMDARs that are responsible for mediating the 
postsynaptic response are also responsible for induction of LTP and STP1 whereas STP2 
is induced by a different population of receptors that do not (at least directly) contribute to 
the postsynaptic response. The NMDAR population that mediates the induction of STP2 
may be located at another cellular location such as on the presynaptic neuron (Berretta and 
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Jones, 1996; McGuinness et al., 2010) or at an extrasynaptic site on the postsynaptic neuron 
(e.g. Brickley et al., 2003; Lozovaya et al., 2004; Harney et al., 2008).  
Despite the overlapping subunit inhibitory activities of NMDAR antagonists used in the 
study by Volianskis and colleagues, constructing concentration-response relationships for 
these antagonists, allowed differences between LTP, STP1 and STP2 to be identified 
(Volianskis et al., 2013a). The results from Volianskis and colleagues (2013a) suggest that 
TBS-induced LTP requires the activation of both GluN2A- and GluN2B-containing 
receptors for induction. This was partly established by the high sensitivity of LTP to D-AP5 
(LTP IC50 = 0.95 µM) and NVP (LTP IC50 = 20 nM), in contrast to the other antagonists 
(Volianskis et al., 2013a). Induction of LTP was also sensitive to high concentrations (> 3 
µM) of Ro (GluN2B-selective antagonist; LTP IC50 = 3.8 µM) however, Ro inhibits 
GluN2A- and GluN2B-containing recombinant triheteromeric NMDARs at these 
concentrations (Lü et al., 2017).  
In contrast to LTP, induction of STP2 was highly sensitive to Ro at low concentrations 
(Ro’s STP2 IC50 = 20 nM), suggesting that GluN2B-containing NMDARs mediate 
induction of STP2 (Volianskis et al., 2013a). The GluN2D-preferring antagonist UBP145 
also inhibited induction of STP2 at concentrations that were selective for GluN2D-
containing NMDARs (UBP145’s STP2 IC50 = 2.18 µM), whereas LTP (IC50 = 31.6 µM) 
and STP1 (IC50 = 30.3 µM) inhibition needed higher concentrations of UBP145 (Volianskis 
et al., 2013a). It can be suggested therefore that induction of STP2 is dependent on GluN2B 
and GluN2D diheteromers or GluN2B/GluN2D triheteromeric receptors. The activity of 
Ro on native GluN2B/GluN2D triheteromeric receptors remains to be determined and it is 
not known whether the inhibition of STP2 induction by Ro is due to its inhibitory action on 
GluN2B/GluN2D triheteromers. Notably, Ro did not block GluN2D diheteromeric 
receptors (at concentrations up to 100 µM) whereas Ro had an IC50 value of ~100 µM on 
GluN2A diheteromeric receptors expressed on HEK293 cells (Volianskis et al., 2013a). 
The exact pharmacological basis of the early phase of STP, which contributes to its 
amplitude, namely STP1 was difficult to ascertain based on the NMDAR antagonists used 
in the study by Volianskis and colleagues because of the overlap in GluN2A and GluN2B 
activities of D-AP5 and NVP (Feng et al., 2005; Frizelle et al., 2006), which prevented 
selective block of GluN2A (and therefore STP1). Whether STP1 and LTP are mediated by 
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the identical population of receptors or those with similar pharmacology requires further 
study.  
In summary, current evidence points to at least two pharmacologically and mechanistically 
distinct forms of STP, namely STP1 and STP2. Moreover, the induction of STP2 may be 
mediated by GluN2B- and GluN2D-containing NMDARs whereas induction of LTP (and 
possibly STP1) is mediated by GluN2A- and GluN2B-containing NMDARs. With regards 
to STP1, the results from the study by Volianskis and colleagues (2013a) supports the 
suggestion that the early phase of LTP (traditionally referred to as STP, but specifically 
STP1) is mediated by similar mechanisms as LTP (Gustafsson and Wigström, 1990).  
In addition to the pharmacological studies mentioned above, genetic knockout animals have 
also provided evidence for subunit-selective roles of NMDARs. Knockout of GluN2A in 
mice led to reduced LTP compared to controls (Sakimura et al., 1995) and an increase in 
the threshold for induction of LTP compared to controls (Kiyama et al., 1998), at the SC-
CA1 synapse. Another study using a genetic mutant mice lacking the C-terminal of 
GluN2A subunit suggests that in the hippocampus of younger animals (P14), GluN2A- and 
GluN2B-mediated components are required for inducing LTP whereas in adult (> P42) 
mice, the GluN2A component of LTP induction dominates even though LTP can be 
induced in genetically GluN2A CTD-truncated mice with multiple tetanisation (Köhr et al., 
2003). In contrast to GluN2A knockout mice, mice lacking the GluN2B subunit globally 
(Kutsuwada et al., 1996) or expressing a CTD-truncated form of the GluN2B subunit 
globally (Sprengel et al., 1998), die at birth. However, conditional knockout of GluN2B in 
hippocampal pyramidal cells leads to mice with reduced (although not statistically 
significant) capability to induce LTP (with single tetanus and four tetani of HFS) at the SC-
CA1 synapse, and deficits in short-term spatial working memory (Engelhardt et al., 2008). 
Conditional knockout of GluN2B in the pyramidal cells of the cortex and hippocampus 
CA1 led to impairment of LTP induction (at the SC-CA1 synapse) using two tetani of HFS 
but the LTP could be restored by repeated tetanisation (Brigman et al., 2010). In the CA3 
region of the hippocampus, conditional knockout of GluN2B in pyramidal cells could not 
induce LTP (using HFS) in the commissural/associational-CA3 pyramidal cell synapses 
but did not affect KAR-mediated LTP induction in the MF-CA3 synapse (Akashi et al., 
2009; see 1.2.5 for a discussion on KAR-mediated LTP in CA3).  
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Knockout of the GluN2D subunit leads to mice with deficits in spontaneous locomoter 
activity (reduced walking distance in an open field compared to wildtype littermates) (Ikeda 
et al., 1995) and lower sensitivity to stress (Miyamoto et al., 2002). Another study used a 
combination of GluN2D knockout mice and the GluN2B antagonist ifenprodil to 
demonstrate that NMDAR currents in CA1 pyramidal cells and parvalbumin positive 
interneurons of young (P3-5) mice but not older (P20-25) mice may be mediated by 
GluN2D-containing NMDARs (Engelhardt et al., 2015). Although GluN2D knockout mice 
have been used to study the role of GluN2D subunits in schizophrenia (e.g. Sapkota et al., 
2016), these mice have not been used to study STP and LTP in the hippocampus.  
In summary, both pharmacological and genetic studies have pointed to a role for GluN2A 
and GluN2B in the induction of NMDAR-mediated LTP in the SC-CA1 synapse (e.g. 
Kiyama et al., 1998; Hrabetova et al., 2000; Köhr et al., 2003; Liu et al., 2004; Bartlett et 
al., 2007; Volianskis et al., 2013a). A pharmacological investigation of the NMDAR 
subunit-specific roles in the induction of the early decremental phase of LTP (known as 
STP) has suggested that STP contains two pharmacologically distinct components (STP1 
and STP2) (Volianskis et al., 2013a). The induction of STP1, which is the faster decaying 
component of STP that contributes mainly to STP amplitude, was selectively inhibited by 
GluN2A-selective antagonists whereas the induction of STP2 was inhibited by GluN2B- 
and GluN2D-selective antagonists (Volianskis et al., 2013a; France et al., 2017).  
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Figure 1.17. Different NMDAR subunits mediate induction of STP and LTP. Schematic 
diagrams in A-D are based on Volianskis et al., 2013a. A, Schematic showing the potentiation of 
field-excitatory postsynaptic potentials (f-EPSPs), which was induced in the presence of 3 µM D-
AP5 (green line) compared to the control potentiation (black line). Residual STP (shaded grey) had 
a decay time constant (τ) of ~16.0 min whereas τ of control STP was ~16.4 min. Residual LTP 
(shaded yellow) was significantly inhibited compared to control LTP (D-AP5’s IC50 of LTP = 0.95 
µM). B, Similar to A but potentiation was induced in the presence of 0.1 µM NVP (red line). 
Residual STP and LTP are similar to that in the presence of 3 µM D-AP5. C, Similar to A but 
potentiation was induced in the presence of 1 µM Ro (blue line). Residual STP had a τ of ~7 min, 
which was different from τ of control potentiation (16.4 min); whereas residual LTP was not 
significantly reduced compared to control LTP (Ro’s IC50 of LTP = 3.8 µM). D, Similar to A but 
potentiation was induced in the presence of 10 µM UBP145 (orange line). Residual STP and LTP 
were similar to that in presence of 1 µM Ro. The component of STP with fast decay (the residual 
STP in C and D), which is inhibited by concentrations of D-AP5 and NVP that block GluN2A, has 
been termed STP1; whereas the slowly decaying component of STP (the residual STP in A and B), 
which depends on GluN2B and GluN2D, has been termed STP2. Amplitude of LTP primarily 
depends on GluN2A- and GluN2B-containing receptors.  
  
Chapter 1 – Introduction 
78 
1.4. Aims of the thesis 
So far, the introduction has focused mainly on two aspects of investigations involving 
iGluRs. Firstly, a need for subunit selective antagonists (namely GluK2-selective) that may 
help to better understand the physiological role of GluK2-containing KARs in physiology 
(see section 1.2.5) and disease (see section 1.2.6). Secondly, while pharmacological studies 
have suggested that GluN2D-containing receptors mediate induction of a component of 
STP (Volianskis et al., 2013a; France et al., 2017; Ingram et al., 2018), confirmation of this 
finding using a combination of GluN2D knockout animals and GluN2D-selective 
antagonists may help to further understand the roles of this subunit for potentiation.  
The Bristol glutamate research group focus on investigating the role of NMDARs and 
KARs in hippocampal synaptic plasticity. We have developed a range of GluK1-selective 
antagonists, but GluK2-selective antagonists are not available, which is hampering research 
into the role of KAR subtypes in synaptic plasticity in the CA3 region of the hippocampus. 
In this study, a series of kynurenate derivatives, developed as potential GluK2-selective 
antagonists, were characterised on recombinant KAR and AMPAR subtypes and NMDARs 
and AMPARs expressed in the hippocampus. 
With regards to NMDARs, we have recently published a study on the role of GluN2A, 
GluN2B and GluN2D in hippocampal synaptic plasticity (Volianskis et al., 2013a). 
UBP145 has only approximately 10-fold selectivity for GluN2D versus GluN2A and 
GluN2B (Costa et al., 2009; Volianskis et al., 2013a), so in this study the GluN2D 
selectivity of UBP145 was validated in GluN2D knockout mice. GluN2D knockout mice 
were also used alongside selective antagonists to investigate the role of GluN2D in STP 
and LTP. It was not possible to be involved in the pharmacological characterisation of 
antagonists on NMDAR subunits as the cloned receptor cell lines were not available in 
Bristol and the testing of compounds on NMDAR subunits expressed in X. laevis oocytes 
is carried out by a collaborator in Nebraska.   
Despite the apparent disparity between the KAR and NMDAR sections of this thesis, the 
pharmacological principles used in the KAR section (which focuses on the development of 
GluK2-selective antagonists) are relevant for the NMDAR section (which focuses on 
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investigation of GluN2D subunits) in that development of novel GluN2D-selective 
antagonists would follow the same principles.  
In summary, the aims of the thesis are: 
1. to pharmacologically characterise novel compounds in order to develop novel 
GluK2-selective competitive antagonists (described in Chapter 2) 
2. to use computational modelling to explain the GluK2-selectivity and potency of 
competitive KAR antagonists (described in Chapter 3) 
3. to investigate the roles that GluN2D play in synaptic potentiation at the SC-CA1 
synapse (described in Chapter 4)
Chapter 2  
Pharmacological characterisation of GluK2-
selective antagonists based on kynurenic 
acid 
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Physiological studies of GluK2 subunits have suffered from a lack of GluK2-selective 
antagonists (Jane et al., 2009; Møllerud et al., 2017). Previous work has led to the 
development of GluK1-selective antagonists using structure-activity relationship (SAR) 
studies and computer-aided drug design, notably based on the willardiine and 
decahydroisoquinoline series of compounds (Jones et al., 2006; Weiss et al., 2006; Dolman 
et al., 2007; Jane et al., 2009). In the study discussed in this chapter, the activities of 
kynurenic acid derivatives on various KAR and AMPAR subunits were determined and 
this SAR was used to develop more selective GluK2 antagonists. Biological 
characterisation of compounds was carried out using human GluK2, GluK1 and GluA1 
homomeric receptors expressed in HEK293 cells using a calcium fluorescence assay. 
Compounds were further characterised on native iGluRs expressed in rat hippocampal 
slices using f-EPSP recordings.  
2.1. Introduction 
2.1.1. Rationale for developing GluK2-selective antagonists 
It has become clear that KARs facilitate or depress both excitatory and inhibitory synaptic 
transmission in a cell type-, region-, and age-specific manner (Lerma and Marques, 2013; 
Carta et al., 2014). The functional differences of KARs is partly due to the combination of 
different subunits that form the KAR complex (Mulle et al., 1998; Contractor et al., 2003). 
The low-affinity KAR subunit, GluK2, is thought to be expressed in many synapses in the 
brain, including in the hippocampus CA3 region (Wisden and Seeburg, 1993; Watanabe-
Iida et al., 2016).  
In the hippocampal MF-CA3 synapse, studies using genetic knockout and antagonists of 
the GluK1 subunit have found that GluK2 may play an important role in potentiation of 
synaptic responses (Contractor et al., 2003), although studies using GluK1-selective 
antagonists have suggested that GluK1, but not GluK2 subunits, are important for the MF-
CA3 synaptic potentiation (Bortolotto et al., 1999; Wallis et al., 2015). This disparity in 
results has been rationalised by the cell type-specific nature of expression of GluK2 
subunits in the CA3 region and the possibility of heteromeric KARs containing both GluK1 
and GluK2 subunits in addition to the high affinity GluK4 or GluK5 subunits (Jane et al., 
2009). Uncertainty regarding the contributions of different KAR subunits to physiological 
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processes in other brain regions is likely to arise in the absence of pharmacological agents 
that allow the selective inhibition of GluK2 subunits.  
From the currently available antagonists of KAR subunits, NS-102 (see section 1.2.2) has 
only ~6-fold selectivity for GluK2 over other KAR subunits and has poor water solubility 
(Verdoorn et al., 1994; Wilding and Huettner, 1996), limiting its use in physiological 
studies where GluK2-containing receptors also contain other KAR subunits and/or high 
concentrations of the compound may need to be used. Another avenue (in addition to NS-
102) for GluK2 antagonists were the anaesthetic barbiturates, pentobarbital and 
phenobarbital, which were shown to inhibit GluK2 responses more potently than GluA3 
responses (based on %-inhibition of kainate-mediated responses in X. laevis oocytes 
expressing GluK2 or GluA3 homomeric receptors) but their selectivity for GluK2 over 
other KAR subunits was not characterised (Dildy-Mayfield et al., 1996). More recent 
attempts at development of GluK2 antagonists have yielded the GluK2 negative allosteric 
modulator, ethyl-2-amino-4-methyl-5-phenylthiophene-3-carboxylate, which has ~16-fold 
selectivity for the GluK2 subunit (IC50 = 0.75 μM, determined from GluK2 homomeric 
receptors expressed in HEK293 cells) over GluK1 but its GluK2 selectivity over AMPARs 
or NMDARs has not been determined (Briel et al., 2010). Therefore, novel GluK2-selective 
antagonists are needed for future studies which investigate functions of the GluK2 subunit. 
2.1.2. Kynurenic acid derivatives as GluK2 antagonists 
Derivatives of kynurenic acid (Figure 2.1A) were previously investigated as potential 
competitive glycine site antagonists of NMDARs (Leeson et al., 1991). The 1991 SAR 
study by Leeson and colleagues found that 5,7-dichloro substituted kynurenic acid was a 
potent antagonist binding to the NMDAR glycine site. Moreover, the same study also found 
that simple substitutions at the 6-position on the phenyl ring of kynurenic acid decreased 
the NMDAR antagonist activity of kynurenic acid derivates but preserved the non-
NMDAR antagonist activity. In the study by Leeson et al. (1991), activity of compounds 
on AMPARs and KARs were mainly characterised in rat cortical slices using the cortical 
wedge preparation in which quisqualic acid (QUIS) and kainic acid (KA) were used to 
induce responses from AMPARs and KARs, respectively, to test for inhibition by 
compounds. However, both QUIS and KA are agonists for AMPARs and KARs (Holm et 
al., 2005; Mayer, 2005), meaning that the compounds that caused inhibition of QUIS-
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induced responses also caused inhibition of KA-induced responses. QUIS is also an agonist 
of group I metabotropic glutamate receptors (mGluRs) (see section 1.1.1) (Abe et al., 1992), 
further confounding the interpretation of results when using this agonist to induce responses 
from cortical slices where functional group I mGluRs are known to be expressed 
(Shigemoto et al., 1992; Wallis et al., 2015). Compounds that inhibited KA-induced 
responses in the cortical wedge preparation did not inhibit [3H]KA binding to rat cortical 
membranes, but did correlate with [3H]AMPA binding in radioligand binding studies, 
suggesting that the KA-induced responses in the cortical wedge preparation were mediated 
through AMPARs (Leeson et al., 1991). As such, the structure activity relationship of 6-
substituted kynurenic acid derivatives in KARs remained unclear.  
Since these initial experiments, specific subunits of KARs and AMPARs have been isolated 
and expressed in heterologous systems, which has greatly facilitated compound screening 
assays, (Bleakman et al., 1996; Alt et al., 2004). Research by Jane and co-workers has led 
to the refinement of assays for testing of compounds using HEK293 cells specifically 
expressing homomeric receptors containing GluK2, GluK1 or GluA1 subunits (Dargan et 
al., 2009). These protocols have been further adapted in the current study, allowing 
compound-library screening and a thorough characterisation of the activity of novel 
kynurenic acid derivatives on GluK2, GluK1 and GluA1 subunits. Suitable kynurenates 
exhibiting high activity on GluK2 in transfected HEK cells could then be further 
characterised on native AMPARs and NMDARs expressed in the Schaffer collateral-CA1 
synapses of the rat hippocampus.  
The kynurenic acid derivatives used in the current study could be classified into those with 
substitutions on the benzene/phenyl ring and those with modifications to the heterocyclic 
ring. Kynurenates with substitutions on the phenyl ring were further classified based on the 
nature of the 6-substitution, which was previously shown to reduce NMDAR activity 
(Leeson et al., 1991). Namely, the 6-substituted compounds were classed as those with 
halogen, polar or non-polar 6-substituents (Figure 2.1B-E). This classification ignored the 
electronegativity of halogens (rank order of electronegativity: F > Cl > Br > I) but provided 
a simple classification that allowed comparison of antagonist activity with functional 
groups at the 6-position with similar properties. Qualitative comparison of GluK2 and 
AMPAR antagonist activity with the hydrophobicity, size and electronic effects of the 6-
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substituent was also carried out to investigate the effect of chemical parameters of the 6-
substituent on the antagonist activity of kynurenates.  
The compounds with substitutions on the heterocyclic ring (Figure 2.1F) were characterised 
due to a finding from a study by Rowley et al., (1993) that substitutions on the heterocyclic 
ring produced 3-acyl-4-hydroxyquinolin-2(1H)-ones which were higher affinity NMDAR 
glycine site antagonists than kynurenates (Rowley et al., 1993). Therefore, the KAR 
affinities of these compounds were also characterised.  
2.1.3. Objectives 
1. To screen kynurenic acid derivatives on human GluK2, GluK1 and GluA1 
homomeric receptors individually expressed in HEK293 cells using a Ca2+ 
fluorescence assay in the FlexStation. 
2. To further characterise the activities of active kynurenic acid derivatives on GluK2, 
GluK1 and GluA1 recombinant receptors individually expressed in HEK293 cells. 
3. To characterise kynurenates with interesting GluK2 antagonist activity on native 
AMPARs and NMDARs in the rat hippocampus using an electrophysiological 
assay 
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Figure 2.1. Structures of kynurenic acid and derivatives used in the current study. 
Kynurenates with substitutions on the phenyl ring of kynurenic acid (A) could be classed broadly 
based on the nature of the 6-substitutent: (B) 5,7-diF substitutuents, (C) halogen 6-substituents, (D) 
polar 6-substitutuents, (E) non-polar 6-substituents, and (F) derivatives with substitutions on the 
heterocyclic ring.  
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2.2. Methods 
2.2.1. Cell lines 
Human embryonic kidney 293 (HEK293) cells stably transfected with human recombinant 
GluK1, GluK2 and GluA1 subunits were originally developed at and supplied by Eli Lilly 
(Hoo et al., 1994; Korczak et al., 1995; Bleakman et al., 1996). All subunits were Q/R 
unedited (Q) at the ion channel pore and therefore were permeable to Ca2+ ions, and the 
cells were transfected so that each cell line only contained homomeric receptors. Within 
successfully transfected cells, the plasmid containing the gene for the receptor subunit also 
contained an antibiotic resistance gene which allowed the selection of cells which contained 
the gene for the receptor from the total cell population.  
2.2.2. Cell culture and preparation of assay plates 
Compounds were characterised by quantifying changes in calcium fluorescence in cells 
expressing the homomeric receptor of choice. Calcium fluorescence in response to 
glutamate addition in the presence of various concentrations of antagonists were measured. 
Preparation of cells in assay plates for the fluorescence recordings is detailed below. 
Cells were grown in Dulbecco’s Modified Eagle’s Medium (DMEM) that was 
supplemented with 2 mM GlutaMAX, 10% v/v foetal bovine serum (FBS), 50 U/ml 
penicillin and 50 μg/ml streptomycin (herein referred to as modified DMEM). Cells were 
incubated at 37 °C with 5% CO2. Cells were passaged when they reached 70-80% 
confluence and treated periodically with a selection antibiotic. In the case of KAR 
expressing cell lines, hygromycin B (200 g/ml) was the selection antibiotic, whereas for 
AMPAR expressing cells, Geneticin™ (200 g/ml) was used.  
Prior to preparation of cells for experiments, cells were counted using a Tali image-based 
cytometer (ThermoFischer, UK) and 50-100k cells suspended in 100 µL of modified 
DMEM was dispensed into each well of a poly-L-lysine coated 96-well plate (Costar 3603) 
then incubated for ~24 hours. Prior to the experiments, the supernatant was removed, and 
wells were rinsed twice with supplemented Hank’s Balanced Salt solution (sHBSS) 
containing 5 mM CaCl2 and 20 mM HEPES. The cells were then incubated with a working 
solution (100 µL/well) of sHBSS supplemented with calcium fluorescence indicator 
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(Calcium 6 dye, Molecular Devices, UK), and a desensitisation blocker (0.25 mg/mL of 
concanavalin A (or con A) for KARs, and 100 µM cyclothiazide for GluA1). Plates were 
incubated for 2-4 hours to allow the fluorescence dye to internalise with the cells.  
2.2.3. Agonist and antagonist concentration-response curves 
A FlexStation 3 instrument (Figure 2.2; Molecular devices, UK) was used to record the 
time-resolved fluorescence during the antagonist and agonist addition. The FlexStation 
allows sampling of fluorescence (in relative fluorescence units, RFU) from individual wells 
of the assay plate at a frequency of 1.52 Hz, and the FlexStation also allows dispensation 
of pre-set volumes of solutions from a source plate into the assay plate (prepared as 
described above) using the SoftMax Pro software (Molecular devices, UK). At the start of 
all experiments, a one-off absorbance reading was taken to verify that the dye had loaded 
equally across all wells in the assay plate. For fluorescence recordings, the excitation 
wavelength was set at 485 nm, and emission was detected at 525 nm, based on the 
specifications of the Calcium 6 dye. Data from timed measurements of fluorescence 
(sampling frequency = 1.52 Hz) was smoothed using a 9-point moving average to 
compensate for noise during data collection. 
 
Figure 2.2. Anatomy of the FlexStation 3 plate reader. FlexStation plate reader was used to 
measure of calcium fluorescence from the assay plate. Dispensation of solution from a source plate 
to the assay plate was performed with pre-programmed routines in SoftMax Pro software. Image 
adapted from www.moleculardevices.com. 
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Concentration-response curves for glutamate were obtained by testing 7 concentrations of 
glutamate in triplicates (see Figure 2.3A for details). Briefly, glutamate was added to the 
wells after 20 s of baseline fluorescence measurement. The baseline fluorescence was 
subtracted from the maximum fluorescence in the presence of glutamate to obtain the 
change in fluorescence induced by agonist addition in a well (ΔF). The ΔF for each 
concentration of glutamate was then normalised to ΔF for the highest glutamate 
concentration (2 mM) and the normalised ΔF was used for further analyses (see Figure 2.4 
for fluorescence recordings).  
The normalised ΔF in response to different glutamate concentrations was fitted to a four-
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where Y is the response (normalised ΔF), T is the maximum response (constrained to 100% 
for the fit), B is the minimum response (constrained to 0%), X is the glutamate 
concentration, EC50 is the concentration of glutamate that produced half-maximal response, 
and H is the slope-factor (also known as the Hill slope). 
To obtain antagonist concentration-response curves, 8 concentrations of antagonist 
(including a zero concentration; see Figure 2.3A for details) were applied to wells for 70 s 
after a baseline of 20 s. A concentration of glutamate that produced 80% of the maximal 
response (EC80) was extrapolated from the curve generated with eq. (2.1) for the glutamate 
concentration-response curve in each plate. The EC80 agonist concentration was added to 
the wells 70 s after the addition of antagonists and the ΔF was measured. The ΔF of each 
antagonist concentration point was then normalised to the ΔF produced with no antagonist 
(0 µM antagonist). The normalised ΔF was then fitted to eq. (2.2) in real time using 
SoftMax Pro. 
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where Y is the response, T is the maximum response (constrained to 100%), B is the 
minimum response (constrained to 0%), X is the antagonist concentration, IC50 is the 
concentration of antagonist that inhibited 50% of the response, and H was the slope-factor. 
Due to the dependence of IC50 on variables such as receptor expression levels, the agonist 
concentration and agonist EC50, it is not a suitable metric to compare the activity of 
compounds between cell lines. Therefore, the inhibition constant, Ki, which is an agonist 
concentration-corrected estimate of affinity, was used to compare affinities of compounds. 









where Ki, IC50 and EC50 are as described above and S is the concentration of agonist used 
to elicit responses. 
All ΔF data points were performed in triplicate on the same assay plate and the median of 
the 3 replicates were used for further analysis. In all experiments, a known (standard) 
antagonist was used as a positive control for each assay plate and when the standard 
antagonist Ki deviated by a factor of > 2 from the cell line-pooled mean Ki, the data from 
the assay plate was discarded. Standard antagonists were chosen based on their solubility 
in the experimental media (sHBSS as mentioned before) and their ability to obtain a 
concentration-response relationship which was well-defined over the concentrations of 
antagonist tested (see Figure 2.5C for example). Therefore, UBP2038 and UBP2039 were 
chosen from the kynurenates as standard antagonists. shows the layout of assay plates for 
concentration-response experiments.  
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2.2.4. Single concentration library screening using the FlexStation 
All compounds were tested at 100 µM on GluK2, GluK1 and GluA1 cell lines to provide a 
general overview of the antagonist activities of test compounds. In single concentration 
screening experiments, glutamate and standard antagonist concentration-response curves 
were obtained as described above. For single concentration screening, wells from columns 
7-12 of the assay plate (Figure 2.3B) were used to screen up to 14 compounds at 100 μM 
in triplicates. The positions of test compounds and vehicle in each column were randomised 
between assay plates.  
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Figure 2.3. Layout of assay plate used for FlexStation experiments. A, Layout of the 96-well 
assay plate (top) showing the arrangement of concentration-response experiment for glutamate 
(pink) and 3 different antagonists (green, red and blue). Median fluorescence from a triplicate 
recording was used for further analysis. The concentrations of glutamate and antagonists used in 
each row (A-H) are shown in the table (bottom). The concentrations of glutamate used in GluK2 
and GluA1 cell lines were different from that used for the GluK1 cell line due to higher EC50 of 
glutamate for GluK1 compared to GluK2 or GluA1 subunit containing receptors. B, Assay plate 
layout for single concentration screening (top) used similar layout as A for columns 1-6 and a 
different layout for columns 7-12 (bottom). Three replicates of 14 compounds (represented by 
letters a – n) could be tested on one plate. Each screening column also contained a vehicle (sHBSS, 
see Methods) well which was used to normalise data from all other wells in the column. 
2.2.5. Analysis and presentation of screening data 
Compounds which had > 10% inhibition in single concentration screening were considered 
for full concentration-response characterisation. The 10% cut-off was chosen based on an 
estimation of the IC50 of antagonists using eq. (2.2) with the slope, T and B constrained to 
1, 100 and 0, respectively. Therefore, > 10% inhibition at 100 μM of test compound 
provided an indicator of a compound with IC50 < 900 μM.  
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2.2.6. Off-line analysis and presentation of concentration-response data 
Statistical comparisons and tabulation of activities of compounds on GluK2, GluK1 and 
GluA1 were carried out using the mean Ki for each compound on the respective cell line. 
Pooled concentration-response curves for glutamate and antagonists as shown in Results 
were prepared using GraphPad Prism 7 (GraphPad, USA). For visualisation purposes, the 
pooled data for glutamate and antagonists were fitted using non-linear regression to 4-
parameter logistic curves based on eq. (2.1) and eq. (2.2), respectively. However, the IC50 
values derived from individual assay plate concentration-response curves, and not from the 
curve-fit of pooled data, were used to calculate Ki values.  
2.2.7. Analysis of physicochemical properties 
The antagonist activity of kynurenates on the GluK2 HEK293 cell line (GluK2 Ki value) 
was qualitatively compared to three physicochemical properties of the substituent at the 6-
position of the kynurenate. This comparison was performed in order to understand the 
properties of the 6-substituent which would provide the highest affinity on GluK2-
containing KARs. First, molar refractivity (MR) was used as a measure of the volume 
occupied by the 6-substituent (larger MR values indicated larger 6-substituents). Secondly, 
the hydrophobicity constant (π) of a substituent was used as a measure of the hydrophobic 
nature of the substituent where positive values indicate compounds that were more 
hydrophobic than hydrogen. The constant π was calculated by subtracting the octanol/water 
partition coefficient of the substituent (bonded to benzene) from the coefficient of 
unsubstituted benzene. Thirdly, electronic effects of the 6-substituent were represented by 
the Hammett substituent constant (σ) of the 6-substituents where positive values indicated 
more electron withdrawing substituents. The electronic effect of substituents is also 
dependant on whether the substituent position is para or meta. Therefore, σp and σm was 
used to indicate the electronic effects of para and meta substitutions, respectively. Values 
for MR, π, σp and σm were taken from Hansch et al., 1973. 
2.2.8. Statistical analysis of FlexStation data 
Non-parametric tests were used to statistically compare data for single concentration 
screening data because the number of observations were too few to test for normality of 
inhibition values. UBP2038 had Ki values that did not follow a normal distribution (p < 
0.05, D'Agostino & Pearson normality test), therefore, non-parametric tests were used to 
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compare Ki values. Inhibition from single concentration screening experiments were 
compared using two-tailed Mann-Whitney (MW) test. Significant differences in Ki values 
between compounds in each cell line was determined using two-tailed MW test by 
comparing the Ki values for compounds of interest. Significant differences in Ki values of 
one compound between different cell lines were determined using Kruskal-Wallis (KW) 
test followed by Dunn’s multiple comparison test (DT). Statistical significance levels were 
set at p < 0.05.  
2.2.9. Slice preparation for electrophysiology 
All experiments involving rats were performed in accordance with Bristol University 
regulations and the UK Scientific Procedures Act, 1986 and European Union guidelines for 
animal care. Wistar rats (Charles River, UK) aged 2-3 months were anaesthetised using 
isofluorane and euthanised by decapitation (Schedule 1 method). The hippocampi from 
each hemisphere were extracted and cooled (0-4°C) in artificial cerebrospinal fluid (aCSF) 
solution consisting of (mM): 124 NaCl, 3.5 KCl, 1.25 NaH2PO4, 26 NaHCO3, 2 CaCl2, 2 
MgSO4 and 10 glucose, saturated with 95% O2 and 5% CO2. Transverse slices (400 µm 
thick) were cut from dorsal end of each hippocampi using a McIllwain tissue chopper. The 
slices were incubated in aCSF (pH ~7.4) for at least 2 hours at ~20 ˚C before being 
transferred to the recording chamber at the beginning of experiments. Extracellular field 
potentials were recorded from the submerged slices in the recording chamber maintained 
at 30 °C and continuously perfused with aCSF at a rate of ~3 mL/min.  
2.2.10. f-EPSP recordings from hippocampal slices 
f-EPSPs mediated by AMPARs and NMDARs were obtained by stimulating the Schaffer 
collateral axons of CA3 pyramidal cells with a bipolar concentric (stimulating) electrode 
placed in the stratum radiatum layer on the border between the CA1 and CA2 subregions 
of the hippocampus. The stimuli were generated using a constant voltage stimulus generator 
(DS2A Mk2; Digitimer). AMPAR-mediated f-EPSPs from the stratum radiatum of the CA1 
subregion were recorded using a maximum stimulation intensity of 3 times that required to 
elicit a f-EPSP. f-EPSPs were recorded with a glass electrode filled with aCSF solution 
(electrode resistance: 1.5-2 MΩ). f-EPSP signals were amplified and hardware filtered at 5 
kHz (AxoPatch 1D; Axon Instruments, USA). Responses evoked using the stimuli were 
sampled at 40 kHz and recorded using the WinLTP software (Anderson and Collingridge, 
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2007). f-EPSPs were evoked at a frequency of 0.067 Hz and average of 4 such f-EPSPs 
(corresponding to average f-EPSPs for 1 min) were used for all further visualisation and 
analyses shown in Results.  
Inhibition of AMPAR-mediated f-EPSPs by all compounds were measured by application 
of the test compound after 30 min of stable baseline AMPAR f-EPSP recording. 
Subsequently, compounds were added (cumulatively) to achieve the concentrations shown 
in the figures and tables in Results. Compounds were applied for 30 min and compounds 
that produced any effects were washed out of the recording chamber by perfusing aCSF to 
show that the effects of compounds were reversible (indicated as washout in figures).  
NMDAR-mediated f-EPSPs were isolated by first obtaining a stable AMPAR f-EPSP 
baseline for at least 20 mins and changing the bath Ca2+ and Mg2+ concentrations to 3 mM 
and 1 mM, respectively, and blocking the AMPAR f-EPSPs with 3 μM NBQX. The 
stimulation intensity was then increased to 3 times that required to obtain AMPAR f-EPSPs 
to obtain NMDAR mediated f-EPSPs (amplitudes of the baseline NMDAR f-EPSPs were 
> 0.1 mV) which were free of population spikes and epileptic activity. At the end of 
NMDAR f-EPSP experiments, 30 µM D-AP5 was added to the bath for 10 min to verify 
NMDAR-mediated responses.  
2.2.11. Data analysis of f-EPSP recordings 
Filtered traces obtained from WinLTP were analysed using Platin (developed by Prof. 
Morten Jensen; University of Aarhus, Denmark). The initial slope of f-EPSPs (measured 
for a time interval of 0.5 ms) was used as a measure of the AMPAR f-EPSPs. The f-EPSP 
slope measurement for the whole experiment was normalised to the mean baseline slope 
such that baseline f-EPSP was 100%. 
In experiments using NMDAR mediated f-EPSPs, the f-EPSP peak amplitude was used to 
calculate inhibition by compounds. In cases where peak amplitude was observed to be 
contaminated by the fibre volley, the fibre volley in the presence of 30 µM D-AP5 was 
subtracted from all f-EPSP recordings in the experiment and the resulting f-EPSPs were 
used for further analyses. Peak amplitudes for the whole experiment were normalised to 
the baseline period as with the AMPAR mediated f-EPSPs and expressed as baseline-
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normalised f-EPSP (such that baseline f-EPSP was 100%). Effect of test compounds on 
AMPAR- and NMDAR-mediated responses were expressed as %-inhibition of baseline 
recordings.  
2.2.12. Statistical comparisons of electrophysiological data 
For statistical comparison of effect sizes for different test compounds, Student’s t-test or 
ANOVA followed by Tukey’s multiple comparison test was used as necessary. Some 
compounds were tested at multiple concentrations to allow estimation of half-maximal 
inhibitory concentration (IC50) of the compound. For such experiments, a concentration-
inhibition curve was constructed using non-linear regression curve fitting (GraphPad, 
Prism). The concentration-pooled normalised f-EPSPs in the presence of multiple 
concentrations of the test compound were fitted using a four-parameter logistic curve with 
eq. (2.2). Top and bottom was constrained to 100% and 0%, respectively. The IC50 values 
of test compounds were estimated from the fitted curve. Statistical comparisons of IC50 
between compounds were conducted using F-test in GraphPad Prism. All data were 
presented as mean ± SEM. Statistically significant differences in bar plots are indicated by 
asterisks (* P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001). 
2.2.13. Chemicals and reagents 
Kynurenic acid derivatives were synthesised by Jane and co-workers at the University of 
Bristol and had 1H nuclear magnetic resonance (NMR) spectra, mass spectra and 
microanalytical data that was consistent with their structure (Thatcher, R, Irvine, M, Jane 
DE, unpublished). D-AP5 and NBQX were acquired from HelloBio Ltd (Bristol, UK). All 
kynurenic acid derivatives were prepared as stock solutions in deionised water (Millipore, 
UK) using 2 equivalents of aqueous NaOH. Compounds with an extra acid group were 
dissolved using 3 equivalents of aqueous NaOH. Stock solutions were stored as frozen and 
added to the perfusion medium for durations as indicated in the figures in Results (for 
electrophysiological field recordings). GlutaMAX was purchased from ThermoFischer, 
UK. FBS was purchased from Biosera. Penicillin, streptomycin, and selection antibiotics 
Hygromycin B and Geneticin™ were purchased from Invitrogen and Gibco, respectively. 
The Calcium 6 dye was purchased from Molecular Devices. All other reagents were 
obtained from Sigma-Aldrich.  
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Table 2.1. Given names and chemical names of compounds used in the study. 
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2.3. Results 
2.3.1. Validation of the calcium fluorescence assay 
The calcium fluorescence assay using GluK2, GluK1 and GluA1 cell lines in the current 
study has previously been used to pharmacologically characterise compounds (Alt et al., 
2004; Dargan et al., 2009). The assay developed for the current study is similar in principle 
and therefore, the results from the current study may be translatable to other studies that 
use the same cell lines. An example experiment showing the concentration-response 
relationship for glutamate and the standard antagonist UBP2038 is shown in Figure 2.4. 
Figure 2.5 shows the concentration-response relationships of glutamate (Figure 2.5A), 
kynurenic acid (Figure 2.5B) and the standard antagonist UBP2038 (Figure 2.5C), on 
GluK2, GluK1 and GluA1 homomeric receptors. The EC50 values and slope-factors for 
glutamate were similar to previously published results on the cell lines containing GluK1 
and GluK2 homomeric receptors expressed in HEK293 cells (Alt et al., 2004) and GluA1 
homomeric receptors expressed in Xenopus oocytes (Donevan et al., 1998). IC50 values and 
slope-factors for kynurenic acid on GluK1 and GluK2 from the current study were broadly 
similar to previously published results (Alt et al., 2004). 
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Figure 2.4. Representative experiments showing fluorescence response to glutamate and the 
standard antagonist UBP2038. A, Data from a representative glutamate concentration-response 
evaluation showing the fluorescence in response to various concentrations of the agonist, glutamate 
on GluK2 homomeric receptors. Each data-point represents median fluorescence from 3 replicate 
wells. Application of various concentrations of glutamate began at 20 s after baseline recording 
(solid line). B, Data from a representative antagonist concentration-response experiment on GluK2 
homomeric receptors. The standard antagonist, UBP2038, was applied at various concentrations 20 
s after baseline recording (dashed line). A concentration of glutamate producing 80% of the 
maximal response (EC80) (calculated from the agonist concentration-response curve generated from 
data in A) was added at 90 s (solid line).  
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Figure 2.5. Concentration-response curves for glutamate, kynurenic acid and UBP2038 on 
HEK293 cells expressing GluK2, GluK1 and GluA1 homomeric receptors. A, Pooled glutamate 
concentration-response curves on homomeric receptors containing GluK2 (red, n = 35), GluK1 
(blue, n = 29), and GluA1 (green, n = 21) subunits. Glutamate EC50 for GluK2 = 7.7 ± 0.4 µM, 
GluK1 = 23.1 ± 1.7 µM, and GluA1 = 8.4 ± 0.8 µM. Slope-factor for GluK2 = 1.2 ± 0.03, GluK1 
= 1.2 ± 0.03, GluA1 = 1.2 ± 0.05. Data are shown as mean, error bars represent SEM. B, Pooled 
concentration-response curves showing the effect of kynurenic acid on homomeric receptors 
containing GluK2 (red, n = 3), GluK1 (blue, n = 3), and GluA1 (green, n = 3) subunits. IC50 for 
GluK2 = 282.5 ± 25.5 µM, GluK1 = 402.3 ± 27.9 µM, and GluA1 = 2836.0 ± 253.6 µM. Slope-
factor for GluK2 = -1.00 ± 0.09, GluK1 = -1.20 ± 0.08, and GluA1 = -0.90 ± 0.07. C, Pooled 
UBP2038 concentration-response curves for homomeric receptors containing GluK2 (red, n = 28), 
GluK1 (blue, n = 27), and GluA1 (green, n = 22) subunits. IC50 for GluK2 = 15.7 ± 1.1 µM, GluK1 
= 52 ± 6.1 µM, and GluA1 = 90.5 ± 8.0 µM. Slope-factor for GluK2 = -1.10 ± 0.04, GluK1 = -0.90 
± 0.04, and GluA1 = -0.90 ± 0.03.  
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2.3.2. Compound screening at a single concentration 
Results from the single concentration screening are shown in Table 2.1. Generally, the 
compounds which exhibited > 10% inhibitory activity have substituents at the 6-position 
of the phenyl ring. Therefore, the compounds were loosely grouped based on the nature of 
the functional group at the 6-position, namely halogen, polar, and non-polar. One exception 
to this grouping was UBP2040 (6-H-5,7-diF, see Figure 2.1B for structure). Some 6-
substituted kynurenates such as UBP2042 (6-SF5) and UBP2007 (6-CO2H) had < 10% 
inhibition of GluK2 homomeric receptors at 100 μM. Kynurenates which had modifications 
on the heterocyclic ring (see Figure 2.1F for structures) had < 10% inhibition of GluK2 
homomeric receptors. Therefore, the compounds with modifications on the heterocyclic 
ring were not considered for studying concentration-response relationship.  
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Table 2.2. Screening of compound library at 100 µM on homomeric GluK2, GluK1 and GluA1 
receptors (ordered by GluK2 activity). Values shown are mean ± SEM percentage-inhibition of 
EC80 glutamate response on the respective receptor. Number of independent recordings (n) is shown 
in parenthesis. Compounds chosen for further characterisation are highlighted based on the type of 
substituent at the 6-position of the benzene ring of the compound (grey: halogen, green: polar, 
yellow: non-polar, red: no substitution). Compounds which were eliminated from further 
characterisation are shown below the red line (indicating an inhibition of < 10% on GluK2 
homomeric receptors).  
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2.3.3. Characterisation of 6-halogen substituted kynurenic acid derivatives 
on recombinant receptors 
Six compounds which were selected for further characterisation from the screening had a 
halogen at the 6-position of the phenyl ring. Concentration-response curves for these 
compounds were obtained on GluK2, GluK1 and GluA1 homomeric receptors (Figure 2.6). 
UBP2038 (5,7-diF-6-I) was the most potent antagonist on GluK2 amongst all 6-halogen 
substituted compounds (Ki = 4.6 ± 0.3 µM, Figure 2.6A). The rank order of affinity of the 
compounds on GluK2 was UBP2038 > UBP2039 (5,7-diF-6-Br) > UBP2020 (6-Br) > 
UBP2002 (6-I) > UBP2037 (5,7-diCl-6-I) > UBP2025 (5,6,7-triCl). This rank order of 
affinity of these compounds was broadly in agreement with that observed in GluK1 and 
GluK2 cell lines. In the GluK1 cell line, UBP2039 was slightly more potent than UBP2038 
but the difference in GluK1 Ki between UBP2038 and UBP2039 was not statistically 
significant (p > 0.05, MW test). UBP2037 and UBP2025 had poor solubility in the sHBSS 
media used in the assay at concentrations above 100 µM which may have contributed to 
the increased variability of the data for UBP2037 and UBP2035 at higher concentrations. 
The affinities of all compounds were highest in the GluK2 cell line, followed by GluK1 
and then GluA1 cell lines. In cases where IC50 was greater than 300 µM, Ki was not 
calculated as the concentration-response curve would be poorly defined because only one 
concentration above 300 µM (2 mM) was tested due to the poor solubility of the compounds 
at high concentrations. Of the 6-halogen substituted compounds that also had substitutions 
at the 5- and 7- positions of the phenyl ring, UBP2038 showed higher inhibition in GluK2 
expressing cells than UBP2002, UBP2020, and UBP2025 (p < 0.05 for all, MW test).  
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Figure 2.6. Characterisation of 6-halogen substituted kynurenates on GluK2, GluK1 and 
GluA1 homomeric receptors. A, Concentration-response curves (left) and summary of IC50 and 
Ki values (right) for 6-halogen substituted compounds on GluK2 homomeric receptors. The key for 
the figure on left is provided in the table. The table is sorted according to activity on GluK2 
homomeric receptors. IC50 and Ki values in the table are shown as mean ± SEM. B, Similar to A 
but for GluK1 homomeric receptors. In cases where IC50 was larger than 300 µM, Kis were not 
calculated because the curve would not be well defined since only one concentration of antagonist 
above 300 µM (2000 µM) was tested. C, Similar to A but for GluA1 homomeric receptors.  
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2.3.4. Characterisation of polar 6-substituted kynurenic acid derivatives on 
recombinant receptors 
From the initial screening (Table 2.2), the polar 6-substituted compounds were further 
characterised on GluK2, GluK1, and GluA1 homomeric receptors (Figure 2.7). The rank 
order of affinity (based on Ki) on GluK2 was UBP2043 (6-OMe-7-F) > UBP2049 (6-OMe) 
> UBP2051 (6-NO2) > UBP2047 (5,7-diF-6-OMe) > UBP2022 (6-NH2) > UBP2007 (6-
CO2H). UBP2007 was excluded from characterisation on GluK1 and GluA1 cell lines due 
to inactivity on GluK2 (Figure 2.7A). A similar rank order of affinity to that in GluK2 cell 
lines was seen in GluK1 and GluA1 cell lines. The affinity of polar 6-substituents was 
highest in GluK2 followed by GluK1 and GluA1.  
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Figure 2.7. Characterisation of polar 6-substituted kynurenates on GluK2, GluK1 and GluA1 
homomeric receptors. Concentration-response curves (left) on GluK2 (A), GluK1(B) and 
GluA1(C) homomeric receptors and the respective mean ± SEM IC50 and Ki values generated from 
the individual experiments (right). The figure key for concentration-response curves are shown next 
to the compound names in the table. Number of independent observations (n) is also shown in the 
table. All tables were sorted according to their affinity for GluK2 homomeric receptors. 
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2.3.5. Characterisation of non-polar 6-substituted kynurenic acid 
derivatives on recombinant receptors 
Compounds with non-polar 6-substitutions on the phenyl ring were further characterised in 
GluK2, GluK1 and GluA1 homomeric receptors (Figure 2.8). Rank order of affinity in 
GluK2 is UBP2046 (6-SMe) > UBP2034 (6-Me) > UBP2054 (6-Et) > UBP2042 (6-SF5) > 
UBP2052 (6,8-diMe), and a similar rank order of affinity was observed for GluK1 and 
GluA1 homomeric receptors.  
UBP2046 had the highest estimated affinity on GluK2 (Ki = 15.2 ± 3.1 µM) which had a 
significantly lower Ki value compared to the estimated Ki of UBP2054 (54 ± 10.9 µM; p < 
0.05, MW test) but not UBP2034 (46 ± 9.3 µM; p > 0.05, MW test). Surprisingly, UBP2054 
had significantly lower inhibitory activity on GluK1 (IC50 > 1000 µM) and GluA1 (IC50 > 
2000 µM) compared to GluK2 subunits.  
  
Chapter 2 – Pharmacological characterisation of GluK2-selective antagonists 
108 
 
Figure 2.8. Characterisation of non-polar 6-substituted kynurenic acid derivatives on 
recombinant GluK2, GluK1 and GluA1 homomeric receptors. Pooled concentration-response 
curves (left) and the IC50 and Ki values (mean ± SEM) generated from the individual experiments 
(right) on GluK2 (A), GluK1 (B) and GluA1 (C) homomeric receptors. The figure key for 
concentration-response curves is shown next to the compound names in the table. Number of 
independent observations (n) is also shown in the table. Table is sorted according to affinity for 
GluK2 homomeric receptors. 
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2.3.6. Subunit selectivity of kynurenic acid derivatives 
To select the kynurenate with highest GluK2 over GluK1 or GluA1 selectivity, the agonist-
corrected affinities of antagonists (Ki) on all three cell lines were compared (Table 2.3). 
Ratios of GluK1/GluK2 Ki values provided a measure of selectivity of the test compound 
for GluK2 over GluK1 homomers based on affinity. Similarly, GluA1/GluK2 Ki ratios were 
also calculated. Some kynurenates had IC50 greater than the highest concentration tested (2 
mM), therefore, their Ki values and selectivity ratios based on Ki values could not be 
calculated. In cases where the Ki values could not be calculated, an estimated selectivity 
ratio for GluK2 over GluK1 or GluA1 was calculated by dividing the IC50 for GluK1 or 
GluA1, respectively by the estimated IC50 value of GluK2 (Table 2.3).   
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Table 2.3. Ki or IC50 values of kynurenates on GluK2, GluK1 and GluA1 homomeric receptors 
and estimated selectivity of kynurenates between subunits. Compound codes are coloured 
according to the nature of the 6-substituent: grey: halogen, green: polar, yellow: non-polar, and red: 
no substitution. Selectivity ratios (GluK1/GluK2 and GluA1/GluK2) is an estimate of the GluK2 
over GluK1 or GluA1 selectivity obtained by dividing respectively the GluK1 or GluA1 Ki by the 
GluK2 Ki of each compound. In cases where Ki values could not be determined, an estimate GluK2 
over GluK1 or GluA1 selectivity ratio was calculated by dividing an estimate of the GluK1 or 
GluA1 IC50 value by the GluK2 IC50 (such values are suffixed with #). 
2.3.7. Substitutions at the 6-position on the benzene ring reduced NMDAR 
activity of kynurenic acid derivatives 
Leeson and colleagues (1991) have shown that simple 6-substitution on the benzene ring 
decreased the affinity of kynurenic acid derivatives on NMDARs but inhibited non-
NMDAR responses (Leeson et al., 1991). To verify this, experiments were carried out on 
native iGluRs in the rat hippocampus (Figure 2.9). f-EPSP recordings were made from the 
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SC-CA1 synapses in the hippocampus where AMPARs and NMDARs mediate synaptic 
transmission (Figure 2.10). 
Characterisation of UBP2040 (5,7-diF), UBP2038 (5,7-diF-6-I), and UBP2002 (6-I) at 100 
µM in native tissue confirmed that 6-substituted compounds have reduced activity on 
NMDARs but significant inhibitory activity on AMPARs (Figure 2.11). These results 
verified previous observations that 6-substituents on the benzene ring decreased NMDAR 
activity of kynurenic acid and provided validity to the technique used in this study to 
characterise compounds on native AMPARs.  
 
Figure 2.9. Setup of recording field potentials from hippocampal neurons. Experimental set-
up for recording responses mediated by native iGluRs in SC-CA1 synapses. Using a stimulating 
electrode (Stim), pulses were delivered to the Schaffer collaterals at a frequency of 1 per 15 s. 
Recordings were made from the stratum radiatum of the CA1 region (see section 2.2.10 for more 
details).  
  
Chapter 2 – Pharmacological characterisation of GluK2-selective antagonists 
112 
 
Figure 2.10. Example f-EPSP experiments from the hippocampus. A, Example experiment 
showing the characterisation of UBP2038 at 1 µM and 10 µM on native AMPARs. Stable baseline 
recordings were made for 30 min, and UBP2038 was added as indicated in the figure (thin solid 
lines). At the end of the experiment, UBP2038 was washed out of the recording chamber for 60 min 
(thick solid line) to verify the reversibility of the compound’s inhibition. Representative AMPAR-
mediated f-EPSP responses from the time-points indicated on the experiment are shown on the 
right. B, Example experiment showing the characterisation of UBP2038 at 100 µM on native 
NMDARs. A stable baseline of AMPAR-mediated f-EPSPs for 30 min was initially recorded. 
Subsequently, the perfusion solution was altered to block AMPARs (3 µM NBQX) and facilitate 
NMDAR-mediated f-EPSPs (3 mM Ca2+, 1 mM Mg2+). The NMDAR-mediated response amplitude 
was increased by increasing the stimulation intensity by 3-fold (red arrowhead). The resulting 
NMDAR-mediated f-EPSPs were re-normalised to a stable baseline containing NMDAR-mediated 
f-EPSPs recorded for 30 min (starting at black arrow). 100 µM UBP2038 was added as indicated 
in the figure and at the end of experiments, NMDAR responses were verified using 30 µM D-AP5. 
Representative f-EPSP responses from the time-points indicated on the experiment are shown on 
the right.  
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Figure 2.11. Substitution on the 6-position of phenyl ring decreases NMDAR activity of 
kynurenic acid derivatives. A, Structures of UBP2040, UBP2038 and UBP2002. B, All 
three compounds inhibited AMPAR-mediated f-EPSPs at 100 µM. AMPAR f-EPSPs were 
more significantly blocked by UBP2038 (inhibition = 101.2 ± 0.5%) compared to UBP2040 
(68.1 ± 2.9%) and UBP2002 (73.3 ± 1.7%), (p < 0.0001 for both, ANOVA, Tukey test). 
Number of independent observations (n) are shown in parenthesis. Inhibition values from 
individual experiments are shown (clear circles), error bars represent SEM. C, NMDAR f-
EPSPs were significantly inhibited by UBP2040 (73.2 ± 1.3%) compared to UBP2038 
(13.3 ± 3.1%) and UBP2002 (7.2 ± 3.1%), (p < 0.0001 for both, ANOVA, Tukey test). 
Number of independent observations (n) are shown in parenthesis. Inhibition values from 
individual experiments are shown (clear circles), error bars represent SEM. 
2.3.8. Characterisation of 6-substituted kynurenic acid derivatives on 
native AMPARs 
A summary of the further characterisation of 6-substituted kynurenic acid derivatives at 
100 µM on native AMPARs is shown in Figure 2.12. All 6-halogen substituted compounds 
inhibited AMPAR mediated f-EPSPs (Figure 2.12A) at 100 µM; UBP2038 (5,7-diF-6-I) 
had the highest inhibition of AMPAR f-EPSP (101 ± 0.5%, n = 6) and UBP2002 (6-I) had 
the lowest inhibition of AMPAR f-EPSP at 100 µM (73.3 ± 1.7%, n = 7). The rank order 
of inhibition of AMPAR f-EPSP for 6-halogen substituted kynurenates: UBP2038 > 
UBP2037 (5,7-diCl-6-I) > UBP2020 (6-Br) > UBP2002, was similar to the rank order of 
affinity on GluK2 and GluA1 homomeric receptors (Figure 2.6A and C, respectively): 
UBP2038 > UBP2037 > UBP2020 > UBP2002. The difference in activity of UBP2037 
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between recombinant and native systems may be explained by the more favourable 
solubility of UBP2037 in the buffer media used for native receptor experiments. 
Polar 6-substituted kynurenic acid derivatives also inhibit AMPAR-mediated f-EPSPs 
(Figure 2.12B). UBP2043 (6-OMe-7-F) had the highest inhibition (91.7 ± 0.5%, n = 3) 
amongst polar 6-substituents tested on native receptors. UBP2049 (6-OMe), UBP2051 (6-
NO2; n = 5), and UBP2047 (5,7-diF-6-OMe; n = 3) inhibited AMPAR f-EPSPs by > 50% 
at 100 µM (Figure 2.12B).  
Kynurenates with non-polar 6-substituents on the phenyl ring also inhibited AMPAR-
mediated f-EPSPs but the non-polar substitution in UBP2054 (6-Et) had the least inhibition 
of native AMPARs amongst all tested compounds (inhibition at 100 µM = 7.8 ± 3%, n = 
4) (Figure 2.12C). The shorter non-polar 6-substituent, UBP2034 (6-Me) inhibited 
AMPAR f-EPSPs by 29.2 ± 3.6% (n = 3) whereas UBP2046 (6-SMe) showed the highest 
inhibition of AMPAR f-EPSPs at 100 µM amongst non-polar substituents (68.2 ± 3%, n = 
6) (Figure 2.12C).  
The activity of UBP2054 (6-Et), UBP2038 (5,7-diF-6-I), UBP2002 (6-I) and UBP2020 (6-
Br) on native AMPARs was characterised at multiple concentrations (Figure 2.13) to 
investigate the concentration-response relationship of these compounds on native 
AMPARs. UBP2054 had < 25% inhibition of AMPAR f-EPSPs at the highest concentration 
tested in the native system (300 µM), therefore the curve-fit was ambiguous and prediction 
of IC50 on native AMPARs included a large error (predicted IC50 for UBP2054 on native 
AMPARs > 300 µM; n = 4). The most potent kynurenic acid derivative tested, UBP2038, 
had an IC50 of 3.6 ± 0.1 µM on native AMPARs (n = 5). The potency of UBP2020 (25.6 ± 
0.4 µM; n = 5) was slightly but statistically significantly higher potency compared to 
UBP2002 (45.2 ± 1.9 µM; n = 4) based on IC50 on native AMPARs (p < 0.05, Student’s t-
test). The rank order of potency on native AMPARs was similar to the rank order of affinity 
on homomeric GluK2 receptors (UBP2038 > UBP2020 > UBP2002 > UBP2054).  
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Figure 2.12. Characterisation of kynurenic acid derivatives on native AMPARs. A, Inhibition 
of AMPAR-mediated f-EPSPs by 6-halogen substituted kynurenic acid derivatives at 100 µM. Data 
from individual experiments are plotted on left (clear circles) and summary of results are shown on 
the right. Values in the table represent mean ± SEM %-inhibition of baseline AMPAR f-EPSPs. 
Compounds in the table are sorted according to activity on GluK2 homomeric receptors expressed 
in HEK293 cells. Number of independent observations (n) are shown in parenthesis. B, Similar to 
A but showing the inhibition of AMPAR f-EPSPs by kynurenates with polar 6-substituents. C, 
Similar to A but showing the inhibition of AMPAR f-EPSPs by kynurenates with non-polar 6-
substituents.   
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Figure 2.13. Concentration-response curves for 6-substituted kynurenates on native 
AMPARs in rat hippocampal slices. Concentration response curves (left) and estimated IC50 
values (right) showing the low inhibition of AMPAR-mediated f-EPSPs by UBP2054. Key for the 
curves are shown next to compound names in the table. Mean ± SEM IC50 values for each compound 
were calculated from the IC50 values extrapolated from the respective curve. Number of 
experiments used to calculate the IC50 values are shown in parenthesis. 
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2.4. Discussion 
In this study, various kynurenic acid derivatives were characterised using two functional 
assays. The first of these assays used recombinant human GluK2, GluK1 and GluA1 
homomeric receptors and the second used native rat hippocampal AMPARs and NMDARs. 
The results from the current study have verified earlier reports (Leeson et al., 1991) that 6-
substituted kynurenic acid derivatives act as non-NMDAR antagonists and have provided 
an understanding of their activity on individual AMPAR and KAR subunits. The current 
study also found that the nature of the substituent at the 6-position affects the affinities of 
kynurenates on KARs and AMPARs. Moreover, some 6-substituents had ~10-fold 
selectivity for GluK2 over GluK1 or GluA1 subunits. In summary, the results provide a 
better understanding of the differences between the ligand binding sites of GluK2, GluK1 
and GluA1 subunits and provides information for the development of antagonists with 
greater subunit selectivity.  
2.4.1. Correlation of results from recombinant receptors and native 
receptors 
In the current study, both assays used to characterise the activity of compounds measured 
the responses mediated by receptors of interest and as such do not directly measure the 
affinity of compounds to KAR or AMPAR subunits. In the calcium fluorescence assay, the 
fluorescence increase caused by the opening of the ion channels of the homomeric receptors 
in response to glutamate application provided a suitable functional assay to characterise a 
large number of kynurenates. The IC50 values, slope-factors, and estimated Ki values from 
the assay using homomeric receptors were similar to previously published results in which 
homomeric GluK2 and GluK1 receptors were used to test glutamate and kynurenic acid 
(Alt et al., 2004). While the Ki provided an affinity constant for one receptor population 
corrected for the potency and concentration of the agonist, using Ki values from 2 receptor 
populations to calculate selectivity of the compound may be flawed, particularly between 
the KAR subunits and AMPAR subunits because the desensitisation blockers for KARs 
and AMPARs, con A and cyclothiazide, respectively, may affect binding of antagonists to 
the receptor. Con A has previously been shown to affect agonist pharmacology of KARs 
(Jones et al., 1997). However, previous results from pharmacological characterisation of 
GluK1 antagonists on recombinant GluK1 (using con A as desensitisation blocker) have 
correlated well with their inhibition of GluK1-mediated mossy-fibre synaptic potentiation 
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(Dolman et al., 2005; Dargan et al., 2009). Thus, due to the effect of con A on kynurenate 
binding being unclear, and the low affinity of compounds on on GluK1 and GluA1 cell 
lines, the primary use of the recombinant receptor assay was to identify GluK2 antagonists 
and to establish a rank order of affinities for different 6-substituted kynurenates on GluK2, 
GluK1 and GluA1 homomeric receptors.  
The native receptor assay measured synaptic responses mediated by native AMPARs and 
NMDARs to characterise test compounds. The baseline SC-CA1 f-EPSPs were mediated 
through AMPARs in the conditions that were used in the study because application of 3 
μM NBQX blocked AMPAR f-EPSPs (Figure 2.10B). NMDAR f-EPSPs were generated 
by changing the conditions to isolate NMDARs and the NMDAR f-EPSPs were blocked 
by 30 µM D-AP5. Using native receptors to characterise compounds also clearly showed 
that some antagonists such as UBP2054 had low native AMPAR inhibition (Figure 2.12 
and Figure 2.13) and a rank-order of potencies for AMPAR inhibitory activity on native 
receptors was also revealed (rank order of AMPAR inhibitory potency was UBP2038 > 
UBP2020 > UBP2002 > UBP2054). 
In addition to comparing activities between GluK2 and GluK1 or GluA1 homomeric 
receptors, comparison of activity in homomeric GluA1 and native AMPARs had some 
caveats. The native AMPARs contained a combination of GluA1 and GluA2 subunits as 
previously shown in the hippocampus (Lu et al., 2009). Therefore, the AMPAR inhibition 
of compounds in native system were likely on a mixed GluA1/GluA2 population of 
receptors. Although GluA2 and GluA1 subunits have > 90% sequence homology, 
noticeable differences in EC50 of glutamate on GluA1 and GluA2 subunits have been 
reported (Coquelle et al., 2000; Traynelis et al., 2010).  
Another difference between GluA1 and GluA2 subunits is that GluA2 subunits in the 
hippocampus are largely in the Q/R-edited form meaning that they have lower calcium 
permeability (Burnashev et al., 1992b). Additionally, the concentration of glutamate in the 
physiological synapse is tightly regulated by glutamate re-uptake mechanisms (Bergles and 
Jahr, 1997). Therefore, the concentration of glutamate available in the synapse to compete 
with competitive antagonists is less than in the calcium fluorescence assay where the EC80 
concentration of glutamate in the presence of 100 µM cyclothiazide could equilibrate in the 
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wells in the assay plate to elicit a response from GluA1 subunits. This could explain the 
lower activity of kynurenates at 100 µM on recombinant GluA1 homomeric receptors 
compared to native AMPARs (Figure 2.14). Some antagonists such as UBP2038 that may 
outcompete glutamate by tighter binding (due to higher affinity) to the receptor may 
provide similar %-inhibition in both the calcium fluorescence and synaptic AMPAR-
mediated f-EPSPs at the same antagonist concentration. However, low affinity antagonists 
(i.e. those easily out-competed by glutamate) would produce less %-inhibition in the 
calcium fluorescence assay due to the much higher glutamate concentration and the 
equilibrium conditions in this assay compared to synaptic AMPARs where the glutamate 
concentration is quickly buffered by reuptake processes in astrocytes (Clark and Barbour, 
1997; Bergles and Jahr, 1997).  
Native KARs and AMPARs are known to be associated with auxiliary subunits such as 
Neto and TARP proteins, respectively (Tomita et al., 2003; Zhang et al., 2009). Auxiliary 
subunits affect the ion channel properties of iGluRs and therefore may affect pharmacology 
of the native receptor which may also explain the greater inhibition of native receptors by 
kynurenates at 100 μM (Figure 2.14). Another difference between recombinant- and native- 
AMPAR assays relate to the difference in receptor expression levels between the two 
assays. Expression of iGluRs in the hippocampus is cell type-specific (Kondo et al., 1997) 
and even specific sub-cellular regions have been shown to express AMPARs and KARs 
specifically (Fabian-Fine et al., 2000; Sun and Dobrunz, 2006; Schmidt-Salzmann et al., 
2014). The functional implications of differences in AMPAR expression in pre-, post- and 
extra-synaptic compartments, on inhibition of AMPAR mediated f-EPSPs warrants further 
investigation. A solution to this problem may be to record the effect of compounds on post-
synaptic AMPARs in the CA1 pyramidal cells by performing intracellular recordings from 
these neurons using techniques such as voltage-clamp.  
Experimental conditions in the native and recombinant assays are different: particularly, 
the difference in temperature of FlexStation recordings (~25 °C) and electrophysiological 
recordings (~31 °C) may affect the pharmacodynamics of kynurenates by equilibrating with 
the slice at a higher rate than in the assay plates in FlexStation recordings. Biophysical 
properties of synaptic transmission in the native assay (Asztely et al., 1997) and the EC50 
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of glutamate in the recombinant assay (by affecting receptor expression levels (Lin et al., 
2015)) would also be affected.  
Despite the verification of AMPAR and NMDAR mediated responses using NBQX and D-
AP5, respectively, the synaptic f-EPSP response is a composite membrane potential from 
neurons also expressing other neuromodulatory proteins such as serotonin receptors, 
metabotropic glutamate receptors and GABA receptors (Vizi and Kiss, 1998; Ross et al., 
2000). Whereas in the recombinant assay the Ca2+ influx following glutamate addition is 
mainly mediated through the receptor expressed on the plasma membranes of HEK293 
cells and Ca2+ released from intracellular stores. Therefore, the effect of compounds on 
these “off” targets in native assays may also pose a difficulty when comparing data from 
recombinant and native assays. Moreover, whether the process of preparation of slices in 
the native assay affects AMPAR expression or function during the experiment remains 
unclear and therefore, experiments from in vitro slice preparations could also be 
complemented by comparison of activity of compounds in in vivo studies.  
While the results from both functional assays provided a rank-order of potency for 
compounds on a receptor population, measuring the binding affinities of compounds using 
radioligand binding studies (with certitude of receptor population) will be necessary to 
obtain accurate data regarding the binding affinity of the compounds to GluK2, GluK1 and 
GluA1 and therefore, the selectivity of compounds for these different subunits. 
Furthermore, obtaining binding affinities for the 6-substituted kynurenates on recombinant 
GluK2, GluK1 and GluA1 homomers may also provide insights into the difference in 
inhibitory activities of the compounds between the recombinant and native receptors.  
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Figure 2.14. Correlation of inhibition of GluA1 recombinant receptors and native AMPARs 
by kynurenates. Data from single concentration screening on recombinant GluA1 subunits and 
native AMPAR f-EPSPs were significantly correlated (p < 0.05, Pearson correlation, r = 0.6). Data 
were taken from Table 2.3 and Figure 2.12. 
2.4.2. Summary of results from the single concentration screening on 
recombinant AMPARs and KARs 
Results from the single concentration screening suggest that one or more of the 1-NH, 2-
carboxyl and 4-oxo groups in kynurenic acid may be involved in interactions with the 
binding sites of GluK2, GluK1 and GluA1 subunits. This can be concluded because the 
compounds in which these substitutions were removed or replaced by modifications of the 
heterocyclic ring, such as UBP2056, UBP2057, UBP2058, UBP2059 and UBP2063 
(Figure 2.1F) had < 10% inhibition on GluK2, GluK1 or GluA1 subunits (Table 2.2). 
Substitution at the 8-position (UBP2052) also decreased the inhibitory activity of 
compounds possibly due to steric hinderance in the binding site caused by the 8-substituent. 
Amongst the compounds that inhibited GluK2 responses by more than 10%, those with 
5,6,7- substituents (UBP2038, UBP2039) had the greatest inhibition on GluK2 homomeric 
receptors. This result matched the trend in previous studies that 5- and 7- substitutions on 
the benzene ring increased binding affinity at the glycine site of NMDARs (Leeson et al., 
1991). While the single concentration screening provided a suitable overview of activity of 
the compounds on GluK2, GluK1 and GluA1 subunits, the activities at 100 µM could not 
be used as a robust measure of inhibitory activity for comparing activities on the same 
subunit or between different subunits because the concentration-response relationship was 
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unknown. Therefore, compounds which produced > 10% inhibition on GluK2 were further 
characterised by evaluating their concentration-response relationships to obtain IC50 and Ki 
values, and the results from concentration response curves on GluK2, GluK1 and GluA1 
were used to study the effect that various substituents had on inhibitory activity of chosen 
compounds.  
2.4.3. Inhibition of GluK2 subunits by 6-substituted kynurenates 
All 6-halogen substituted compounds tested in the current study inhibited GluK2 
homomeric receptors. In the earlier study by Leeson et al., 1991, addition of substituents at 
the 5- and 7-position on the benzene ring was shown to increase the inhibitory activity at 
the NMDAR glycine site. Similarly, addition of fluoro groups at 5 and 7 positions in 
addition to the 6-halogen substitution, UBP2038 (5,7-diF-6-I) and UBP2039 (5,7-diF-6-
Br) resulted in greater inhibitory activity on the GluK2 subunit, compared to just 6-halogen 
alone as in UBP2002 (6-I) and UBP2020 (6-Br) (A). Moreover, the nature of the 5- and 7- 
substituent may also contribute to the activity because the 5,7-diCl substituted UBP2037 
(5,7-diCl-6-I) and 5,6,7-trichloro substituted UBP2025 (5,6,7-triCl had lower inhibitory 
activity compared to the 5,7-diF substituted UBP2038 and UBP2039 on GluK2 (Figure 
2.6A). In addition, the nature of the 5- and 7-halogen substituent may also affect solubility 
of the compound because 5,7-diCl substituted UBP2037 and UBP2025 had solubility issues 
at 100-2000 µM, concentrations at which 5,7-diF substituted UBP2038 and UBP2039 were 
water soluble.  
From the polar 6-substituted kynurenates tested in the study, UBP2043 (6-OMe-7-F) had 
the highest affinity on GluK2, which further highlights the influence of 7-substitution for 
GluK2 affinity because UBP2049 (6-OMe), which had no 7-F substituent, had lower 
affinity on GluK2 (Figure 2.7A). UBP2047 (5-F, 6-OMe, 7-F) had lower affinity than 
UBP2049 on GluK2 (Figure 2.7A) and solubility issues were not observed for UBP2049 at 
concentrations up to 2 mM. Therefore, the nature of the substituents at the 5 and 7 positions 
and their electronic influence on the kynurenate molecule may affect the inhibitory activity 
– e.g. by affecting 4-keto/enol tautomerization and influencing the equilibrium of ionisation 
of the kynurenic acid molecule in an aqueous environment. Thus, the effects of different 5-
,7- substituents on GluK2 affinity requires further investigation. 
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2.4.4. Qualitative comparison of physicochemical properties and GluK2 
affinity of 6-substituted kynurenates  
The GluK2 affinity of 6-substituted compounds were analysed based on the 
physicochemical properties of the 6-substituent such as its size (MR), hydrophobicity (π), 
and electronic effects (σm and σp) (Table 2.4). Lack of sufficient affinity data for a wide 
range of 6-substituents prevented a full quantitative structure activity relationship (QSAR) 
from being determined. However, the effect of one physicochemical parameter on GluK2 
affinity was compared using compounds which had similar values of other physicochemical 
properties but varying values of the compared parameter.  
The rank order of GluK2 affinity: SMe > OMe > Et, did not appear to be related to size of 
the 6-substituent (rank order of MR values SMe > Et > OMe) or hydrophobicity (rank order 
of π values: Et > SMe > OMe). However, GluK2 affinity did seem to be related to rank 
order of σm (rank order of σm values: SMe > OMe > Et) but not σp (rank order of σp values: 
SMe > Et > OMe).  
Given that σm was related to the GluK2 affinity, it may be that more electron withdrawing 
6-substituents affect the keto/enol tautomerisation of the kynurenate such that the keto-
form is stabilised. In the enol form of kynurenates, the 1-NH group loses the proton and 
this group has been shown to be important for binding of kynurenic acid to NMDAR and 
therefore the keto form would have higher affinity (Furukawa and Gouaux, 2003).  
An important consideration is that the electronic effects quantified by the σm value alone 
do not explain the GluK2 affinity of the 6-substituent. This is exemplified by the 6-
substituent NO2 which had the highest σm value but did not have the highest affinity (Table 
2.4). An explanation can be reached by comparing the 6-substituents NO2 and OMe. Both 
NO2 and OMe have similar size (as judged by MR values) but OMe has higher affinity for 
GluK2 than NO2. It appears that the lower hydrophobicity of NO2 (much more negative π 
value than that of OMe) offsets its greater electron withdrawing ability (high σm value), 
thereby lowering affinity. The lack of activity of 6-CO2H is likely due to the negative 
charge on the substituent which lowers hydrophobicity considerably. 
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Thus, it appears that amongst the compounds characterised in this study, electron 
withdrawing ability and hydrophobicity of the 6-substituent play a role in determining 
GluK2 affinity, while size is less important. This explains why 6-NH2 is not tolerated, as it 
is electron donating (negative σm value) and hydrophilic (negative π value). There is likely 
to be an upper limit to the size of the 6-substituent. The higher GluK2 affinity of 6-Br 
versus 6-I, which have similar electron withdrawing and hydrophobicity parameters, 
suggests that the size of the iodo group (of 6-I) may be slightly detrimental to activity. 
 
Table 2.4. Summary of GluK2 Ki and physicochemical properties of 6-substituted 
kynurenates. Data for GluK2 Ki was taken from Table 2.3. Data for π, MR, σm and σp were 
published in (Hansch et al., 1973). 
2.4.5. Inhibition of GluK1 subunits by 6-substituted kynurenates 
All 6-subsituted kynurenates which were further characterised after the initial screen, 
inhibited the GluK1 subunit (Table 2.3). UBP2054 (6-Et) had GluK1 IC50 > 1 mM but 
inhibited GluK2 receptors with Ki of ~54 μM. UBP2037 (5,6,7-triCl) also had GluK1 and 
GluA1 IC50 values > 1 mM and GluK2 Ki ~22.8 μM. As noted earlier, the solubility issues 
of UBP2037 prevented a consistent estimation of the concentration-response relationship 
(and hence the Ki). However, the high GluK1 IC50 of UBP2054 (6-Et) suggests that 
differences in the binding sites of GluK2 and GluK1 subunits may be used to improve 
GluK2 over GluK1 selectivity because the smaller 6-substituent in UBP2034 (6-Me) 
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caused greater inhibition of GluK1 compared to UBP2054 (UBP2034 GluK1 Ki ~47.8 μM; 
Figure 2.8B, Table 2.3).  
The difference between GluK2 and GluK1 binding sites may also be due to the allowed 
volume available for the 6-substituent to bind because UBP2020 (6-Br) and UBP2034 (6-
Me) both had higher affinity compared to their corresponding larger 6-substituted 
analogues UBP2002 (6-I) and UBP2054 (6-Et), respectively. Interestingly, the difference 
between GluK2 affinities of UBP2034 (6-Me) and the larger substituent UBP2054 (6-Et) 
is smaller than the difference between GluK1 affinities of UBP2034 and UBP2054 (Table 
2.3), suggesting that the binding region close to the 6-substituent in GluK1 may be less 
tolerant of larger non-polar groups compared to the binding region in GluK2.  
2.4.6. Inhibition of GluA1 subunits and native AMPARs by 6-substituted 
kynurenates 
Data from characterisation of 6-substituted kynurenates on recombinant GluA1 homomeric 
receptors suggests that 6-substituted kynurenates may have lower affinity on GluA1 
compared to GluK2 (Table 2.2). However, differences in AMPAR vs. KAR calcium 
fluorescence assay prevented the reaching of this conclusion based on activity on 
recombinant receptors alone as discussed above. The activity of 6-substituted kynurenates 
on recombinant GluA1 correlated with the activity on native AMPARs (Figure 2.14) and 
revealed that UBP2054 (6-Et) may have higher GluK2 over native AMPAR selectivity 
(Table 2.3 and Figure 2.13).  
GluA1 inhibitory potency of kynurenate derivatives could not be fully characterised due to 
inactivity of compounds on GluA1 homomeric receptors in the recombinant assay and lack 
of solubility at concentrations > 1 mM. However, qualitative assessment of GluA1 Ki and 
inhibition of native AMPARs suggest that in GluA1, the size of the 6-substituent may be 
even more influential on the antagonist activity than in GluK1 and GluK2. The influence 
of the size of the 6-substitution is highlighted by the difference in activity between pairs of 
similar 6-substituted compounds with different sizes: UBP2020 (6-Br) vs. UBP2034 (6-I) 
and UBP2034 (6-Me) vs UBP2054 (6-Et). In both cases, inhibition of GluA1 and native 
AMPARs by the smaller 6-substituent is greater compared to larger 6-substituent (Table 
2.3, Figure 2.12). 
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2.4.7. Using UBP2054 as a template for novel GluK2-selective antagonists 
The first hurdle in developing GluK2-selective antagonists is to eliminate the AMPAR 
activity of candidate molecules. We have found that the 6-Et kynurenic acid, UBP2054, 
blocked GluK2 homomeric receptors with a Ki ~50 µM, while at 100 µM, minimal effect 
on native AMPARs was observed (Figure 2.13). As such, UBP2054 may serve as a useful 
pharmacological tool for investigating the physiological roles of GluK2 when used in 
conjunction with KAR subunit knockouts and GluK1 selective antagonists. Our results for 
UBP2054 in native tissue resembled results from a previous study using cortical slices 
which showed that UBP2054 had Kb > 100 µM on native quisqualate-activated receptors, 
and UBP2054 was shown to be inactive on native NMDA-activated receptors at 100 µM 
(Leeson et al., 1991). The results from this study have also shown that a combination of 
polarity and electronic effects of the 6-substituent may affect the affinity of antagonists on 
GluK2 homomeric receptors. The current study also confirmed that adding 5- and 7-fluoro 
substitutions on the benzene ring may increase affinity of the antagonist on GluK2 (Table 
2.3). However, it is likely that substitutions at the 5 and 7 positions may also increase 
antagonist activity on GluK1 and GluA1 subunits. Therefore, further studies of 5,7-diF-6-
Et substitutions on the phenyl ring may provide a better understanding of the molecular 
determinants of GluK2 potency and enhanced GluK2 over AMPAR selectivity. However, 
as already noted, the poor solubility of kynurenates might prevent the usage of kynurenates 
for physiological studies. Therefore, the findings of this SAR study might assist in the 
development of novel compounds that mimic the pharmacophore of UBP2054 while 
improving solubility and GluK2 affinity with the aim of producing antagonists with high 
selectivity for GluK2 over GluK1/AMPARs.
Chapter 3  
Molecular modelling of the binding of 
kynurenate derivatives to ionotropic 
glutamate receptors  
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3.1. Introduction 
3.1.1. Molecular docking as a tool for development of novel antagonists for 
GluK2 
Computational molecular modelling techniques have become important tools for drug 
development with the advent of affordable hardware. Molecular docking has been used for 
virtual screening of large numbers of compounds on a well-defined target molecule such 
as a receptor protein (e.g. Schiavini et al., 2015; also see Kapetanovic, 2008). X-ray 
crystallography has been used to obtain the high resolution (< 2 Å) structures of iGluRs 
used for molecular docking (e.g. Møllerud et al., 2017). X-ray crystal structures of GluA2 
LBD in the apo (unoccupied) form and agonist-, and antagonist-bound forms, provided 
early insights about the tertiary structure of the protein and the conformational changes that 
follow ligand binding (Armstrong et al., 1998; Armstrong and Gouaux, 2000). Particularly, 
the apo- and antagonist-bound forms of the LBD is a bi-lobed structure that resembles a 
clamshell (Armstrong et al., 1998). The amount of separation between the two lobes (or 
LBD opening) is lowest in the agonist-bound form and highest in the resting apo-form 
whereas binding of antagonists induces an intermediate separation (Armstrong and 
Gouaux, 2000).  
Since the initial X-ray structure of GluA2, LBD X-ray structures of other iGluR subunits 
including the NMDAR GluN1 subunit (Furukawa and Gouaux, 2003) and KAR GluK1 and 
GluK2 subunits (Alushin et al., 2011; Mayer, 2005; Mayer et al., 2006; Møllerud et al., 
2017) have been solved. The NMDAR and KAR LBD structures share similarities with 
that of the GluA2 structure, namely, agonist- and partial agonist-induced LBD closures 
(Furukawa and Gouaux, 2003; Mayer, 2005) and the antagonist-bound LBD in the open 
conformation (Furukawa and Gouaux, 2003). In subsequent years, more X-ray structures 
of GluK1 LBD in complex with antagonists have emerged (Naur et al., 2005; Mayer et al., 
2006; Dolman et al., 2007; Dargan et al., 2009; Demmer et al., 2015). In some cases, 
molecular docking studies using the GluK1 X-ray structures have been helpful in 
developing GluK1 antagonists such as ACET (Mayer et al., 2006; Dolman et al., 2007).  
Results from these and more recent studies have shown that the LBD closure in the ligand-
bound GluA2 and GluK1 LBD vary significantly depending on the nature of the ligand (see 
Figure 3.1) and that the differences in the residues lining the ligand binding cleft could be 
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used to develop high-affinity GluK1 antagonists (Dolman et al., 2006; Alushin et al., 2011; 
Atlason et al., 2010). Particularly, mutagenesis studies have been helpful in identifying 
residues that are involved in binding of GluK1 antagonists based on willardiine derivatives 
(Atlason et al., 2010).  
 
Figure 3.1. LBD closure of GluA2 and GluK1 upon agonist and antagonist binding. Alignment 
of D1 α-carbons (coloured grey) of the peptide chain in the GluA2 LBD in the apo form (D2 colour: 
red), antagonist-bound form (D2 colour: blue) or the agonist-bound form (D2 colour: green). In 
both the GluA2 LBD (left) and GluK1 LBD (right), antagonist binding leads to LBD opening 
whereas glutamate binding leads to LBD closure. Structures were obtained from Armstrong and 
Gouaux, 2000 and Mayer, 2005.  
3.1.2. Homology modelling of GluK2 receptors 
While antagonist-bound GluA2 and GluK1 X-ray crystal structures have been available 
(Armstrong and Gouaux, 2000; Mayer et al., 2006), X-ray structures of the antagonist-
bound GluK2 LBD are lacking partly due to a lack of high affinity water-soluble 
antagonists (Jane et al., 2009; Mayer, 2017). Therefore, it is necessary to create models of 
the GluK2 LBD based on X-ray structures of homologous proteins, such as those obtained 
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for the GluK1 LBD in complex with antagonists (Mayer et al., 2006; Hald et al., 2007; 
Alushin et al., 2011). The rationale behind homology modelling is that proteins with high 
amino acid sequence similarity may also share the same secondary and tertiary structural 
features. Therefore, the unknown structure of proteins may be estimated by overlaying its 
amino acid sequence onto the known structure of a highly homologous protein and solving 
the mismatches by predicted protein folding using information from previously solved, 
homologous protein sequences (Greer, 1980). 
3.1.3. Differences in the GluK2 LBD binding site compared to GluK1 and 
GluA2 
The X-ray structures of glutamate bound to the GluK2 LBD reveal the residues that may 
form conserved interactions with all known orthosteric ligands that have been crystallised 
in complex with iGluR LBDs (Figure 3.2; see Møllerud et al., (2017) for a review). In the 
glutamate-bound state, conserved interactions formed by residues lining the GluK2 LBD 
D1 include: a salt-bridge between the side chain of Arg-492 and the α-carboxyl group of 
glutamate, hydrogen bonding (H-bond) between Ala-487 (Thr in GluK1 and GluA2) via 
the peptide backbone NH and the α-carboxyl oxygen of glutamate, and an H-bond between 
the peptide backbone carbonyl group of Pro-485 and the α-amino group of glutamate. The 
agonist-induced closure of the LBD clamshell allows the residues lining D2 of the LBD to 
form further H-bond interactions with glutamate.  
The interactions of D2 residues are not conserved amongst all orthosteric ligands and 
depends on the domain closure and functional groups of the ligands. D2 interactions for 
glutamate include: H-bond interactions between the carboxyl side-chain of Glu-707 and 
amino group of glutamate, H-bond interactions between backbone amino group of Ala-658 
(Ser in GluK1 and GluA2) and both carboxyl groups of glutamate, and H-bond interactions 
between the peptide backbone NH group and the side chain OH group of Thr-659 and the 
distal carboxyl group of glutamate.  
In addition to the direct interactions provided by the LBD cleft-lining residues, glutamate 
also forms H-bond interactions with water molecules, which may also form indirect H-
bond networks between the ligand and the residues lining the cleft, leading to further 
stabilisation of ligand binding and increased binding affinity. Despite the inadequate 
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resolution of X-ray crystallography in locating the positions of water molecules in ligand 
binding sites, many studies of iGluR LBDs have reported that water molecules may be 
critical in the binding of glutamate in the ligand binding pocket (Armstrong and Gouaux, 
2000; Mayer, 2005).  
Importantly, the residues lining the cleft from the D2 of GluK2, GluK1 and GluA2 are more 
variable compared to the cleft-lining residues from D1 (Figure 3.2). The Ala-487 residue 
which provides H-bond for ligand binding through its backbone oxygen is replaced by the 
more polar threonine residue in GluK1 and GluA2. The polar side chain of threonine 
residues in GluK1 and GluA2 is close enough to the α-carboxyl group of glutamate to form 
H-bond interactions and further stabilise the glutamate-bound state (Figure 3.2, (Armstrong 
and Gouaux, 2000; Mayer, 2005)). The binding pocket volumes of GluK2 and GluK1 are 
16% and 40% larger, respectively, compared to GluA2 (Mayer, 2005). The intermediate 
volume in GluK2 compared to GluK1 and GluA2 is explained by the differences in 3 amino 
acids: Asn-690, Phe-704 and Thr-710 in GluK2 which are replaced by the smaller Ser-706, 
Leu-720 and Ser-726, respectively, in GluK1; in GluA2, these residues correspond to Thr-
686, Tyr-702 and Met-708.  
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Figure 3.2. Differences in the residue composition of the orthosteric ligand GluK2 binding site 
compared to GluK1 and GluA2. A, D1-D2 cleft of glutamate-bound GluK2 LBD (PDB [Protein 
Data Bank] identifier: 1S50) and the residues that form hydrogen bonds with glutamate are shown. 
Also shown are residues that are different between GluK2, GluK1 and GluA2. Inset shows a cartoon 
representation of a single LBD and the location of the D1-D2 cleft. Glutamate and residues are 
shown as thick and thin sticks, respectively. Water molecules are shown as red spheres. H-bond 
interactions are shown as green dashed lines. B, Similar to A but different residues in GluK1 (green; 
PDB id: 1TXF) and GluA2 (orange; PDB id: 1FTJ; PDB id: 1S50) are also shown in addition to 
the corresponding GluK2 residues (black carbons) and bound agonist, glutamate, from A. Positions 
of GluK1 and GluA2 residues were determined by alignment of glutamate-bound LBD α-Carbons 
atoms in GluK2, GluK1 and GluA2.  
3.1.4. Objectives 
In this study of the pharmacological activity of kynurenic acid derivatives (Chapter 2), it 
was observed that some 5,6,7- and 6-substituted compounds have higher affinity on GluK2 
compared to kynurenic acid (Table 2.3). In the present molecular docking study, predicted 
binding of kynurenic acid, UBP2002 (6-I) and UBP2038 (5,7-diF-6-I) was examined to 
identify the residues, which are necessary for interactions that improve the GluK2 affinity 
of kynurenic acid derivatives. It was also found that UBP2054 (6-Et) has the best GluK2 
over GluK1 and GluA1 selectivity of the kynurenate derivatives that were tested (Table 2.3 
and Figure 2.13). Therefore, the predicted binding of UBP2054 was compared between 
Chapter 3 – Molecular modelling of kynurenate binding to iGluRs 
133 
GluK2, GluK1 and GluA2 in modelling studies to explain its favourable GluK2 selectivity. 
The GluA2 LBD was used instead of GluA1 in modelling studies, as antagonist X-ray 
structures are only available for GluA2 and there are no differences in ligand binding 
residue composition in the GluA1 and GluA2 LBDs (see methods section). 
The much reduced NMDAR activity of 6-substituted kynurenates observed in the present 
study and in a previous study (Leeson et al., 1991) was also investigated by docking 
UBP2040 (5,7-diF) and UBP2002 (6-I) into the GluN1 LBD and comparing to the 5,7-
diCl-GluN1 LBD X-ray structure.  
The objectives of computational docking used in this chapter were to study: 
1. the increased affinity of 5,6,7-trisubstituted compounds on GluK2, 
2. the reduced affinity of UBP2054 on GluK1 compared to GluK2 
3. the reduced affinity of UBP2054 on AMPARs compared to GluK2 
4. the reduced activity of 6-substituted kynurenates on NMDARs by modelling their 
interaction with the glycine binding site on GluN1 
3.2. Methods 
3.2.1. Ionotropic glutamate receptor amino acid sequence comparison 
The amino acid sequences for iGluR subunits were taken from the UniProt database 
(Bateman et al., 2017), and the Uniprot ID for the sequences used in this study are shown 
in Table 3.1. Amino acid sequence homology was calculated using the Clustal Omega 
webserver (Sievers et al., 2011). Most of the X-ray crystallisation studies of KARs were 
based on the rat version of the protein (reviewed in Møllerud et al., 2017). Therefore, the 
X-ray crystal structures used in this study were based on the rat version of the iGluR LBD 
whereas human recombinant receptors were used to pharmacologically characterise 
kynurenates. The amino acid sequences of rat GluK1, GluK2 and GluA2 LBD were 
compared to human versions and the percentage-identity of the LBD sequences are shown 
in Figure 3.3. The GluK2 LBD had the lowest similarity in amino acid sequence between 
the rat and human versions (87.6%) whereas GluA1, GluA2 and GluK1 LBDs had > 98% 
sequence homology (Figure 3.3). Therefore, an alignment of amino acid sequences of LBD 
from rat- and human-GluK2, and rat -GluK1, -GluA1, and -GluA2 was conducted to find 
the differences between amino acids lining the ligand binding site (Figure 3.4).  
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Table 3.1. Uniprot sequences used for alignment and homology modelling.  
 
Figure 3.3. Percentage amino acid residue identity of rat and human versions of ligand 
binding domains of GluA1, GluA2, GluK1 and GluK2. Percentage identity matrix showing the 
%-similarity in LBD (S1 and S2 polypeptides) amino acid sequences of rat and human GluA1, 
GluA2, GluK1 and GluK2 subunits. Generated using Clustal Omega. 
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Figure 3.4. Alignment of the amino acid sequences lining the orthosteric ligand binding site. 
Alignment of amino acids near the glutamate binding site from D1 (A) and D2 (B) domains of the 
LBD. Residues which were the same as in rat GluK2 LBD are highlighted in green. Residues 
capable of forming hydrogen bonds and van der Waals interactions with agonists are marked with 
white circles and black squares, respectively. 
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3.2.2. Structures of ligand binding domains 
X-ray crystal structures of LBDs were taken from the Research Collaboratory for Structural 
Bioinformatics (RCSB) protein data bank (PDB) (Berman et al., 2000). The PBD 
identification codes for structures used in this study are quoted in text.  
3.2.3. GluK2 LBD homology model building 
Homology models of the antagonist-bound GluK2 LBD were generated using the X-ray 
crystal structure of GluK1 in complex with antagonists. The GluK1 LBD was used because 
of the high amino acid sequence homology between GluK1 and GluK2 rat LBDs (~87%) 
(Figure 3.3). The GluK1 LBD used for obtaining the X-ray crystal structures in this study 
was synthesised using the S1 and S2 polypeptide segments linked by two residues: glycine 
and threonine (GT-linker), as S1 and S2 are not normally directly linked but are two 
individual polypeptide chains separated by the TMD (Armstrong and Gouaux, 2000; 
Alushin et al., 2011). Therefore, when building the GluK2 homology model, only the amino 
acid sequences of rat GluK2 S1 and S2 polypeptide chains were used. 
Homology models of the GluK2 LBD from the GluK1 LBD were built using the Swiss-
model server which uses the ProMod3 modelling engine (Bienert et al., 2017). The program 
generated homology models by initially overlaying the GluK2 S1S2 sequence onto the 
appropriate GluK1 LBD X-ray structure. The secondary and tertiary structures of the 
GluK2 LBD are predicted using information from the GluK1 structure and homologous 
structures in a curated database which is regularly updated using structures from the PDB 
(Bienert et al., 2017). Following the solving of residue conformations in the homology 
model, ProMod3 also performed energy minimisation on the homology model using the 
CHARMM27 force field to resolve any unfavourable interactions introduced by the model 
building (Mackerell et al., 2004). 
The overall quality of the model is indicated by the Global Model Quality Estimate 
(GMQE) score, a value between 0 and 1, which reflects the accuracy of the model built 
with the alignment of the GluK1 LBD X-ray structure to the amino acid sequence of the 
GluK2 LBD. Therefore, the GMQE score of 0.97 obtained for the GluK2 homology model 
indicates a high prediction of accuracy. The QMEAN Z-score provides a measure of the 
total model quality based on geometrical properties of residues in the model and reports the 
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number of standard-deviations that the homology model differs from other structures of 
similar size (Benkert et al., 2008). A QMEAN Z-score value close to 0 indicates a good 
quality (0.33 for the GluK2 model). Another measure of the model quality is the QMEAN 
local quality estimate which predicts the similarity of inter-atomic distances for individual 
residues in the homology model compared to experimentally determined structures that 
have homologous amino acid sequence to the GluK2 LBD sequence (Figure 3.5). A 
predicted similarity less than 0.6 is typically considered a low quality and a value of 1 
indicated a high quality of prediction of interatomic distances in the model.  
 
Figure 3.5. Prediction of quality of homology model using QMEAN local quality estimate for 
the GluK2 homology model based on GluK1-UBP315. QMEAN of individual residues in the 
homology model and the alignment of the model’s amino acid sequence to the GluK1-UBP315 
structure. The bars show local quality estimate (color scale: blue = 1, red = 0). The green lines above 
the alignment shows residues lining the ligand binding cleft. Adapted from Swiss-model model 
quality report. Majority of the residues in the model had good residue placement when compared 
to homologous structures (indicated by predominantly blue bars especially for the ligand binding 
cleft residues). 
3.2.4. Preparation of protein structures for molecular docking 
Protein structures obtained from PDB did not contain information regarding hydrogen 
atoms which are required when predicting ligand binding. In some cases, some residues 
were only partially resolved (usually only affects a few residues that do not take part in 
ligand binding) and in some cases alternative conformations of the same residue are 
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contained in the pdb file of the X-ray structure. Moreover, unwanted atoms such as 
crystallisation solvents in addition to water were sometimes present in the X-ray structure 
files from PDB. Water molecules and non-ligand atoms obtained from the X-ray structures 
were removed and hydrogen atoms were added to the X-ray crystal structures using the 
protein preparation routine in Schrödinger (Schrödinger LLC). Assignment of bond orders, 
correction of missing side chains and creation of disulphide bonds in the X-ray crystal 
structures were performed before energy minimisation of the protein structure using the 
OPLS3 force field in Schrödinger.  
A further validity check for a homology model structure is to check that the backbone bond 
angles of the homology model structure is acceptable. A Ramachandran plot of the prepared 
protein structure was used to ascertain that the nitrogen-alpha carbon (Phi) and alpha 
carbon-carbon (Psi) bond-angles of the protein backbone fell within expected regions 
(Figure 3.6). The main variation from the expected distribution of angles in the structures 
used in the study were due to glycine residues. 
 
Figure 3.6. Ramachandran plot for the GluK2 homology model based on GluK1-UBP315. The 
phi and psi bond angles for residues in the GluK2 homology model is shown as black symbols. 
Triangles represent glycine, squares represent proline, and other residues are shown as circles. 
Preferred and acceptable regions of phi and psi angles are highlighted. Red areas show the preferred 
angles, yellow areas show acceptable angles and white areas show disallowed areas.  
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3.2.5. Building the ligand library 
Ligand structures were prepared using Maestro (Schrödinger LLC) and energy minimised 
using the Macromodel utility in Schrödinger using the OPLS3 force field, which was shown 
to predict small molecule conformations with high accuracy (Harder et al., 2016). The 
minimum energy of the ligand structure was estimated by the gradient convergence method 
in which the energy minima search for the ligand structure was conducted such that the 
gradient was as close to 0 as possible (convergence threshold was set at 0.05). Ligand 
structures were further optimised using the LigPrep utility in Schrödinger: possible 
ionisation states within a pH range of 7.4 ± 1.0 and probable tautomers of ligands were 
generated using the Epik module in Schrödinger.  
3.2.6. Molecular docking 
The semi-automated Induced Fit Docking (IFD) workflow in Schrödinger was used to dock 
ligands into the LBD structures and generate ligand poses. IFD uses the Glide docking 
program (Friesner et al., 2004) which has been reported to have high accuracy for ranking 
poses for molecules in test datasets when compared with other scoring functions (Zhou et 
al., 2007). The first step of the IFD routine is an initial docking of ligands with reduced van 
der Waals radii and increased cut-off for electrostatic and other van der Waals interactions 
between the ligand and protein. For each pose generated from the initial docking, the Prime 
module in Schrödinger was used to refine the amino acid side-chains near the ligand to 
predict the structure of the ligand-bound binding site. Subsequently, the structures of the 
refined residues in complex with the ligand were energy minimised. Finally, each ligand 
was docked into the lowest energy binding site for the ligand determined from the Prime 
refinement stage using Glide extra precision (XP), which conducts extended sampling of 
ligand poses and scores the ligand binding using two scoring functions: Emodel and 
Glidescore (Friesner et al., 2004).  
The areas in the receptor structure which were used by Glide to search for ligand 
conformations are defined as the search space for molecular docking. The search space for 
structures used in this study were defined by the residues around the binding cleft such that 
the search space encompassed the whole binding cleft. Based on GluK2 numbering, the 
key ligand binding residues used to define the search space were: Tyr-457, Ala-487, Arg-
492, Val-654, Gly-657, Ala-658, Asn-690, Thr-709, and Thr-710. For docking of GluK1, 
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GluA2 and GluN1 LBDs, residues corresponding to the GluK2 residues listed above were 
used to mark the search space for the docking program.  
3.2.7. Analysis of binding poses 
When comparing docking poses, poses of docked ligands were selected based on some 
“conserved” interactions that have been previously observed within all iGluRs in complex 
with orthosteric agonists. Particularly, the Arg-492, Ala-487 and Pro-485 in GluK2 and the 
corresponding residues in GluK1, GluA2 and GluN1 have been shown to be involved in H-
bond interactions with orthosteric ligands. Therefore, poses of ligands where one or more 
of these interactions were absent were excluded. Another indicator of a “poor” pose was 
extensive refining of some bulky hydrophobic cleft-lining residues to accommodate the 
ligand – suggesting that steric clashes would have occurred had the refinement been 
omitted.  
Upon successful docking of ligands, the IFD module ranked the ligand poses based on IFD 
score – a composite score that accounts for the scores generated by Glide’s scoring 
functions and the energy of the LBD with the refined residues in complex with the docked 
ligand (generated by the Prime module). Glide generated two scores, one of which was the 
Emodel score – the result of the scoring function which mainly searches for electrostatic 
and van der Waals ligand-receptor interactions and is used by the IFD program to choose 
the best pose for the prime refinement stage. The second scoring function used by Glide, 
Glidescore, includes terms for electrostatic and van der Waals interactions, and also 
includes penalties for buried polar groups and for freezing rotatable bonds (Friesner et al., 
2004).  
After selecting suitable poses by qualitative assessment after visual inspection, the 
numerical scores from the IFD workflow (IFD score, Emodel score and Glidescore) could 
also be considered for explaining binding affinity. However, given the exploratory nature 
of the current study and the similarities in the affinities of kynurenates within each type of 
subunits tested, the scores generated by the IFD were only used to find a rank order of 
ligand poses after qualitative assessment. 
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To analyse steric clashes between the ligand and receptor, the overlap of van der Waals 
volumes of the docked ligand and the LBD was calculated using the phase_volCalc utility 
in Schrodinger.  
The choice of ligands used for the docking routine was dependent on the research question 
which was addressed. However, all docking studies used kynurenic acid as a reference 
structure to compare the effect that substitutions on the benzene ring made to the ligand 
interaction. Additionally, the quality of the docking program was assessed by docking the 
structure of the crystallised ligand (prepared using the same techniques as kynurenates) into 
the LBD and comparing the docked pose to the X-ray crystal pose of the ligand.  
3.2.8. Presentation of poses 
Images showing solvent accessible van der Waals surfaces of the LBD binding cavity and 
ligands were prepared using PyMol. Ligand interaction diagrams, generated in Maestro, 
were used to show the residues that were in 4 Å proximity to the receptor and would 
therefore influence ligand-receptor interactions. Images showing overlays of LBD D1 α-
carbons and overlay of docked and X-ray crystal ligand poses were prepared in PyMol.  
3.3. Results and Discussion of Modelling Studies 
3.3.1. Choice of KAR structural models 
Many high resolution (< 2 Å) X-ray structures of the GluK1 LBD in complex with 
antagonists are available (for a review, see Møllerud et al., 2017). The degree of LBD 
closure caused by different antagonists has also been shown to vary significantly (Mayer, 
2005; Alushin et al., 2011; Demmer et al., 2015). Therefore, the choice of the receptor X-
ray structure used for the docking study was based on a prediction of LBD closure caused 
by kynurenate binding to the KAR LBD. The domain closure of the LBD is an important 
factor for estimating an accurate binding pose for docked ligands and for interpretation of 
the possible ligand-receptor interactions. A domain that is closed would increase the 
number of good/bad ligand-receptor interactions and conversely, an open domain would 
decrease the number of ligand-receptor interactions assessed by the docking program when 
ranking the ligand poses.  
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The similarity of the antagonist used for X-ray crystallisation to kynurenic acid provided a 
good indicator of LBD opening in the kynurenate-bound structures. A ligand similar to 
kynurenic acid that was crystallised with GluK1 was (S)-2-Amino-4-(2,3-dioxo-1,2,3,4-
tetrahydroquinoxalin-6-yl)butanoic acid (CNG10300) (Demmer et al., 2015). The 
CNG10300-bound structure showed a large variation in LBD opening compared to the 
glutamate bound GluK1 LBD (25 - 40°), which highlights the degree of LBD flexibility 
that is possible in the antagonist-bound state of the receptor (Demmer et al., 2015). The 
UBP series of GluK1 antagonists based on the natural product willardiine were amongst 
the first compounds to be crystallised with the GluK1 LBD. The UBP315-bound GluK1 
LBD crystal structure has a domain opening of ~25° compared to the glutamate-bound 
GluK1 LBD (Alushin et al., 2011). Other UBP compounds such as UBP310 and UBP318 
had higher domain opening angles (~30°) (Mayer et al., 2006; Alushin et al., 2011).  
An exploratory docking routine was carried out on the UBP315 (PDB id: 2QS1), UBP318 
(PDB id: 2QS2), and CNG10300 (PDB id: 4QF9) GluK1 LBD structures and the IFD 
routine successfully found binding poses in all three X-ray structures for the standard 
antagonist UBP2038 (5,7-diF-6-I). Given the similarities in the success for finding docking 
poses for all three X-ray structures, the UBP315-bound X-ray structure was used as the 
GluK1 structure for docking studies. It was also used for GluK2 homology model building 
because UBP315 binding led to the lowest LBD opening and therefore increases the chance 
of finding interactions with both D1 and D2 residues, which could then be qualitatively 
assessed.  
3.3.2. Choice of AMPAR structural model 
Currently available X-ray structures of the AMPAR subunit were based on the GluA2 
subunit. Therefore, to explain the activity of kynurenate derivatives on AMPARs, the 
GluA2 subunit was chosen. The choice of using the GluA2 LBD X-ray crystal structure 
instead of a GluA1 LBD homology model based on the GluA2 structure was that the GluA1 
homology model building process would reduce the accuracy of the predicted structure. 
Additionally, GluA2 and GluA1 are both expressed in the rat hippocampus where the 
kynurenates were characterised (Lu et al., 2009). Moreover, there was ~87% amino acid 
sequence similarity between the GluA1 and GluA2 LBD and all residues that interacted 
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with orthosteric agonists in the ligand binding site were conserved in rat GluA1 and GluA2 
(Figure 3.4).  
The degree of opening of the LBD structure to be used for docking is likely to influence 
the ligand-receptor interactions. In the absence of solved structures of kynurenates in 
complex with AMPARs, it is difficult to predict the degree of LBD closure when 
kynurenates are bound. The quinoxaline-2,3-dione family of AMPAR antagonists has been 
used to solve the structure of the antagonist-bound GluA2 LBD (Armstrong and Gouaux, 
2000; Menuz et al., 2007). The number of rings in 6,7-dinitroquinoxaline-2,3-dione 
(DNQX) and 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX) and the planarity of the 
molecule were similar to kynurenic acid. Moreover, both DNQX (Armstrong and Gouaux, 
2000) and CNQX (Menuz et al., 2007) caused similar levels of LBD domain closure (3-7°) 
compared to the GluA2-apo structure. Therefore, LBD structures solved using DNQX and 
CNQX provided a suitable model for computationally docking kynurenic acid derivatives. 
In the current study, DNQX bound GluA2 (PDB id: 1FTL) was used as the structural model 
due to its higher resolution (1.8 Å) compared to the CNQX (2.5 Å) structure.  
3.3.3. GluK2 binding site interactions of kynurenic acid 
The binding mode of kynurenic acid in the GluK2 LBD revealed similarities to the 
glutamate-bound GluK2-LBD, such as the H-bond interactions between D1 Arg-492, Ala-
487, Pro-485 and the carboxyl group of kynurenic acid (Figure 3.7). The open nature of the 
binding cleft of the GluK2 model based on the GluK1 LBD-UBP315 crystal structure 
meant that Glu-707, which was involved in H-bond interactions with glutamate was not 
close enough to be involved in an H-bond with the kynurenic acid carboxyl group (Figure 
3.7). The Tyr-457 residue was in proximity to the ligand to allow a favourable π-π stacking 
interaction. The peptide chain NH group of Ala-658 in the D2 region was observed to form 
a H-bond with the 4-oxo group of kynurenic acid.  
The structure of kynurenic acid docked into GluK2 LBD also revealed that the 5-, 7- and 
6-positions may all be exposed to the solvent due to the presence of polar residues that line 
the phenyl ring of kynurenic acid (Figure 3.7). This could be interpreted as the reason for 
low affinity of GluK2 binding by kynurenic acid because the hydrophobic nature of the 5-
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, 6- and 7-position of kynurenic acid would not allow favourable interactions with the 
nearby polar/charged residues (Figure 3.7A). 
 
Figure 3.7. Kynurenic acid docked into GluK2 LBD homology model. A, Predicted pose of 
kynurenic acid docked into the GluK2 homology model based on GluK1-UBP315 (PDB id: 2QS1). 
Predicted H-bond interactions are shown with dashed yellow lines. Single letter amino acid code 
and the position of residues in the mature protein is shown in this and all 3-dimensional figures 
showing binding poses. B, Molecular surface area of the binding cavity (5 Å around kynurenic acid) 
in the GluK2 homology model. The cavity enclosure is shown as mesh coloured according to the 
electrostatic property of the cleft-lining residues (green: hydrophobic, light-blue: polar, red: 
negatively charged, blue: positively charged). The van der Waals volume of kynurenic acid is 
shown as spheres (coloured magenta). The volumes available to the 6- and 7-substituents are filled 
by hydrogen atoms in the kynurenic acid-docked GluK2 model.  
3.3.4. Explanation for increased GluK2 affinity of UBP2038 compared to 
kynurenate and UBP2002 
Pharmacological characterisation of kynurenates revealed an increase in GluK2 affinity of 
the 5,7-difluoro-6-iodo substituted UBP2038 compared to 6-iodo substituted UBP2002 and 
6-H in kynurenic acid. Docking of kynurenic acid, UBP2002 and UBP2038 into the GluK2 
homology model revealed the same rank order of docking scores for poses as the GluK2 
affinity determined in the functional assay (Figure 3.8); rank order of IFD score for chosen 
poses (docking scores (unit: kcal/mol) in parenthesis, lower score indicates more 
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favourable pose energy): UBP2038 (-531.556) > UBP2002 (-529.871) > Kynurenic acid (-
529.723). The 5-fluoro group of UBP2038 was positioned 3.1 Å and 3.7 Å from the Asn-
690 and Met-706 residues, respectively, which may allow weak but favourable H-bond or 
van der Waals interactions. The 7-fluoro group was in proximity (3.2 Å) to Tyr-412, raising 
possibilities for van der Waals interactions with the tyrosine aromatic ring. The 7-fluoro 
substituent may also form weak electrostatic interactions with the side-chain methyl of Thr-
709 (4 Å) or the hydroxyl group of Tyr-733 (3.5 Å).  
In the chosen poses, the 6-I substituent of UBP2002 and UBP2038 was close to the D2 
polar side-chains of Asn-690 (3.4 Å) and Thr-710 (3.3 Å) residues, which would allow 
electrostatic interactions and explains the increased affinity of the 6-I substitution in 
UBP2002 and UBP2038 compared to 6-H in kynurenic acid. 
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Figure 3.8. Schematic of GluK2 binding by kynurenic acid, UBP2002 and UBP2038. Ligand 
interaction diagrams showing the residues (single letter code) in the ligand binding cleft (4 Å from 
the ligand) for kynurenic acid (A), UBP2002 (B) and UBP2038 (C). Contours are coloured 
according to the nature of the residues lining the binding cleft (see legend for the colour scheme). 
Note that the 6-I substituent in UBP2002 and UBP2038 forms additional interactions with T710 
and N690 compared to kynurenate. The 5,7-difluoro substituents of UBP2038 form additional 
interactions with M706, N690, E409, Y412 and Y733 compared to kynurenate and UBP2002. 
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3.3.5. Explanations for the inactivity of UBP2007 and UBP2052 on GluK2 
The polar 6-substituted kynurenate, UBP2007 (6-CO2H), had no effect on GluK2 (see 
Table 2.2). Compared to UBP2038, the orientation of UBP2007’s quinolone ring was 
significantly altered such that the conserved π-π stacking interaction with Tyr-457 and the 
H-bond interaction with Pro-485 would be detrimentally affected (Figure 3.9A).  
To accommodate UBP2007 into the binding pocket, the conformations of Asn-690, Glu-
707 and Thr-710 were all refined during the induced fit procedure (Figure 3.9A). Moreover, 
the hydrophobic Met-706 which usually occupied the space close to the 6-position binding 
region of kynurenic acid was rearranged significantly to avoid clashes with the ionic 6-
substituent of UBP2007 compared to the UBP2038-docked structure. These movements 
suggested the transformation of the binding pocket from a previously mixed 
hydrophobic/polar environment to a polar binding region. Such a transformation would 
have a high energetic penalty and may prevent UBP2007 and other charged 6-substituents 
from binding to GluK2. 
The 6,8-dimethyl substituted kynurenic acid, UBP2052, has no activity on GluK2 
homomeric receptors at concentrations up to 2 mM (see Figure 2.8). Docking revealed that 
the bulky 8-methyl substituent could introduce steric clashes with Pro-485 (Figure 3.9B). 
As a result, the quinolone ring of UBP2052 was located such that the π-π stacking 
interactions with Tyr-457 and the H-bond interactions with Pro-485 would be reduced. 
Another consequence of the relocation was the closer proximity of the non-polar 6-methyl 
substituent of UBP2052 to the polar Asn-690 residue in D2. Such a rearrangement would 
be detrimental to the binding of UBP2052 and explains the lack of activity of UBP2052 in 
GluK2 subunits.  
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Figure 3.9. Docking of UBP2007 and UBP2052 in the GluK2 homology model reveals 
detrimental interactions and changes to residue conformations. A, Overlay of GluK2 docked 
ligand and residue structures of UBP2007 (green carbons) and UBP2038 (black carbons) showings 
the movement of 1-amino group in UBP2007 which may lead to weakening of the H-bond to the 
peptide carbonyl group of Pro-487. B, Similar to A but for UBP2052 (orange carbons). Steric 
clashes by the 8-methyl substituent of UBP2052 meant the 6-Me group would be in a polar 
environment near the Asn-690 residue. 
3.3.6. Binding of kynurenates to the GluK1 LBD 
Kynurenic acid docked into the GluK1-UBP315 structure (PDB id: 2QS1) (Alushin et al., 
2011) highlighted the larger pocket in GluK1 compared to GluK2 in the antagonist-bound 
state (Figure 3.10) as previously described (Mayer, 2005). However, the larger binding 
pocket in GluK1 also meant that the 5-position of kynurenates would have greater exposure 
to solvent in GluK1 compared to GluK2 (see Figure 3.10B and Figure 3.8A). The D1 
interactions of Arg-508 and Pro-501 to the 2-carboxylate and NH groups of kynurenic acid, 
respectively, were preserved in kynurenic acid-docked GluK1. The presence of Thr-503 in 
GluK1 instead of Ala-487 in GluK2 led to an extra H-bond between GluK1 D1 and 
kynurenic acid (Figure 3.10B). Greater exposure to solvent in GluK1 also suggests loss of 
weak but favourable hydrophobic interactions between the 7-substituents and residues 
lining the D2 domain and possibly explains lower affinity of kynurenic acid in GluK1. 
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The docking program also predicted a change in the positioning of kynurenates docked into 
the GluK1 structure – possibly due to the extra H-bond provided by the Thr-503 sidechain 
to the 2-carboxylate group of kynurenic acid (Figure 3.10). The change in position meant 
that atoms of 4-oxo group and 5- and 6-positions in kynurenic acid moved further away 
(1.8 Å) from D2 residues compared to the respective atoms in kynurenic acid-GluK2 
docked model. This movement is likely to be detrimental to the binding of kynurenic acid 
as it increases the amount of ligand exposure to solvent and may also explain kynurenic 
acid’s reduced affinity in GluK1 compared to GluK2 subunits.  
 
Figure 3.10. Kynurenic acid docked into GluK1 LBD. A, Kynurenic acid docked into the GluK1-
UBP315 LBD (PDB id: 2QS1). B, Schematic showing the interactions of kynurenic acid in the 
GluK1-LBD. Note the grey circles denoting exposure with water in the LBD, especially around the 
5- and 6-position carbon atoms. 
3.3.7. Explanation for the GluK2 over GluK1 selectivity of UBP2054 
In the pharmacological assay on recombinant homomeric KARs, UBP2054 (6-Et) has 
significant selectivity for GluK2 over GluK1 (GluK2 Ki = 54.0 ± 10.9 μM, GluK1 IC50 > 
1 mM) (Table 2.3). To find explanations for this selectivity, the binding modes of UBP2054 
in GluK1 and GluK2 LBDs were compared to that of UBP2034 (6-Me) (Figure 3.11). 
UBP2034 does not have the GluK2 over GluK1 selectivity of UBP2054 (UBP2034’s 
GluK2 Ki = 46.5 ± 9.3 μM and UBP2034’s GluK1 Ki = 47.8 ± 7.2 μM). Therefore, it 
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seemed that increasing the chain length of the hydrophobic 6-substituent may have 
beneficially improved GluK2 over GluK1 selectivity.  
The highest ranked poses in the GluK1 LBD (Figure 3.11A) demonstrated that the 
orientation of UBP2054 is such that the 4-oxo group of UBP2054 is 1.5 Å above the docked 
4-oxo group of UBP2038 (GluK1 Ki = 11.2 ± 1.0 μM). Such an orientation is likely to be 
preferred by the docking program because it avoids steric clashes and/or maximises the 
ligand-receptor interactions. However, whether such an orientation would be favourable in 
reality is unknown because it would also require the rearrangement of the Tyr-474 residue 
such that the hydrophobic π-π stacking interactions between the tyrosine ring and the 
heterocyclic ring of kynurenate are maximised.  
Docking of UBP2054 and UBP2034 into the GluK2 homology model showed that the cleft-
lining residues can be refined to increase ligand-receptor interactions (Figure 3.11B). The 
refinement of the conformation of residues to accommodate UBP2054 into GluK2 LBD is 
distinct such that the Met-706 residue is accommodated underneath the phenyl ring of 
UBP2054 and may form hydrophobic interactions with the 6-Et group. Another notable 
movement of a GluK2 residue in the UBP2054-docked structure is by the Asn-690 residue 
which may have been refined to prevent unfavourable interactions with the 6-Et substituent 
and/or to allow the Met-706 to be accommodated (Figure 3.11B). The UBP2034-docked 
GluK2 model revealed that the 6-Me substituent induces similar refinements of Asn-690 
and Met-706 as kynurenic acid (Figure 3.11B) such that Met-706 could not form 
interactions with the 6-Me group.  
The binding pocket interactions of non-polar 6-substituted compounds, UBP2034 (6-Me) 
and UBP2054 (6-Et), showed that the larger binding pocket of GluK1 may detrimentally 
expose the bulkier 6-Et to solvent (Figure 3.12A). This was reflected in the estimated 
affinities from pharmacological assays where UBP2054 had > 10-fold lower affinity on 
GluK1 compared to UBP2034: GluK1 Ki value for UBP2034 was ~48 μM whereas 
UBP2054 GluK1 IC50 was > 1 mM. However, in GluK2, increased protection from solvent 
exposure was provided by the larger residues (Thr-710 and Asn-690 in GluK2 instead of 
Ser-726 and Ser-706 in GluK1) lining the GluK2 binding cleft (Figure 3.12B). 
Chapter 3 – Molecular modelling of kynurenate binding to iGluRs 
151 
The molecular surface of the GluK1 and GluK2 binding sites in the docked structure with 
UBP2054 shows that the UBP2054 van der Waals volume is well tolerated by both GluK1 
and GluK2 structures (Figure 3.13). In GluK1, the 6-Et chain was closer to the polar Ser-
706 residue whereas in GluK2, the positioning of Met-706 under the 6-Et chain may have 
protected the 6-Et chain from solvent exposure. 
In summary, the molecular modelling studies suggest that UBP2054 is more selective for 
GluK2 compared to GluK1 due to a combination of firstly, increased hydrophobic 
interactions between the 6-Et of UBP2054 and Thr-710 of GluK2 and secondly, reduced 
exposure of 6-Et group of UBP2054 to solvent in GluK2 compared to GluK1. Moreover, 
the docking score for the best pose of UBP2054 (6-Et) and UBP2034 (6-Me) in GluK2 
were -529.67 kcal/mol and -529.153 kcal/mol, respectively. This similarity in docking 
score is in accordance with the similarity in GluK2 Ki values of both UBP2054 and 
UBP2034 (Table 2.3). However, the docking score of the best pose of UBP2054-bound 
GluK1 was -536.838 kcal/mol and for UBP2034-bound GluK1 was -540.544 kcal/mol. The 
less favourable GluK1 docking score of UBP2054 compared to UBP2034 further highlights 
the GluK2 over GluK1 selectivity of UBP2054. 
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Figure 3.11. Binding of UBP2054 in GluK1 and GluK2. A, UBP2054 (green carbon atoms), 
UBP2034 (orange), UBP2038 (black) and kynurenic acid (yellow) were docked into GluK1-
UBP315 structure (PDB id: 2QS1). There were no visible refinements of residue side chains in the 
binding cleft after docking of UBP2054 compared to UBP2038 or UBP2034. To accommodate the 
UBP2054 6-Et substituent nearer to Met-722, the ligand structure was rotated compared to the 
UBP2038 ligand structure such that the 4-oxo group in UBP2054 was ~1.5 Å above the 4-oxo group 
in UBP2038. B, Similar to A but kynurenates were docked into a GluK2 homology model based on 
GluK1-UBP315. Asn-690 and Met-706 conformations were refined by Prime to accommodate 
UBP2054. 
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Figure 3.12. GluK1 and GluK2 LBD binding schematic for UBP2034 and UBP2054. A, In the 
GluK1 LBD, the 6-substituents of UBP2034 and UBP2054 are exposed to solvent in the GluK1 
ligand binding pocket. Due to the larger hydrophobic 6-substituent of UBP2054, the binding of 
UBP2054 to GluK1 is likely to be less favourable compared to binding of UBP2034 to GluK1. B, 
In GluK2, 6-substituents of UBP2034 and UBP2054 were closer to the residues lining the binding 
cleft. The proximity to hydrophobic Tyr-733 and Tyr-412 of the 7-position meant that there is a 
greater likelihood of hydrophobic interactions in the GluK2 LBD. More importantly, the 6-ethyl in 
UBP2054 could form van der Waals interactions to Thr-710 and Met-706 which are absent in 
UBP2034 due to its smaller 6-methyl substituent. 
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Figure 3.13. Molecular surfaces of UBP2054-bound GluK1 and GluK2 ligand clefts. A, 
Surface of the GluK1 binding site, coloured according to the nature of the residue side chains that 
form the cleft (light-blue = polar, red = negatively charged, dark-blue = positively charged, green 
= hydrophobic). Residues near the 5-, 6- and 7-positions of the benzene ring of the ligand are shown. 
UBP2054’s van der Waals surface is represented as spheres (coloured magenta). B, Similar to A 
but showing the surfaces in GluK2 LBD. Note the interaction of the 6-ethyl group with the methyl 
group of Thr-710 and possibilities for van der Waals interactions between the 6-ethyl group and 
Met-706. These interactions explain the GluK2 over GluK1 selectivity of UBP2054. 
3.3.8. GluK2 over AMPAR selectivity of UBP2054 
UBP2054 (6-Et) showed > 10-fold selectivity for GluK2 (Ki value = 54.0 ± 10.9 μM) over 
GluA1 (IC50 > 2 mM) homomeric receptors, and UBP2054 also had low activity on 
AMPARs expressed in the hippocampus (IC50 > 300 μM). The GluK2 over AMPAR 
selectivity of UBP2054 was investigated by docking UBP2054, UBP2002 (6-I; GluA1 IC50 
> 1mM) and the kynurenate with the highest GluA1 affinity tested in the study, UBP2038 
(5,7-diF-6-I; GluA1 Ki = 22.6 ± 2.2 μM), into the GluA2-DNQX X-ray structure (PDB id: 
1FTL) (Armstrong and Gouaux, 2000) (Figure 3.14).  
GluA2 has a smaller binding cavity compared to GluK2 in part due to the presence of Met-
708 (in the place of Thr-710 in GluK2) where the 6-position group of kynurenates is 
located. In GluA2, overall ligand orientation in the highest-ranking pose of UBP2054 had 
similarities with the UBP2054 orientations in GluK1. However, compared to the higher 
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affinity UBP2038, the quinolone ring in UBP2054 was oriented such that the 4-oxo group 
in UBP2054-GluA2 model was 2.1 Å below that of UBP2038-GluA2 (Figure 3.14A). Such 
an orientation would negatively influence the π-π stacking interaction provided by Tyr-450 
and the conserved H-bond interactions between the ligand and Arg-485, Thr-480 and Pro-
478 and therefore is an indication of a poor binding mode. The difference in orientation of 
UBP2054 compared to UBP2038 may have been caused by the program trying to increase 
the likelihood of ligand-receptor electrostatic interactions by the phenyl ring substituents 
of kynurenates.  
The 6-Et group of UBP2054-GluA2 model was oriented in a similar manner to that found 
in UBP2054-GluK1 and UBP2054-GluK2, with the terminal carbon of the ethyl chain 
pointing towards the polar Thr-686. In the UBP2038 (5,7-diF, 6-I) docked GluA2 structure, 
the Met-708 residue was accommodated beneath the 6-I group and provided possibilities 
for hydrophobic interactions (Figure 3.14A). However, the 6-Et substituent of UBP2054 
was accommodated into the GluA2 LBD by refining the conformation of Met-708 to avoid 
steric clashes (Figure 3.14A). The movement of Met-708 also indicated that the bulkier 6-
Et substituent was less well tolerated in the GluA2 cavity compared to the 6-I substituent 
of UBP2002 and therefore explains the low GluA2 affinity of UBP2054. The polar side-
chain of Glu-705, which was involved in H-bond interactions with glutamate, was also 
refined to accommodate UBP2054 whereas in the UBP2002 and UBP2038 docked 
structures, the corresponding Glu residues were in similar locations (Figure 3.14A).  
The 6-iodo substituents of both UBP2002 and UBP2038 were found to be in locations to 
form favourable interactions with nearby residues Thr-686 and Met-706 in GluA2 (Figure 
3.14B and Figure 3.14C). However, the hydrophobic 6-Et substituent in UBP2054 was 
found to be in a polar environment, which is likely to be detrimental for binding of 
UBP2054 (Figure 3.14D). 
The overlap in the volumes of UBP2054 with the binding cavity surface was also a 
qualitative indicator of possibilities for steric clashes with Met-708 and Thr-686 (Figure 
3.15C). In the UBP2054-bound GluA2 LBD, there was higher overlap of the ligand and 
receptor volumes compared to UBP2002 and UBP2038. The favourable electrostatic and 
van der Waals interactions involving 5- and 7-substituents of UBP2038 may explain its 
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lower volume overlap with the receptor because the residues lining the 5- and 7-substituents 
would have been conformationally refined to maximise the ligand-receptor interactions and 
would subsequently avoid steric clashes of those residues with the 6-iodo atom of 
UBP2038. An example of such refinement was seen in the Thr-686 residue which was 
refined to maximise interactions of the Thr-686 hydroxyl group with the 5-F atom of 
UBP2038 and therefore avoid steric clashes with the 6-I group of UBP2038 (Figure 3.15B). 
However, UBP2002- and UBP2054-docked structures did not have such refinements 
(Figure 3.15A and C) and therefore the Thr-686 residue contributed to the overlap in 
volumes of the 6-iodo group of UBP2002 and 6-ethyl group of UBP2054.  
In summary, the GluK2 over GluA2 selectivity of UBP2054 can be best explained by steric 
clashes between the 6-ethyl substituent and the residues Thr-686 and Met-706 in the GluA2 
LBD. The GluA2 binding cleft is also surrounded by the negatively charged Glu-402 and 
Glu-705 located above and below the quinolone ring of kynurenates, respectively. These 
glutamate residues are also likely to contribute to preventing the hydrophobic 6-ethyl group 
being located optimally in the binding cleft. Despite these detrimental interactions in the 
GluA2, the docking scores of best poses of GluA2 docked with UBP2002 (-499.491 
kcal/mol), UBP2038 (-500.077 kcal/mol) and UBP2054 (-500.023 kcal/mol) were all 
similar. This shows that the docking scores alone cannot explain the affinity of the 
compound despite clear evidence that the unfavourable orientation of UBP2054 (Figure 
3.14) and the steric clash between the 6-Et of UBP2054 and Met-708 in GluA2 (Figure 
3.15) will limit the affinity of UBP2054 for GluA2 (and probably GluA1).  
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Figure 3.14. Docking of UBP2002, UBP2038 and UBP2054 into the GluA2 LBD. A, 3D overlay 
of binding modes and residue refinements in the GluA2 LBD docked with UBP2002 (orange 
carbons), UBP2038 (black carbons) and UBP2054 (green carbons). Non-polar hydrogens are 
hidden for clarity. B-D, Ligand interaction schematics for UBP2002 (B), UBP2038 (C) and 
UBP2054 (D) docked into the GluA2 LBD Note differences in interactions of 6-I and 6-Et 
substituents and possible clashes 
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Figure 3.15. Steric clash of the 6-ethyl substituent of UBP2054 in GluA2 LBD. A-C, the 
molecular surfaces of the GluA2 binding cavity docked with UBP2002 (A), UBP2038 (B) and 
UBP2054 (C). The 6-ethyl substituent of UBP2054 occupies a disallowed space near Thr-686 and 
Met-708 in the GluA2 binding cavity (C). UBP2002’s 6-I substituent also has steric clashes but 
fewer than UBP2054 (A). UBP2038’s van der Waals volume is better accommodated into the 
GluA2 binding cavity compared to UBP2002 or UBP2054 and explains its higher affinity for 
GluA1. Binding cavity surface are coloured according to the nature of residues lining the cavity; 
light-blue = polar, red = negatively charged, dark-blue = positively charged, green = hydrophobic). 
Ligand van der Waals surfaces are shown as spheres (magenta and transparent). 
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3.3.9. Explaining the reduced NMDAR activity of 6-substituted kynurenates 
Two X-ray structures of the NMDAR GluN1 LBD in complex with 5,7-diCl kynurenic acid 
(DCKA) are available (Furukawa and Gouaux, 2003; Jespersen et al., 2014). Given the 
similarities in the X-ray crystal structures, the higher resolution (1.9 compared to 2 Å) 
GluN1 LBD-DCKA structure was used for docking studies (PDB id: 1PBQ) (Furukawa 
and Gouaux, 2003). The GluN1-DCKA structure overlaid over the GluA2-apo structure 
suggested that LBD opening of DCKA-bound GluN1 LBD was smaller than the GluA2-
apo LBD. The computationally docked DCKA had a similar pose to the X-ray crystal 
DCKA, which highlighted the pose predictive capability of Glide and the InducedFit 
protocol. The interactions of the 2-carboxyl group and 1-NH group of DCKA with the 
GluN1 cleft residues were similar to those predicted by computational docking of 
kynurenates into GluK2, GluK1 and GluA2 -LBDs. Another feature of DCKA binding to 
GluN1 was the π-π stacking provided by Phe-484 to the heterocyclic ring of DCKA, which 
is similar to the π-π stacking provided by the tyrosine aromatic ring in GluK2, GluK1 and 
GluA2 (Figure 3.16).  
Pharmacological characterisation on native NMDARs showed that 100 μM UBP2040 (5,7-
diF) inhibited native NMDARs significantly (~73%) compared to 100 μM UBP2002 (6-I) 
(~7%). To explain the reduced activity of 6-substituted kynurenates, UBP2002 and 
UBP2040 were docked into the GluN1 X-ray structure (Figure 3.16). As found with 
DCKA, the 5- and 7-fluoro substituents in UBP2040 form van der Waals interactions with 
Phe-408 and Trp-731, respectively (Figure 3.16A). Moreover, the fluoro substituents in 
UBP2040 are more electronegative than the chloro substituents in DCKA and therefore, 
may form more favourable van der waals interactions (with Phe-408 and Trp-731) 
compared to DCKA. However, the smaller size of fluoro substituents in UBP2040 
compared to the larger 5-,7-Cl atoms in DCKA means that the van der Waals interactions 
are weaker between UBP2040 and GluN1 and explains the lower affinity of UBP2040 for 
GluN1 compared to DCKA (Leeson et al., 1991). Docking scores of UBP2040 (-597.153 
kcal/mol) and DCKA (-597.672 kcal/mol) suggests that DCKA has a slightly more 
energetically favourable pose compared to UBP2040.  
Overlay of the UBP2002-docked structure onto the DCKA-docked structure showed that 
the UBP2002 ligand molecule was rearranged such that the 4-oxo group moved 1 Å towards 
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the D2 residues compared to the DCKA ligand structure (Figure 3.16B). The bulky side-
chain of Trp-731 did not relocate to accommodate UBP2002 and there was a slight 
conformational refinement of Val-735 (~0.8 Å movement of the side chain carbon) to 
accommodate UBP2002 but the movement of the Val-735 side chain was unlikely to 
provide enough space to accommodate the 6-iodo group of UBP2002 (Figure 3.16B).  
Analysis of the molecular surfaces of the GluN1 binding cavities in the UBP2040- and 
UBP2002-bound structures revealed a substantial overlap of the van der Waals surfaces of 
the cleft lining residues and UBP2002 (Figure 3.17B). Such an overlap of volumes was not 
seen in the UBP2040-GluN1 model (Figure 3.17A) and suggests that steric occlusion of 
the 6-iodo substitution in UBP2002 may have reduced its affinity for GluN1 and therefore 
for NMDARs.  
 
Figure 3.16. Docking of UBP2040 and UBP2002 into the GluN1 LBD showing that while 
DCKA and UBP2040 can be accommodated in the binding site, UBP2002 cannot. A, UBP2040 
(green carbon atoms) docked into the GluN1 LBD overlaid onto the DCKA-bound GluN1 LBD 
structure (black carbons; PDB id: 1PBQ) for comparison of docked structure and X-ray structure. 
Note the 5,7-diF substituents of UBP2040 and 5,7-diCl substituents of DCKA form favourable 
interactions with Phe-408 and Trp-731. Only polar hydrogen atoms are shown for clarity. B, 
Overlay of docked structures of UBP2002 (orange carbons) with the DCKA-bound LBD X-ray 
structure (black carbons). Note the 6-iodo group of UBP2002 (purple) forms steric clashes with 
Val-735 and Trp-731. 
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Figure 3.17. Overlap of molecular surfaces in UBP2040- and UBP2002-docked GluN1 binding 
cavity. Molecular surfaces of the binding cavity are shown for UBP2040 (A) and UBP2002 (B) 
docked into the GluN1 LBD. The binding cleft surface is coloured according to the nature of the 
residues lining the cleft. The van der Waals surfaces of ligands are shown as magenta spheres. Note 
that the 6-iodo group of UBP2002 forms steric clashes with Val-735 and Trp-731 while the 5,7-
difluoro groups of UBP2040 are accommodated. 
3.4. Further discussions 
In this study, molecular modelling was used to explain the features of GluK2, GluK1 and 
GluA2 ligand binding clefts that may have determined some of the results from 
pharmacological characterisation experiments (Chapter 2). Using the knowledge gained 
from the current work, it may be possible to develop novel antagonists with greater GluK2 
affinity and selectivity over AMPARs and potentially GluK1.  
3.4.1. Methodological limitations 
There are some caveats when using molecular modelling to predict affinity. The total 
binding energy of a ligand depends on the ligand-receptor interactions, the solvation-
desolvation energy (the energy required for the compound to shed its solvent water 
molecules and displace water molecules from the ligand binding site), and the 
conformational energy of binding. The poor water solubility of the kynurenates suggests 
that the desolvation penalty of this class of antagonists may be low; therefore, the main 
contribution to total binding energy of the ligands may be dictated by the ligand-receptor 
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interactions and the conformational energy penalty during ligand binding. In this study, the 
Glide docking algorithm could estimate the ligand-receptor interactions using the 
glidescore function. While the conformational energy penalty was included in the 
glidescore function through a penalty for freezing rotatable bonds, the total conformational 
energy penalty of the ligand binding also depends on the water molecules present in the 
binding site. Water molecules can contribute to the total conformational energy of the 
binding site by decreasing the enthalpic contribution: H-bond networks provided by the 
binding cleft water molecules may help to increase the stability of the open LBD in the apo 
state of the receptor. Water molecules also contribute to the entropy of the system and 
removing the ordered water molecules increases entropy and therefore increases the free 
energy of the system – increasing the binding affinity.  
Due to unavailability of X-ray crystal structures of antagonist-bound GluK2 LBD and the 
limitations of X-ray structures in identifying the positions of water molecules, the 
prediction of binding site water molecules in the GluK2 homology model was not possible. 
Therefore, the rank order of poses and the selection of “acceptable” poses by the docking 
program would likely underestimate the energy penalty that would result from releasing 
water molecules from the binding sites to accommodate the docked ligand. The docking 
program also did not estimate H-bond interactions between the ligand and the receptor that 
occur through water molecules. Such H-bond interactions coordinated by water molecules 
serve to stabilise the receptor-ligand complex and may be important for the binding of 
kynurenates to the LBD of iGluRs (Armstrong and Gouaux, 2000; Mayer, 2005). 
Another caveat of the IFD routine was that the docking program could underestimate the 
conformational energy penalty which would result from moving residues that may cause 
unfavourable interactions with the ligand. The best example for this phenomenon is the 
docking of UBP2007 (6-CO2H) to the GluK2 homology model. In the case of UBP2007, 
the hydrophobic sidechain of Met-706 was refined by the program to accommodate the 6-
carboxy group of UBP2007 in order to gain at-least 2 H-bond interactions between the 6-
carboxyl group of UBP2007 and the polar sidechains of Thr-710 and Glu-707. In reality, 
the movements of the residue side chains would usually require breaking of inter-residue 
electrostatic and van der Waals interactions and the ligand-receptor interactions must 
therefore overcome the energy barrier by providing more favourable interactions. 
Chapter 4  
Investigations into the roles of GluN2D 
subunits in hippocampal synaptic plasticity 
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4.1. Introduction 
4.1.1. Biophysical features of GluN2D subunits 
GluN2D subunits share the structural features of other NMDAR subunits and form 
functional diheteromeric receptors when assembled as a dimer of dimers with two GluN1 
subunits. However, two different GluN2 subunits are also capable of forming 
triheteromeric receptors by assembling with two GluN1 subunits, e.g. as a 
GluN1/GluN2B/GluN2D or GluN1/GluN2A/GluN2D complex (Dunah et al., 1998; 
Cheffings and Colquhoun, 2000; Jones and Gibb, 2005). NMDARs mediate synaptic 
currents that have slower activation and decay kinetics than AMPARs or KARs. The gating 
properties of the channel and its subunit composition are responsible for dictating kinetics 
of NMDAR mediated macroscopic currents (Monyer et al., 1992). Particularly, GluN2D-
containing diheteromeric receptors have longer agonist deactivation times compared to 
GluN2A-, GluN2B- and GluN2C-containing dihetermeric NMDARs, meaning that the 
GluN2D-containing receptor binds glutamate for longer periods compared to other 
NMDAR subunits (Vance et al., 2011). The physiological mechanisms that underlie 
NMDAR mediated synaptic plasticity are also influenced by the kinetics of Ca2+ influx 
through the NMDAR channel (Lisman, 1989; Yang et al., 1999) and therefore subunit 
composition of NMDARs might be responsible for regulating synaptic plasticity. 
Diheteromeric NMDARs containing the GluN2D subunit show slower current decay than 
receptors containing other GluN2 subunits, with a decay time constant in the range of 1–2 
s for GluN2D diheteromeric NMDARs (compared to 22-230 ms and 110-430 ms for 
GluN2A and GluN2B, respectively) (Monyer et al., 1994; Vicini et al., 1998). However, 
when GluN2D subunits are found in triheteromeric complexes with either GluN2A or 
GluN2B subunits, a faster decay time is observed i.e. 2A or 2B subunits dominate over the 
2D decay kinetics (Cheffings and Colquhoun, 2000; Jones and Gibb, 2005). On the basis 
of these findings, it has been suggested that distinct GluN2 subunits may be involved in 
distinct neuronal plasticity processes based on the distinct profile of Ca2+ charge transfer 
that each GluN2 subunit confers to the NMDAR (Shipton and Paulsen, 2014). GluN2A, 
GluN2B and GluN2D subunit containing diheteromeric and triheteromeric NMDARs may 
therefore act as switches that control the activity required to trigger distinct plasticity 
processes in the hippocampal synapse. 
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4.1.2. Using pharmacological tools to investigate GluN2D subunits 
The GluN2D subunit, like other GluN2 subunits, has a ligand binding domain that binds 
glutamate as the endogenous agonist (Vance et al., 2011). Potency of glutamate for the 
GluN2D subunit is higher than for other GluN2 subunits; glutamate rank order of potency 
(represented by EC50 in parenthesis): GluN2D (0.5 µM) > GluN2C (1.7 µM) > GluN2B 
(2.9 µM) > GluN2A (3.3 µM) (Erreger et al., 2007). Another pharmacological feature of 
GluN2D-containing diheteromeric NMDARs is that they are less susceptible to Mg2+ block 
than GluN2A- and GluN2B-containing diheteromeric NMDARs (Monyer et al., 1994). 
Additionally, the prototypical NMDAR competitive antagonist D-AP5 has lower antagonist 
potency on GluN2D compared to other GluN2 subunits: D-AP5 rank order of antagonist 
activity (represented by equilibrium-dissociation constant, Ki, in parenthesis): GluN2A 
(0.28 μM) > GluN2B (0.46 μM) > GluN2C (1.6 μM) > GluN2D (3.7 μM) (Buller and 
Monaghan, 1997; Feng et al., 2005). Development of GluN2D-selective competitive 
antagonists in this lab has resulted in a series of antagonists with moderate selectivity for 
GluN2C/D over other GluN2 subunits. UBP145, which has ~10-fold selectivity for 
GluN2C/D over GluN2A or GluN2B subunits, is a well-characterised (using NMDARs 
expressed in X. laevis oocytes and HEK293 cells, see section 1.3.3) member of this family 
of competitive antagonists (Irvine et al., 2012; Volianskis et al., 2013a). UBP791 is a novel 
GluN2C/D preferring compound, which has greater selectivity for GluN2D over GluN2A 
(~200-fold) and GluN2B (~30-fold) (Jane and co-workers, unpublished data) than UBP145. 
A positive allosteric modulator selective for GluN2C and 2D subunits, CIQ, was shown to 
potentiate currents mediated by GluN2D diheteromeric NMDARs expressed in X. laevis 
oocytes and GluN2D-containing NMDARs in hippocampal slices (Mullasseril et al., 2010; 
Perszyk et al., 2016). Therefore, even though pharmacological studies of GluN2D subunits 
have lagged compared to those for GluN2A and GluN2B subunits, it has become clear that 
GluN2D subunits may be selectively targeted by pharmacological agents.  
Physiological studies that use pharmacological agents to investigate the roles of individual 
GluN2 subunits in synaptic plasticity have used different antagonists which have different 
relative affinities for individual subunits due to a lack of antagonists with high subunit-
selectivity. Particularly, GluN2A is preferably inhibited by NVP-AAM077 (NVP), a 
competitive antagonist with 5- to 10-fold selectivity for GluN2A over other GluN2 subunits 
(Feng et al., 2004; Neyton and Paoletti, 2006; Volianskis et al., 2013a). The GluN2B 
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subunit is selectively inhibited using the negative allosteric modulator (NAM), Ro 25-6981 
(Ro), which has ~5000-fold selectivity for GluN2B over GluN2A (Fischer et al., 1997). 
While the effect of Ro has not been characterised in detail on native triheteromeric 
receptors, ifenprodil, a structurally similar allosteric modulator as Ro, inhibited 
GluN2A/2B triheteromeric receptors with a potency of ~6-fold that of its IC50 on GluN2B 
diheteromeric receptors (Hansen et al., 2014). Recently, the cryo-EM structure of a 
recombinant GluN2A/2B triheteromeric receptor in complex with Ro was solved, and Ro 
was found to bind recombinant GluN2A/2B triheteromer with a Kd of ~130 nM (Lü et al., 
2017). Therefore, Ro can be used to detect the presence of GluN2A/GluN2B-containing 
triheteromeric NMDARs due to its intermediate activity on such receptors. However, Ro is 
also an activity dependent antagonist which blocks GluN2B currents more potently at 
higher agonist concentrations (Fischer et al., 1997). The activity dependence of Ro may 
potentially complicate interpretation of results from slice experiments where glutamate 
spillover and glutamate uptake mechanisms determine agonist concentration at NMDARs 
at different locations in relation to the release site. Such complications can be overcome 
whilst using different concentrations of D-AP5, NVP, Ro or UBP145 to study synaptic 
plasticity, which allows the relative potencies of each antagonist on the studied 
physiological process to be determined (Volianskis et al., 2013a; Ingram et al., 2018). 
4.1.3. Expression of GluN2D subunits in the hippocampus 
In the hippocampus, GluN2D subunit mRNA and protein levels are highest at birth and 
decreases with age (Monyer et al., 1994; Ikeda et al., 1995). GluN2A, GluN2B and GluN2C 
subunits are also expressed in the hippocampus (Buller et al., 1994; Monyer et al., 1994). 
Expression of GluN2-containing NMDARs is developmentally regulated. GluN2B subunit 
expression is highest after birth but decreases with age whereas GluN2A expression 
increases with age (Monyer et al., 1994). Immunohistochemical studies have shown that 
the GluN2A, GluN2B and GluN2D proteins are found in the CA1 region of the 
hippocampus of adult mice (Hrabetova et al., 2000; Thompson et al., 2002), and that 
interneurons are likely to express GluN2D subunits in the CA1 region (Engelhardt et al., 
2015). GluN2D protein levels were also found at lower levels in the dendritic regions of 
the CA1 and GluN2D antibodies were colocalised with GluN2A and GluN2B antibodies, 
suggesting that GluN2D may form triheteromeric complexes with GluN2A or GluN2B 
subunits (Thompson et al., 2002). These findings suggest that the GluN2D subunit may be 
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available to participate in synaptic plasticity at hippocampal synapses involving both 
principal cells (pyramidal cells in the CA3 and CA1) and interneurons. 
4.1.4. NMDA receptors and synaptic plasticity in the hippocampus 
Long term potentiation (LTP) of synaptic transmission is believed to represent the 
physiological cellular processes that underlie the long-term storage of information by 
synapses (Bliss and Collingridge, 1993). Therefore, the hippocampal SC-CA1 synapse has 
been used extensively to study the properties of NMDAR subunits and the involvement of 
different NMDAR subunits in mediating synaptic plasticity.  
Potentiation induced by moderate high-frequency stimulation (such as theta-burst 
stimulation (TBS) or 100 Hz tetanus for 1 s (referred to as high-frequency stimulation, 
HFS)) in the Schaffer collateral-CA1 pyramidal cell (SC-CA1) synapse is mediated by 
NMDARs (Collingridge et al., 1983; Larson et al., 1986) whereas some types of overt 
stimulation of the pathway activates other sources of Ca2+ that can also induce LTP (Jia et 
al., 1996; Plant et al., 2006; Park et al., 2016). NMDARs mediate induction of potentiation 
by allowing Ca2+ influx into the cell (Lynch et al., 1983; Yang et al., 1999), and by making 
intracellular associations with proteins such as calcium/calmodulin-dependent protein 
kinase II (CaMKII) (Lisman et al., 2002).  
Recently, the canonical potentiation in the SC-CA1 synapse of the rat hippocampus was 
further divided into different phases based on the sensitivity of each phase of potentiation 
to GluN2A, GluN2B or GluN2D subunit-preferring antagonists (Volianskis et al., 2013a). 
Potentiation induced by TBS consists of the initial potentiation that decays (STP), and the 
stable long-lasting phase of potentiation (generally referred to as LTP). STP was found to 
contain two components, namely STP1 which is mediated largely by GluN2A- and 
GluN2B-containing NMDARs, and STP2 which is mediated by GluN2B- and GluN2D-
containing NMDARs, whereas LTP was found to be mediated by GluN2A- and GluN2B-
containing NMDARs (Volianskis et al., 2013a). Importantly, constructing concentration 
response curves for the different antagonists led to the finding that STP2 may be mediated 
through GluN2B- and GluN2D-containing triheteromers because STP2 had intermediate 
sensitivity to the GluN2B antagonist, Ro, and was sensitive to the 2D selective antagonist 
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UBP145 (Volianskis et al., 2013a). All of the above experiments were performed in rats 
and dependences of STP and LTP on NMDAR subunit activation in mice is unknown. 
4.1.5. Objectives 
The objectives of the current study were: 
1. to verify that GluN2A- and GluN2B-containing receptors mediate LTP and the 
amplitude of STP in the SC-CA1 synapse of adult mice 
2. to investigate the role(s) that GluN2D subunits play in LTP in the SC-CA1 synapse 
using a combination of genetic GluN2D knockout mice and GluN2 subunit 
selective antagonists 
3. to characterise the effects of UBP145 and UBP791 (GluN2C/2D-preferring 
antagonists) on the induction of STP and LTP in the GluN2D knockout mice and 
in the wild type controls. 
4.2. Methods 
4.2.1. Animals and slice preparation 
All experiments involving animals were performed according to University of Bristol 
regulations and the UK Scientific Procedures Act, 1986 and European Union guidelines for 
animal care. Adult (3-6 months old) wild type (WT) mice of the C57BL/6 strain and 
GluN2D KO mice generated from the WT background (Charles River, UK) were used in 
the study. Mice were anaesthetised with isofluorane and killed by decapitation after cervical 
dislocation. The hippocampus was dissected and cooled (0 – 4 °C) in artificial cerebrospinal 
fluid (aCSF), which contained (in mM): 124 NaCl, 3.5 KCl, 1.25 NaH2PO4, 26 NaHCO3, 
2 CaCl2, 2 MgSO4 and 10 glucose, saturated with 95% O2 and 5% CO2. Transverse slices 
(400 µm) of the dorsal hippocampus were cut using a McIllwain tissue chopper (The 
Mickle Laboratories) and incubated in aCSF (pH ~7.4) at room temperature (~20 °C) for 
at least 2 hours before the start of the experiments. During the experiments, slices were kept 
submerged and perfused with aCSF that was heated to 33 °C.  
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4.2.2. Chemicals 
NMDAR antagonists D-AP5, Ro 25-6981 maleate, and NVP-AAM 077 were purchased 
from HelloBio Ltd (Bristol, UK), and L-689,560 was purchased from Tocris Bioscience 
(Bristol, UK). UBP145 and UBP791 were synthesized in house as described previously 
(Morley et al., 2005; Burnell, Fang, Irvine, Jane, unpublished data). GABA receptor 
antagonists, picrotoxin, (-)-bicuculline methochloride and CGP 55845 hydrochloride were 
purchased from HelloBio Ltd (Bristol, UK). All antagonists were prepared as stock 
solutions, stored as frozen and added to perfused aCSF at times indicated in Results. All 
other chemicals and salts were purchased from Sigma (Dorset, UK) or Fischer Scientific 
(Loughborough, UK).  
4.2.3. Electrophysiological recordings 
Field-excitatory post-synaptic potentials (f-EPSPs) were recorded from the CA1-B area of 
the stratum radiatum (population spikes were recorded from stratum pyramidale in some of 
the experiments) of the hippocampus after stimulation of the Schaffer collaterals (SCs) 
using a bipolar concentric platinum core electrode with a tip diameter of 12.5 µm (FHC, 
Inc, USA) (Figure 4.1). Recording electrodes (made of borosilicate) were filled with aCSF 
and had a resistance of 1.5-2 MΩ. Stimulus pulses (pulse duration of 100 µs) were 
generated using DS2A Mk2 (Digitimer Ltd, Hertfordshire, UK). Recorded signals were 
amplified and filtered at 5 kHz (AxoPatch 1D; Axon Instruments, USA), and digitised at 
40 kHz (National Instruments, USA). Stimulation intensity was set to three times the 
threshold for evoking f-EPSPs. Signals were recorded, digitised and stored on a desktop 
PC using the WinLTP software (Anderson and Collingridge, 2007) for offline analysis.  
Baseline and potentiated responses were evoked by stimulating once every 15 seconds and 
are shown in Results as averages of 4 responses. LTP was induced using either a TBS 
protocol which comprised of four stimuli at 100 Hz, repeated 10 times at a frequency of 5 
Hz (referred to as 10-bursts herein), or a more intense stimulation protocol of 4 stimuli at 
100 Hz, repeated 30 times at a frequency of 15 Hz (referred to as 30-bursts). The 30-bursts 
protocol was used to investigate the role of specific GluN2 subunits on the decaying phase 
of LTP which was shown to contribute more significantly when the number of bursts during 
tetanisation was increased (Volianskis and Jensen, 2003). The maximal potentiation (Pmax) 
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was recorded four minutes after the delivery of tetanus to prevent contamination of the Pmax 
from post-tetanic potentiation (PTP). 
To record baseline transmission, the input-output relationship for the Schaffer collateral-
CA1 pyramidal cells (SC-CA1) synapse was obtained by recording the f-EPSP response to 
increasing levels of stimulation intensities (expressed as multiples of the threshold intensity 
required to evoke an f-EPSP) as shown in Results. Simultaneous recordings from stratum 
radiatum and stratum pyramidale of the CA1-B region were obtained to construct the input-
output relationship for f-EPSPs and population spikes (Figure 4.1). 
4.2.4. Data analysis and plotting 
F-EPSP responses used for analysis of LTP experiments were measured as the rate of rise 
of the f-EPSPs which was obtained by dividing the amplitude of the initial deflection of f-
EPSPs (following the fibre volley) by the time window of the deflection (set at 0.5 ms in 
this study). Responses for each experiment were normalised to the baseline responses 
(stable responses obtained before tetanus) and responses are shown according to the level 
of potentiation, baseline recordings having 0% potentiation. LTP amplitude was 
represented by the average potentiation at the plateau phase at the end of recordings. STP 
amplitude was calculated as the difference between Pmax and LTP amplitude for each 
experiment. Decay of STP was calculated by fitting a mono-exponential fitting routine 
using non-linear regression to the decay of potentiation following tetanus delivery. The 
following equation was used to fit the decay of potentiation: 
P = LTP + (STP × e−
t
τ) (4.1) 
Where P is the total amplitude of potentiation, LTP and STP are amplitudes of potentiation 
as described above, t is the time since start of decay, τ is the time constant of decay (the 
time required for the potentiation to decay to 1/e of Pmax). LTP amplitude, STP amplitude, 
and τ were calculated for each experiment and are reported as mean ± S.E.M for 
experimental groups described in Results.  
Baseline transmission was assessed using input-output (IO) experiments. IO experiments 
were carried out by measuring the following features of the response waveform in response 
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to various multiples of stimulus intensities required to induce the first f-EPSP: amplitude 
of the fibre volley (FV), the initial slope of f-EPSP recorded from the stratum radiatum, the 
area of the population spikes recorded from the stratum pyramidale (see also Results -
Figure 4.1). The relationship between FV and stimulus intensity in IO experiments was 
characterised in each experiment by plotting the FV amplitude against the stimulus 
intensity and fitting the data using linear regression and the slope of the best-fit line was 
used for further comparisons. The relationship between f-EPSP slope and FV amplitude in 
IO experiments was characterised by fitting data from individual experiments using linear-
regression where the line was constrained to pass through y = 0, x = 0, because the f-EPSP 
was preceded by a FV and both components were clearly visible in all experiments. The 
slope of the best-fit line was then used as a measure of the input-output relationship between 
FVs and f-EPSPs.  
To characterise the excitability in slices, excitation-spike (ES) coupling relationship 
between f-EPSPs and population spikes were investigated. Population spike areas and f-
EPSP slopes from each IO experiment were fitted using non-linear regression to a four-
parameter logistic curve with the following equation:  






H  (4.2) 
where Y is the population spike area, T is the maximum value of the curve, B is the 
minimum value of the curve, constrained to 0, because population spikes required f-EPSPs, 
X was the f-EPSP slope; E50 was the f-EPSP slope at half-maximal population spike area; 
H was the slope-factor.  
Paired pulse facilitation ratio, a measure of presynaptically induced STP (see section 
1.1.4.3), was measured by evoking 2 f-EPSPs using 2 stimulus pulses at an inter-pulse 
interval of 50 ms and dividing the rate of rise of the second f-EPSP by rate of rise of the 
first f-EPSP. 
Analysis of data was performed offline using Platin (Morten Jensen, University of Aarhus, 
Denmark) and WinLTP (Anderson and Collingridge, 2007). Statistical comparisons and 
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plotting were performed using GraphPad Prism 7 (GraphPad Software, Inc., LaJolla, CA, 
USA). LTP and STP amplitudes were compared using parametric tests; analysis of variance 
(ANOVA) followed by Dunnett's multiple comparison test (DT) was used for multiple 
comparisons. Decay time constants of STP were compared using Mann-Whitney (MW) 
test because the pooled control decay time constant data from 10-bursts and 30-bursts 
experiments did not conform to samples from a normal distribution (p < 0.01, D'Agostino 
& Pearson omnibus normality test). In cases where normality of data could not be 
determined due to low experimental observations, paired testing of before- and after-
treatment effects from the same slice was performed using Wilcoxon matched pairs signed 
rank (WMPSR) test. Statistical significance was set at p < 0.05. Significant differences in 
bar plots are indicated by asterisks (* p < 0.05, ** p < 0.01, *** p < 0.001). 
 
Figure 4.1. Setup for recording field potentials from the hippocampus. Schematic illustrating 
the positioning of stimulating and recording electrodes and showing example responses that were 
recorded from the stratum pyramidale and stratum radiatum in a transverse hippocampal slice. 
Stimulating electrode (Stim) was placed in the stratum radiatum at the border between CA1 and 
CA2 areas. Fibre volleys (FVs) and field excitatory post-synaptic potentials (f-EPSPs) were 
recorded from the stratum radiatum and population spikes (PSs) were recorded from stratum 
pyramidale in the CA1 area. Dashed line shows a representative time-point at which the slope of f-
EPSP was measured for all experiments in this study. 
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4.3. Results 
4.3.1. Investigation of baseline transmission in WT and GluN2D KO 
hippocampal slices  
Baseline transmission was characterised in slices from wild type (WT) and GluN2D 
knockout mice (KO) (Figure 4.2). The relationship between the amplitude of fibre volley 
and the stimulation intensity was not significantly different between WT and GluN2D KO 
slices (Figure 4.2A, p > 0.05, Student’s t-test). The input-output relationship for fibre volley 
and f-EPSPs suggests that slices from both genotypes generate similar f-EPSPs for the same 
presynaptic input (Figure 4.2B, p > 0.05, Student’s t-test). The relationship between f-EPSP 
and population spike was best fit using a sigmoidal polynomial curve, which could be used 
to compare differences in maximal population spike (a measure of excitability in the slices) 
and the E50 (the f-EPSP slope at half-maximal population spike) between the genotypes 
(Figure 4.2C). Maximal population spike was larger in WT slices compared to KO slices 
(p < 0.05, Student’s t-test) but the E50 was not significantly different between WT and KO 
slices (p > 0.05, Student’s t-test). The PPF of f-EPSPs were characterised using an inter-
pulse interval (IPI) of 50 ms (Figure 4.2D) and both genotypes had similar PPF ratios (p > 
0.05, Student’s t-test).  
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Figure 4.2. Characterisation of baseline transmission in WT and GluN2D KO hippocampal 
slices. A, FV was plotted against stimulus intensity and the relationship was compared between WT 
and GluN2D KO slices using linear regression. Slope of the WT line (-0.042 ± 0.0054 mV/stim 
intensity, n = 14) was not significantly different (P > 0.05, Student’s t-test) from the KO line (-
0.045 ± 0.0061 mV/stim intensity, n =13). B, f-EPSP to FV relationship was compared between the 
2 genotypes. The slopes of lines for WT = 1.9 ± 0.20 ms-1 (n = 14) and KO = 1.91 ± 0.30 ms-1 (n = 
13) were not significantly different (p > 0.05, Student’s t-test). C, PS to f-EPSP input-output 
relationships were evaluated by fitting sigmoidal curves to WT and KO datasets. The f-EPSP slope 
at half maximal population spike (E50) for WT slices (-0.39 ± 0.062 mV/ms) was not different from 
that for the KO slices (-0.44 ± 0.064 mV/ms, p > 0.05, Student’s t-test). Maximal PS area for WT 
(4.00 ± 0.44 mV * ms, n = 8) was higher than the maximal PS area for KO (2.49 ± 0.16 mV * ms, 
n = 7. p < 0.05, Student’s t-test). D, Paired pulse facilitation (PPF, 50 ms interpulse interval) ratio 
was not significantly different between WT (2.10 ± 0.069, n = 15) and KO (2.07 ± 0.056, n = 15, p 
> 0.05, Student’s t-test) slices. 
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4.3.2. Effects of GABA receptors on baseline transmission in WT and KO 
slices 
Maximal neuronal excitability was significantly depressed in GluN2D KO slices when 
compared to WT slices (Figure 4.2). Therefore, the effects that deletion of GluN2D 
receptors expressed on interneurons had on baseline synaptic transmission were 
characterised. To do this, the baseline transmission before and after inhibition of 
GABAergic transmission using antagonists of GABAA (50 µM picrotoxin and 20 µM 
bicuculline) and GABAB (2 µM CGP 55845) receptors in WT and KO slices were 
investigated (Figure 4.3, Figure 4.4 and Figure 4.5). In WT and KO slices, inhibition of 
GABAA and GABAB receptors did not affect the relationship between stimulus intensity 
and FV (Figure 4.3), or FV and f-EPSP (Figure 4.4), or f-EPSP and population spikes (E50, 
Figure 4.5A3 and Figure 4.5B3) (p > 0.05 for all, WMPSR test). Similarly, upon inhibition 
of GABAergic transmission, maximum population spike was not significantly different 
compared to controls in WT (Figure 4.5A2) or KO (Figure 4.5B2) slices (p > 0.05, WMPSR 
test). 
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Figure 4.3. Characterisation of the effects of inhibition of GABAergic transmission on 
stimulus intensity to fibre volley ratio in WT and GluN2D KO slices. A1 and B1, Example 
experiments showing the FV to stimulus intensity relationship in WT slices (A1) and KO slices 
(B1) with (white circles) and without (black circles) blockage of GABAergic transmission. The 
data were fitted using linear regression and the best-fit lines are shown. A2 and B2, Pooled data 
(mean ± SEM, left) and data from individual experiments (right) showing the effect of inhibition of 
GABAergic transmission on the FV to stimulus intensity relationship in WT slices (A2; n = 4) and 
KO slices (B2; n = 3). In WT slices, there was no statistically significant difference in the slope of 
the fitted line following blockage of GABAergic transmission (-0.025 ± 0.007 mV/stim intensity) 
compared to controls (-0.027 ± 0.007 mV/stim intensity, p > 0.05, WMPSR test). In KO slices, 
there was no statistically significant difference in the slope of the fitted line following blockage of 
GABAergic transmission (-0.034 ± 0.003 mV/stim intensity) compared to controls (-0.027 ± 0.006 
mV/stim intensity, p > 0.05, WMPSR test).  
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Figure 4.4. Characterisation of the effects of inhibition of GABAergic transmission on f-EPSP 
to stimulus intensity ratio in WT and GluN2D KO slices. A1 and B1, Example experiment 
showing the f-EPSP to FV relationship in WT slices (A1) and KO slices (B1) in the absence (black 
circles) and presence (white circles) of GABAergic transmission blockers. A2 and B2, Pooled data 
(left) and results from the individual experiments (right) showing the effect of blockage of 
GABAergic transmission on the f-EPSP to FV relationship in WT slices (A2, n = 4) and KO slices 
(B2, n = 3). In WT slices, there was no significant difference f-EPSP to FV ratio following blockage 
of GABAergic transmission (4.9 ± 1.1 ms-1) compared to controls (2.9 ± 0.6 ms-1, p > 0.05, WMPSR 
test). In KO slices, there was no significant difference after blockage of GABAergic receptors (1.5 
± 0.49 ms-1) compared to controls (1.3 ± 0.52 ms-1; p > 0.05, WMPSR test). 
  
Chapter 4 – GluN2D and synaptic plasticity 
178 
 
Figure 4.5. Characterisation of the effects of inhibition of GABAergic transmission on 
population spike in WT and GluN2D KO slices. A1 and B1, Example experiment showing the 
relationship between f-EPSPs and population spikes in WT slices (A1) and KO slices (B1) in the 
absence (black circles) and presence (white circles) of GABAergic transmission block. The data 
were described using a non-linear, sigmoidal fit. A2 and B2, In WT slices (A2, n = 4), maximum 
population spike area was not significantly different after inhibition of GABAergic transmission 
(3.5 ± 0.7 mV * ms) compared to the presence of GABAergic transmission (3.1 ± 0.6 mV * ms), in 
WT slices (p > 0.05, WMPSR test). In KO slices (B2, n = 3), maximum population spike area was 
similar in the presence of GABA receptor antagonists (1.0 ± 0.05 mV * ms) compared to controls 
(1.1 ± 0.04 mV * ms; p > 0.05, WMPSR test). A3 and B3, In WT slices (A3, n = 4) there was no 
significant difference in the E50 value after inhibition of GABAergic transmission (-0.45 ± 0.05 
mV/ms) compared to controls (-0.69 ± 0.13 mV/ms; p > 0.05, WMPSR test). In KO slices (B3, n = 
3), there was no significant difference in the E50 value after inhibition of GABAergic transmission 
E50 = -0.21 ± 0.02 mV/ms) compared to controls (E50 = -0.27 ± 0.04 mV/ms; p > 0.05, WMPSR 
test). 
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4.3.3. GluN2D KO hippocampal slices have higher levels of STP and LTP 
compared to WT hippocampal slices 
Control potentiation induced by 10-bursts in WT slices had a mean amplitude of STP of 
58.0 ± 5.0% that decayed to a stable LTP of 38.6 ± 4.1% with a mean decay time constant 
of 11.4 ± 1.5 min (Figure 4.6A). In GluN2D KO slices, potentiation induced by 10-bursts 
had STP of 82.8 ± 5.8% that decayed to a stable LTP of 54.29 ± 5.49% with a mean decay 
time constant of 11.4 ± 1.5 min (Figure 4.6A). Comparing potentiation that was induced by 
10-bursts between WT and KO slices showed that STP and LTP in GluN2D KO slices were 
greater than in WT slices (Figure 4.6C and D, p < 0.01 and p < 0.05, respectively, Student’s 
t-test) whereas the decay time constants of STP were similar in both WT and GluN2D KO 
slices (p > 0.05, MW test).  
 
Figure 4.6. Control STP and LTP are larger in hippocampal slices from GluN2D KO mice 
than in the WT. A, Pooled data showing the time course of potentiation of f-EPSPs (Mean ± SEM) 
induced by theta burst stimulation (10-bursts (10B), 4 pulses at 100 Hz repeated 10 times at 5 Hz) 
in WT (green circles, n = 21) and GluN2D KO mice slices (white circles, n = 17). Arrowhead 
indicates the time of TBS. Decay of STP after 10-bursts was fitted using a mono-exponential decay 
function (green curve fits WT and red curve fits KO). Decay time constants for WT and KO (τ, 
indicated in figure) were not significantly different between the genotypes (p > 0.05, MW test). 
Inset shows schematic illustrating the 10-bursts protocol. B, Representative f-EPSPs for WT and 
KO at the time-points indicated in A. C, Amplitude of STP was significantly larger in GluN2D KO 
slices (82.8 ± 5.8%) than in WT controls (58.0 ± 5.0%, p < 0.01, Student’s t-test). D, LTP was 
larger in GluN2D KO (54.29 ± 5.49%) when compared to LTP in WT (38.6 ± 4.1%, p < 0.05, 
Student’s t-test). 
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4.3.4. STP and LTP amplitudes were similar in WT and GluN2D KO 
hippocampal slices in the presence of GABA receptor antagonists 
It was previously shown that GluN2D KO slices have increased STP and LTP induced by 
10-bursts compared to WT slices (Figure 4.6). A possible reason for this difference could 
be the expression of GluN2D receptors on GABAergic interneurons in the WT mice. 
GABAergic interneurons expressing GluN2D-containing NMDARs are a part of 
feedforward inhibition in the SC-CA1 signalling pathway (Engelhardt et al., 2015; Perszyk 
et al., 2016) and have been shown to be involved in induction of NMDAR-dependent 
potentiation (Wigström and Gustafsson, 1983). Therefore, 10-bursts LTP experiments were 
conducted in slices from both the WT and GluN2D KO mice after blockade of GABAA 
(using 50 µM picrotoxin and 20 µM bicuculline) and GABAB (using 2 µM CGP 55845) 
receptors (Figure 4.7A and B). STP (Figure 4.7C) and LTP (Figure 4.7D) amplitudes in WT 
slices and GluN2D KO slices were similar after inhibition of GABAergic transmission (p > 
0.05, ANOVA, DT). This supports the suggestion that the greater amplitudes of STP and 
LTP that were observed in KO mice when compared to WT (Figure 4.6) were due to 
differences in GABAergic transmission. Interestingly, amplitudes of STP and LTP induced 
in the presence of GABA receptor antagonists were significantly higher than pooled control 
STP and LTP amplitudes in WT but not GluN2D KO slices (Figure 4.7C and D). While the 
decay of STP in WT and GluN2D KO slices was similar in the pooled control experiments 
(p > 0.05 for both, MW test), decay of STP was significantly faster in GluN2D KO slices 
after inhibition of GABAergic neurotransmission (p < 0.05, MW test). 
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Figure 4.7. LTP and STP levels in WT and GluN2D KO slices were similar in the presence of 
GABA receptor antagonists. A, In WT slices, potentiation induced by 10-burst stimulation was 
greater after inhibition of GABA receptors (white circles, STP = 116.0 ± 13.1%, LTP = 79.4 ± 
8.1%, n = 4) compared to pooled controls (green circles, STP = 58.1 ± 5%, LTP = 34.4 ± 4.6%, n 
= 16). In WT slices, the decay time constant of STP was not significantly different in the presence 
of GABA receptor antagonists compared to controls (p > 0.05, MW test). B, In KO slices, 
potentiation induced by 10-burst stimulation was similar when GABA receptors were blocked 
(white circles, STP = 109.4 ± 17.9%, LTP = 67.8 ± 10.2%, n = 5) compared to controls (green 
circles, STP = 82.8 ± 5.8%, LTP = 54.7 ± 5.8%, n = 16). The decay time constant of STP in 
experiments with GABA antagonists was significantly lower compared to control (p < 0.05, MW 
test). C - D, In WT slices, the amplitude of STP (C) and LTP (D) induced by 10-burst stimulation 
in the presence of GABA receptor antagonists was significantly greater compared to controls (p < 
0.001 and p < 0.01, respectively, ANOVA, DT). Whereas in KO slices, there was no difference in 
amplitude of STP (C) or LTP (D) after inhibition of GABA receptors compared to controls (p > 
0.05 for both, ANOVA, DT). E, Representative f-EPSPs from WT and KO slices at the time-points 
indicated in A and B.  
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4.3.5. Concentration-dependent effects of D-AP5 on STP and LTP 
D-AP5, a competitive antagonist of NMDARs was used to study the inhibition of NMDAR 
mediated LTP in the SC-CA1 synapses of WT and GluN2D KO slices (Figure 4.8). D-AP5 
blocks 2A and 2B subunits but not GluN2C or GluN2D subunits at sub-micromolar 
concentrations (Feng et al., 2005). Therefore, D-AP5 was tested at 100 µM, a concentration 
that blocks all GluN2 subunits and at 1 µM, a concentration that is selective for 2A and 2B 
containing receptors (Figure 4.8A, B and E). 100 µM D-AP5 blocked STP and LTP in slices 
from both genotypes equally (Figure 4.8C and D, p > 0.05 for both, Student’s t-test), 
whereas 1 µM D-AP5 blocked more STP in GluN2D KO slices compared to WT slices 
(Figure 4.8C, p < 0.05, Student’s t-test). Application of 1 µM D-AP5 led to inhibition of 
LTP to similar levels in both WT and GluN2D KO slices (Figure 4.8D; p > 0.05, Student’s 
t-test). 
A small, residual STP component was visible even in the presence of 100 µM D-AP5, this 
may have been a result of increased glutamate concentration during tetanus which 
outcompetes the competitive antagonist D-AP5 to cause potentiation. Therefore, inhibition 
of LTP was also verified using the NMDAR glycine site antagonist 10 µM L689,560, which 
blocked both STP and LTP in WT and KO slices (Figure 4.9). Application of 10 µM 
L689,560 caused similar levels of STP (Figure 4.9C) and LTP (Figure 4.9D) inhibition in 
WT and GluN2D KO slices (p > 0.05, Student’s t-test). 
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Figure 4.8. D-AP5 blocks induction of STP more potently in GluN2D KO than WT 
hippocampal slices. A, Pooled experiments from WT slices showing induction of STP and LTP by 
10-bursts in interleaved control experiments (green circles, STP = 48.3 ± 5.0%, LTP = 38.9 ± 7.7%, 
n = 8), and following application of 1 µM (white circles, STP = 40.9 ± 4.1%, LTP = 27.2 ± 4.1%, 
n = 6) and 100 µM (grey circles, STP = 12.4 ± 3.2%, LTP = 3.8 ± 4.1%, n = 5) D-AP5. τ of STP 
were not significantly different following 1 µM or 100 µM D-AP5 application when compared to 
control (p > 0.05, MW test). B, Similar to A but data are from GluN2D KO slices. Interleaved 
controls (green circles, STP = 91 ± 7.6%, LTP = 62.1 ± 7.0%, n = 6), 1 µM D-AP5 (white circles, 
STP = 38.5 ± 5.4%, LTP = 30.6 ± 4.1%, n = 5), and 100 µM D-AP5 (grey circles, STP = 20 ± 4.0%, 
LTP = 7.5 ± 3.9%, n = 5). τ of STP for controls was not different from τ in 1 µM or 100 µM D-AP5 
(p > 0.05, MW test). C, 1 µM D-AP5 inhibited the amplitude of STP in WT slices by 15.2 ± 8.6%, 
whereas in KO slices it was more potent (55.2 ± 6.3%, p < 0.01, Student’s t-test). 100 µM AP5 
inhibited STP to the same extent in both the WT (74.3 ± 6.7%) and KO (76.7 ± 4.6%, p > 0.05, 
Student’s t-test). D, There was no statistical difference in LTP inhibition between the WT and 
GluN2D KO mice in the presence of 1 µM (30.4 ± 10.4% for WT and 50.8 ± 6.5% for KO, p > 
0.05, Student’s t-test) and 100 µM D-AP5 (90.2 ± 10.4% for WT and 88.0 ± 6.3%; for KO, p > 0.05, 
Student’s t-test). E, Representative f-EPSPs from WT and KO slices at the time-points indicated in 
A and B. 
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Figure 4.9. Induction of STP and LTP is blocked by glycine-site NMDAR antagonist 
L689,560. A, In WT slices, 10 µM L689,560 (white circles, STP = 9.6 ± 0.9%, LTP = 2.0 ± 2.8%, 
n = 3) blocked induction of STP and LTP compared to control (green circles, STP = 44.7 ± 8.9%, 
LTP = 22.4 ± 3.6%, n = 3). τ of STP were not significantly different between control and L689,560 
treated groups (p > 0.05, MW test). B, Induction of LTP and STP was also blocked in GluN2D KO 
slices by 10 µM L689,560 (white circles, STP = 11.6 ± 1.2%, LTP = 5.6 ± 1.7%, n = 4) compared 
to control (green circles, STP = 73.1 ± 14.3%, LTP = 32.4 ± 5.2%, n = 4). τ of STP were not 
significantly different between control and L689,560 treatment groups (p > 0.05, MW test). C, 10 
µM L689,560 inhibited the amplitude of STP in WT slices by 78.6 ± 2.0%, which was not different 
from the inhibition of STP in KO slices (84.1 ± 1.7%, p > 0.05, Student’s t-test). D, LTP amplitude 
was inhibited by 10 µM L689,560 to similar levels in WT slices (90.9 ± 12.6%) and KO slices (82.7 
± 5.3%, p > 0.05, Student’s t-test). E, Representative f-EPSPs from WT and KO slices at the time-
points indicated in A and B. 
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4.3.6. GluN2A preferring antagonist NVP partially inhibits LTP in 
GluN2D KO and WT hippocampal slices 
To further investigate the role of the GluN2A subunit in the induction of LTP, NVP, a 
competitive antagonist with modest subunit selectivity for GluN2A over 2B and 2D 
containing receptors was used at a concentration of 0.1 µM (Figure 4.10A and B). NVP 
blocked STP and LTP in GluN2D KO and WT slices by a similar extent (Figure 4.10C and 
D). However, there was a significant prolongation of STP decay in WT slices (Figure 
4.10A, p < 0.05, MW test) but not GluN2D KO slices (Figure 4.10B, p > 0.05, MW test) 
by NVP. These results suggest that in SC-CA1 synapses, GluN2A-containing receptors 
mediate the amplitudes of STP and LTP in adult mice. These results are different from 
experiments in adult rat hippocampal slices where 0.1 µM NVP blocked close to 100% 
LTP (Volianskis et al., 2013a). Thus, LTP in SC-CA1 synapse in adult mice does not appear 
to be completely mediated by GluN2A-containing receptors but by a combination of 
GluN2A and other GluN2 subunits. Likewise, STP amplitude in SC-CA1 synapses in adult 
mice also appears to be mediated by GluN2A-containing receptors - a finding that was 
previously reported in adult rat slices (Volianskis et al., 2013a).  
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Figure 4.10. GluN2A antagonist NVP slows the decay of STP in WT but not GluN2D KO 
hippocampal slices. A, 0.1 µM NVP (white circles, STP = 24.4 ± 3.4%, LTP = 10.4 ± 12.2%, n = 
4) partially inhibited induction of LTP compared to control (green circles, STP = 43.8 ± 7%, LTP 
= 22.3 ± 5.7%, n = 4) in WT slices. Application of 0.1 µM NVP also slowed the decay of STP 
compared to controls (p < 0.05, MW test). B, In KO slices, induction of LTP and STP was partially 
inhibited by 0.1 µM NVP (white circles, STP = 43.6 ± 8.3%, LTP = 23.4 ± 6.3%, n = 5) compared 
to control (green circles, STP = 92.3 ± 12.6%, LTP = 54.3 ± 12.3%, n = 5) however, there was no 
difference in decay of STP after application of 0.1 µM NVP compared to control (p > 0.05, MW 
test). C, The amplitude of STP was inhibited to similar levels in WT (44.2 ± 7.8%) and KO (52.7 
± 9.0%) slices by 0.1 µM NVP compared to control (p > 0.05, Student’s t-test). D, 0.1 µM NVP 
inhibited LTP amplitude to similar levels in WT (53.4 ± 8.7%) and KO (56.9 ± 11.6%, p > 0.05, 
Student’s t-test). E, Representative f-EPSPs from WT and KO slices at the time-points indicated in 
A and B. 
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4.3.7. Effects of GluN2B antagonist Ro (1 & 10 µM) on STP and LTP in 
WT and GluN2D KO hippocampal slices  
The increased sensitivity of STP and LTP in KO slices to 1 µM D-AP5 concentration when 
compared to the WT could also be due to the inhibition of GluN2B-containing receptors 
(in addition to GluN2A) by sub-micromolar concentrations of D-AP5. Therefore, Ro 25-
6981 (Ro), a negative allosteric modulator with 1000-fold selectivity for GluN2B over the 
2A subunit (Fischer et al., 1997) was used to investigate the GluN2B component of 
potentiation in both genotypes (Figure 4.11). 1 µM Ro had minimal effects on both STP 
and LTP in WT and KO slices (Figure 4.11, p > 0.05, Student’s t-test), whereas increasing 
Ro concentration to 10 µM resulted in greater block of STP and LTP in WT slices than in 
KO slices (Figure 4.11C, D, p < 0.05 for both, Student’s t-test). Additionally, τ of STP after 
application of 10 µM Ro had a trend towards a faster decay time constant in KO slices 
(Figure 4.11E, p = 0.06, MW test). 
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Figure 4.11. Ro 25-6981 blocks induction of STP and LTP more potently in WT than in 
GluN2D KO hippocampal slices. A, STP and LTP in WT slices: 1 µM Ro (white circles, STP = 
63.0 ± 12.9%, LTP = 52.8 ± 10%, n = 7), 10 µM Ro (grey circles, STP = 4.2 ± 4.1%, LTP = -2.2 ± 
4.7%, n = 3) and controls (green circles, STP = 58.3 ± 10.6%, LTP = 51.6 ± 2%, n = 7). Ro had no 
significant effects on the decay time constants of STP at 1 or 10 µM (p > 0.05 for both, MW test). 
B, STP and LTP in KO slices: 10 µM Ro (grey circles, STP = 31.7 ± 5.1%, LTP = 27.8 ± 5.8%, n 
= 5), 1 µM Ro (white circles, STP = 71.3 ± 7.0%, LTP = 56.8 ± 6.1%, n = 5), controls (green circles, 
STP = 84.3 ± 9.7%, LTP = 55.2 ± 3%, n = 9). The decay of STP after 10 µM Ro application had a 
trend towards faster decay compared to control (p = 0.06, MW test). Decay time constant of STP 
after application of 1 µM Ro was not statistically different to controls (p > 0.05, MW test). C, 10 
µM Ro was more potent at inhibiting amplitude of STP in WT slices (92.8 ± 7.0%) when compared 
to the KO STP (62.4 ± 6.0%, p < 0.05, Student’s t-test), but no significant differences were observed 
with 1 µM Ro (p > 0.05, Student’s t-test). D, 10 µM Ro inhibited LTP to a greater extent in WT 
slices than in KO slices (p < 0.05, Student’s t-test) whereas 1 µM Ro had no effects on LTP (p > 
0.05, Student’s t-test). E, Representative f-EPSPs from WT and KO slices at the time-points 
indicated in A and B. 
Chapter 4 – GluN2D and synaptic plasticity 
189 
4.3.8. GluN2D preferring antagonist UBP145 blocks STP and LTP in WT 
but not in GluN2D KO hippocampal slices 
GluN2D containing receptors have been suggested to contribute to the induction of STP, 
especially affecting its decay time constant (Volianskis et al., 2013a; Ingram et al., 2018). 
To investigate the roles of GluN2D containing receptors, UBP145, a competitive antagonist 
with modest (~10-fold) selectivity for GluN2D over the GluN2A subunit was used in this 
study. 10 µM UBP145 had no significant effect on the amplitude of STP (p > 0.05, 
Student’s t-test) but caused significant inhibition of LTP in WT slices (Figure 4.12A and 
D, p < 0.05, Student’s t-test). Differently, STP and LTP from GluN2D KO slices were not 
significantly affected by 10 µM UBP145 (Figure 4.12B, p > 0.05, Student’s t-test). These 
results suggest that in adult mice, GluN2D-containing NMDARs contribute to the induction 
of LTP and prolong the decay of STP. In contrast, in KO slices the GluN2D contribution 
to STP and LTP seems to be compensated by GluN2B- (Figure 4.11B) and GluN2A- 
(Figure 4.8 and Figure 4.10) containing receptors. Differences in decay time constants of 
potentiation between control and UBP145 treatment groups in WT and KO slices were not 
statistically significant (p > 0.05, MW test). 
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Figure 4.12. GluN2D antagonist UBP145 blocks induction of LTP in WT but not GluN2D KO 
hippocampal slices. A, Pooled experiments from WT slices showing that 10 µM UBP145 (white 
circles, STP = 55.8 ± 10.3%, LTP = 22.3 ± 5.3%, n = 7) blocked LTP compared to controls (green 
circles, STP = 71.0 ± 9.0%, LTP = 43.8 ± 7.4%, n = 7). UBP145 also had a moderate but non-
significant effect on decay time constant of STP in WT slices (p > 0.05, MW test). B, In KO slices, 
UBP145 (white circles, STP = 65.3 ± 8.8%, LTP = 50.4 ± 7.2%, n = 9) had no effect on induction 
STP or LTP compared to controls (green circles, STP = 83.2 ± 14.0%, LTP = 45.8 ± 12.1%, n = 6). 
Decay time constants of STP were similar in 10 µM UBP145 and control groups in KO slices (p > 
0.05, MW test). C, Inhibition of STP amplitudes were similar in WT (21.4 ± 14.5%) and KO (21.5 
± 10.6%) slices after 10 µM UBP145 application (p > 0.05, Student’s t-test). D, Inhibition of LTP 
in WT (49.2 ± 12.1%) was greater compared to inhibition in KO slices (-10.1 ± 15.8%, p < 0.05). 
E, Representative f-EPSPs from WT and KO slices at the time-points indicated in A and B. 
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4.3.9. Increasing the number of bursts during induction of potentiation 
slows the decay of STP  
Increasing the number of pulses during induction of potentiation has been shown to induce 
STP with a slower decay time constant (Volianskis and Jensen, 2003), which could suggest 
an increase in GluN2D and GluN2B mediated components of STP, although this has not 
been investigated using subunit-preferring antagonists. The contribution of GluN2B and 
GluN2D containing receptors to the decay phase of STP was investigated after inducing 
potentiation with higher number of pulses (referred to as 30-bursts in this study). In WT 
slices, the decay of STP was significantly slower when it was induced with 30-bursts when 
compared to 10-bursts (Figure 4.13A, p < 0.05, MW test). A noticeable slowing of STP 
decay was also observed in GluN2D KO slices, but the difference was non-significant (p > 
0.05, MW test). 30-burst induction paradigm led to an increase in LTP in WT slices (Figure 
4.13A and D, p < 0.05, Student’s t-test) whereas the amplitude of STP remained the same 
as in the 10-bursts group (Figure 4.13A and C). In contrast, 30-burst induction did not affect 
the amplitudes of either STP or LTP in KO slices (Figure 4.13B, C and D). These results 
demonstrate that more intense stimulation can induce additional LTP in WT slices whereas 
LTP appears to be saturated in the KO slices (Figure 4.13D).  
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Figure 4.13. Number of bursts during LTP-induction affects the LTP and decay of STP in 
WT hippocampal slices. A, STP and LTP in WT slices: 10-bursts (green circles, n = 21) and 30-
bursts (white circles, n = 11). Decay time constant for STP was significantly larger in the 30-bursts 
group compared to 10-bursts, in WT slices (p < 0.001, MW test). B, STP and LTP in KO slices: 10-
bursts (green circles, n = 17) and 30-bursts (white circles, n = 16). In KO slices there was a ~2-fold 
increase in decay time constant of STP in 30-bursts group compared to 10-bursts group but the 
difference in decay time constants was not statistically significant (p > 0.05, MW test). C, STP 
amplitude was significantly higher in KO slices (82.8 ± 5.8%) compared to WT (58.1 ± 5.0%) in 
the 10-bursts group (data from Figure 4.6, p < 0.05, ANOVA, DT). STP amplitude were not 
different in the 30-bursts group between WT (51.0 ± 5.8%) and KO (52.0 ± 8.2%) slices (p > 0.05, 
ANOVA, DT). STP amplitude in KO slices was significantly lower in the 30-burst group than in 
the 10-burst group (p < 0.05, ANOVA, DT). STP amplitude was not different between 10-bursts 
and 30-bursts stimulation groups in WT slices (p > 0.05, ANOVA, DT). D, LTP induced by 10-
bursts was significantly larger in KO slices (51.7 ± 5.7%) compared to WT slices (38.6 ± 4.5%) 
(data from Figure 4.6, p < 0.05, Student’s t-test). Differently, LTP induced by 30-bursts in WT 
(66.9 ± 8.4%) and KO (60.7 ± 6.8%) slices were not statistically different (p > 0.05, Student’s t-
test). In WT slices, 30-bursts induced greater LTP when compared to 10-bursts (p < 0.05, ANOVA, 
DT). E, Representative f-EPSPs from WT and KO slices at the time-points indicated in A and B.  
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4.3.10. GluN2B antagonist Ro inhibits 30-bursts induced potentiation in 
WT and GluN2D KO slices  
The amplitude and decay of STP and the amplitude of LTP, which were induced by 10-
bursts in both WT and KO slices, were sensitive to 10 µM Ro but not to 1 µM Ro (Figure 
4.11). These results appear to be in disagreement with the previously published 
observations in rat showing that decay of STP is highly sensitive to low concentrations of 
Ro (Volianskis et al., 2013a). Notably, STP decays noticeably slower in rat than in mice 
and the sensitivities of STP and LTP, which were induced by 30-bursts stimulation, to 
GluN2B antagonist Ro were therefore also tested (Figure 4.14). 1 µM Ro did not inhibit 
30-bursts STP or LTP in WT slices but significantly blocked 30-bursts STP in GluN2D KO 
slices (p < 0.01, Student’s t-test) and caused a trend towards inhibition of 30-bursts LTP (p 
= 0.09, Student’s t-test) in KO slices.  
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Figure 4.14. 1 µM Ro inhibits induction of STP and LTP induced by 30-bursts in GluN2D KO 
hippocampal slices. A, Pooled experiments from WT slices showing the effect of 1 µM Ro (white 
circles, STP = 63.6 ± 14.0%, LTP = 64.9 ± 8.5%, n = 4) on induction of STP and LTP compared to 
pooled control (green circles, STP = 51.0 ± 5.8%, LTP = 66.9 ± 8.3%, n = 11). Decay of STP was 
significantly faster in 1 µM Ro group compared to controls (p < 0.05, MW test). B, In KO slices, 
induction of STP and LTP by 30-bursts was inhibited by application of 1 µM Ro (white circles, 
STP = 30.4 ± 4.4%, LTP = 40.5 ± 7.2%, n = 6) compared to pooled control (green circles, STP = 
52.0 ± 8.2%, LTP = 60.7 ± 6.8%, n = 16). There was a trend towards faster decay of STP by 1 µM 
Ro compared to control (p = 0.07, MW test). C, Inhibition of STP by 1 µM Ro was significantly 
higher in GluN2D KO slices (41.5 ± 8.5%) compared to WT (-24.7 ± 27.4%, p < 0.01, Student’s t-
test). D, Ro 1 μM produced a noticeably greater inhibition of 30-bursts induced LTP in GluN2D 
KO slices (27.1 ± 12.9%) compared to WT slices (-10.5 ± 14.5%); but the difference between WT 
and KO was not statistically significant (p = 0.09, Student’s t-test). E, Representative f-EPSPs from 
WT and KO slices at the time-points indicated in A and B.  
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4.3.11. GluN2D subunits contribute to the induction of LTP by 30-bursts 
tetanus 
In this study, GluN2D containing receptors contributed to the induction of 10-bursts LTP 
in WT slices, supported by the observation of a larger LTP amplitude in WT than in KO 
slices (Figure 4.6), and application of the GluN2D preferring antagonist UBP145 
effectively reduced STP in the WT but not in the GluN2D KO (Figure 4.12). UBP145 was 
also tested with the 30-bursts induction paradigm (Figure 4.15). 10 µM UBP145 noticeably 
reduced amplitudes of STP and LTP in WT slices (Figure 4.15A, C, D) but the differences 
were not statistically significant compared to the effect on STP and LTP in KO slices 
(Figure 4.15B, C, D, p > 0.05 for both, Student’s t-test). Interestingly, UBP145 also caused 
a non-significant but noticeable speeding up of the STP decay in WT (Figure 4.15A) but 
not KO slices (Figure 4.15B).  
To further confirm the role of GluN2D in 30-bursts LTP in mice, a higher affinity 
antagonist with greater selectivity for GluN2D subunit, UBP791, was tested at 1 µM 
(Figure 4.16). UBP791 reduced 30-bursts LTP in WT slices more potently than in KO slices 
(Figure 4.16D, p < 0.05, Student’s t-test) without affecting the amplitude of STP in either 
WT or KO slices (Figure 4.16C). However, 1 μM UBP791 caused a noticeable speeding 
up of decay of STP in WT (Figure 4.16A) but not GluN2D KO slices (Figure 4.16B). Taken 
together, these results provide further support for a role of GluN2D containing receptors in 
the induction of LTP in adult mice.  
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Figure 4.15. Effects of 10 µM UBP145 on 30-bursts-induced potentiation in WT slices. A, 
Pooled experiments from WT slices showing that 10 µM UBP145 (white circles, STP = 46.9 ± 
10%, LTP = 47.8 ± 8.5%, n = 4) inhibited induction of LTP when compared to control (green 
circles, STP = 51.0 ± 5.8%, LTP = 66.9 ± 8.3%, n = 11). Decay time constant of STP was noticeably 
decreased by 10 µM UBP145 compared to controls but the difference was not statistically 
significant (p > 0.05, MW test). B, In KO slices, induction of STP and LTP by the 30-burst induction 
paradigm was not reduced by application of 10 µM UBP145 (white circles, STP = 39.9 ± 7.1%, 
LTP = 51.9 ± 7.1%, n = 6) compared to control (green circles, STP = 52.0 ± 8.2%, LTP = 60.7 ± 
6.8%, n = 16). There was no significant difference in decay time constant of STP after application 
of 10 µM UBP145 compared to control (p > 0.05, MW test). C, STP induced by 30-bursts was 
inhibited by 10 µM UBP145 to similar levels in WT (-4.4 ± 22.3%) and KO (16.4 ± 14.9%) slices 
(p > 0.05, Student’s t-test). D, Inhibition of 30-burst induced LTP by 10 µM UBP145 was not 
significantly different between WT (18.7 ± 14.4%) and GluN2D KO slices (6.4 ± 12.7%, p > 0.05, 
Student’s t-test). E, Representative f-EPSPs from WT and KO slices at the time-points indicated in 
A and B. 
Chapter 4 – GluN2D and synaptic plasticity 
197 
 
Figure 4.16. 1 µM UBP791 inhibits LTP induced by 30-bursts in WT slices. A, LTP, induced 
by 30-burst stimulation, was reduced by 1 µM UBP791 in WT slices (white circles, STP = 53.1 ± 
15.2%, LTP = 41.5 ± 7.4%, n = 4) when compared to control (green circles, STP = 51.0 ± 5.8%, 
LTP = 66.9 ± 8.3%, n = 11). Decay time constant of STP was noticeably decreased in the 1 µM 
UBP791 group than in controls but the effect was not statistically significant (p > 0.05, MW test). 
B, In GluN2D KO slices, 1 µM UBP791 (white circles, STP = 44.6 ± 7.4%, LTP = 61.5 ± 6.0%, n 
= 4) did not inhibit induction of STP or LTP (green circles, STP = 52.0 ± 8.2%, LTP = 60.7 ± 6.8%, 
n = 16). There was no significant difference in the decay time constant of STP after application of 
1 µM UBP791 when compared to that in the control (p > 0.05, MW test). C, The amplitude of STP 
induced by 30-bursts was inhibited by 1 µM UBP791 by similar levels in WT (-18.2 ± 33.8%) and 
in KO slices (6.6 ± 15.5%, p > 0.05, Student’s t-test). D, LTP induced by 30-burst was inhibited 
more by 1 µM UBP791 in WT slices (29.4 ± 12.5%) compared to KO slices (-10.9 ± 10.7%, p < 
0.05, Student’s t-test). E, Representative f-EPSPs from WT and KO slices at the time-points 
indicated in A and B. 
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4.4. Discussion 
Investigations into the contribution of GluN2D subunits to hippocampal synaptic plasticity 
have suffered due to a lack of GluN2D selective antagonists. In this study, a combination 
of global GluN2D knockout mice and GluN2A, 2B or 2D subunit antagonists with 
moderate-good subunit selectivity were used to dissect the roles of GluN2D receptors in 
synaptic plasticity in the hippocampus of adult mice.  
4.4.1. Significance of GluN2D receptors for synaptic neurotransmission 
WT and GluN2D KO slices had similar synaptic baseline transmission at the SC-CA1 
synapse but maximum neuronal excitability in the CA1 region of the hippocampus was 
lower in GluN2D KO slices compared to WT slices (Figure 4.2). This change in maximum 
excitability may not be due to impaired interneuron function in GluN2D KO slices because 
blocking GABAergic transmission in GluN2D KO mice did not increase maximum 
population spike area (Figure 4.5). However, long-term GluN2D knockout could lead to 
emergence of compensating mechanisms that control maximum cell excitability 
independently from GABAergic transmission. Additionally, the cell excitability may also 
be controlled by extrasynaptic GluN2D-containing receptors in the CA1 (Lozovaya et al., 
2004).  
4.4.2. GluN2D receptors and STP 
A GluN2A and GluN2B selective concentration of D-AP5 (1 µM) inhibited STP in WT and 
GluN2D KO slices (Figure 4.8). Moreover, inhibition of GluN2A subunits with 1 µM NVP 
reduced STP in WT and KO slices (Figure 4.10) and 10 µM (but not 1 µM) Ro reduced 
STP in both WT and KO slices (Figure 4.11). Collectively, these results suggest that 
GluN2A- and GluN2B-containing receptors (possibly as GluN2A/GluN2B triheteromeric 
receptors) mediate induction of STP in adult mice, as found in rats (Volianskis et al., 2013a; 
France et al., 2017; Ingram et al., 2018).  
GluN2D KO slices had an enhanced amplitude of STP but similar decay of STP compared 
to WT slices (Figure 4.6). The increase in STP in KO slices may be due to the impairment 
of GABAergic transmission that is mediated by interneurons that express GluN2D-
containing receptors (Engelhardt et al., 2015; Perszyk et al., 2016). In support of this 
hypothesis, inhibition of GABAergic transmission resulted in similar levels of STP in both 
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WT and KO slices (Figure 4.7). Another explanation for the higher levels of STP in 
GluN2D KO slices is that diheteromeric and/or triheteromeric formations of GluN2A and 
GluN2B subunits compensated for lack of GluN2D subunits in the GluN2D KO slices 
which may have led to higher levels of STP in KO slices. In support of this, STP in GluN2D 
KO slices had greater sensitivity to block by GluN2A- and GluN2B-selective concentration 
of D-AP5 compared to WT slices (Figure 4.8C), and 10 µM Ro inhibited STP in WT slices 
more potently when compared to KO slices (Figure 4.11C) whereas 1 µM Ro had no effect 
on STP in WT or KO slices (Figure 4.11C). Therefore, the increased STP in KO slices may 
be due to an increase in the contribution from GluN2A containing diheteromers and/or 
GluN2A/2B triheteromers to the induction of STP because 1 µM D-AP5 inhibits GluN2A 
and GluN2B subunits (Feng et al., 2005) and 10 µM Ro may inhibit GluN2A/2B 
triheteromers according to binding affinity data on the recombinant GluN2A/2B 
triheteromeric receptor (Kd ~130 nM) (Lü et al., 2017). Interestingly, the GluN2D-selective 
antagonist UBP145 had no significant effect on STP in adult WT mice (Figure 4.12C), 
suggesting that GluN2D-containing receptors are not directly involved in induction of STP 
in adult mice. This is different from previous findings that GluN2D subunits contribute to 
STP decay in adult rats (Volianskis et al., 2013a; Ingram et al., 2018), and this observation 
may be explained most simply by the difference in species. We also confirmed previous 
observations that GluN2B-containing diheteromeric receptors may not contribute to 
induction of STP in the SC-CA1 synapse of adult mice (Köhr et al., 2003; Romberg et al., 
2009). This result further highlights the species difference compared to rat SC-CA1 
synapse, where 1 µM Ro inhibited ~60% of STP, a large part of which contributed to the 
decay of STP in rat slices (Volianskis et al., 2013a). Another notable difference between 
mouse and rat slices is that TBS-induced STP in WT mice decayed at a faster rate (τ ≈ 11 
min) in the current study (Figure 4.6A) compared to the study in Wistar rats (τ ≈ 16 min) 
(Volianskis et al., 2013a). Whether this difference in decay rate reflects the difference in 
underlying subunit population between the two species is a valid question that needs further 
investigation. 
Increasing both the number of bursts (from 10 to 30) and the frequency of the bursts (from 
5 to 15 Hz) in the train whilst keeping the total duration of the train unchanged during 
induction of potentiation led to a decrease in STP amplitude in GluN2D KO mice and a 
considerable slowing of STP decay in both WT and KO mice when compared to 10-bursts 
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induced STP (Figure 4.13). The simplest explanation for this increase in decay of STP in 
WT slices is an increase in contribution from GluN2B- and GluN2D-containing 
triheteromeric receptors to STP. Indirect evidence for this suggestion is provided from 
experiments where 1 µM Ro had no effect on 30-bursts STP amplitude or decay in WT 
slices but resulted in a significant inhibition of STP amplitude in GluN2D KO slices (Figure 
4.9). It is possible that in GluN2D KO mice, the triheteromeric GluN2B/2D NMDARs that 
contribute to STP at 30-bursts in WT animals are replaced by diheteromeric GluN2B 
containing NMDARs. In support of this idea, UBP145 and the more GluN2D selective 
antagonist, UBP791, had no effect on STP amplitude or decay at concentrations that are 
selective for GluN2D containing diheteromeric receptors.  
In summary, the 30-burst experiment results suggest that an additional population of 
receptors containing the GluN2B-subunit may be involved when the number of bursts 
during tetanus is increased to 30-bursts. Whether this receptor population also contains the 
GluN2D-subunit in addition to GluN2B requires further investigation. Receptors that are 
recruited during 30-bursts could be extrasynaptic, activated by glutamate spillover due to 
saturation of uptake mechanisms (Asztely et al., 1997). Whether these extrasynaptic 
GluN2B/2D containing receptors also contribute to neuronal excitability is a valid question 
that also requires further investigation. 
4.4.3. GluN2D receptors and LTP 
LTP in adult mice was mediated by GluN2A- (Figure 4.10), GluN2B- (Figure 4.11), and 
GluN2D- (Figure 4.12) containing receptors. The contribution of the GluN2B subunit to 
LTP in adult mice was likely as part of a triheteromeric receptor containing the GluN2A 
subunit. This conclusion can be reached because 1 µM Ro, which is selective for 
diheteromeric 2B containing receptors, had no effect on LTP (Figure 4.11D) but 10 µM Ro 
(Figure 4.11D) and 1 µM D-AP5 (Figure 4.8D) (both of which block GluN2A and GluN2B 
subunits) caused inhibition of LTP. Whether the inhibition of LTP by NVP is due to its 
effect on GluN2A-containing diheteromeric receptors or GluN2A/2B-containing 
triheteromers needs further investigation. Therefore, in adult mice as in adult and in P14 
rat hippocampus (Volianskis et al., 2013a; France et al., 2017), GluN2A- and GluN2B-
containing receptors are involved in the induction of LTP in the SC-CA1 synapse. 
However, in mouse hippocampus unlike in rat hippocampus, GluN2D-containing receptors 
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also contribute to the induction of LTP in the SC-CA1 synapse (Figure 4.12). This GluN2D 
component of LTP seems to be in addition to the GluN2A and GluN2B mediated 
component(s) because in WT slices, LTP is completely blocked by 10 µM Ro, a 
concentration of Ro that has been shown to not affect diheteromeric GluN2D-containing 
NMDARs expressed in HEK293 cells (Volianskis et al., 2013a).  
Pooled data showed that LTP in GluN2D KO slices was enhanced compared to WT slices 
(Figure 4.6). One explanation for this result was that the absence of GluN2D-containing 
receptors in GABAergic interneurons may have caused reduced inhibitory control of LTP 
induction in GluN2D KO slices. Inhibition of GABAergic transmission resulted in similar 
levels of LTP in both WT and GluN2D KO slices (Figure 4.7). These results corroborate 
previous findings that postsynaptic GABAergic transmission contributes to the threshold 
for induction of LTP at the SC-CA1 synapse (Wigström and Gustafsson, 1983) and that 
GluN2D receptors may be expressed on interneurons in the CA1 (Engelhardt et al., 2015; 
Perszyk et al., 2016; Alsaad et al., 2019).  
Another possible explanation for the enhancement of LTP induction in GluN2D KO slices 
is that GluN2D-containing receptors directly contribute to the induction of LTP in WT mice 
and that long-term deletion of the GluN2D subunit leads to compensation via increased 
contribution from GluN2A- and/or GluN2B-containing receptors. However, GluN2A and 
GluN2B selective concentrations of D-AP5 (1 µM) partially inhibited LTP induction in 
GluN2D KO slices and WT slices to similar amounts. LTP in WT slices was more potently 
inhibited by 10 µM Ro compared to KO slices (Figure 4.11D), suggesting that the 
contribution of GluN2A/2B triheteromeric NMDARs to LTP in WT slices is larger than in 
KO slices. The remaining LTP in KO slices in the presence of 10 µM Ro may have been 
mediated by GluN2A-containing diheteromers because this residual LTP component in 
GluN2D KO slices was not present when all NMDAR subunits were blocked with 100 µM 
D-AP5 (Figure 4.8D) or 10 µM L689,560 (Figure 4.9D).  
Interestingly, when inducing LTP with 30-bursts, LTP amplitude in WT slices increased 
but the LTP in GluN2D KO slices remained at the same levels as after 10-burst induction 
(Figure 4.13D). This increase in LTP at 30-bursts in WT slices may be due to an increase 
in contribution from GluN2B and GluN2D containing receptors. Moreover, 10 µM 
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UBP145 in WT slices non-significantly reduced 30-burst LTP (Figure 4.15D) and the 
higher affinity GluN2D antagonist UBP791 significantly reduced LTP amplitude (Figure 
4.16D), suggesting that GluN2D-containing receptors may also mediate LTP when the 
numbers of bursts used for induction of potentiation increase. Surprisingly, 30-burst LTP 
in GluN2D KO slices was sensitive to 1 µM Ro (Figure 4.14D), a concentration that 
produced no effect in 10-burst LTP, suggesting that in the absence of GluN2D-containing 
receptors, GluN2B-containing diheteromers may have had an increased contribution to 
induction of LTP (as in the case for STP, above) when the number of bursts is increased in 
KO slices. The GluN2D-containing receptors in WTs (and the compensatory GluN2Bs in 
KOs), which contribute to the induction of LTP in mice, may be located extrasynaptically 
on the CA1 pyramidal cells or presynaptically on Schaffer collateral boutons. To verify 
whether the CA1 pyramidal cells express GluN2D-containing receptors, the GluN2D 
selective antagonist UBP791 can be used to investigate the current decay of CA1 pyramidal 
cells when glutamate reuptake is inhibited (using TBOA, a blocker of excitatory amino acid 
transporters) to allow glutamate activation of the extrasynaptic GluN2D-containing 
receptors.
Chapter 5  
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The current study focused on enquiries into two types of studies involving the development 
of new pharmacological tools for GluK2-containing KARs and the functions of GluN2D-
containing NMDARs. Firstly, biological characterisation and molecular modelling of 
chemical entities that targeted GluK2 subunits were carried out, in order to aid the 
development of novel high-affinity GluK2-selective antagonists. The main findings of the 
present study have corroborated previous observations (Culley, Mallah, Thatcher, Irvine, 
Wood and Jane, unpublished) and developed novel SAR hypotheses for obtaining GluK2 
over GluK1/AMPAR selectivity. Using computational modelling and evidence from 
pharmacological characterisation of kynurenic acid derivatives, it was found that in the 
GluK2 LBD, the space occupied by 6-substituents of kynurenic acid derivatives, near 
residues Asn-690, Met-706, and Thr-710 in GluK2, may be targeted for improvement of 
GluK2 over AMPAR (GluA1/GluA2) and GluK1 selectivity (Chapter 3). Secondly, a 
physiological study of the NMDAR subunit GluN2D was conducted, which demonstrated 
that GluN2D subunits control neuronal excitability and contribute to potentiation of 
synaptic transmission in the SC-CA1 hippocampal synapse (Chapter 4). The study of 
GluN2D subunits also corroborated the GluN2D selectivity of UBP145 and the novel 
GluN2D antagonist UBP791 (Sapkota, 2016).  
5.1. Conclusions from pharmacological characterisation and 
molecular modelling of novel GluK2-selective antagonists 
5.1.1. The need for GluK2-selective antagonists 
The KAR family of glutamate receptors are comprised of five subunits (GluK1-5) that are 
expressed throughout the CNS (Monaghan and Cotman, 1982; Wisden and Seeburg, 1993). 
Studies of KARs in the hippocampus have suggested that KAR subunits are expressed in a 
target-, region- and age-specific manner (Bahn et al., 1994; Castillo et al., 1997; Bortolotto 
et al., 1999; Mulle et al., 2000; Sun and Dobrunz, 2006). Therefore, studies examining the 
roles of distinct KAR subunits will require the ability to target specific subunits. Advances 
in genetic techniques mean that region- and age-specific conditional knockouts of one or 
more types of KAR subunits are possible (Contractor et al., 2001; Xu et al., 2017). 
However, structural studies, in vitro and in vivo functional studies, and therapeutic 
targeting of KAR subunits can be enhanced using subunit-selective pharmacological tools.  
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Development of KAR subunit-selective antagonists have been difficult due to the overlap 
in pharmacology between KARs and AMPARs, and between KAR subunits themselves. 
Using a combination of GluK1-selective antagonists (Dolman et al., 2005; Jones et al., 
2006) (some with possible activity on GluK3 subunits (Perrais et al., 2009)), pan-KAR 
antagonists (Jane et al., 2009), genetic knockout mice lacking KAR subunits (Contractor et 
al., 2001) and AMPAR-selective antagonists (Paternain et al., 1995; Bortolotto et al., 1999) 
(with possible activity on GluK3 at high concentrations (Perrais et al., 2009)), KARs have 
been found to be involved in positive and negative regulation of synaptic transmission in 
the hippocampus (Carta et al., 2014). However, the identity of the specific subunits that 
carry out many KAR functions are still unknown due to a lack of subunit selective 
antagonists (Jane et al., 2009). As a result, questions regarding the contribution of GluK1 
or GluK2 subunits to synaptic plasticity mechanisms have been raised (Bortolotto et al., 
1999; Contractor et al., 2001; Breustedt and Schmitz, 2004), highlighting the need for 
GluK2 selective antagonists.  
Few studies have focused on the development of GluK2-selective antagonists. The early 
KAR antagonist, NS-102, had ~6-fold selectivity for GluK2 over GluK1 but suffered from 
poor water solubility (Verdoorn et al., 1994; Wilding and Huettner, 1996). Studies in the 
intervening period also revealed that a class of GluK2 antagonists based on 2-
aminothiopene inhibited GluK2 subunits with ~16-fold selectivity over GluK1 but these 
compounds were not fully characterised on other KAR subunits or AMPARs (Briel et al., 
2010). Other studies too have found GluK2 antagonists with at best moderate (~10-fold) 
selectivity for GluK2 over GluK1 or AMPARs but suffered from lack of characterisation 
on GluK1, GluK3, AMPARs or NMDARs (Dildy-Mayfield et al., 1996; Schiavini et al., 
2015). Therefore, a new a lead for the development of GluK2-selective antagonists was 
required.  
5.1.2. Findings from the current study 
Kynurenic acid derivatives with 5,7-substitutions have found use as potent antagonists of 
the glycine site of NMDARs (Baron et al., 1990). However, 6-substitutions made on 
kynurenic acid reduced NMDAR activity (Leeson et al., 1991). Due to the cross-activation 
of AMPARs and KARs by both kainate and quisqualate (the agonists first used to assay 
antagonists), the affinity of 6-substituted kynurenic acid derivatives on KARs and 
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AMPARs remained to be determined (Leeson et al., 1991). Earlier investigations by Jane 
and co-workers have shown that 6-substituted kynurenic acid derivatives had different 
activities on GluK2 subunits compared to GluK1 or GluA1 (Culley, Mallah, Thatcher, 
Irvine, Wood and Jane, unpublished). However, conflicting results regarding the activity 
of kynurenates on recombinant homomeric AMPARs warranted further characterisation of 
kynurenic acid derivatives. In addition to the older 6-substituted kynurenates, novel newly 
synthesised kynurenic acid derivatives were also characterised on two functional assays: a 
calcium fluorescence assay using recombinant GluK2, GluK1 and GluA1 homomeric 
receptors, and an electrophysiological assay in which activities of compounds were 
characterised on AMPAR- and NMDAR-mediated f-EPSPs from hippocampal slices. 
In the current study, an SAR for the kynurenic acid derivatives was developed (Chapter 2). 
The results demonstrated that UBP2038 (5,7-diF-6-I) had the highest affinity on GluK2 
(Table 2.3). Removal of the 5,7-diF substituents from UBP2038 leads to UBP2002 (6-I) 
which had noticeably lower affinity on GluK2 than UBP2038. Furthermore, presence of 
the 6-ethyl hydrophobic group at the 6-position led to significantly lower activity on GluK1 
(IC50 > 1 mM) and GluA1 (IC50 > 2mM) but retained the GluK2 activity (Ki = 54.0 ± 10.9 
μM) (Table 2.3). The activity profile of UBP2054 (6-Et) is different from that UBP2034 
(6-Me) which had no GluK2 over GluK1 selectivity (ratio of GluK1 and GluK2 Ki values 
= 1.0, Table 2.3). 
Improving the GluK2 affinity is an important factor in developing effective 
pharmacological agents. Based on results from the present study, a possibility for 
improving GluK2 affinity of kynurenates was the introduction of halo substituents on the 
5,7-positions of kynurenic acid. In support of this, it was shown that the high GluK2 affinity 
of UBP2038 (5,7-difluoro-6-iodo) may be due to increased number of electrostatic and van 
der Waals interactions between the 5- and 7-substituents of UBP2038 and the Tyr-412 and 
Asn-690, respectively, compared to UBP2002 (6-iodo) which lacked the 5,7-substitutions 
(Figure 3.8). It may be possible to improve the affinity of the more GluK2 over 
GluK1/AMPAR selective UBP2054 (6-Et) by introducing 5,7-diF substitutions on 
UBP2054. Such a modification could lead to increased affinity but with no detrimental 
effect on selectivity because it is the 6-Et substituent’s increased solvent exposure and steric 
clashes, which determines the GluK2 selectivity over GluK1 and AMPARs. 
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Validation of SAR using data from the pharmacological studies was carried out with 
molecular docking studies using X-ray crystal structures of GluN1, GluK1 and GluA2 
LBDs (Armstrong and Gouaux, 2000; Furukawa and Gouaux, 2003; Alushin et al., 2011), 
and a GluK2 homology model based on the X-ray crystal structure of GluK1 bound to 
UBP315 (Alushin et al., 2011). 
Results from the present study showed that steric clashes between the 6-substituent and 
Trp-731 and Val-735 residues in GluN1 LBD may explain the reduced activity of 6-
substituted kynurenic acids on NMDARs (Figure 3.16). In support of this, docking revealed 
that the 6-substituent of UBP2002 (6-I) had steric clashes with the surface of the binding 
cavity near the tryptophan and valine residues, whereas UBP2040 (5,7-diF-6-H) was well 
accommodated into the binding cavity (Figure 3.17) with minimal van der Waals volume 
overlaps. 
The initial hurdle for obtaining GluK2 (and other KAR subunits) selective antagonists is to 
ensure high selectivity of compounds for GluK2 over AMPARs. This task is made difficult 
by the high level of amino acid sequence similarity between the AMPARs and GluK2 at 
the ligand binding site (Figure 3.4). Results from the current study suggest that a 
combination of reduced binding site volume in AMPARs compared to GluK2, and the 
switch of Thr-686 and Met-708 residues in GluA2/GluA1 to Asn and Thr in GluK2 (near 
the kynurenic acid 6-substituent) may be exploited to obtain GluK2 over AMPAR 
selectivity (Figure 3.14). Using the 6-ethyl kynurenate, UBP2054, and the smaller 6-
substituent in UBP2002 (6-iodo) it was shown that the bulkier 6-substituent in UBP2054 
had greater steric clashes with Thr-686 and Met-708 residues in the GluA2 LBD, whereas 
steric clashes were reduced with UBP2002 (Figure 3.15); however, the larger 6-ethyl 
substituent of UBP2054 was accommodated into the binding site in the GluK2 LBD (Figure 
3.13).  
An additional aim of the pharmacological studies was to obtain compounds with greater 
GluK2 over GluK1 selectivity. This task was hampered by even greater amino acid 
sequence homology between the GluK2 and GluK1 subunits than between GluK2 and 
AMPARs (Figure 3.3). Surprisingly, we found that the UBP2054 (6-Et) had noticeably 
lower GluK1 activity compared to the smaller 6-substituent UBP2034 (6-Me). The 
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molecular modelling study provided 2 main explanations for the reduced GluK1 affinity of 
UBP2054: firstly, the greater volume available in the GluK1 binding site exposed larger 
portions of the hydrophobic 6-Et substituent of UBP2054 to solvent than the smaller 6-Me 
substituent in UBP2034; secondly, the smaller binding site of GluK2 meant that the 
hydrophobic Met-706 residue in GluK2 was in proximity to the 6-Et substituent of 
UBP2054 to be involved in van der Waals interactions and therefore, improve GluK2 
affinity. A third explanation for the GluK2 over GluK1 affinity of UBP2054 was provided 
by the presence of Thr-710 in GluK2 near the 6-substituent. The non-conserved Thr-710 
residue in GluK2 contains a methyl group which may be able to form hydrophobic 
interactions with the 6-Et substituent in UBP2054. The Thr-710 is replaced by a serine in 
GluK1 which lacks the methyl group that can form interactions with 6-Et group of 
UBP2054.  
In summary, the results from the current study provide a novel basis for development of 
GluK2 antagonists with greater GluK2 affinity and GluK2 over GluK1 and AMPAR 
selectivity. In addition, UBP2054 has been identified as a GluK2 antagonist with good 
selectivity vs AMPARs and ~10-fold selectivity for GluK2 versus GluK1. As such it is the 
most selective GluK2 antagonist reported to date and will be a useful pharmacological tool 
in functional studies to probe the physiological roles of GluK2. 
5.2. Future studies of GluK2 antagonists 
5.2.1. Validating results from the current study 
While pharmacological characterisation of UBP2054 has led to discovering its potential as 
a GluK2-selective antagonist, more work is required to validate the conclusions from SAR 
and modelling studies regarding the molecular basis of its GluK2 selectivity. 
The hypotheses regarding GluK2 over GluK1/AMPAR selectivity of UBP2054 developed 
in this study can be tested by point-mutation of non-conserved GluK2 residues to those in 
GluK1 or GluA1 LBDs, followed by radioligand binding assays to test the affinities of 
UBP2054 on the receptor which containing the point-mutated version of the subunit. 
Similar mutagenesis studies have been used previously to explain the GluK1 selectivity of 
willardiine derived GluK1 antagonists such as UBP310 and ACET (Atlason et al., 2010).  
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The residues which were found to be responsible for GluK2 selectivity over GluK1 and 
GluA2 in the current modelling study were Asn-690, Met-706 and Thr-710 in GluK2, 
which corresponded to Ser-706, Met-722 and Ser-726 in GluK1, and Thr-686, Leu-704, 
Met-706 in GluA2 (residues were the same in GluA1), respectively. The GluK2 over 
GluK1 selectivity can be investigated by point-mutating the Asn-690 and Thr-710 residues 
in GluK2 to the corresponding residues found in GluK1: which expresses serine in both 
positions, to eliminate the hydrophobic interactions provided by the two GluK2 residues 
which were absent in GluK1 due to the larger binding site volume. GluK2 subunits with 
these point mutations should have lower binding affinity (closer to the affinity for GluK1 
subunits) for UBP2054. The hypothesis for GluK2 over AMPAR selectivity can be verified 
by point mutating GluA2 residues (or the corresponding GluA1 residues): Thr-686 and 
Met-706 in GluA2 to the asparagine and threonine, respectively, found in GluK2. GluA2 
or GluA1 subunits with these point-mutations should have higher affinity for binding of 
UBP2054 compared to the WT, non-mutated subunit.  
A more time- and effort-intensive method for validation of the GluK2 binding mode of 
UBP2054 is to obtain the X-ray crystal structure of the isolated GluK2 LBD in complex 
with UBP2054. The X-ray structure of GluN1 in complex with DCKA has greatly aided 
the structural understanding of the GluN1 LBD in the antagonist-bound state and has helped 
to validate docking poses of kynurenates used in this study (Furukawa and Gouaux, 2003) 
(Figure 3.16). A similar advantage could be gained with solving of the GluK2 LBD 
structure in combination with UBP2054. The process of obtaining a GluK2 structure is 
made difficult by the poor affinity and water solubility of co-crystallised ligands (Jane et 
al., 2009; Møllerud et al., 2017). According to the current study, UBP2054 had GluK2 Ki 
of 54 μM (Table 2.3), which may not be sufficient to obtain X-ray crystal structures. 
Therefore, the higher affinity but lower GluK2-selective kynurenate, UBP2038, may be 
used to obtain the X-ray crystal structure, as it has greater water solubility compared to 
UBP2054.  
Another strategy for improving GluK2 affinity of UBP2054 is to introduce substitutions on 
the quinolone ring at positions other than the 6-position which will lead to formation of a 
higher number of contacts with residues in the D2 of the GluK2 ligand binding cleft by 
UBP2054. GluK1 antagonists such as ACET (Dargan et al., 2009) or LY466195 (Alushin 
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et al., 2011) and AMPAR antagonist ATPO have all been shown to have many interactions 
with residues in the D2 of LBD, which likely explains their high affinities. A residue in the 
D2 of KARs that has been found to be important for increasing affinity of ACET is Val-
654 in GluK2 and Val-670 in GluK1 which is replaced by the larger Leu-650 in GluA2. 
Therefore, substitutions that would interact with the valine in KARs may improve the 
affinity and GluK2 versus AMPAR selectivity of novel compounds. 
5.2.2. Improving GluK2 affinity and selectivity of UBP2054 
Improving GluK2 affinity and selectivity of UBP2054 requires additional substitutions to 
be made on the kynurenate’s structure such that greater number of interactions with D2 
residues can be made (for affinity) and specific interactions that target the non-conserved 
residues in GluK2 can be made (for selectivity).  
However, the task of increasing ligand-receptor contacts by kynurenates is made difficult 
by the planarity of the kynurenate structure which reduces the number of rotatable bonds 
in the kynurenate structure and therefore limits the contacts it can make with non-conserved 
residues in the GluK2 LBD’s D2 region. Kynurenates are oriented in the GluK2 ligand 
binding cleft to form H-bond interactions between the kynurenate’s 2-carboxy group and 
arginine and alanine residues in the D1, and the kynurenate’s 1-NH and proline residue in 
the D1 (Figure 3.7). Such an orientation of the kynurenate in the ligand binding site limits 
the number of interactions that are possible between kynurenates and D2 residues of GluK2 
LBD.  
One solution to improve the number of ligand-receptor interactions is to “open” the 
kynurenate structure by increasing the number of rotatable bonds and hence the flexibility 
of the ligand. However, a greater conformational penalty that is required to bind more 
“open” compounds means that there is a greater loss of entropy upon binding of the “open” 
compounds and this entropic penalty must be compensated by electrostatic or van der 
Waals interactions between the compound and the LBD to ensure high binding affinity. 
Thus, further work is needed to modify the structure of open chain compounds to increase 
the number of interactions with residues in the S1 and S2 domains 
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In addition to improving the GluK2 selectivity and affinity, the aqueous solubility of novel 
compounds based on UBP2054 must be adequate for use in physiological studies and 
therapeutics. To complement the 1-NH, 2-carboxyl, and 4-oxo groups, all of which can 
form H-bond interactions with water molecules, heteroatom substitutions, particularly 
nitrogen substitutions, can be made on the kynurenate ring structure to improve aqueous 
solubility. An example of improving water solubility by inducing nitrogen atoms in a 
structure similar to kynurenic acid was provided by the quinoxalinedione derivative, CNG-
10300, which had a substituent containing a three-carbon chain terminated by 
electronegative oxygen and nitrogen atoms (Demmer et al., 2015). This modification 
improved the water solubility of CNG-10300 significantly compared to other 
quinoxalinediones such as DNQX which did not have this modification (Demmer et al., 
2015). However, any modifications to improve water solubility in UBP2054 must not 
interrupt the ligand-receptor interactions that are necessary for the GluK2 affinity or 
selectivity.  
5.2.3. Further characterisation of UBP2054 
Although UBP2054 has been characterised on recombinant GluK2, GluK1, GluA1 
homomeric receptors, the activity of UBP2054 and other kynurenates on heteromeric 
KARs is yet to be determined. The activity of potential GluK2 antagonists on heteromeric 
KARs is important because in native tissue, KAR subunits are found as part of a 
heteromeric complex containing at least two different KAR subunits – usually a high 
affinity subunit (GluK4 or GluK5) in combination with a low affinity subunit (GluK1-3). 
In the hippocampus, all five KAR subunits are expressed but GluK5 and GluK2 shows the 
highest level of expression (Herb et al., 1992; Wisden and Seeburg, 1993; Paternain et al., 
2000). GluK1 is thought to be expressed in hippocampal CA1 interneurons due to its 
punctate expression throughout all layers of the hippocampus, while GluK2 is expressed in 
the principle cells of CA3 and CA1 (Monaghan and Cotman, 1982; Wisden and Seeburg, 
1993). GluK3 expression is highest in the dentate gyrus of the hippocampus and GluK4 is 
highly expressed in the CA3 pyramidal cell layer (Monaghan and Cotman, 1982; Wisden 
and Seeburg, 1993). Functional KARs are thought to be expressed as heteromers (Mulle et 
al., 2000). Therefore, the characterisation of UBP2054 and other kynurenates on 
heteromeric GluK2/GluK5 and GluK2/GluK3 KARs requires urgent consideration. 
Heteromeric GluK2/GluK5 complexes of KARs that are useful for characterisation of 
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UBP2054 and other kynurenates may be expressed in heterologous systems such as 
HEK293 cells (Paternain et al., 2000; Alt et al., 2004; Perrais et al., 2009) or may be found 
in CA3 pyramidal cells of hippocampal slices (Herb et al., 1992).  
An important validation of the usefulness of UBP2054 for physiological studies is to 
confirm that it inhibits native GluK2-containing KARs. Postsynaptic responses mediated 
by KARs have been isolated in the interneurons in CA1 (Cossart et al., 1998; Frerking et 
al., 1998). In the CA3 synapses made by mossy fibre axons, postsynaptic excitatory 
potentials mediated by GluK2-containing KARs have been observed (Castillo et al., 1997). 
Postsynaptic currents in the MF-CA3 synapses is mediated by GluK2, GluK4 and GluK5 
subunits whereas presynaptic GluK2/GluK3-containing KARs also mediates synaptic 
plasticity at the MF-CA3 synapse (Castillo et al., 1997; Contractor et al., 2001, 2003). 
Various manifestations of synaptic plasticity including frequency facilitation of MF-CA3 
postsynaptic responses, LTP, and paired pulse facilitation have all been shown to involve 
participation by GluK2 in the MF-CA3 pyramidal cell synapse (Mulle et al., 1998; 
Contractor et al., 2001). Therefore, the different forms of synaptic plasticity in the MF-CA3 
synapse provides a suitable candidate for characterisation of UBP2054 on native GluK2-
mediated mechanisms. Although it was shown that UBP2054 had native AMPAR IC50 > 
300 μM in the CA1 (Figure 2.13), the slight inhibition of AMPARs in the CA3 by UBP2054 
(Figure 2.12C) may complicate interpretation of physiological studies of UBP2054. 
Therefore AMPARs can be completely inhibited using the AMPAR-selective antagonist 
GYKI53655 (Paternain et al., 1995) at low concentration to avoid cross-inhibition of 
GluK3 subunits (or GluK2/GluK3 heteromeric KARs) (Perrais et al., 2009). Such 
pharmacological inhibition of AMPARs would help an isolated study of KARs and 
investigations into actions of KAR antagonists. In addition to AMPARs, the presence of 
GluK1 subunits in the MF-CA3 synapses may also complicate native inhibition of GluK2 
by UBP2054 (Wisden and Seeburg, 1993). One solution is to isolate GluK2 response using 
GluK1 antagonists such as LY466195 or ACET (Jones et al., 2006; Dargan et al., 2009). 
However, the unwanted inhibition of these GluK1 antagonists on heteromeric KARs also 
containing the GluK2 subunit may complicate the interpretation of results because these 
antagonists were shown to have similar potency on GluK1 heterodimers with GluK2 or 
GluK5 as the potency on homodimeric receptor (Alt et al., 2004). An alternative technique 
is to isolate GluK2-mediated responses by using genetic knockout of GluK1 subunits 
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(Contractor et al., 2001). MF-CA3 synaptic responses from hippocampal slices from GluK1 
knockout mice can be used to study synaptic plasticity and postsynaptic responses mediated 
by GluK2-containing KARs in isolation. However, long-term genetic knockouts of GluK1 
may lead to compensating mechanisms that may take over the synaptic plasticity functions 
of GluK1. Therefore, conditional knockouts of GluK1 must be preferred for synaptic 
plasticity studies which investigate the roles of GluK2 using genetic knockout mice. 
Conditional dentate gyrus specific GluK1 knockout mice are already available 
(Collingridge and co-workers, Bristol) and therefore, presents a suitable model for further 
characterisation of UBP2054 in a native system. 
KARs are also thought to be expressed with a wide range of auxiliary subunits (Lerma and 
Marques, 2013). One example is Neto1, which when coexpressed with GluK1 or GluK2, 
alters channel kinetics by decelerating the onset of desensitisation and acceleration of 
recovery from desensitisation (Copits et al., 2011; Fisher, 2015). Therefore, the inhibition 
of GluK2-containing KARs by UBP2054 must also be investigated in the presence of 
auxiliary subunits to better estimate the functional inhibition of GluK2-containing KARs 
by UBP2054. GluK2 has been expressed together with Neto1 and Neto2 auxiliary subunits 
in HEK293 cells (Fisher, 2015) and this provides a suitable avenue for characterising the 
GluK2 affinity of UBP2054 in the presence of the auxiliary subunit. 
An important reason for the development of GluK2-selective antagonists was to study the 
roles of GluK2 in disease states such as epilepsy, pain and behavioural disorders. Following 
further characterisation of UBP2054 to establish its activity on native GluK2-containing 
KARs, it can be used to study the roles of GluK2 in disease models. The GluK2 subunit 
has been implicated in epilepsy because GluK2 knockout mice were found to be less 
susceptible to induction of seizures by kainate injections (Mulle et al., 1998). However, the 
contribution of the GluK2 subunit for development of seizures remains to be determined 
because association with the GluK2 is thought to be critical for assembly of functional 
KARs and therefore the lack of seizures in GluK2 knockout mice may be through the lack 
of KAR subunits other than GluK2, particularly the GluK1 subunit (Gryder and Rogawski, 
2003). Therefore, studying the effect of UBP2054 in reducing epileptic activity in slice 
models of epilepsy induced through electrical stimulation, such as kindling model of 
epilepsy (Löscher et al., 1999), or through pharmacological induction mechanisms such as 
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through kainate infusions (Mulle et al., 1998) may provide an avenue to study the role of 
GluK2 in epilepsy.  
5.3. Conclusions from the investigation of the roles of the 
NMDAR GluN2D subunit in synaptic plasticity in the 
hippocampal CA1 region 
5.3.1. GluN2D subunits affect baseline excitability and mediate LTP 
induction in hippocampal neurons 
The GluN2D subunit protein has been shown to be expressed in the CA1 region of the 
hippocampus (Hrabetova et al., 2000; Thompson et al., 2002) but their precise location and 
their roles in synaptic transmission in the CA1 region remained unclear. Although the 
GluN2D protein expression has been shown to decrease with age (Monyer et al., 1994), its 
functional role in adult hippocampus has been investigated only a few times (Harney et al., 
2008; Volianskis et al., 2013a; Engelhardt et al., 2015; Ingram et al., 2018). A study by 
Lozovaya et al., (2004) suggested that GluN2D receptors might be expressed in 
extrasynaptic surfaces in CA1 of adult hippocampus based on analysis of the faster decay 
of NMDAR-mediated f-EPSPs induced by burst stimulation after inhibition of GluN2D 
using PPDA (Lozovaya et al., 2004). The speeding of the decay of f-EPSPs induced by 
burst stimulation may be a result of glutamate spillover due to saturation of glutamate 
reuptake transporter during bursts of pulses. The spillover of glutamate leads to activation 
of the extrasynaptic NMDARs, possibly containing GluN2D subunits (Lozovaya et al., 
2004). GluN2D containing NMDARs have higher affinity for glutamate compared to other 
GluN2 subunits (Feng et al., 2005), which would allow them to be activated even at low 
glutamate concentrations in the extrasynaptic space and therefore contribute to the late 
phase of the synaptic response. However, PPDA’s poor selectivity for GluN2D over 
GluN2B and GluN2A (at the concentration used in the study by Lozovaya et al: 10 μM) 
meant that the speeding of decay of f-EPSP in the study could also be due to inhibition of 
GluN2B.  
Other studies, which have investigated the roles of GluN2D in the hippocampus have found 
that using the GluN2B NAM, ifenprodil, the GluN2D-mediated slow decay phase of the 
NMDAR EPSC could be uncovered in hippocampal slices from P3-12 mice (Engelhardt et 
al., 2015). Additionally, a possibility for the presence of GluN2B/GluN2D-containing 
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triheteromeric receptors was also raised based on the observation that ifenprodil reduced 
the amplitude but not the decay time constant of NMDAR EPSCs from interneurons of 
p20-25 old mice (Engelhardt et al., 2015). In another study, the GluN2D/GluN2C PAM, 
CIQ, potentiated NMDAR-mediated EPSCs in CA1 interneurons but not pyramidal cells 
(Perszyk et al., 2016).  
Meanwhile, a pharmacological study that investigated the potency of GluN2A/2B or 2D 
antagonists with relative subunit-selectivity on LTP and STP in SC-CA1 synapses found 
that GluN2D and GluN2B-containing NMDARs (most likely as GluN2B/GluN2D 
trihetermeric receptors), which are activated during induction of potentiation, prolong the 
duration of STP decay (Volianskis et al., 2013a). These findings provided an exciting 
avenue for further investigations of the GluN2D subunit in synaptic plasticity mechanisms 
in the hippocampal CA1 region.  
The present study utilised subunit-selective pharmacological agents for GluN2A (NVP-
AAM077), GluN2B (Ro 25-6981) and GluN2D (UBP145 and UBP791) subunits, in 
combination with genetic knockout mice lacking the GuN2D subunit, to study the roles of 
GluN2D subunits in hippocampal synaptic transmission in both the knockout mouse and in 
the wild-type control. The lack of activity of GluN2D antagonists in the GluN2D knockout 
slices also provided validation for the selectivity of UBP145 (10 μM) and UBP791 (1 μM) 
for antagonising GluN2D-mediated components of LTP (Figure 4.15 and Figure 4.16). This 
further highlights the advantages of combined use of pharmacological and genetic 
techniques to study physiological phenomena.  
A significant finding of the present study was that the amplitude of LTP of SC-CA1 
synaptic transmission in WT mice hippocampal slices also involved a GluN2D component 
(Figure 4.12). On the contrary, the amplitude and decay time constant of STP in WT mice 
slices were not affected by UBP145, a GluN2D antagonist (Figure 4.12). This finding in 
mice was different from that in rats where inhibition of GluN2D-containing NMDARs 
using UBP145 decreased the decay time constant of STP but had no effect on amplitudes 
of STP or LTP (Volianskis et al., 2013a). These differences highlight that the roles that 
different GluN2 subunits play in synaptic potentiation are interchangeable between species 
and points to the redundancy in induction of STP and LTP by different GluN2 subunits. 
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Additionally, if the faster decay of STP in WT mice slices (τ of STP ≈ 11 min) compared 
to rat slices (τ of STP ≈ 16 min) (Volianskis et al., 2013a) is a true difference, STP in mice 
may be induced through NMDARs containing different subunits from those in rats.  
Another key observation from the current study was that CA1 neurons in the GluN2D KO 
slices have lower maximal excitability compared to WT slices (Figure 4.2C). Results from 
the current study suggest that blocking GABAergic transmission did not increase the 
maximum population spike in GluN2D KO slices compared to WT slices (when comparing 
mean maximum population spike area values) (Figure 4.5A2 and B2). However, maximal 
neuron excitability after inhibition of GABAergic transmission was not significantly 
different from controls in GluN2D KO slices (Figure 4.5B2). Therefore, the reason(s) for 
the impaired neuronal excitability in GluN2D KO slices compared to controls remains to 
be determined. 
The present study also suggests that GluN2D lacking mice may have a larger amplitude of 
STP and LTP due to reduced inhibitory control from GABAergic interneurons, which were 
shown to contain functional GluN2D-containing NMDARs (Perszyk et al., 2016), and/or 
due to increased expression of GluN2A or GluN2B subunits to compensate for the long-
term deletion of GluN2D. In support of the GABAergic involvement, blocking GABAA 
and GABAB transmission prior to induction of potentiation led to similar amplitudes of 
STP and LTP (Figure 4.7). In support of the GluN2A/GluN2B compensation hypothesis, 
the GluN2B antagonist, Ro, at a concentration high enough to inhibit GluN2A/GluN2B 
triheteromeric NMDARs (10 μM), inhibited LTP more potently in GluN2D KO slices. 
Another piece of evidence for the compensation by GluN2A and GluN2B in KO slices was 
that D-AP5 inhibited STP more potently in GluN2D KO slices at concentrations selective 
for GluN2A and GluN2B (Figure 4.8). 
The rate of STP decay was previously shown to depend on the number of bursts delivered 
during induction of potentiation (Volianskis and Jensen, 2003). Moreover, previous studies 
have shown that activation of GluN2B- and GluN2D-containing receptors may be 
responsible for prolonging STP decay (Volianskis et al., 2013a; Ingram et al., 2018). 
Therefore, the current study also investigated the roles of GluN2B and GluN2D subunits 
in STP and LTP induced by a higher number of bursts (30-bursts).  
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In agreement with published studies, we found that 30-bursts induced STP had slower 
decay in WT slices and demonstrated a trend towards slower decay in GluN2D KO slices. 
This slowing of decay in the WT is most simply explained by the enhanced recruitment of 
GluN2B/GluN2D containing triheteromeric receptors during the 30-burst tetanus. Due to 
the deletion of GluN2D, this extra recruited population of NMDARs may be GluN2B-
containing diheteromers in GluN2D KO slices. This suggestion was supported by a 
significant reduction in STP amplitude and halving of decay time constant by 1 μM Ro in 
GluN2D KO slices, and a more potent inhibition of 30-bursts induced STP amplitude in 
KO slices compared to WT by 1 μM Ro (Figure 4.14). 
Importantly, we also found that amplitudes of STP and LTP induced with 30-bursts were 
larger compared to those induced with 10-bursts in WT mice but not in GluN2D KO slices 
(Figure 4.13). Together, these results suggest that the presence of the GluN2D subunit 
limits the amount of maximal potentiation in physiological/lower frequency stimulation 
patterns (10-bursts, which was given as theta-burst stimulation), a characteristic that is lost 
upon deletion of GluN2D in the KO mice. The loss in control of maximal potentiation in 
GluN2D KO slices may have been due to reduced GABAergic control mediated through 
GluN2D-containing receptors on interneurons and/or increased contribution from 
GluN2A/GluN2B triheteromeric NMDARs to induction of STP and LTP after deletion of 
GluN2D.  
The GluN2D receptors on interneurons may be involved in maintaining the excitation-
inhibition balance during induction of potentiation by potentiating the interneuron (Lamsa 
et al., 2005) and therefore leading to lowering the threshold for generation of action 
potentials in the interneurons. This also explains the higher STP and LTP amplitudes in 
response to 10-bursts stimulation in GluN2D KO slices compared to WT slices because the 
excitation-inhibition balance would shift to excitation in the absence of GluN2D-mediated 
interneuron potentiation. The presence of GluN2A/GluN2B triheteromeric NMDARs is 
also in agreement with observation that 10 μM Ro more potently blocked 10-bursts induced 
LTP in KO compared to WT slices. In agreement with LTP induced using 10-bursts tetanus, 
LTP induced with 30-bursts was also dependent on GluN2D, as verified using UBP145 
(~10-fold GluN2D over GluN2B selectivity) and UBP791 (~30-fold GluN2D over GluN2B 
selectivity). 
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In summary, the results from the current study show that the GluN2D subunit mediates a 
component of LTP in the mouse SC-CA1 synapse and GluN2D deletion affects neuronal 
excitability through a yet to be determined process and increases amplitudes of STP and 
LTP through at-least two mechanisms: 1, by reducing the influence of the GABAergic 
feedforward/feedback inhibition in the SC-CA1 neuronal connection and 2, by causing 
compensation from GluN2A- and/or GluN2B-containing receptors.  
5.3.2. Physiological significance of GluN2D-induced synaptic plasticity 
LTP and STP reflect synaptic plasticity mechanisms, which permit modulation of neuronal 
signals at the single-cell and network levels, based on the activity of afferent neurons. 
Previous results from long-term and whole brain GluN2B and GluN2A genetic knockout 
studies have suggested that there is some redundancy between different GluN2 subunits 
with regards to their involvement in NMDAR dependent synaptic plasticity, particularly 
with GluN2A subunits (Kiyama et al., 1998). However, there may also be unique 
contributions of individual NMDAR subunits, such as the intracellular proteins to which 
each subunits couple and through which they can fulfil unique roles in signal processing in 
the neurons. An example is the association of GluN2B subunit with CaMKII, which has 
been shown to be critical for activation of GluN2B-mediated protein synthesis during LTP 
(Li et al., 2002). Therefore, genetic models with inducible cell type and age specific, 
deletion or over-expression of GluN2 subunits are needed to fully understand the roles that 
these subunits play at specific developmental stages. GluN2D subunit knockout mice have 
been shown to have behavioural deficits in rearing, which may be an anxiety-like behaviour 
(Ikeda et al., 1995). Ketamine’s anti-depressant effects have also been suggested to be due 
to its ability to inhibit the GluN2D mediated component of STP (Ingram et al., 2018). 
GluN2D containing receptors expressed on interneurons, which are important for 
maintaining network level synchrony in neuronal oscillations have also been implicated in 
schizophrenia (Sapkota et al., 2016). The roles that the GluN2D subunit plays in neuronal 
signalling in the human brain and how these roles are disrupted during disease are questions 
that require further study.  
While the physiological significance of STP is yet to be determined, STP can be induced 
independently or in combination with LTP in in vitro and in vivo settings (Kauer et al., 
1988; Buschler et al., 2012). STP may also be expressed independently or co-expressed 
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with LTP (Debanne et al., 1999). STP has also been shown to be activity dependent in its 
decay, in that stopping stimulation of the afferent neurons will “pause” the decay of 
potentiation for upto 6 hours, whereas restarting stimulation of afferent neurons resumes 
the decay of potentiation (i.e. STP) (Volianskis and Jensen, 2003). Therefore, STP has been 
suggested to represent short-term memory which can be stored in inactive synapses and 
once recalled loses relevance unless reinforced with further afferent synaptic activity 
(Volianskis et al., 2013a; Ingram et al., 2018). Previous studies have shown that GluN2D 
mediates the decay component of STP in rats (Volianskis et al., 2013a; Ingram et al., 2018).  
In summary, the effect of GluN2D on LTP in mice shows the heterogeneity in the origins 
of synaptic plasticity between species. Our data suggests that future experiments of SC-
CA1 LTP in mice must consider the role of GluN2D-containing receptors. Additionally, 
the results from our studies suggest that the decay time constant (τ) of STP may be lower 
after blockage of GluN2D receptors but these differences were not statistically significant. 
If the lowering of τ by GluN2D antagonists is a real effect, GluN2D-containing receptors 
may also play a role in SC-CA1 STP in mice. Therefore, STP and LTP may be mediated 
by either the same population of GluN2D-containing receptors or by two separate 
populations of GluN2D-containing receptors. 
5.4. Future studies on the physiological roles of GluN2D 
subunits 
5.4.1. Determining the location and composition of GluN2D-containing 
NMDARs in the CA1 of hippocampus  
In the present study, the process(es) that contributed to the impairment of neuronal 
excitability in GluN2D KO slices could not be determined. Although the results suggest 
that inhibition of GABAergic transmission did not affect maximal excitability (Figure 
4.5A2 and B2). The possibility that compensation by GluN2A- or GluN2B-containing 
receptors led to the impaired neuronal excitability can be tested by comparing the sizes of 
maximal population spikes in the presence and absence of D-AP5 in WT and GluN2D KO 
slices.  
To investigate the possibility that extrasynaptic GluN2D-containing receptors on the CA1 
pyramidal cells are responsible for the higher maximal neuronal excitability in WT slices, 
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the subunit composition of extrasynaptic NMDARs may be determined using the whole-
cell voltage clamp recording technique. A strategy for such investigations could be to block 
synaptic NMDARs using a slowly dissociating channel blocker similar to MK-801 under 
baseline synaptic activation and study the currents mediated by the unblocked extrasynaptic 
NMDARs in isolation. The blocking of synaptic NMDARs with MK-801 has been 
successfully performed to study the contribution of extrasynaptic GluN2B subunits to 
synaptic plasticity in CA1 (Yang et al., 2017) and to study extrasynaptic GluN2D 
containing receptors in dentate gyrus principle cells (Harney et al., 2008). 
Evidence from previous studies suggest that the GluN2D-containing extrasynaptic 
receptors in the CA1 may be triheteromeric GluN2B/GluN2D (Volianskis et al., 2013a; 
Engelhardt et al., 2015). But inhibition of GluN2B/GluN2D triheteromers using 
pharmacological tools has been rarely studied partly due to lack of information about 
activity of many antagonists on the GluN2B/GluN2D-containing triheteromeric receptor. 
Verification of the activity of UBP145 and UBP791 on GluN2B/GluN2D triheteromers is 
important for further physiological studies of GluN2D subunits which use these 
antagonists. The antagonist affinity on triheteromeric NMDARs can be determined on 
recombinant GluN2B/GluN2D triheteromers expressed in heterologous systems as 
previously characterised for the GluN2A/GluN2B triheteromer (Hansen et al., 2014), or in 
native CA1 hippocampal interneurons or substantia nigra pars compacta dopaminergic 
neurons where GluN2B/GluN2D triheteromers are believed to be expressed synaptically 
(Brothwell et al., 2008). 
The presence of extrasynaptic diheteromeric GluN2D- or extrasynaptic triheteromeric 
GluN2B/GluN2D-containing receptor populations can be verified by studying the decay of 
extrasynaptic currents caused by glutamate spillover after the blockage of glutamate 
reuptake transporter using TBOA (Shimamoto et al., 1998). The deactivation time 
constants of currents mediated by GluN2D (2-4 s) and GluN2B (71, 538 μs) diheteromers 
are distinct and can be indicative of their presence at extrasynaptic sites (Monyer et al., 
1992; Vicini et al., 1998). 
Another possibility to reveal the subunit composition is to conduct immunohistochemistry 
studies using GluN2B- and GluN2D-specific antibodies. Co-staining of GluN2B and 
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GluN2D subunits may be able to detect the possible presence of diheteromeric or 
triheteromeric GluN2D-containing populations of NMDARs in the CA1 of adult mice. The 
biggest hurdle for such investigations is the lack of subunit-specific antibodies. But 
antibodies with greater specificity are emerging and may pave the way for better 
understanding of NMDAR subunit protein expression patterns in the brain (Swanger et al., 
2015).  
Another finding from the present study that GluN2D antagonists partially inhibited LTP 
induced by TBS and by 30-bursts in the SC-CA1 synapse provides novel evidence for a 
GluN2D diheteromeric component in LTP in these synapses. In many experiments in the 
present study, the inhibition of STP and LTP by one antagonist was partial. However, high 
concentrations of D-AP5 (100 μM) or L689,560 (10 μM) inhibited both STP and LTP 
completely (Figure 4.8 and Figure 4.9). Therefore, further experiments using a combination 
of 10 μM UBP145 (or 1 μM UBP791) and 1 μM Ro may help to isolate the GluN2A 
component of potentiation. In a similar manner, combinations of 10 μM UBP145 (or 1 μM 
UBP791) and 0.1 μM NVP may help to isolate the GluN2B component of potentiation. 
However, the lack of GluN2A over GluN2B selectivity of NVP (5- to 10-fold) may limit 
its use and would require another novel antagonist with higher GluN2A selectivity. 
Moreover, the block of GABA receptors before induction of potentiation using 30-bursts 
may give clues as to the contribution of interneurons to maximal potentiation. 
In addition to the activities of UBP145 and UBP791 on triheteromeric GluN2D-containing 
NMDARs, activity of Ro on GluN2B/GluN2D triheteromeric NMDAR remains to be 
determined. A recent structural study of a recombinant GluN2A/GluN2B triheteromer 
revealed that affinity (Kb) for Ro was ~130 nM (Lü et al., 2017). This affinity is closer to 
Ro’s affinity on GluN2B diheteromer than to its affinity on GluN2A diheteromer (Fischer 
et al., 1997). Therefore, whether Ro’s affinity on GluN2B/GluN2D triheteromer is in a 
range that would selectively inhibit the GluN2B/GluN2D triheteromer without inhibiting 
GluN2A diheteromeric receptors requires further study using triheteromers expressed in 
heterologous or native systems. Once the activities of both UBP145 and Ro on 
GluN2B/GluN2D triheteromers are determined, a suitable next step would be to inhibit 
GluN2B/GluN2D-containing triheteromeric receptors without affecting GluN2A-
containing receptors to show that STP is completely blocked in WT slices. This could be 
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done by development of novel antagonists that binds to GluN2B/GluN2D selectively – one 
approach is to improve the selectivity of UBP791 such that it binds to GluN2B with similar 
affinity as GluN2D but without affinity on GluN2A. Another approach is to develop 
allosteric antagonists that bind selectively to the interface between GluN2B/GluN2D 
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